6-K

Use these links to rapidly review the document
TABLE OF CONTENTS

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2017

FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrant's name into English)

Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
       Form 20-F    ý        Form 40-F    o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):            

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
       Yes    o                    No    ý

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 –             .

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations for the three and nine months ended September 30, 2017 and 2016

	Page
FINANCIAL INFORMATION
Management's Discussion and Analysis
Forward-looking Statements	1
Financial Condition and Results of Operations	3
Non-IFRS Measures	8
Business Metrics for Care Coordination	15
Sources of Liquidity	37
Balance Sheet Structure	40
Outlook	41
Financial Statements (unaudited)
Consolidated Statements of Income	42
Consolidated Statements of Comprehensive Income	43
Consolidated Balance Sheets	44
Consolidated Statements of Cash Flows	45
Consolidated Statement of Shareholders' Equity	46
Notes to Consolidated Financial Statements	47
Quantitative and Qualitative Disclosures About Market Risk	78
Controls and Procedures	79
OTHER INFORMATION
Legal and Regulatory Matters	80
Exhibits	81
Signatures	82

i

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

FINANCIAL INFORMATION

Management's Discussion and Analysis

       Since 1996, Fresenius Medical Care AG & Co. KGaA has filed with the U.S. Securities and Exchange Commission ("SEC"), annual and interim reports containing Consolidated Financial Statements prepared in accordance with U.S. Generally Accepted Accounting Principles ("U.S. GAAP"), using the U.S. dollar as our reporting currency. Since 2007, Fresenius Medical Care AG & Co. KGaA has also been required by German and European law to prepare Consolidated Financial Statements in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union. As of January 1, 2017, the consolidated financial statements and other financial information included in our quarterly reports on Form 6-K have been, and commencing with our Annual Report on Form 20-F for 2017 the financial statements in our annual reports will be prepared solely in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"), using the euro as our reporting currency, and we have discontinued publishing U.S. GAAP financial information as of the end of 2016. At September 30, 2017, there were no IFRS or International Financial Reporting Interpretation Committee ("IFRIC") interpretations as endorsed by the European Union relevant for interim reporting that differed from IFRS as issued by the IASB. You should read the following discussion and analysis of our results of operations and our subsidiaries in conjunction with our unaudited Consolidated Financial Statements and related notes contained elsewhere in this report, the disclosures and discussions in our IFRS Consolidated Financial Statements for the year ended December 31, 2016 as well as historical financial data prepared in accordance with IFRS for the years 2012 through 2015. These documents are available on our website.

       In this report, "FMC-AG & Co. KGaA," or the "Company," "we," "us" or "our" refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term "North America Segment" refers to our North America operating segment, the term "EMEA Segment" refers to the Europe, Middle East and Africa operating segment, the term "Asia-Pacific Segment" refers to our Asia-Pacific operating segment, and the term "Latin America Segment" refers to our Latin America operating segment. The term "Corporate" includes certain headquarters' overhead charges, including accounting and finance, centrally managed production, asset management, quality management, procurement and research and development. The term "Constant Currency" or at "Constant Exchange Rates" means that we have translated local currency revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items for the current reporting period into euro using the prior year exchange rates to ensure a comparable analysis without effect from exchange rate fluctuations on translation, as described below under "Financial Condition and Results of Operations – II. Discussion of Measures – Non – IFRS Measures – Constant Currency."

Forward-looking Statements

       This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). When used in this report, the words "outlook," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions are generally intended to identify forward looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated, and future events and actual results, financial and otherwise, could differ materially from those set forth in or contemplated by the forward-looking statements contained elsewhere in this report. We have based these forward-looking statements on current estimates and assumptions made to the best of our knowledge. By

1

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

their nature, such forward-looking statements involve risks, uncertainties, assumptions and other factors which could cause actual results, including our financial condition and profitability, to differ materially positively or negatively relative to the results expressly or implicitly described in or suggested by these statements. Moreover, forward-looking estimates or predictions derived from third parties' studies or information may prove to be inaccurate. Consequently, we cannot give any assurance regarding the future accuracy of the opinions set forth in this report or the actual occurrence of the projected developments described herein. In addition, even if our future results meet the expectations expressed herein, those results may not be indicative of our performance in future periods.

       These risks, uncertainties, assumptions, and other factors, including associated costs, could cause actual results to differ from our projected results include, among others, the following:

•

changes in governmental and commercial insurer reimbursement for our complete products and services portfolio, including the United States ("U.S.") Medicare reimbursement system for dialysis and other health care services, including potentially significant changes that could be enacted due to the announced intention of the Trump administration to continue its efforts to repeal and replace the Patient Protection and Affordable Care Act;

•

the outcome of government and internal investigations as well as litigation;

•

risks relating to compliance with current and future government regulations applicable to our business including, in the U.S., the Anti-Kickback Statute, the False Claims Act, the Stark Law, the Health Insurance Portability and Accountability Act, the Health Information Technology for Economic and Clinical Health Act, the Foreign Corrupt Practices Act, the Food, Drug and Cosmetic Act, and outside the U.S., the EU Medical Device Directive, the EU General Data Protection Regulation, the two invoice policy and the Tendering and Bidding Law in China and other related local legislation as well as other comparable regulatory regimes in many of the more than 120 countries in which we supply health care services and/or products;

•

the influence of commercial insurers and managed care organizations, including efforts by these organizations to manage costs by limiting healthcare benefits, reducing provider reimbursement and/or restricting options for patient funding of health insurance premiums;

•

the impact of health care, tax and trade law reforms and regulation, including those proposed by the Trump administration in the U.S.;

•

product liability risks;

•

risks relating to our ability to continue to make acquisitions;

•

risks relating to our ability to attract and retain skilled employees, including shortages of skilled clinical personnel;

•

the impact of currency fluctuations;

•

potential impairment loss on assets in the Latin America Segment due to decreases in the recoverable amount of those assets relative to their book value;

•

the United Kingdom initiation, on March 29, 2017, of its withdrawal from the European Union and its possible effects on the tax, tax treaty, currency, operational, legal and regulatory regimes to which our businesses in the region are subject, as well as the present uncertainty regarding these and related issues;

•

our ability to protect our information technology systems against cyber security attacks or prevent other data privacy or security breaches;

•

changes in our costs of purchasing and utilization patterns for pharmaceuticals;

2

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

•

introduction of generic or new pharmaceuticals that compete with our products or services;

•

launch of new technology that competes with our medical equipment and device businesses;

•

changes in raw material and energy costs or the inability to procure raw materials;

•

collectability of our receivables, which depends primarily on the efficacy of our billing practices and the financial stability and liquidity of our governmental and commercial payors;

•

our ability to achieve cost savings in various health care risk management programs in which we participate or intend to participate; and

•

the greater size, market power, experience and product offerings of certain competitors in certain geographic regions and business lines.

       Important factors that could contribute to such differences are noted in "Financial Condition and Results of Operations – I. Overview" below, in Note 12 of the Notes to Consolidated Financial Statements (unaudited), "Commitments and Contingencies" included in this report, in Note 18 of the Notes to Consolidated Financial Statements, "Commitments and Contingencies" included in our Annual Report on Form 20-F for the year ended December 31, 2016, as well as under "Risk Factors," "Business Overview," "Operating and Financial Review and Prospects," and elsewhere in that report.

       Our business is also subject to other risks and uncertainties that we describe from time to time in our public filings. Developments in any of these areas could cause our results to differ materially from the results that we or others have projected or may project.

       Our reported financial condition and results of operations are sensitive to accounting methods, assumptions and estimates that are the basis of our financial statements. The actual accounting policies, the judgments made in the selection and application of these policies as well as the sensitivities of reported results to changes in accounting policies, assumptions and estimates are factors to be considered along with our financial statements and the discussion under "Financial Condition and Results of Operations – III. Results of Operations financial position and net assets – Results of operations" below. As of January 1, 2017, we migrated to reporting in accordance with IASB IFRS and discontinued preparing U.S. GAAP financial information. Please refer to our significant and critical accounting policies and estimates in Note 1 "The Company, Basis of Presentation and Significant Accounting Policies" and Note 2 "Discretionary Decisions and Sources of Estimation Uncertainties" in our Consolidated Financial Statements in accordance with IFRS, as adopted in the European Union, for the year ended December 31, 2016. Those Consolidated Financial Statements are available on our website at https://www.freseniusmedicalcare.com/en/home/ and have not been filed with the SEC. In furnishing our website address in this report, however, we do not intend to incorporate any information on our website into this report, and you should not consider any information on our website to be part of this report.

       Rounding adjustments applied to individual numbers and percentages shown in this and other reports may result in these figures differing immaterially from their absolute values.

Financial Condition and Results of Operations

I. Overview

       We are the world's largest kidney dialysis company, based on publicly reported sales and number of patients treated. We provide dialysis care and related services to persons who suffer from end stage renal

3

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

disease ("ESRD") as well as other health care services. We develop and manufacture a wide variety of health care products, which includes both dialysis and non-dialysis products. Our dialysis products include dialysis machines, water treatment systems and disposable products while our non-dialysis products include acute cardiopulmonary and apheresis products. We sell our health care products to customers in more than 120 countries and we also use them in our own health care service operations. Our dialysis business is therefore vertically integrated. We describe certain other health care services that we provide in our North America and Asia-Pacific segments as "Care Coordination." Care Coordination currently includes, but is not limited to, coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician nephrology and cardiology services, health plan services, ambulatory surgery center services and urgent care services. Care Coordination also includes the coordinated delivery of emergency, intensivist and hospitalist physician services as well as transitional care which we refer to as "hospital related physician services." All of these Care Coordination services together with dialysis care and related services represent our health care services. We estimated the volume of the global dialysis market was approximately €68 billion in 2016. Due to the complexity and evolving nature of care coordination services, we are currently unable to estimate the global volume of this market. Dialysis patient growth results from factors such as the aging population and increased life expectancies; shortage of donor organs for kidney transplants; increasing incidence of kidney disease and better treatment of and survival of patients with diabetes, hypertension and other illnesses, which frequently lead to the onset of chronic kidney disease; improvements in treatment quality, new pharmaceuticals and product technologies, which prolong patient life; and improving standards of living in developing countries, which make life-saving dialysis treatment available. We are also engaged with entities, in which we have ownership of less than 100%, to fund different areas of health care research.

       As a global company delivering health care services and products, we face the challenge of addressing the needs of a wide variety of stakeholders, such as patients, customers, payors, regulators and legislators in many different economic environments and health care systems. In general, government-funded programs (in some countries in coordination with private insurers) pay for certain health care items and services provided to their citizens. Not all health care systems provide for dialysis treatment. Therefore, the reimbursement systems and ancillary services utilization environment in various countries significantly influence our business.

Premium Assistance Programs

       On August 18, 2016, the Center for Medicare & Medicaid Services ("CMS") issued a request for information ("RFI") seeking public comment on concerns about providers' steering patients inappropriately to individual plans offered on the Patient Protection and Affordable Care Act individual health insurance market. We and other dialysis providers, commercial insurers and other industry participants responded to the RFI, and in that response, we reported that we do not engage in such steering. On January 3, 2017, we received a subpoena from the United States Attorney for the District of Massachusetts inquiring into our interactions and relationships with the American Kidney Fund ("AKF" or "the Fund"), including our charitable contributions to the Fund and the Fund's financial assistance to patients for insurance premiums. On December 14, 2016, CMS published an Interim Final Rule ("IFR") titled "Medicare Program; Conditions for Coverage for End-Stage Renal Disease Facilities-Third Party Payment" that would amend the Conditions for Coverage for dialysis providers, like Fresenius Medical Care Holdings ("FMCH"). The IFR would have effectively enabled insurers to reject premium payments made by patients who received grants for individual market coverage from the AKF and therefore, could have resulted in those patients losing their individual market health insurance coverage. The loss of individual market coverage for these patients would have a material and adverse impact on our operating results. On January 25, 2017, a federal district court in Texas, responsible for litigation initiated by a patient

4

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

advocacy group and dialysis providers including FMCH, preliminarily enjoined CMS from implementing the IFR (Dialysis Patient Citizens v. Burwell (E.D. Texas, Sherman Div.)). The preliminary injunction was based on CMS' failure to follow appropriate notice-and-comment procedures in adopting the IFR. The injunction remains in place and the court retains jurisdiction over the dispute. On June 22, 2017, CMS requested a stay of proceedings in the litigation pending further rulemaking concerning the IFR. CMS stated, in support of its request, that it expects to publish a Notice of Proposed Rulemaking in the Federal Register and otherwise pursue a notice-and-comment process. Plaintiffs in the litigation, including FMCH, consented to the stay, which was granted by the court on June 27, 2017.

       The operation of charitable assistance programs like that of the AKF is also receiving increased attention by state insurance regulators. The result may be a regulatory framework that differs from state to state. Even in the absence of the IFR or similar administrative actions, insurers are likely to continue efforts to thwart charitable premium assistance to our patients for individual market plans and other insurance coverages. If successful, these efforts would have a material adverse impact on our operating results.

Significant U.S. Reimbursement Developments

       The majority of health care services we provide are paid for by governmental institutions. For the nine months ended September 30, 2017, approximately 34% of our consolidated revenue is attributable to U.S. federally-funded health care benefit programs, such as Medicare and Medicaid reimbursement, under which reimbursement rates are set by CMS. Legislative changes could affect Medicare reimbursement rates for a significant portion of the services we provide. To date, while we have generally experienced stable reimbursement globally, the stability of reimbursement in the U.S. has been affected by (i) the implementation of the ESRD prospective payment system ("ESRD PPS") in January 2011, (ii) the U.S. federal government across the board spending cuts in payments to Medicare providers commonly referred to as "U.S. Sequestration," (iii) the reduction to the ESRD PPS rate to account for the decline in utilization of certain drugs and biologicals associated with dialysis pursuant to the American Taxpayer Relief Act of 2012 ("ATRA") as subsequently modified under the Protecting Access to Medicare Act of 2014 ("PAMA") and (iv) CMS's 2016 final rule on the Physician Fee Schedule with material decreases in reimbursement for certain procedures. Please see the broader discussion of these legislative developments below:

•

Under the Medicare Improvements for Patients and Providers Act of 2008 ("MIPPA"), for patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate, ESRD PPS, to encompass substantially all goods and services provided during the dialysis treatment. MIPPA further created the ESRD quality incentive program ("QIP") which provides that dialysis facilities that fail to achieve quality standards established by CMS could have payments reduced by up to 2 percent.

•

MIPPA also includes a provision for an annual adjustment to the ESRD PPS base rate based on changes in the costs of a "market basket" of certain healthcare items and services, less a productivity adjustment.

•

Additionally, as a result of the Budget Control Act of 2011 ("BCA") and subsequent activity in Congress, U.S. Sequestration ($1.2 trillion in across-the-board spending cuts in discretionary programs) took effect on March 1, 2013 and is expected to continue through mid-2024. In particular, a 2% reduction to Medicare payments took effect on April 1, 2013 and continues in force. Spending cuts pursuant to U.S. Sequestration have adversely affected and will continue to adversely affect our operating results.

5

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

•

In 2014, as mandated by ATRA, CMS issued a final rule for the ESRD PPS, which phased in payment reductions to account for changes in utilization of certain drugs and biologicals that are included in the ESRD PPS, which were subsequently modified by PAMA. These reductions reduced our market basket inflation adjustment by 1.25% in 2016, and will reduce our inflation adjustment by 1.25% in 2017, and 1% in 2018.

•

On November 15, 2016, CMS published a final rule that modifies certain payment policies, payment rates, and quality provisions in the Physician Fee Schedule for calendar year 2017. The final rule includes material decreases in the reimbursement rates for many of the procedures performed routinely by Fresenius Vascular Care, now known as "Azura Vascular Care." These reimbursement cuts may have a material adverse impact on our operating results.

•

On October 27, 2017, CMS issued the final rule updated the ESRD PPS rate for 2018. We and other large dialysis organizations will experience a 0.4% increase in payments under this final rule. The base rate per treatment is $232.37 which represents a 0.3% increase from the 2017 base rate. The 2017 final rule reflects a market basket increase of 0.3% (1.9% market basket increase that is partially offset by a 1% reduction under PAMA and a 0.6% multifactor productivity adjustment) and application of the wage index budget-neutrality adjustment factor of 1.000531. The 2018 ESRD PPS rate does not contain any changes to the previous wage index floor of 0.4000.

•

The ESRD PPS final rule also updated the ESRD QIP, including for payment years 2019, 2020, and 2021, under which payment incentives are made to dialysis facilities to improve the quality of care that they provide. The final rule includes updates to the ESRD QIP Extraordinary Circumstances Exception Policy, Performance Score Certificate, National Healthcare Safety Network dialysis event data validation sampling methodology, and quality measures. The final rule also updated the payment for dialysis provided to patients with acute kidney injuries to be equal to the 2018 ESRD PPS base rate.

       Presently, there is considerable uncertainty regarding possible future changes in health care regulation, including the regulation of reimbursement for dialysis services. See "Risk Factors – We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results" which is included in our Annual Report on Form 20-F for the year ended December 31, 2016.

       On November 6, 2015, CMS published a final rule to update payment policies and rates under the ESRD PPS for renal dialysis services furnished on or after January 1, 2016. In this final rule, CMS clarified that once any non-oral drug in a category previously considered "oral only" is approved by the U.S. Food and Drug Administration ("FDA"), such category of drugs will cease to be considered oral only. CMS has designated a process for determining when a product is no longer an oral-only drug and for including new injectable and intravenous drugs into the PPS. Under this process, Amgen's new intravenous calcimimetic, Parsabiv™, which is used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, will be included in the ESRD PPS as of January 1, 2018. Because calcimimetics are used to treat a condition for which there is no current functional category in the ESRD PPS, both Parsabiv™ and its oral equivalent, Sensipar®, will be reimbursed separately by CMS for a two-year period beginning January 1, 2018, using a transitional drug add-on payment adjustment ("TDAPA"). We continue to prepare for the transition of this drug category under the TDAPA process. This type of transition has not occurred previously under the ESRD PPS and could have a material adverse effect on our business, results of operations and financial condition.

6

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       As a consequence of the pressure to decrease health care costs, government reimbursement rate increases in the U.S. have historically been limited and are expected to continue in this fashion. We have generally experienced stable reimbursement globally, including the balancing of unfavorable reimbursement changes in certain countries with favorable changes in other countries. However, any significant decreases in Medicare or commercial reimbursement rates or patient access to commercial insurance plans could have material adverse effects on our health care services business and, because the demand for dialysis products is affected by Medicare reimbursement, on our products business. To the extent that increases in operating costs that are affected by inflation, such as labor and supply costs, are not fully reflected in a compensating increase in reimbursement rates, our business and results of operations may be adversely affected.

Participation in new Medicare payment arrangements

       Twenty-four of our dialysis organizations participate in CMS's Comprehensive ESRD Care Model (the "Model"), which involves ESRD Seamless Care Organizations, or "ESCOs." This Model seeks to deliver better health outcomes for ESRD patients while lowering Medicare's costs. ESCOs that achieve the program's minimum quality thresholds and generate reductions in CMS's cost of care above certain thresholds for the ESRD patients covered by the ESCO will receive a share of the cost savings. Our ESCOs also share in the risk of cost increases and are obligated to reimburse CMS for a share of any such increases if actual costs rise above set thresholds. For six of our ESCOs, the Model commenced on October 1, 2015, and for the other eighteen ESCOs, the Model commenced on January 1, 2017. The initial agreement period for all ESCOs participating in the Model lasts through 2018. As originally specified, CMS and an ESCO would then have the option of extending the ESCO's agreement for an additional two years based on the ESCO's performance. CMS relied on authority granted by the Patient Protection and Affordable Care Act ("ACA") to implement this project. Congress is expected to continue to pursue efforts to repeal, replace or revise the ACA, and the posture of CMS in the Trump administration toward projects of this sort may differ from that of the Obama administration. Such changes may affect the project's future prospects in ways which we cannot predict.

       The Bundled Payments for Care Improvement ("BPCI") initiative is a CMS three-year pilot initiative involving bundled payments for the individual services, including acute inpatient hospital services, physician services, and post-acute services, furnished to Medicare beneficiaries during a single episode of illness or course of treatment. Our majority-owned subsidiary, Sound Inpatient Physicians, Inc. ("Sound"), commenced participation under BPCI in April 2015 in several markets. Under the BPCI, Sound has the ability to receive additional payments from CMS if its physicians are able to deliver quality care at a cost that is lower than certain established benchmarks, but it also has the risk of incurring financial penalties if it is unsuccessful. Should Sound fail to perform as required under its BPCI agreement, CMS may terminate Sound's participation in the BPCI program, in whole or in part. This project was also implemented under ACA authority and is subject to the same caveats and uncertainties noted above with respect to ESCOs.

       We have entered into various arrangements which involve taking risk for the complete care of certain ESRD patients in exchange for set payments. CMS approved our application to offer Medicare Advantage ESRD Chronic Special Needs Plans ("MA-CSNPs") in five states as of January 1, 2017. MA-CSNPs are Medicare Advantage health plans offered by private companies that contract with Medicare to provide patients with Medicare benefits. Enrolment in these plans is limited to special needs individuals with specific severe or disabling chronic conditions, such as ESRD. Our MA-CSNPs will provide services, including Care Coordination services, and receive capitated payments from Medicare for the complete care of enrolled ESRD patients.

7

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       We have also entered into sub-capitation and other shared savings arrangements with certain Medicare Advantage plans under which we assume risk in providing care to the plans' ESRD patients (those patients that develop ESRD while they are plan members) while paid on a per patient per month basis. The 21^st Century Cures Act, enacted December 13, 2016, removes the prohibition that previously barred individuals who already have ESRD from enrolling in a Medicare Advantage plan beginning 2021. We anticipate that this provision may present us with expanded business opportunities, but we cannot quantify its impact on our business at this time.

Company Structure

       Our operating segments are the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment. The operating segments are determined based upon how we manage our businesses with geographical responsibilities. All segments are primarily engaged in providing health care services and the distribution of products and equipment for the treatment of ESRD and other extracorporeal therapies. Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate IFRS measures are revenue, operating income and operating income margin. We do not include income taxes as we believe this is outside the segments' control. Financing is a corporate function which our segments do not control. Therefore, we do not include interest expense relating to financing as a segment measurement. Similarly, we do not allocate certain costs which relate primarily to certain headquarters' overhead charges, including accounting and finance, because we believe that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement related to production are centrally managed at Corporate. Global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment according to IFRS 8. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenue for the product transfers and their elimination are recorded as Corporate activities (See Note 14 of the Notes to Consolidated Financial Statements (unaudited) "Segment and Corporate Information" found elsewhere in this report). Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but accounted for as Corporate. Accordingly, all of these items are excluded from our analysis of segment results which are discussed below in the discussion of our consolidated results of operations.

II. Discussion of Measures

Non-IFRS Measures

       Certain key performance indicators and other financial information, as well as discussions and analyses, set out in this report include measures which are not defined by IFRS (Non-IFRS). We believe this information, along with comparable IFRS measurements, is useful to our investors as it provides a basis for measuring our performance. Non-IFRS financial measures should not be viewed or interpreted as a substitute for financial information presented in accordance with IFRS. Wherever appropriate, we provide reconciliations to the most directly comparable IFRS measures.

8

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Constant Currency

       Some key performance indicators and other financial measures used in this report such as changes in revenue, operating income and net income attributable to shareholders of FMC-AG & Co. KGaA include the impact of translating local currencies to our reporting currency for financial reporting purposes. We calculate these non-IFRS financial measures at constant exchange rates in our filings to show changes in our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-euro) currency are translated into euro at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. The single quarter, excluding the first quarter, results are calculated as the variance between the current year-to-date results less the preceding quarter's year-to-date which makes the single quarter subject to further foreign exchange fluctuation. This resulting percentage is a non-IFRS measure referring to a change as a percentage at constant currency. These currency-adjusted financial measures are identifiable by the designated terms "Constant Exchange Rates" or "Constant Currency."

       We believe that the measures at Constant Currency (Non-IFRS) are useful to investors, lenders and other creditors because such information enables them to gauge the impact of currency fluctuations on our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items from period to period. However, we also believe that the usefulness of data on Constant Currency period-over-period changes is subject to limitations, particularly if the currency effects that are eliminated constitute a significant element of our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA or other items and significantly impact our performance. We therefore limit our use of Constant Currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into euro. We do not evaluate our results and performance without considering both Constant Currency period-over-period changes in non-IFRS revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items and changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We caution the readers of this report to follow a similar approach by considering data on Constant Currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from IFRS measures next to the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items. As the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

Delivered EBIT

       As a result of the significance of noncontrolling interest holders in our operations, we believe a measure that is meaningful to investors is operating income less noncontrolling interests ("Delivered EBIT"). Delivered EBIT approximates the operating income attributable to the shareholders of FMC-AG & Co. KGaA. As such, we believe that operating income, or EBIT, is the closest comparable

9

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

IFRS measure. Below is a table showing the reconciliation of Operating Income to Delivered EBIT for each of our reporting segments:

Delivered EBIT Reconciliation
in € millions
	Three months ended September 30				Nine months ended September 30
	2017		2016		2017		2016
Total
Operating income (EBIT)	609		611		1,843		1,679
less noncontrolling interests	(62	)	(65	)	(199	)	(195	)
Delivered EBIT	547		546		1,644		1,484
North America
Operating income (EBIT)	483		490		1,478		1,348
less noncontrolling interests	(59	)	(63	)	(192	)	(189	)
Delivered EBIT	424		427		1,286		1,159
Dialysis
Operating income (EBIT)	437		460		1,424		1,289
less noncontrolling interests	(51	)	(59	)	(169	)	(169	)
Delivered EBIT	386		401		1,255		1,120
Care Coordination
Operating income (EBIT)	46		30		54		59
less noncontrolling interests	(8	)	(4	)	(23	)	(20	)
Delivered EBIT	38		26		31		39
EMEA
Operating income (EBIT)	106		113		333		354
less noncontrolling interests	(1	)	(1	)	(2	)	(2	)
Delivered EBIT	105		112		331		352
Asia-Pacific
Operating income (EBIT)	77		76		237		202
less noncontrolling interests	(2	)	(1	)	(5	)	(4	)
Delivered EBIT	75		75		232		198
Dialysis
Operating income (EBIT)	68		76		222		202
less noncontrolling interests	(2	)	(1	)	(5	)	(4	)
Delivered EBIT	66		75		217		198
Care Coordination
Operating income (EBIT)	9		-		15		-
less noncontrolling interests	0		-		0		-
Delivered EBIT	9		-		15		-
Latin America
Operating income (EBIT)	18		18		45		42
less noncontrolling interests	0		0		0		0
Delivered EBIT	18		18		45		42

EBITDA

       EBITDA (earnings before interest, tax, depreciation and amortization expenses) was approximately €2,397 million, 17.9% of revenue for the nine-months period ended September 30, 2017,

10

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

and €2,192 million, 18.0% of revenue for the same period of 2016. EBITDA is the basis for determining compliance with certain covenants contained in our Amended 2012 Credit Agreement or may be relevant in other major financing arrangements. You should not consider EBITDA to be an alternative to net earnings determined in accordance with IFRS or to cash flow from operations, investing activities or financing activities. In addition, not all funds depicted by EBITDA are available for management's discretionary use. For example, a substantial portion of such funds are subject to contractual restrictions and functional requirements for debt service, to fund necessary capital expenditures and to meet other commitments from time to time as described in more detail elsewhere in this report. EBITDA, as calculated, may not be comparable to similarly titled measures reported by other companies. A reconciliation of EBITDA to cash flow provided by (used in) operating activities, which we believe to be the most directly comparable IFRS financial measure, is calculated as follows:

Reconciliation of EBITDA to net cash provided by (used in) operating activities
in € millions
	For the nine months ended September 30,
	2017		2016
Total EBITDA	2,397		2,192
Interest expense (net of interest income)	(274	)	(276	)
Income tax expense	(484	)	(427	)
Change in deferred taxes, net	(46	)	(44	)
Changes in operating assets and liabilities	67		(257	)
Compensation expense related to share-based plans	42		24
Other items, net	(38	)	(52	)
Net cash provided by (used in) operating activities	1,664		1,160

Debt/EBITDA

       The ratio of debt to EBITDA is a key financial performance indicator used for overseeing the Company. To determine the total debt to EBITDA ratio, financial debt is compared to EBITDA for the last twelve months (adjusted for acquisitions and divestitures with a purchase price above a €50 million threshold as defined in the Amended 2012 Credit Agreement and non-cash charges). The Company's ratio of net debt to EBITDA is also used to determine pricing under the Amended 2012 Credit Agreement. See Note 8 of the Notes to Consolidated Financial Statements, "Long-term Debt and Capital Lease Obligations." We believe this ratio provides more reliable information regarding the extent to which we are able to meet our payment obligations than considering only the total amount of financial debt. The

11

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

following table shows the reconciliation of debt to EBITDA ratio as of September 30, 2017 and December 31, 2016.

Reconciliation of Debt to EBITDA
in € millions, except where otherwise specified
	September 30, 2017	December 31, 2016
Debt	7,662	8,132
Cash	729	709
Net Debt	6,933	7,423
Operating Income(1)(2)	2,583	2,398
Depreciation and amortization(1)(2)	747	710
Non-cash charges(2)	54	65
EBITDA(1)(2)	3,384	3,173
Debt/ EBITDA ratio(1)	2.3	2.6
Net Debt/ EBITDA ratio(1)	2.0	2.3

(1) Including adjustments for acquisitions and divestitures made within the reporting period with a purchase price above a €50 million threshold as defined in the Amended 2012 Credit Agreement.

(2) Last 12 months.

Return on Invested Capital ("ROIC")

       ROIC is the ratio of operating income, for the last twelve months, after tax ("Net Operating Profit After Tax" or "NOPAT") to average invested capital of the last five balance sheet dates and expresses how efficiently we allocate the capital under our control or how well we employ our capital with regard to a specific investment project which is presented in the table below. Additionally, the table below presents a

12

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

reconciliation of average invested capital to the IFRS measure total assets, which we believe to be the most directly comparable IFRS financial measure.

Reconciliation of Average Invested Capital and ROIC
in € millions, except where
otherwise specified
	September 30,		June 30,		March 31,		December 31,		September 30,
2017	2017		2017(2)		2017(2)		2016(2)		2016(2)
Total assets	24,250		24,715		26,106		25,917		24,469
Plus: Cumulative goodwill amortization	400		413		438		444		422
Minus: Cash and cash equivalents	(729	)	(721	)	(673	)	(711	)	(568	)
Minus: Loans to related parties	(127	)	(149	)	(199	)	(199	)	(151	)
Minus: Deferred tax assets	(333	)	(308	)	(311	)	(292	)	(264	)
Minus: Accounts payable	(518	)	(484	)	(505	)	(584	)	(481	)
Minus: Accounts payable to related parties	(224	)	(217	)	(271	)	(264	)	(233	)
Minus: Provisions and other current liabilities(1)	(2,763	)	(2,822	)	(2,790	)	(2,865	)	(2,572	)
Minus: Income tax payable	(251	)	(234	)	(276	)	(242	)	(228	)
Invested capital	19,705		20,193		21,519		21,204		20,394
Average invested capital as of September 30, 2017	20,603
Operating income(2),(3)	2,583
Income tax expense(3),(4)	(907	)
NOPAT(3)	1,676
ROIC in %	8.1%

2016	December 31, 2016		September 30, 2016(2)		June 30, 2016(2)		March 31, 2016(2)		December 31, 2015(2)
Total assets	25,504		24,074		24,108		23,262		23,680
Plus: Cumulative goodwill amortization	444		422		424		413		431
Minus: Cash and cash equivalents	(709	)	(566	)	(653	)	(466	)	(516	)
Minus: Loans to related parties	(199	)	(144	)	(152	)	(197	)	(182	)
Minus: Deferred tax assets	(291	)	(262	)	(248	)	(245	)	(261	)
Minus: Accounts payable	(576	)	(473	)	(518	)	(495	)	(585	)
Minus: Accounts payable to related parties	(264	)	(231	)	(196	)	(208	)	(141	)
Minus: Provisions and other current liabilities(1)	(2,857	)	(2,573	)	(2,583	)	(2,341	)	(2,470	)
Minus: Income tax payable	(242	)	(228	)	(228	)	(245	)	(216	)
Invested capital	20,810		20,019		19,954		19,478		19,740
Average invested capital as of December 31, 2016	20,000
Operating income(2)(3)	2,398
Income tax expense(3)(4)	(840	)
NOPAT(3)	1,558
ROIC in %	7.8%

(1) Including non-current provisions and variable payments outstanding for acquisitions and excluding pension liabilities and noncontrolling interests subject to put provisions.

13

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

(2) Including adjustments for acquisitions and divestitures made within the reporting period with a purchase price above a € 50 million threshold as defined in the Amended 2012 Credit Agreement.

(3) Last 12 months.

(4) Adjusted for noncontrolling partnership interests.

Cash flow measures

       Our consolidated statement of cash flows indicates how we generated and used cash and cash equivalents. When used in conjunction with the other primary financial statements, it provides information that helps us evaluate the changes in our net assets and our financial structure (including our liquidity and solvency). The net cash provided by (used in) operating activities is used to assess whether our business can generate the cash required to make replacement and expansion investments. Net cash provided by (used in) operating activities is impacted by the profitability of our business and development of working capital, principally receivables. The financial key performance indicator of net cash provided by (used in) operating activities in percentage of revenue shows the percentage of our revenue that is available in terms of financial resources.

       Free cash flow is the cash flow provided by (used in) operating activities after capital expenditures for property, plant and equipment but before acquisitions and investments. The key performance indicator used by management is free cash flow in percentage of revenue. This represents the percentage of revenue that is available for acquisitions, dividends to shareholders or the reduction of debt financing including required payments under our Amended 2012 Credit Agreement.

       The following table shows the significant cash flow key performance indicators for the nine months ended September 30, 2017 and 2016 and reconciles free cash flow and free cash flow as a % of revenue to Net cash provided by (used in) operating activities and Net cash provided by (used in) operating activities as a % of revenue, respectively:

Cash Flow Measures
in € millions, except where otherwise specified	For the nine months ended September 30,
	2017		2016
Revenue	13,355		12,153
Net cash provided by (used in) operating activities	1,664		1,160
Capital expenditures	(632	)	(670	)
Proceeds from sale of property, plant and equipment	18		12
Capital expenditures, net	(614	)	(658	)
Free cash flow	1,050		502
Net cash provided by (used in) operating activities as a % of revenue	12%		10%
Free cash flow as a % of revenue	8%		4%

14

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Business Metrics for Care Coordination

       The measures for the North America Segment and the Asia-Pacific Segment discussed below include current and future programs that we will be participating in and will be reflected in the discussion of our business. Currently, in our North America Segment, sub-capitation, BPCI, ESCO programs, MA-CSNPs and other shared savings programs are included within the Member Months and Medical Cost Under Management calculations below. In the future, there may be other programs that could be included in the metrics below. The Asia-Pacific Segment Care Coordination metric currently used for discussion purposes is patient encounters, which includes ambulant treatment services in day care hospitals, comprehensive and specialized health check-ups, inpatient and outpatient services for dialysis patients, vascular access and other chronic treatment services.

       These metrics may be developed further in future periods. Note that due to the timing required by CMS to review the BPCI and ESCO program data that we provide, estimates have been used in order to report these metrics in a timely manner. These metrics are neither IFRS measures nor non-IFRS measures, and are therefore not accompanied by or reconciled to IFRS measures.

Member Months Under Medical Cost Management

       In our North America Segment, Member months under medical cost management is calculated by multiplying the number of members who are included in value-based reimbursement programs, such as Medicare Advantage plans or other value-based programs in the U.S., by the corresponding number of months these members participate in those programs ("Member Months"). In the aforementioned programs, we are assuming the risk of generating savings. The financial results will be recorded in earnings as our performance is determined. The membership offerings within Care Coordination are sub-capitation arrangements, MA-CSNPs, ESCO and BPCI programs as well as other shared savings programs. An increase in patient membership may indicate future earnings or losses as our performance is determined through these managed care programs.

Medical Cost Under Management

       In our North America Segment, Medical cost under management represent the management of medical costs associated with our patient membership in value-based programs. For ESCO, BPCI and other shared savings programs, this is calculated by multiplying the Member Months in each program by the benchmark of expected medical cost per member per month. The sub-capitation and MA-CSNPs calculation multiplies the premium per member of the program per month by the number of Member Months associated with the plan, as noted above.

Care Coordination Patient Encounters

       Care Coordination patient encounters represents the total patient encounters and procedures conducted by certain of our Care Coordination activities and, we believe, is an indicator of the revenue generated. Specifically, Care Coordination patient encounters in the North America Segment is the sum of all encounters and procedures completed during the period by Sound, MedSpring Urgent Care Centers, Azura Vascular Care, and National Cardiovascular Partners, the trade name of Laurus Healthcare L.P., as well as patients in our Fresenius Medical Care Rx Bone Mineral Metabolism ("Rx BMM") program.

15

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

III. Results of operations, financial position and net assets

       The following sections summarize our results of operations, financial position and net assets as well as key performance indicators by reporting segment and Corporate for the periods indicated. We prepared the information using a management approach, consistent with the basis and manner in which management internally disaggregates financial information to assist in making internal operating decisions and evaluating management performance.

Results of operations

Segment data (including Corporate)
in € millions	For the three months ended September 30,				For the nine months ended September 30,
	2017		2016		2017		2016
Total revenue
North America	3,115		3,050		9,715		8,828
EMEA	632		605		1,888		1,776
Asia-Pacific	411		383		1,206		1,074
Latin America	175		172		535		466
Corporate	3		1		11		9
Total	4,336		4,211		13,355		12,153
Operating income
North America	483		490		1,478		1,348
EMEA	106		113		333		354
Asia-Pacific	77		76		237		202
Latin America	18		18		45		42
Corporate	(75	)	(86	)	(250	)	(267	)
Total	609		611		1,843		1,679
Interest income	12		8		35		34
Interest expense	(98	)	(98	)	(309	)	(310	)
Income tax expense	(152	)	(152	)	(484	)	(427	)
Net Income	371		369		1,085		976
Less: Net Income attributable to noncontrolling interests	(62	)	(65	)	(199	)	(195	)
Net Income attributable to shareholders of FMC-AG & Co. KGaA	309		304		886		781

       Revenue and operating income generated in countries outside the eurozone are subject to currency fluctuations. The three and nine months ended September 30, 2017 and 2016 were negatively impacted by the development of the euro against the U.S. dollar. For the respective three- and nine-months period ended September 30, 2017, approximately 72% and 73% of revenue and approximately 79% and 80% of operating income were generated in U.S. dollars.

16

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Three months ended September 30, 2017 compared to three months ended September 30, 2016

Consolidated Financials

Key Indicators for Consolidated Financial Statements
in € millions, except where otherwise specified	For the three months ended		Change in %
	September 30		As	Constant
	2017	2016	reported	Currency(1)
Revenue	4,336	4,211	3%	8%
Health Care Services	3,532	3,438	3%	8%
Health Care Products	804	773	4%	8%
Number of dialysis treatments	12,205,278	11,833,493	3%
Same market treatment growth in %	2.2%	3.0%
Gross profit as a % of revenue	32.8%	33.6%
Selling, general and administrative costs as a % of revenue	18.5%	18.8%
Operating income	609	611	0%	4%
Operating income margin in %	14.0%	14.5%
Delivered EBIT(2)	547	546	0%	5%
Net income attributable to shareholders of FMC-AG & Co. KGaA	309	304	2%	6%
Basic earnings per share	1.01	0.99	1%	6%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

       Health care services revenue increased by 3%, including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care services revenue increased by 8% driven by increases in organic revenue per treatment (4%), growth in same market treatments (2%) and contributions from acquisitions (2%).

       Dialysis treatments increased by 3% as a result of growth in same market treatments (2%) and contributions from acquisitions (1%).

       At September 30, 2017, we owned, operated or managed (excluding those managed but not consolidated in the U.S.) 3,714 dialysis clinics compared to 3,579 dialysis clinics at September 30, 2016. During the three months ended September 30, 2017, we acquired 12 dialysis clinics, opened 23 dialysis clinics and combined or closed 11 clinics. The number of patients treated in dialysis clinics that we own, operate or manage (excluding patients of dialysis clinics managed but not consolidated in the U.S.) increased by 4% to 317,792 at September 30, 2017 from 306,366 at September 30, 2016.

17

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       Health care product revenue increased by 4%, including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care product revenue increased by 8%. Dialysis product revenue increased by 3% including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, dialysis product revenue increased by 7% due to higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care treatments. Non-dialysis product revenue increased by 58% to €19 million from €12 million with no foreign currency translation effects. The increase of 58% was due to the acquisition of Xenios AG, which operates in the area of acute cardiopulmonary products ("Xenios").

       The decrease period over period in the gross profit margin was 0.8 percentage points with virtually no impact from foreign currency translation in the current period. The decrease primarily reflects reduced margins in the North America Segment, the EMEA Segment and the Asia-Pacific Segment. The gross profit margin decrease in the North America Segment was mainly due to higher costs in our pharmacy services business, cost effects net of anticipated recoveries from natural disasters ("Natural Disaster Costs"), the impact from lower revenue for vascular services, and higher personnel expense, partially offset by lower costs for health care supplies, the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services as well as increased earnings recognized related to ESCOs. The gross profit margin decrease in the EMEA Segment was driven by unfavorable foreign currency transaction effects, an unfavorable impact from acquisitions and pressure on reimbursement in some countries. The gross profit margin decrease in the Asia-Pacific Segment was due to an unfavorable mix effect related to acquisitions with lower margins as well as unfavorable foreign currency transaction effects, partially offset by a favorable impact from business growth, mainly in China.

       The decrease period over period in the selling, general and administrative ("SG&A") expenses as a percentage of revenue was 0.3 percentage points with virtually no impact from foreign currency translation in the current period. The decrease was primarily driven by decreases in the North America Segment and the Asia-Pacific Segment, partially offset by an increase in the Latin America Segment. The decrease in the North America Segment was mainly driven by the impact from higher revenue, the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services, the prior year cost impact related to the vesting of long-term incentive plan grants and increased earnings recognized related to ESCOs, partially offset by higher bad debt expense. The decrease in the Asia-Pacific Segment was due to favorable foreign currency transaction effects and a favorable impact from acquisitions. The increase in the Latin America Segment was driven by higher overhead costs as well as unfavorable foreign currency transaction effects, partially offset by reimbursement rate increases which mitigated inflationary cost increases

       Research and development expenses decreased by 29% to €28 million from €40 million. The decrease period over period, as a percentage of revenue, of 0.3 percentage points largely driven by capitalized development costs and lower project costs, partially offset by expenses incurred related to the development of cardiopulmonary products at Xenios and an increased project portfolio.

       Income from equity method investees decreased by 49% to €13 million from €26 million. The decrease was primarily driven by lower income from Vifor Fresenius Medical Care Renal Pharma Ltd., an entity in which we have ownership of 45%, due to increased costs to support the launch and development of new projects as well as the impact of contractually related adjustments in 2016.

18

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       The decrease period over period in the operating income margin was 0.5 percentage points with virtually no impact from foreign currency translation in the current period. The decrease was largely driven by decreased gross profit margin and a decrease in income from equity method investees, partially offset by decreases in SG&A and research and development expenses, as a percentage of revenue, as discussed above. Excluding Natural Disaster Costs of approximately €12 million, operating income margin decreased by 0.1 percentage point to 14.4% from 14.5%. Foreign currency translation effects represented a 0.2 percentage point increase in the operating income margin in the current period.

       Delivered EBIT remained stable including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, delivered EBIT increased by 5%, primarily a result of increased Constant Currency operating income.

       Net interest expense decreased by 4% to €86 million from €90 million, including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, net interest expense remained stable.

       Income tax expense remained stable at €152 million. The effective tax rate decreased to 29.0% from 29.2% for the same period of 2016. Excluding the tax effects of Natural Disaster Costs of approximately €4 million, the effective tax rate remained stable at 29.2% as compared to the prior period.

       Net income attributable to noncontrolling interests decreased by 5% to €62 million from €65 million, including a 6% negative impact resulting from foreign currency translation. At Constant Exchange Rates, net income attributable to noncontrolling interests remained relatively flat.

       Net income attributable to shareholders of FMC-AG & Co. KGaA increased by 2% to €309 million from €304 million including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, net income attributable to shareholders of FMC-AG & Co. KGaA increased by 6% driven by the combined effects of the items discussed above. Excluding (i) the effects of approximately €2 million net of tax related to the agreement with the United States Departments of Veterans Affairs and Justice for reimbursement for services performed during the period of January 2009 through February 15, 2011 ("VA Agreement") and (ii) Natural Disaster Costs of approximately €8 million, net of tax, net income attributable to shareholders of FMC-AG & Co. KGaA, excluding the items above, increased by 5%, including a 3% negative impact resulting from foreign currency translation. At Constant Exchange Rates, excluding the items above, the increase in net income attributable to shareholders of FMC-AG & Co. KGaA was 8%.

       Basic earnings per share increased by 1%, including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, basic earnings per share increased by 6%. The average weighted number of shares outstanding for the period was approximately 306.6 million in 2017 (306.0 million in 2016).

       We employed 113,648 people (full-time equivalents) as of September 30, 2017 compared to 108,851 as of September 30, 2016, an increase of 4%, primarily due to organic growth in our business and acquisitions.

       The following discussions pertain to the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment and the measures we use to manage these segments.

19

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

North America Segment

Key Indicators and Business Metrics for North America Segment
in € millions, except where otherwise specified	For the three months ended		Change in %
	September 30		As		Constant
	2017	2016	Reported		Currency(1)
Total North America Segment
Revenue	3,115	3,050	2%		8%
Health Care Services	2,904	2,841	2%		8%
Health Care Products	211	209	1%		6%
Operating income	483	490	(1%	)	4%
Operating income margin in %	15.5%	16.1%
Delivered EBIT(2)	424	427	(1%	)	4%
Dialysis
Revenue	2,410	2,462	(2%	)	4%
Number of Dialysis treatments	7,528,893	7,330,325	3%
Same market treatment growth in %	2.4%	2.7%
Operating income	437	460	(5%	)	0%
Operating income margin in %	18.1%	18.7%
Delivered EBIT(2)	386	401	(4%	)	1%
Care Coordination
Revenue	705	588	20%		26%
Operating income	46	30	53%		53%
Operating income margin in %	6.6%	5.1%
Delivered EBIT(2)	38	26	48%		47%
Member Months Under Medical Cost Management(3)(4)	142,364	97,197	46%
Medical Cost Under Management(3)(4)	908	643	41%		50%
Care Coordination Patient Encounters(3)(4)	1,786,534	1,411,251	27%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

(3) For further information on these metrics, please refer to the discussion above of our Care Coordination measures under "Business Metrics for Care Coordination"

(4) The metrics may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the BPCI and ESCO metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

Dialysis

Revenue

       Dialysis care revenue decreased by 2% to €2,199 million from €2,253 million, including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, dialysis care revenue

20

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

increased by 3% mainly due to growth in same market treatments (2%) and increases in organic revenue per treatment (1%).

       Dialysis treatments increased by 3% largely due to growth in same market treatments (2%) and contributions from acquisitions (1%). At September 30, 2017, 195,027 patients (4% increase from September 30, 2016) were being treated in the 2,363 dialysis clinics that we own or operate in the North America Segment, compared to 187,611 patients treated in 2,277 dialysis clinics at September 30, 2016.

       In the U.S., the average revenue per treatment, increased to $352 (€315 at Constant Exchange Rates) from $350 (€314). The development was mainly attributable to favorable impact from the increase in the ESRD PPS rate for 2017.

       Cost per treatment in the U.S., excluding Natural Disaster Costs of $2 per treatment, increased to $282 (€253 at Constant Exchange Rates) from $278 (€249). This development was largely driven by higher personnel expense, higher bad debt expense as well as increased property and other occupancy related costs, partially offset by lower cost for health care supplies.

       Health care product revenue increased by 1% including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care product revenue increased by 6% due to higher sales of peritoneal dialysis products, machines, renal pharmaceuticals, hemodialysis solutions and concentrates as well as dialyzers.

Operating Income Margin

       The decrease period over period in the dialysis operating income margin was 0.6 points with virtually no impact from foreign currency translation in the current period. The decrease was driven by Natural Disaster Costs, higher personnel expense and higher costs such as other supplies and rent expense, higher bad debt expense and lower income from equity method investees, partially offset by lower costs for health care supplies and the prior year cost impact related to the vesting of long-term incentive grants. Excluding Natural Disaster Costs of approximately €11 million, the dialysis operating income margin remained stable at 18.7% as compared to the prior period.

Delivered EBIT

       Dialysis delivered EBIT decreased by 4% including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, dialysis delivered EBIT increased by 1% mainly as the result of decreased income from noncontrolling interests driven by lower performance in entities in which we have less than 100% ownership.

21

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Care Coordination

Revenue

       Care Coordination revenue increased by 20%, including a 6% negative impact resulting from foreign currency translation. At Constant Exchange Rates, Care Coordination revenue increased by 26% driven by increases in organic revenue growth (20%) and contributions from acquisitions (6%).

Operating Income Margin

       The increase period over period in the Care Coordination operating income margin was 1.5 percentage points. Foreign currency translation effects represented 0.4 percentage points of the increase. At Constant Exchange Rates, the increase was mainly driven by the impact from higher revenue, the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services, increased earnings recognized related to ESCOs and the impact from the improved margin contributions for laboratory services, partially offset by higher bad debt expense, the impact from lower revenue for vascular services and increased costs for pharmacy services. Excluding Natural Disaster Costs of approximately €1 million, Care Coordination operating income margin increased to 6.7% from 5.1% in the comparable period. Foreign currency translation effects represented 0.3 percentage points of the increase in the current period.

Delivered EBIT

       Care Coordination delivered EBIT increased by 48%. Foreign currency translation effects represented 1% of the increase. At Constant Exchange Rates, Care Coordination delivered EBIT increased by 47% mainly as the result of increased operating income, partially offset by increased income from noncontrolling interests.

Care Coordination Business metrics

       The increase in member months under medical cost management was primarily attributable to an increase in our participation in ESCO programs from 6 to 24 ESCOs in 2017 as well as the addition of new payer shared savings and sub-capitation agreements, partially offset by a decrease in BPCI due to our voluntary elimination of certain non-performing risks from our BPCI portfolio. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

       Care Coordination's medical cost under management increased by 41%, including a 9% negative impact resulting from foreign currency translation. At Constant Exchange Rates, Care Coordination's medical cost under management increased by 50% primarily attributable to an increase in our participation in ESCO programs from 6 to 24 ESCOs in 2017 as well as the addition of new payer shared savings and sub-capitation agreements, partially offset by a decrease in BPCI due to our voluntary elimination of certain non-performing risks from our BPCI portfolio. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

       The increase in patient encounters was primarily driven by increased encounters for hospital related physician services. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

22

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

EMEA Segment

Key Indicators for EMEA Segment
in € millions, except where otherwise specified	For the three months ended		Change in %
	September 30		As		Constant
	2017	2016	Reported		Currency(1)
Revenue	632	605	5%		6%
Health Care Services	311	300	4%		5%
Health Care Products	321	305	5%		7%
Number of dialysis treatments	2,375,370	2,281,346	4%
Same market treatment growth in %	2.7%	3.8%
Operating income	106	113	(5%	)	(6%	)
Operating income margin in %	16.8%	18.6%
Delivered EBIT(2)	105	112	(6%	)	(6%	)

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

Revenue

       Health care service revenue increased by 4%, including a 1% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care service revenue increased by 5% as a result of growth in same market treatments (3%) and contributions from acquisitions (3%), partially offset by decreases in organic revenue per treatment (1%).

       Dialysis treatments increased by 4% mainly due to growth in same market treatments (3%) and contributions from acquisitions (2%), partially offset by the effect of closed or sold clinics (1%). As of September 30, 2017, we had 61,983 patients (5% increase from September 30, 2016) being treated at the 732 dialysis clinics that we own, operate or manage in the EMEA Segment compared to 59,233 patients treated at 701 clinics at September 30, 2016.

       Health care product revenue increased by 5%, including a 2% negative impact resulting from foreign exchange currency translation. At Constant Exchange Rates, health care product revenue increased by 7%. Dialysis product revenue increased by 3%, including a 2% negative impact resulting from foreign exchange currency translation. At Constant Exchange Rates, the increase of 5% in dialysis product revenue was due to higher sales of dialyzers, peritoneal dialysis products, products for acute care and renal pharmaceuticals, partially offset by lower sales of bloodlines. Non-Dialysis product revenue increased by 58% to €19 million from €12 million with virtually no impact from foreign currency translation effects. The increase was due to the acquisition of Xenios.

Operating Income Margin

       The decrease period over period in the operating income margin was 1.8 percentage points. Foreign currency translation effects represented a 0.2 percentage point increase in the operating income margin. At Constant Exchange Rates, operating income margin decreased mainly due to investments in Xenios,

23

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

unfavorable impacts from foreign currency transaction effects, lower income from equity method investees as a result of costs to support the launch and development of new projects as well as pressure on reimbursement in some countries, partially offset by a favorable impact from a legal settlement and lower bad debt expense.

Delivered EBIT

       Delivered EBIT decreased by 6% with virtually no impact from foreign exchange currency translation. The decrease at Constant Exchange Rates was primarily due to decreased operating income.

Asia-Pacific Segment

Key Indicators for Asia-Pacific Segment
in € millions, except where
otherwise specified	For the three months ended		Change in %
	September 30		As		Constant
	2017	2016	Reported		Currency(1)
Total Asia-Pacific Segment
Revenue	411	383	7%		14%
Health Care Services	194	173	12%		21%
Health Care Products	217	210	4%		9%
Operating income	77	76	1%		7%
Operating income margin in %	18.8%	19.9%
Delivered EBIT(2)	75	75	1%		6%
Dialysis
Revenue	359	383	(6%	)	0%
Number of dialysis treatments	1,076,929	1,006,992	7%
Same market treatment growth in %	2.4%	4.3%
Operating income	68	76	(11%	)	(6%	)
Operating income margin in %	18.9%	19.9%
Delivered EBIT(2)	66	75	(11%	)	(6%	)
Care Coordination
Revenue	52	-	Not applicable		Not applicable
Operating income	9	-	Not applicable		Not applicable
Operating income margin in %	17.7%	-
Delivered EBIT(2)	9	-	Not applicable		Not applicable
Care Coordination Patient Encounters(3)	229,318	-	Not applicable		Not applicable

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

(3) For further information on patient encounters, please refer to the discussion above of our Care Coordination measures under "Business Metrics for Care Coordination"

24

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       Key indicators are now provided separately for Dialysis and Care Coordination in the Asia-Pacific Segment due to an acquisition in Australia during the second quarter of 2017. Previously, there were immaterial amounts of services performed in Care Coordination within the Asia-Pacific Segment. We are presenting our Care Coordination activities in Asia-Pacific starting in 2017 as we are now able to appropriately rely on the data collected and presented during the period. For comparative purposes in our 2017 analysis, the Asia-Pacific Segment will be discussed on an overall segment basis. Care Coordination services include ambulant treatment services in day care hospitals where we provide treatment infrastructure, comprehensive and specialized health check-ups, inpatient and outpatient services for dialysis patients, vascular access and other chronic treatment services.

Revenue

       Health care service revenue increased by 12%, including a 9% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care service revenue increased by 21% as a result of contributions from acquisitions (16%), increases in organic revenue growth per treatment (3%) and growth in same market treatments (2%).

       Dialysis treatments increased by 7% mainly due to contributions from acquisitions (5%) and growth in same market treatments (2%). As of September 30, 2017, we had 30,151 patients (3% increase from September 30, 2016) being treated at the 389 dialysis clinics that we own, operate or manage in the Asia-Pacific Segment compared to 29,358 patients treated at 369 clinics at September 30, 2016.

       Health care product revenue increased by 4%, including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care product revenue increased by 9% as a result of increased sales of machines, dialyzers, bloodlines, and peritoneal dialysis products.

Operating Income Margin

       The decrease period over period in the operating income margin was 1.1 percentage points. Foreign currency translation effects represented a 0.2 percentage point increase in the operating income margin. At Constant Exchange Rates, the operating income margin decreased due to an unfavorable mix effect related to acquisitions with lower margins, unfavorable foreign currency transaction effects as well as lower income from equity method investees.

Delivered EBIT

       Delivered EBIT increased by 1%, including a 5% negative impact resulting from foreign currency translation. At Constant Exchange Rates, delivered EBIT increased by 6% mainly due to increased operating income at Constant Currency, partially offset by increased income from noncontrolling interests.

25

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Latin America Segment

Key Indicators for Latin America Segment
in € millions, except where otherwise specified	For the three months			Change in %
	ended September 30			As		Constant
	2017		2016	Reported		Currency(1)
Revenue	175		172	2%		11%
Health Care Services	123		124	(1%	)	11%
Health Care Products	52		48	9%		13%
Number of dialysis treatments	1,224,086		1,214,830	1%
Same market treatment growth in %	(0.2%	)	2.0%
Operating income	18		18	0%		6%
Operating income margin in %	10.2%		10.4%
Delivered EBIT(2)	18		18	0%		6%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non-IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non-IFRS Measures – Delivered EBIT" above.

Revenue

       Health care service revenue decreased by 1% including a 12% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care service revenue increased by 11% as a result of increases in organic revenue per treatment (9%) and contributions from acquisitions (2%).

       Dialysis treatments increased by 1% mainly due to contributions from acquisitions (2%), partially offset by the effect of closed or sold clinics (1%). As of September 30, 2017, we had 30,631 patients (an 2% increase from September 30, 2016) being treated at the 230 dialysis clinics that we own, operate or manage in the Latin America Segment compared to 30,164 patients treated at 232 clinics at September 30, 2016.

       Health care product revenue increased by 9% including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care product revenue increased by 13% primarily driven by higher sales of machines, bloodlines and hemodialysis solutions and concentrates, partially offset by lower sales of renal pharmaceuticals.

Operating Income Margin

       The decrease period over period in the operating income margin was 0.2 percentage points. Foreign currency translation effects represented a 0.3 percentage point increase in the operating income margin. At Constant Exchange Rates, the operating income margin decreased mainly due to unfavorable foreign currency transaction effects and higher overhead costs, partially offset by reimbursement rate increases which mitigated inflationary cost increases in the region.

26

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Delivered EBIT

       Delivered EBIT remained stable including a 6% negative impact resulting from foreign currency translation. At Constant Exchange Rates, delivered EBIT increased by 6% due to increased operating income at Constant Currency.

Nine months ended September 30, 2017 compared to nine months ended September 30, 2016

Consolidated Financials

Key Indicators for Consolidated Financial Statements
in € millions, except where otherwise specified	For the nine months		Change in %
	ended September 30		As	Constant
	2017	2016	reported	Currency(1)
Revenue	13,355	12,153	10%	10%
Health Care Services	10,950	9,910	11%	10%
Health Care Products	2,405	2,243	7%	7%
Number of dialysis treatments	35,960,897	34,654,614	4%
Same market treatment growth in %	2.6%	3.3%
Gross profit as a % of revenue	33.8%	33.4%
Selling, general and administrative costs as a % of revenue	19.6%	19.2%
Operating income	1,843	1,679	10%	10%
Operating income margin in %	13.8%	13.8%
Delivered EBIT(2)	1,644	1,484	11%	11%
Net income attributable to shareholders of FMC-AG & Co. KGaA	886	781	13%	14%
Basic earnings per share	2.89	2.56	13%	13%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non-IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non-IFRS Measures – Delivered EBIT" above.

       Health care services revenue increased by 11%. Foreign currency translation effects represented 1% of the increase. At Constant Exchange Rates, health care services revenue increased by 10% driven by increases in organic revenue per treatment (4%), growth in same market treatments (3%), contributions from acquisitions (2%) and an increase due to the VA Agreement of approximately €96 million as of September 30, 2017 (1%).

       Dialysis treatments increased by 4% as a result of growth in same market treatments (3%) and contributions from acquisitions (2%), partially offset by the effect of closed or sold clinics (1%).

       Health care product revenue increased by 7% with virtually no impact from foreign currency translation. Dialysis product revenue increased by 6% with virtually no impact from foreign currency translation. The increase in dialysis product revenue was due to higher sales of dialyzers, machines, peritoneal dialysis products, products for acute care treatments, renal pharmaceuticals, bloodlines and

27

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

hemodialysis solutions and concentrates. Non-dialysis product revenue increased by 64% to €60 million from €36 million with no foreign currency translation effects. The increase of 64% was due to the acquisition of Xenios.

       The increase period over period in the gross profit margin was 0.4 percentage points with virtually no impact from foreign currency translation in the current period. The increase primarily reflects an increase in the North America Segment. The gross profit margin increase in the North America Segment was mainly due to the VA Agreement, lower costs for health care supplies, higher revenue from commercial payors and a favorable impact due to the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services, partially offset by higher costs in our pharmacy services business, higher personnel expense and the impact from lower revenue for vascular services.

       The increase period over period in the selling, general and administrative ("SG&A") expenses as a percentage of revenue was 0.4 percentage points with virtually no impact from foreign currency translation in the current period. The increase was driven by increases in the North America Segment, the EMEA Segment and the Latin America Segment, partially offset by a decrease in the Asia-Pacific Segment and a favorable impact of varying margins across our four reporting segments. The increase in the North America Segment was mainly driven by higher bad debt expense, higher personnel expense and the change in fair value of subsidiary stock-based compensation, partially offset by the impact from higher revenue, the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services, a positive impact from income attributable to a consent agreement on certain pharmaceuticals and the impact from higher revenue resulting from the VA Agreement. The increase in the EMEA Segment was due to unfavorable effects from foreign currency transactions and acquisitions as well as higher overhead costs, partially offset by lower bad debt expense and a favorable impact from a legal settlement. The increase in the Latin America Segment was due to an unfavorable impact from foreign currency transaction effects and higher overhead costs, partially offset by reimbursement rate increases which mitigated inflationary cost increases in the region. The decrease in the Asia-Pacific Segment was due to the prior year's costs related to the change in the Management Board and a favorable impact from acquisitions.

       Research and development expenses decreased by 12% to €95 million from €108 million. The decrease period over period, as a percentage of revenue, was 0.2 percentage points, largely driven by capitalized development costs, partially offset by expenses incurred related to the development of cardiopulmonary products at Xenios and an increased project portfolio.

       Income from equity method investees decreased by 7% to €51 million from €55 million. The decrease was driven by lower income from Vifor Fresenius Medical Care Renal Pharma Ltd., an entity in which we have ownership of 45%, due to increased costs to support the launch and development of new projects.

       The period over period operating income margin remained stable with virtually no impact from foreign currency translation in the current period. Operating income margin remained stable as a result of increased gross profit margin and decreased research and development expenses, as a percentage of revenue, offset by increased SG&A, as a percentage of revenue, and decreased income from equity method investees, as discussed above. Excluding (i) the VA Agreement impact of approximately €88 million and (ii) Natural Disaster Costs of approximately €12 million, operating income margin decreased by 0.5 percentage points to 13.3% from 13.8% with virtually no impact from foreign currency translation.

28

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       Delivered EBIT increased by 11% with virtually no impact from foreign currency translation. The increase was largely a result of increased operating income at Constant Currency, partially offset by increased income from noncontrolling interests.

       Net interest expense decreased by 1% to €274 million from €276 million with virtually no impact from foreign currency translation. The decrease was largely due to the replacement of interest bearing Senior Notes, repaid in 2016 and 2017, by debt instruments at lower interest rates, partially offset by a higher average debt level.

       Income tax expense increased by 13% to €484 million from €427 million. The effective tax rate increased to 30.8% from 30.4% for the same period of 2016 mainly driven by a lower portion of tax-free income attributable to noncontrolling interests compared to income before taxes as well as higher tax expense related to the VA Agreement, approximately €34 million, as the tax rate in the U.S is higher than the average tax rate outside of the U.S. Excluding (i) the impact from the VA Agreement of approximately €34 million and (ii) the tax effects associated with Natural Disaster Costs of approximately €4 million, the effective tax rate remained stable at 30.4%.

       Net income attributable to noncontrolling interests increased by 2% to €199 million from €195 million with virtually no impact from foreign currency translation. The increase was primarily driven by the portion of the VA Agreement reimbursement of approximately €2 million attributable to and an increase of partner investments in clinics in which we have ownership of less than 100% as well as increased noncontrolling interest expense related to Care Coordination, partially offset by decreased noncontrolling interest expense related to dialysis in the North America Segment driven by lower operating income in less than wholly-owned clinics.

       Net income attributable to shareholders of FMC-AG & Co. KGaA increased by 13% to €886 million from €781 million, including a 1% negative impact resulting from foreign currency translation. At Constant Exchange Rates, the increase of 14% was driven by the combined effects of the items discussed above. Excluding (i) the impact of the VA Agreement of approximately €52 million, after tax, and (ii) Natural Disaster Costs of approximately €8 million, net income attributable to shareholders of FMC-AG & Co. KGaA, excluding the items above, increased by 8% with virtually no impact from foreign currency translation.

       Basic earnings per share increased by 13% with virtually no impact from foreign currency translation. The increase was primarily due to the increase in net income attributable to shareholders of FMC-AG & Co. KGaA described above. The average weighted number of shares outstanding for the period was approximately 306.4 million in 2017 (305.6 million in 2016).

       The following discussions pertain to the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment and the measures we use to manage these segments.

29

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

North America Segment

Key Indicators and Business Metrics for North America Segment
in € millions, except where otherwise specified	For the nine months		Change in %
	ended September 30		As		Constant
	2017	2016	Reported		Currency(1)
Total North America Segment
Revenue	9,715	8,828	10%		10%
Health Care Services	9,086	8,224	10%		10%
Health Care Products	629	604	4%		4%
Operating income	1,478	1,348	10%		9%
Operating income margin in %	15.2%	15.3%
Delivered EBIT(2)	1,286	1,159	11%		11%
Dialysis
Revenue	7,621	7,213	6%		5%
Number of Dialysis treatments	22,188,996	21,551,727	3%
Same market treatment growth in %	2.6%	3.2%
Operating income	1,424	1,289	10%		10%
Operating income margin in %	18.7%	17.9%
Delivered EBIT(2)	1,255	1,120	12%		12%
Care Coordination
Revenue	2,094	1,615	30%		29%
Operating income	54	59	(8%	)	(8%	)
Operating income margin in %	2.6%	3.6%
Delivered EBIT(2)	31	39	(20%	)	(20%	)
Member Months Under Medical Cost Management(3)(4)	441,996	281,964	57%
Medical Cost Under Management(3)(4)	2,990	1,824	64%		64%
Care Coordination Patient Encounters(3)(4)	5,069,546	4,057,022	25%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non-IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non-IFRS Measures – Delivered EBIT" above.

(3) For further information on these metrics, please refer to the discussion above of our Care Coordination measures under "Business Metrics for Care Coordination."

(4) The metrics may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the BPCI and ESCO metrics are subject to finalization by CMS, which may result in changes from previously reported metrics.

Dialysis

Revenue

       Dialysis care revenue increased by 6% to €6,992 million from €6,609 million with virtually no impact from foreign currency translation in the current period. The increase was mainly due to same market

30

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

treatment growth (3%), an increase related to the VA Agreement, approximately €96 million as of September 30, 2017 (1%), increases in organic revenue per treatment (1%) and contributions from acquisitions (1%).

       Dialysis treatments increased by 3% primarily due to same market treatment growth (3%) and contributions from acquisitions (1%), partially offset by a decrease in dialysis days (1%).

       In the U.S., the average revenue per treatment, excluding the VA Agreement of approximately $5 per treatment, increased to $353 (€316 at Constant Exchange Rates) from $350 (€313). The increase was mainly attributable to a favorable impact from commercial payors as well as a favorable impact from the increase in the ESRD PPS rate for 2017.

       Cost per treatment in the U.S., excluding Natural Disaster Costs of $0.60 per treatment, increased to $285 (€255 at Constant Exchange Rates) from $281 (€251). This increase was largely driven by higher personnel expense, increased property and other occupancy related costs as well as depreciation, partially offset by decreased costs for health care supplies.

       Health care product revenue increased by 4% with virtually no impact from foreign currency translation in the current period. The increase was driven by higher sales of peritoneal dialysis products, renal pharmaceuticals, hemodialysis solutions and concentrates as well as dialyzers, partially offset by lower sales of machines.

Operating Income Margin

       The increase period over period in the dialysis operating income margin was 0.8 percentage points with virtually no impact from foreign currency translation in the current period. The increase was largely driven by the VA Agreement, approximately €96 million, higher revenue from commercial payors and lower costs for health care supplies, partially offset by higher personnel expense and higher costs such as other supplies and rent expense. Excluding (i) the VA Agreement impact of approximately €96 million and (ii) Natural Disaster Costs of approximately €11 million, operating income margin decreased by 0.1 percentage points to 17.8% from 17.9% the prior period with virtually no impact from foreign currency translation.

Delivered EBIT

       Dialysis delivered EBIT increased by 12% with virtually no impact from foreign currency translation in the current period. The increase was the result of increased operating income.

Care Coordination

Revenue

       Care Coordination revenue increased by 30%. Foreign currency translation effects represented 1% of the increase. At Constant Exchange Rates, Care Coordination revenue increased by 29% driven by increases in organic revenue growth (22%) and contributions from acquisitions (7%).

31

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Operating Income Margin

       The decrease period over period in the Care Coordination operating income margin was 1.0 percentage point with virtually no impact from foreign currency translation in the current period. The decrease was mainly driven by higher bad debt expense, the impact from lower revenue for vascular services, increased costs for pharmacy services and the change in fair value of subsidiary stock based compensation, partially offset by the impact from higher revenue, the initial recognition in the calendar year 2017 of earnings from the BPCI initiative for hospital related physician services, increased earnings recognized related to ESCOs as well as the impact from the improved margin contribution for laboratory services. The Natural Disaster Costs of approximately €1 million had no effect on Care Coordination operating income margin.

Delivered EBIT

       Care Coordination delivered EBIT decreased by 20% with virtually no impact from foreign currency translation in the current period. The decrease was mainly a result of decreased operating income coupled with increased income from noncontrolling interests.

Care Coordination Business metrics

       The increase in member months under medical cost management was primarily attributable to an increase in our participation in ESCO programs from 6 to 24 ESCOs in 2017 as well as the addition of new payer shared savings and sub-capitation agreements, partially offset by a decrease in BPCI due to our voluntary elimination of certain non-performing risks from our BPCI portfolio. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

       Care Coordination's medical cost under management increased by 64% with virtually no impact from foreign currency translation in the current period. The increase was primarily attributable to an increase in our participation in ESCO programs from 6 to 24 ESCOs in 2017 as well as the addition of new payer shared savings and sub-capitation agreements, partially offset by a decrease in BPCI due to our voluntary elimination of certain non-performing risks from our BPCI portfolio. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

       The increase in patient encounters was primarily driven by increased encounters for hospital related physician services. See note 4 to the table "Key Indicators and Business Metrics for North America Segment," above.

32

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

EMEA Segment

Key Indicators for EMEA Segment
in € millions, except where otherwise specified	For the nine months ended		Change in %
	September 30		As		Constant
	2017	2016	Reported		Currency(1)
Revenue	1,888	1,776	6%		6%
Health Care Services	925	866	7%		6%
Health Care Products	963	910	6%		6%
Number of dialysis treatments	6,969,487	6,594,063	6%
Same market treatment growth in %	3.3%	3.7%
Operating income	333	354	(6%	)	(6%	)
Operating income margin in %	17.7%	19.9%
Delivered EBIT(2)	331	352	(6%	)	(6%	)

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

Revenue

       Health care service revenue increased by 7%. Foreign currency translation effects represented 1% of the increase. At Constant Exchange Rates, health care service revenue increased by 6% as a result of contributions from acquisitions (5%) and same market treatment growth (3%), partially offset by the effect of closed or sold clinics (1%) and decreases in organic revenue growth per treatment (1%).

       Dialysis treatments increased by 6% mainly due to contributions from acquisitions (3%) and same market treatment growth (3%).

       Health care product revenue increased by 6% with virtually no impact from foreign currency translation in the current period. Dialysis product revenue increased by 3% including negative foreign currency translation effects of 1%. At Constant Exchange Rates, dialysis product revenue increased by 4% due to higher sales of dialyzers, peritoneal dialysis products, products for acute care treatments and renal pharmaceuticals, partially offset by lower sales of hemodialysis solutions and concentrates. Non-Dialysis product revenue increased by 64% to €60 million from €36 million with virtually no foreign currency translation effects. The increase was due to the acquisition of Xenios.

Operating Income Margin

       The decrease period over period in the operating income margin was 2.2 percentage points with virtually no impact from foreign currency translation in the current period. The decrease was mainly due to unfavorable impacts from investments in Xenios and foreign currency transaction effects, higher overhead costs, pressure on reimbursement in some countries as well as lower income from equity method investees

33

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

as a result of increased costs to support the launch and development of new projects, partially offset by lower bad debt expense and a favorable impact from a legal settlement.

Delivered EBIT

       Delivered EBIT decreased by 6% with virtually no impact from foreign currency translation in the current period. The decrease was primarily due to decreased operating income at Constant Currency.

Asia-Pacific Segment

Key Indicators for Asia-Pacific Segment
in € millions, except where otherwise specified	For the nine months ended		Change in %
	September 30		As	Constant
	2017	2016	Reported	Currency(1)
Total Asia-Pacific Segment
Revenue	1,206	1,074	12%	13%
Health Care Services	553	482	15%	16%
Health Care Products	653	592	10%	11%
Operating income	237	202	17%	18%
Operating income margin in %	19.7%	18.8%
Delivered EBIT(2)	232	198	17%	18%
Dialysis
Revenue	1,095	1,074	2%	2%
Number of dialysis treatments	3,188,080	2,956,107	8%
Same market treatment growth in %	3.6%	4.9%
Operating income	222	202	10%	11%
Operating income margin in %	20.3%	18.8%
Delivered EBIT(2)	217	198	9%	10%
Care Coordination
Revenue	111	-	Not Applicable	Not Applicable
Operating income	15	-	Not Applicable	Not Applicable
Operating income margin in %	13.7%	-
Delivered EBIT(2)	15	-	Not Applicable	Not Applicable
Care Coordination Patient Encounters(3)	494,538	-	Not Applicable	Not Applicable

34

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

(3) For further information on patient encounters, please refer to the discussion above of our Care Coordination measures under "Business Metrics for Care Coordination."

       Key indicators are now provided separately for Dialysis and Care Coordination in the Asia-Pacific Segment due to an acquisition in Australia during the second quarter of 2017. Previously, there were immaterial amounts of services performed in Care Coordination within the Asia-Pacific Segment. We are presenting our Care Coordination activities in Asia-Pacific starting in 2017 as we are now able to appropriately rely on the data collected and presented during the period. For comparative purposes in our 2017 analysis, the Asia-Pacific Segment will be discussed on an overall segment basis. Care Coordination services include ambulant treatment services in day care hospitals where we provide treatment infrastructure, comprehensive and specialized health check-ups, inpatient and outpatient services for dialysis patients, vascular access and other chronic treatment services.

Revenue

       Health care service revenue increased by 15%, including a 1% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care service revenue increased by 16% as a result of contributions from acquisitions (11%), same market treatment growth (4%) and increases in organic revenue growth per treatment (1%).

       Dialysis treatments increased by 8% mainly due to contributions from acquisitions (5%) and same market treatment growth (4%), partially offset by the effect of closed or sold clinics (1%).

       Health care product revenue increased by 10%, including a 1% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care product revenue increased by 11% as a result of increased sales of dialyzers, machines, products for acute care treatments, bloodlines and peritoneal dialysis products.

Operating Income Margin

       The increase period over period in the operating income margin was 0.9 percentage points with virtually no impact from foreign currency translation in the current period. The increase was largely due to a favorable impact from business growth, mainly in China, and the prior year impact from costs associated with changes in the Management Board, partially offset by unfavorable impacts from foreign currency transaction effects and an unfavorable mix effect related to acquisitions with lower margins.

Delivered EBIT

       Delivered EBIT increased by 17%, including a 1% negative impact resulting from foreign currency translation. At Constant Exchange Rates, delivered EBIT increased by 18% mainly due to increased operating income, partially offset by increased income from noncontrolling interests.

35

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Latin America Segment

Key Indicators for Latin America Segment
in € millions, except where otherwise specified	For the nine months ended		Change in %
	September 30		As	Constant
	2017	2016	Reported	Currency(1)
Revenue	535	466	15%	15%
Health Care Services	386	338	14%	16%
Health Care Products	149	128	16%	10%
Number of dialysis treatments	3,614,334	3,552,717	2%
Same market treatment growth in %	0.9%	1.9%
Operating income	45	42	6%	10%
Operating income margin in %	8.4%	9.0%
Delivered EBIT(2)	45	42	6%	10%

(1) For further information on Constant Exchange Rates, see "– II. Discussion of Measures – Non – IFRS Measures – Constant Currency" above.

(2) For further information on Delivered EBIT, including a reconciliation of Delivered EBIT to Operating Income on a consolidated basis and for each of our operating segments, see "– II. Discussion of Measures – Non – IFRS Measures – Delivered EBIT" above.

Revenue

       Health care service revenue increased by 14%, including a 2% negative impact resulting from foreign currency translation. At Constant Exchange Rates, health care service revenue increased by 16% as a result of increases in organic revenue per treatment (14%), contributions from acquisitions (2%), and same market treatment growth (1%), partially offset by the effect of closed or sold clinics (1%).

       Dialysis treatments increased by 2% mainly due to contributions from acquisitions (2%) and same market treatment growth (1%), partially offset by the effect of closed or sold clinics (1%).

       Health care product revenue increased by 16%. Foreign currency translation effects represented 6% of the increase. At Constant Exchange Rates, health care product revenue increased by 10% driven by higher sales of dialyzers, machines, hemodialysis solutions and concentrates as well as bloodlines, partially offset by lower sales of peritoneal dialysis products.

Operating Income Margin

       The decrease period over period in the operating income margin was 0.6 percentage points, including a negative foreign currency translation effect of 0.2 percentage points in the current period. The decrease was mainly due to unfavorable foreign currency transaction effects, higher overhead costs and an unfavorable impact from manufacturing, partially offset by reimbursement rate increases which mitigated inflationary cost increases in the region.

36

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Delivered EBIT

       Delivered EBIT increased by 6%, including a 4% negative impact resulting from foreign currency translation. At Constant Exchange Rates, delivered EBIT increased by 10% due to increased operating income at Constant Currency.

Financial Position

Sources of Liquidity

       Our primary sources of liquidity are typically cash provided by operating activities, cash provided by short-term debt from third parties and related parties, as well as proceeds from the issuance of long-term debt and equity securities. We require this capital primarily to finance working capital needs, fund acquisitions and clinics in which we have ownership of less than 100%, develop free-standing renal dialysis clinics and other health care facilities, purchase equipment for existing or new renal dialysis clinics and production sites, repay debt and pay dividends (see "Net Cash Provided By (Used In) Investing Activities" and "Net Cash Provided By (Used In) Financing Activities" below).

       In our long-term financial planning, we focus primarily on the leverage ratio, defined as debt/EBITDA ratio, a non-IFRS measure, see "– II. Discussion of Measures – Non-IFRS Measures – Debt/EBITDA" above. At September 30, 2017 and December 31, 2016, the debt/EBITDA ratio was 2.3 and 2.6, respectively. At September 30, 2017 and December 31, 2016, the net debt/EBITDA ratio, was 2.0 and 2.3, respectively.

       At September 30, 2017, we had cash and cash equivalents of €729 million compared to €709 at December 31, 2016.

       Free cash flow (Net cash provided by (used in) operating activities, after capital expenditures, before acquisitions and investments) amounted to €1,050 million and €502 million for the nine months ended September 30, 2017 and September 30, 2016, respectively. Free cash flow is a non-IFRS measure. For a reconciliation to Net cash provided by (used in) operating activities, the most directly comparable IFRS measure, see "– II. Discussion of Measures – Non-IFRS Measures – Cash flow measures" above. Free cash flow in percent of revenue was 8% and 4% for nine months ended 2017 and 2016, respectively.

Net Cash Provided By (Used In) Operating Activities

       In the first nine months of 2017 and 2016, we generated net cash provided by operating activities of €1,664 million and €1,160 million, respectively. Net cash provided by operating activities in percent of revenue increased to 12% for the first nine months of 2017 as compared to 10% in the same period in 2016. Cash provided by operating activities is impacted by the profitability of our business, the development of our working capital, principally inventories, receivables and cash outflows that occur due to a number of specific items as discussed below. The increase in net cash provided by operating activities was largely driven by the payment from the United States Departments of Veterans Affairs and Justice for reimbursement, the impact of the 2016 discretionary contribution of €90 million to pension plan assets in the United States and the timing of other working capital items.

37

FRESENIUS MEDICAL CARE AG & Co. KGaA


Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

       The profitability of our business depends significantly on reimbursement rates. Approximately 82% of our revenue is generated by providing health care services, a major portion of which is reimbursed by either public health care organizations or private insurers. For the nine months ended September 30, 2017, approximately 34% of our consolidated revenue was attributable to U.S. federal health care benefit programs, such as Medicare and Medicaid reimbursement. Legislative changes could affect Medicare reimbursement rates for a significant portion of the services we provide, as well as the scope of Medicare coverage. A decrease in reimbursement rates or the scope of coverage could have a material adverse effect on our business, financial condition and results of operations and thus on our capacity to generate cash flow. See "I. Overview," above.

       We intend to continue to address our current cash and financing requirements using cash provided by operating activities, our existing and future credit agreements, issuances under the Commercial Paper Program (See Note 7 of the Notes to the Consolidated Financial Statements (unaudited), "Short-Term Debt and Short-Term Debt from Related Parties," included in this report) as well as the issuance of debt securities. In addition, when funds are required for acquisitions or to meet other needs, we expect to successfully complete long-term financing arrangements, such as the issuance of senior notes. We aim to preserve financial resources with a minimum €500 million of committed and unutilized credit facilities.

       Cash provided by operating activities depends on the collection of accounts receivable. Commercial customers and governments generally have different payment cycles. A lengthening of their payment cycles could have a material adverse effect on our capacity to generate cash flow. In addition, we could face difficulties in enforcing and collecting accounts receivable under some countries' legal systems and due to the economic conditions in some countries. Accounts receivable balances, net of valuation allowances, represented Days Sales Outstanding ("DSO") of 67 days at September 30, 2017, a decrease as compared to 70 days at December 31, 2016.

       DSO by segment is calculated by dividing the segment's accounts receivable, as converted to euro using the average exchange rate for the period presented, less any value added tax included in the receivables, by the average daily sales for the last twelve months of that segment, as converted to euro using the average exchange rate for the period. Receivables and sales are adjusted for amounts related to significant acquisitions made during the periods presented. The development of DSO by reporting segment is shown in the table below:

DSO by Reporting Segment
	September 30, 2017	December 31, 2016
North America days sales outstanding	52	54
EMEA days sales outstanding	105	101
Asia-Pacific days sales outstanding	97	105
Latin America days sales outstanding	130	143
FMC-AG & Co. KGaA average days sales outstanding	67	70

       The DSO decrease in the North America Segment was largely due to the impact of the VA Agreement, partially offset by an influx of accounts receivable following the assignment of new billing numbers for the 18 added ESCOs as of January 1, 2017. The DSO increase in the EMEA Segment was due to payment fluctuations in the region. The Asia-Pacific Segment's DSO decrease reflects an improvement of payment

38

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

collections in China. The Latin America Segment's DSO decrease reflects collections from public health care organizations in certain countries.

       Due to the fact that a large portion of our reimbursement is provided by public health care organizations and private insurers, we expect that most of our accounts receivable will be collectible.

Net Cash Provided By (Used In) Investing Activities

       Net cash used in investing activities was €1,011 million in the first nine months of 2017 compared to net cash used in investing activities of €831 million in the first nine months of 2016.

       Capital expenditures for property, plant and equipment, net of proceeds from sales of property, plant and equipment were €614 million and €658 million in the first nine months of 2017 and 2016, respectively. In the first nine months of 2017, capital expenditures were €358 million in the North America Segment, €145 million at Corporate, €65 million for the EMEA Segment, €24 million for the Asia-Pacific Segment and €22 million for the Latin America Segment. Capital expenditures in the first nine months of 2016 were €392 million in the North America Segment, €150 million at Corporate, €74 million for the EMEA Segment, €23 million for the Asia-Pacific Segment and €19 million for the Latin America Segment. The majority of our capital expenditures were used for maintaining existing clinics, equipping new clinics, maintenance and expansion of production facilities (primarily in the North America Segment, France and Germany) and capitalization of machines provided to our customers and for Care Coordination. Additionally, for the first nine months of 2017, construction in progress costs of €18 million were recognized at Corporate. Capital expenditures remained stable at approximately 5% of total revenue in the first nine months of 2017 as compared to the same period in 2016.

       In addition to the capital expenditures discussed above, we invested approximately €428 million of cash in the first nine months of 2017, €215 million in the North America Segment, €148 million in the Asia-Pacific Segment, €56 million in the EMEA Segment, €6 million at Corporate and €3 million in the Latin America Segment. The investments were mainly driven by acquisitions of dialysis clinics in the North America Segment and a Care Coordination acquisition in the Asia-Pacific Segment. Additionally, in the first nine months of 2017, we received €31 million from divestitures mainly related to the sale of a provider of outsourced clinical services in the North America Segment as well as available for sale financial assets. In the first nine months of 2016, we invested approximately €348 million cash, €272 million in the North America Segment, €49 million in the EMEA Segment , €12 million in the Asia-Pacific Segment, €9 million at Corporate and €6 million in the Latin America Segment. The investment was primarily driven by acquisitions of dialysis clinics, available for sale financial assets, acquisitions in our hospital related physician services business, a loan provided to an equity method investee in the North America Segment as well as the acquisition of dialysis clinics in the EMEA Segment. Additionally, in the first nine months of 2016, we received €173 million from divestitures, including approximately €100 million related to available for sale financial assets as well as approximately €72 million for the repayment of unsecured loans provided to an equity method investee in 2015 and 2016.

       We anticipate capital expenditures of €0.9 billion and expect to make acquisitions of approximately €0.6 billion in 2017. See "Outlook" below.

39

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Net Cash Provided By (Used In) Financing Activities

       Net cash used in financing activities was €555 million in the first nine months of 2017 compared to net cash used in financing activities of €279 million in the first nine months of 2016.

       In the first nine months of 2017, cash was mainly used in the repayments of long-term debt and capital lease obligations including the repayment of Senior Notes due in July 2017 and partial repayment of a USD term loan under the Amended 2012 Credit Agreement, distributions to noncontrolling interests and the payment of dividends, partially offset by proceeds from long-term debt and capital lease obligations including the issuance of a euro term loan under the Amended 2012 Credit Agreement as well as proceeds from short-term debt including draws under the commercial paper program. In the first nine months of 2016, cash was mainly used in the repayments of long-term debt and capital lease obligations, payment of dividends, distributions to noncontrolling interests, and repayments of short-term debt, partially offset by proceeds from short-term debt.

       On May 16, 2017, we paid a dividend with respect to 2016 of €0.96 per share (for 2015 paid in 2016 €0.80). The total dividend payment was €294 million as compared to €244 million in the prior year.

Balance Sheet Structure

       Total assets as of September 30, 2017 decreased by 5% to €24.3 billion from €25.5 billion as compared to December 31, 2016 including a 9% negative impact resulting from foreign currency translation. At Constant Exchange Rates, total assets increased by 4% to €26.5 billion from €25.5 billion.

       Current assets as a percent of total assets remained stable at 27% at September 30, 2017 as compared to December 31, 2016. The equity ratio, the ratio of our equity divided by total liabilities and shareholders' equity, increased to 44% at September 30, 2017 as compared to 43% at December 31, 2016. ROIC increased to 8.1% at September 30, 2017 as compared to 7.8% at December 31, 2016.

Management's General Assessment

       On a Constant Currency basis, we delivered a strong quarter despite the effects from several natural disasters. Please see the "Outlook" below for further information on management's assessment.

Report on Post-balance Sheet Date Events

       No further significant activities have taken place subsequent to the balance sheet date September 30, 2017 that have a material impact on the key figures and earnings presented. Currently, there are no other significant changes in the Company's structure, management, legal form or personnel.

40

FRESENIUS MEDICAL CARE AG & Co. KGaA

Interim Report of Financial Condition and Results of Operations
for the three and nine months ended September 30, 2017 and 2016

Outlook

       Below is a table showing our growth outlook for 2017. The outlook for 2017 is based on exchange rates prevailing at the beginning of 2017:

	Targets 2017
Revenue(1)	Growth 8 – 10% (at Constant Exchange Rates)
Operating income(1)	Growth ³ revenue growth
Delivered EBIT(1)	Growth ~ revenue growth
Net income growth(1)(2)	7 – 9% (at Constant Exchange Rates)
Basic earnings per share growth(1)(2)	based on development of net income
Capital Expenditures	€0.9 billion
Acquisitions and investments	~ €0.6 billion
Net cash provided by (used in) operating activities in % of revenue	> 10%
Free cash flow in % of revenue	> 4%
Debt/EBITDA Ratio	< 2.5
ROIC	³ 8.0%
Employees(3)	> 117,000
Research and development expenses	€130 – 140 million

(1) Targets 2017 exclude the effects of the agreement with the United States Departments of Veterans Affairs and Justice resolving reimbursement for services provided to veterans between January 2009 and February 2011 as well as Natural Disaster Costs.

(2) Net income attributable to shareholders of FMC AG & Co. KGaA

(3) Full-time equivalents

       Including the adjustments for capital expenditures, acquisitions and investments as well as research and development expenses, we confirm the outlook above for 2017 but anticipate we will be at the low-end of the guidance range on net income attributable to shareholders of FMC-AG & Co. KGaA.

Recently Issued Accounting Standards

       Refer to Note 1 of the Notes to the Consolidated Financial Statements (unaudited) in this report for information regarding recently issued accounting standards.

41

FRESENIUS MEDICAL CARE AG & Co. KGaA

Financial Statements

Consolidated Statements of Income

(unaudited)

Consolidated Statements of Income
in € thousands, except per share data
	For the three months ended September 30,				For the nine months ended September 30,
	2017		2016		2017		2016
Revenue:
Health Care Services	3,532,449		3,438,149		10,950,405		9,909,724
Health Care Products	803,253		773,454		2,404,438		2,243,516
	4,335,702		4,211,603		13,354,843		12,153,240
Costs of revenue:
Health Care Services	2,544,047		2,459,324		7,801,947		7,107,657
Health Care Products	367,425		337,543		1,042,002		982,974
	2,911,472		2,796,867		8,843,949		8,090,631
Gross profit	1,424,230		1,414,736		4,510,894		4,062,609
Operating (income) expenses:
Selling, general and administrative	801,232		790,862		2,623,908		2,330,745
Research and development	27,695		39,177		94,927		107,577
Income from equity method investees	(13,278	)	(26,001	)	(51,102	)	(54,715	)
Operating income	608,581		610,698		1,843,161		1,679,002
Other (income) expense:
Interest income	(12,384	)	(8,817	)	(35,201	)	(34,354	)
Interest expense	98,497		98,375		309,008		310,116
Income before income taxes	522,468		521,140		1,569,354		1,403,240
Income tax expense	151,529		151,950		483,617		427,284
Net income	370,939		369,190		1,085,737		975,956
Net income attributable to noncontrolling interests	61,663		64,928		199,601		194,805
Net income attributable to shareholders of FMC-AG & Co. KGaA	309,276		304,262		886,136		781,151
Basic earnings per share	1.01		0.99		2.89		2.56
Fully diluted earnings per share	1.01		0.99		2.89		2.55

See accompanying notes to unaudited Consolidated Financial Statements.

42

FRESENIUS MEDICAL CARE AG & Co. KGaA


Consolidated Statements of Comprehensive Income

(unaudited)

Consolidated Statements of Comprehensive Income
in € thousands
	For the three months ended September 30,				For the nine months ended September 30,
	2017		2016		2017		2016
Net income	370,939		369,190		1,085,737		975,956
Other comprehensive income (loss):
Components that may be reclassified subsequently to profit or loss:
Gain (loss) related to foreign currency translation	(334,486	)	(35,504	)	(1,096,035	)	(124,860	)
Gain (loss) related to cash flow hedges	4,840		7,231		23,012		18,266
Income tax (expense) benefit related to components of other comprehensive income that may be reclassified	(1,284	)	(2,163	)	(7,003	)	(5,370	)
Other comprehensive income (loss), net of tax	(330,930	)	(30,436	)	(1,080,026	)	(111,964	)
Total comprehensive income	40,009		338,754		5,711		863,992
Comprehensive income attributable to noncontrolling interests	30,188		60,826		90,694		175,783
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA	9,821		277,928		(84,983	)	688,209

See accompanying notes to unaudited Consolidated Financial Statements.

43

FRESENIUS MEDICAL CARE AG & Co. KGaA


Consolidated Balance Sheets

Consolidated Balance Sheets
in € thousands, except share data
	September 30, 2017		December 31, 2016
	(unaudited)		(audited)
Assets
Cash and cash equivalents	729,240		708,882
Trade accounts receivable less allowance for doubtful accounts of €529.384 in 2017 and €482,461 in 2016	3,172,500		3,343,819
Accounts receivable from related parties	137,320		209,465
Inventories	1,308,945		1,337,477
Other current assets	1,286,755		1,284,306
Total current assets	6,634,760		6,883,949
Property, plant and equipment, net	3,450,480		3,579,626
Intangible assets	685,755		803,120
Goodwill	12,141,049		12,955,574
Deferred taxes	333,553		291,394
Investment in equity method investees	633,280		598,154
Other non-current assets	371,481		391,723
Total non-current assets	17,615,598		18,619,591
Total assets	24,250,358		25,503,540
Liabilities
Accounts payable	518,422		575,556
Accounts payable to related parties	223,804		264,069
Current provisions and other current liabilities	2,748,619		3,036,708
Short-term debt	936,003		572,010
Short-term debt from related parties	3,015		3,000
Current portion of long-term debt and capital lease obligations	890,949		724,218
Income tax payable	124,914		123,336
Total current liabilities	5,445,726		5,298,897
Long-term debt and capital lease obligations, less current portion	5,832,349		6,832,886
Non-current provisions and other non-current liabilities	1,021,644		1,027,983
Pension liabilities	532,947		512,539
Income tax payable	126,120		118,182
Deferred taxes	618,551		661,921
Total non-current liabilities	8,131,611		9,153,511
Total liabilities	13,577,337		14,452,408
Shareholders' equity:
Ordinary shares, no par value, €1.00 nominal value, 385,913,972 shares authorized, 307,961,483 shares issued and 306,961,532 outstanding as of September 30, 2017 and 385,913,972 shares authorized, 307,221,791 issued and 306,221,840 outstanding as of December 31, 2016 respectively	307,961		307,222
Treasury stock, at cost	(50,993	)	(50,993	)
Additional paid-in capital	3,947,277		3,960,115
Retained earnings	6,761,154		6,085,876
Accumulated other comprehensive income (loss)	(1,295,682	)	(324,563	)
Total FMC-AG & Co. KGaA shareholders' equity	9,669,717		9,977,657
Noncontrolling interests	1,003,304		1,073,475
Total equity	10,673,021		11,051,132
Total liabilities and equity	24,250,358		25,503,540

See accompanying notes to unaudited Consolidated Financial Statements.

44

FRESENIUS MEDICAL CARE AG & Co. KGaA


Consolidated Statements of Cash Flows

(unaudited)

Consolidated Statements of Cash Flows
in € thousands
	For the nine months ended September 30,
	2017		2016
Operating activities
Net income	1,085,737		975,956
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	553,764		513,447
Change in deferred taxes, net	(46,115	)	(43,808	)
(Gain) loss on sale of fixed assets and investments	4,370		(2,772	)
Compensation expense related to share-based plans	42,213		24,228
Investments in equity method investees, net	(42,917	)	(49,945	)
Changes in assets and liabilities, net of amounts from businesses acquired:
Trade accounts receivable, net	(105,957	)	(241,854	)
Inventories	(71,270	)	(40,484	)
Other current and non-current assets	28,724		5,196
Accounts receivable from related parties	69,777		(17,456	)
Accounts payable to related parties	(31,635	)	90,696
Accounts payable, provisions and other current and non-current liabilities	430,427		232,162
Paid interest	(299,726	)	(309,884	)
Received interest	28,127		22,487
Income tax payable	516,609		452,046
Paid income taxes	(498,332	)	(449,886	)
Net cash provided by (used in) operating activities	1,663,796		1,160,129
Investing activities
Purchases of property, plant and equipment	(632,330	)	(669,810	)
Proceeds from sale of property, plant and equipment	18,346		12,172
Acquisitions and investments, net of cash acquired, and purchases of intangible assets	(427,872	)	(346,683	)
Proceeds from divestitures	30,746		173,029
Net cash provided by (used in) investing activities	(1,011,110	)	(831,292	)
Financing activities
Proceeds from short-term debt	437,160		733,463
Repayments of short-term debt	(60,601	)	(195,547	)
Proceeds from short-term debt from related parties	116,079		124,300
Repayments of short-term debt from related parties	(116,079	)	(53,200	)
Proceeds from long-term debt and capital lease obligations	583,994		202
Repayments of long-term debt and capital lease obligations	(995,351	)	(495,472	)
Increase (decrease) of accounts receivable securitization program	22,442		(45,691	)
Proceeds from exercise of stock options	39,100		42,776
Dividends paid	(293,973	)	(244,251	)
Distributions to noncontrolling interests	(320,676	)	(210,304	)
Contributions from noncontrolling interests	32,875		64,918
Net cash provided by (used in) financing activities	(555,030	)	(278,806	)
Effect of exchange rate changes on cash and cash equivalents	(77,298	)	9,559
Cash and cash equivalents:
Net increase (decrease) in cash and cash equivalents	20,358		59,590
Cash and cash equivalents at beginning of period	708,882		504,730
Cash and cash equivalents at end of period	729,240		564,320

See accompanying notes to unaudited Consolidated Financial Statements.

45

FRESENIUS MEDICAL CARE AG & Co. KGaA

Consolidated Statement of Shareholders' Equity

For the nine months ended September 30, 2017 and 2016 (unaudited)

Consolidated Statements of Shareholders' Equity
in € thousands, except share data
													Accumulated other comprehensive income (loss)						Total FMC-
	Ordinary Shares				Treasury Stock				Additional				Foreign						AG & Co. KGaA
	Number of shares		No par value		Number of shares		Amount		paid in capital		Retained earnings		currency translation		Cash Flow Hedges		Pensions		shareholders' equity		Noncontrolling interests		Total Equity
Balance at December 31, 2015	312,863,071		312,863		(7,548,951	)	(384,966	)	4,224,395		5,369,493		(364,636	)	(55,271	)	(232,311	)	8,869,567		936,024		9,805,591
Proceeds from exercise of options and related tax effects	827,252		827		-		-		36,247		-		-		-		-		37,074		-		37,074
Compensation expense related to stock options	-		-		-		-		20,692		-		-		-		-		20,692		-		20,692
Withdrawal of treasury stock	(6,549,000	)	(6,549	)	6,549,000		333,973		(327,424	)	-		-		-		-		-		-		-
Dividends paid	-		-		-		-		-		(244,251	)	-		-		-		(244,251	)	-		(244,251	)
Purchase/ sale of noncontrolling interests	-		-		-		-		11,113		-		-		-		-		11,113		64,141		75,254
Contributions from/ to noncontrolling interests	-		-		-		-		-		-		-		-		-		-		(159,481	)	(159,481	)
Noncontrolling interests subject to put provisions	-		-		-		-		-		(161,619	)	-		-		-		(161,619	)	-		(161,619	)
Net Income	-		-		-		-		-		781,151		-		-		-		781,151		194,805		975,956
Other comprehensive income (loss) related to:
Foreign currency translation	-		-		-		-		-		-		(112,882	)	1,359		5,685		(105,838	)	(19,022	)	(124,860	)
Cash flow hedges, net of related tax effects	-		-		-		-		-		-		-		12,896		-		12,896		-		12,896
Comprehensive income	-		-		-		-		-		-		-		-		-		688,209		175,783		863,992
Balance at September 30, 2016	307,141,323		307,141		(999,951	)	(50,993	)	3,965,023		5,744,774		(477,518	)	(41,016	)	(226,626	)	9,220,785		1,016,467		10,237,252
Balance at December 31, 2016	307,221,791		307,222		(999,951	)	(50,993	)	3,960,115		6,085,876		(26,019	)	(38,107	)	(260,437	)	9,977,657		1,073,475		11,051,132
Proceeds from exercise of options and related tax effects	739,692		739		-		-		37,491		-		-		-		-		38,230		-		38,230
Compensation expense related to stock options	-		-		-		-		13,257		-		-		-		-		13,257		-		13,257
Dividends paid	-		-		-		-		-		(293,973	)	-		-		-		(293,973	)	-		(293,973	)
Purchase/ sale of noncontrolling interests	-		-		-		-		(63,586	)			-		-		-		(63,586	)	29,500		(34,086	)
Contributions from/ to noncontrolling interests	-		-		-		-		-				-		-		-		-		(190,365	)	(190,365	)
Noncontrolling interests subject to put provisions	-		-		-		-		-		83,115		-		-		-		83,115		-		83,115
Net Income	-		-		-		-		-		886,136		-		-		-		886,136		199,601		1,085,737
Other comprehensive income (loss) related to:
Foreign currency translation	-		-		-		-		-		-		(1,000,829	)	97		13,604		(987,128	)	(108,907	)	(1,096,035	)
Cash flow hedges, net of related tax effects	-		-		-		-		-		-		-		16,009		-		16,009		-		16,009
Comprehensive income	-		-		-		-		-		-		-		-		-		(84,983	)	90,694		5,711
Balance at September 30, 2017	307,961,483		307,961		(999,951	)	(50,993	)	3,947,277		6,761,154		(1,026,848	)	(22,001	)	(246,833	)	9,669,717		1,003,304		10,673,021

See accompanying notes to unaudited Consolidated Financial Statements.

46

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

1.    The Company and Basis of Presentation

The Company

       Fresenius Medical Care AG & Co. KGaA ("FMC-AG & Co. KGaA" or the "Company"), a German partnership limited by shares (Kommanditgesellschaft auf Aktien) registered in the commercial registry of Hof an der Saale under HRB 4019, with its business address at Else-Kröner-Str. 1, 61352 Bad Homburg v. d. Höhe, is the world's largest kidney dialysis company, based on publicly reported sales and number of patients treated. The Company provides dialysis treatment and related dialysis care services to persons who suffer from end-stage renal disease ("ESRD"), as well as other health care services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. The Company's dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company's non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products and also sells dialysis products to other dialysis service providers. The Company describes certain of its other health care services as "Care Coordination." Care Coordination currently includes, but is not limited to, the coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician nephrology and cardiology services, health plan services, ambulatory surgery center services and urgent care services. Care Coordination also includes the coordinated delivery of emergency, intensivist and hospitalist physician services as well as transitional care which the Company refers to as "hospital related physician services." All of these Care Coordination services together with dialysis care and related services represent the Company's health care services.

       In these unaudited Consolidated Financial Statements, "FMC-AG & Co. KGaA," or the "Company" refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. "Fresenius SE" and "Fresenius SE & Co. KGaA" refer to Fresenius SE & Co. KGaA, a German partnership limited by shares resulting from the change of legal form of Fresenius SE (effective as of January 2011), a European Company (Societas Europaea) previously called Fresenius AG, a German stock corporation. "Management AG" and the "General Partner" refer to Fresenius Medical Care Management AG which is FMC-AG & Co. KGaA's general partner and is wholly owned by Fresenius SE. "Management Board" refers to the members of the management board of Management AG and, except as otherwise specified, "Supervisory Board" refers to the supervisory board of FMC-AG & Co. KGaA. The term "North America Segment" refers to the North America operating segment, the term "EMEA Segment" refers to the Europe, Middle East and Africa operating segment, the term "Asia-Pacific Segment" refers to the Asia-Pacific operating segment, and the term "Latin America Segment" refers to the Latin America operating segment. For further discussion of the Company's operating segments, see Note 14 "Segment and Corporate Information."

Basis of Presentation

       Since 1996, the Company filed with the U.S. Securities and Exchange Commission ("SEC") annual and interim reports containing Consolidated Financial Statements prepared in accordance with U.S. Generally Accepted Accounting Principles ("U.S. GAAP"), using the U.S. dollar as the Company's reporting currency. Since 2007, the Company has also been required by German and European law to prepare Consolidated Financial Statements in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union.

47

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       In 2007, the Company adopted IFRS 1 and began publishing Consolidated Financial Statements based upon IFRS as adopted by the European Union with the federal gazette in Germany. The Company's effective date of transition to IFRS was January 1, 2006. As required by IFRS 1, the Company has applied all IFRS standards and interpretations that were effective as of December 31, 2007, the reporting date for the first IFRS consolidated Financial Statements for the year ending December 31, 2007, consistently and retrospectively through the transition date.

       As of January 1, 2017, the consolidated financial statements and other financial information included in the Company's quarterly reports on 6-K have been, and commencing with its Annual Report on 20-F for 2017 the financial statements in our annual reports will be prepared solely in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"), using the euro as the Company's reporting currency, and the Company has discontinued publishing U.S. GAAP financial information. At September 30, 2017, there were no IFRS or International Financial Reporting Interpretation Committee ("IFRIC") interpretations as endorsed by the European Union relevant for interim reporting that differed from IFRS as issued by the IASB. As such, the accompanying condensed interim report complies with the requirements of International Accounting Standard ("IAS") 34, Interim Financial Reporting as well as with the rules concerning interim reporting as issued by the IASB.

       The preparation of Consolidated Financial Statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature.

       The results of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results of operations for the year ending December 31, 2017.

Recently Implemented Accounting Pronouncements

       The Company has prepared its Consolidated Financial Statements at September 30, 2017 in conformity with IFRS in force for the interim periods on January 1, 2017. In the first nine months of 2017, the Company did not apply any new standards which would be relevant for its business.

Recent Accounting Pronouncements Not Yet Adopted

       The IASB issued the following new standards which are relevant for the Company:

•

IFRS 15, Revenue from Contracts with Customers

•

IFRS 9, Financial Instruments

•

IFRS 16, Leases

48

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

•

Amendments to IAS 7, Statement of Cash Flows

•

IFRS 17, Insurance Contracts

       In May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers. This new standard specifies how and when companies reporting under IFRS will recognize revenue as well as providing users of financial statements with more informative and relevant disclosures. IFRS 15 supersedes IAS 18, Revenue, IAS 11, Construction Contracts and a number of revenue-related interpretations. While this standard applies to nearly all contracts with customers, the main exceptions are leases, financial instruments and insurance contracts. In September 2015, the IASB issued the amendment "Effective Date of IFRS 15", which defers the effective date of IFRS 15 by one year to fiscal years beginning on or after January 1, 2018. Earlier adoption is permitted. The Company decided that IFRS 15 will not be adopted early and is currently evaluating the impact of IFRS 15, in conjunction with all amendments to the standard, on its Consolidated Financial Statements. Based on findings the Company obtained so far, it expects differences from the current accounting mainly in the calculation of the transaction price for health care services provided. IFRS 15 requires the consideration of implicit price concessions when determining the transaction price. This will lead to a corresponding decrease of revenue from health care services and thus, the implicit price concessions will no longer be included in selling, general and administrative expenses as an allowance for doubtful accounts. The first analysis of this issue showed a decrease of revenue by approximately 2 - 3% without any effect on net income. A more detailed quantification of the impact of IFRS 15 is not yet possible. The Company expects to implement IFRS 15 using the cumulative effect method and is continuing to evaluate accounting policy options. The Company intends to apply IFRS 15 only to open contracts as of January 1, 2018.

       In July 2014, the IASB issued a new version of IFRS 9, Financial Instruments. This IFRS 9 version is considered the final and complete version, thus, mainly replacing IAS 39 as soon IFRS 9 is applied. It includes all prior guidance on the classification and measurement of financial assets and financial liabilities as well as hedge accounting and introduces requirements for impairment of financial instruments as well as modified requirements for the measurement categories of financial assets. The impairment provisions reflect a model that relies on expected losses (expected loss model). This model comprises a two stage approach. Upon recognition an entity shall recognize losses that are expected within the next 12 months. If credit risk deteriorates significantly, from that point in time, impairment losses shall amount to lifetime expected losses. The provisions for classification and measurement are amended by introducing an additional third measurement category for certain debt instruments. Such instruments shall be measured at fair value with changes recognized in other comprehensive income (fair value through other comprehensive income). The standard is accompanied by additional disclosure requirements and is effective for fiscal years beginning on or after January 1, 2018. Earlier adoption is permitted. The Company decided that IFRS 9 will not be adopted early and is currently evaluating the impact on its Consolidated Financial Statements. In accordance with IAS 39, the majority of the non-derivative financial assets are measured at amortized costs. The analysis on the business model and the contractual cash flow characteristics of each instrument is still ongoing. The requirements for the classification and measurement of non-derivative financial liabilities have not changed significantly. Thus, the Company expects a limited impact on its Consolidated Financial Statements. Derivatives not designated as hedging instruments will continue to be classified and measured at fair value through profit and loss.

       The Company intends to implement the simplified method to determine the provisions for risks from trade accounts receivable, receivables from lease contracts and capitalized contract costs according to IFRS 15. A quantification of the impact is not yet possible. Based on currently available information,

49

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

derivative financial instruments presently designated as hedging instruments are also qualified for hedge accounting according to the requirements of IFRS 9. The Company also evaluates accounting policy choices and transition methods of IFRS 9.

       In January 2016, the IASB issued IFRS 16, Leases, which supersedes the current standard on lease-accounting, IAS 17, as well as the interpretations IFRIC 4, SIC-15 and SIC-27. IFRS 16 significantly improves lessee accounting. For all leases, a lessee is required to recognize a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. Depreciation of the right-of-use asset and interest on the lease liability must be recognized in the income statement for every lease contract. Therefore, straight-line rental expenses will no longer be shown. The lessor accounting requirements in IAS 17 are substantially carried forward. The standard is effective for fiscal years beginning on or after January 1, 2019. Earlier application is permitted for entities that have also adopted IFRS 15 Revenue from Contracts with Customers. The Company decided that IFRS 16 will not be adopted early. The Company expects a balance sheet extension due to the on balance sheet recognition of right of use assets and liabilities for agreed lease payment obligations, currently classified as operating leases, resulting in particular from leased clinics and buildings. Based on a first impact analysis as of December 31, 2015, using certain assumptions and simplifications, the Company expects a financial debt increase of approximately €4,000,000. Referring to the consolidated statement of income, the Company expects an operating income improvement due to the split of rent expenses in depreciation and interest expenses, by having unchanged cash outflows. The Company also expects that its Leverage Ratio (debt as compared to EBITDA, Earnings before Interest, Taxes, Depreciation and Amortization, adjusted for acquisitions and divestitures made during the year with a purchase price above a €50,000 threshold as defined in the Amended 2012 Credit Agreement and non-cash charges) will increase by about 0.5. The impact on the Company will depend on the contract portfolio at the effective date, as well as the transition method. Based on a first impact analysis, the Company decided to apply the modified retrospective method. Currently, the Company is evaluating the accounting policy options of IFRS 16.

       In January 2016, the IASB issued amendments to IAS 7, Statement of Cash Flows. The amendments are intended to improve the information related to the change in a company's debt by providing additional annual disclosures. The standard is effective for fiscal years beginning on or after January 1, 2017. Earlier application is permitted. The Company will initially present the amendments to IAS 7 in the Consolidated Financial Statements as of December 31, 2017.

       In May 2017, the IASB issued IFRS 17, Insurance Contracts. IFRS 17 establishes principles for the recognition, measurement, presentation and disclosure related to the issuance of insurance contracts. IFRS 17 replaces IFRS 4, Insurance Contracts, which was brought in as an interim Standard in 2004. IFRS 4 permitted the use of national accounting standards for the accounting of insurance contracts under IFRS. As a result of the varied application for insurance contracts there was a lack of comparability among peer groups. IFRS 17 eliminates this diversity in practice by requiring all insurance contracts to be accounted for using current values. The frequent updates to the insurance values are expected to provide more useful information to users of financial statements. IFRS 17 is effective for fiscal years beginning on or after January 1, 2021. Earlier adoption is permitted for entities that have also adopted IFRS 9 Financial Instruments and IFRS 15 Revenue from Contracts with Customers. The Company is evaluating the impact of IFRS 17 on the Consolidated Financial Statements.

       In the Company's view, all other pronouncements issued by the IASB do not have a material impact on the Consolidated Financial Statements, as expected.

50

FRESENIUS MEDICAL CARE AG & Co. KGaA


Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

2.    Notes to the Consolidated Statements of Income

a)   Research and Development Expenses

       Research and development expenses of €94,927 for the nine months ended September 30, 2017 (for the nine months ended September 30, 2016: €107,577) include expenditure for research and non-capitalizable development costs as well as depreciation and amortization expenses related to capitalized development costs of €351 (for the nine months ended September 30, 2016: €620).

b)   Earnings per Share

       The following table contains reconciliations of the numerators and denominators of the basic and fully diluted earnings per share computations for 2017 and 2016:

Reconciliation of Basic and Diluted Earnings per Share
in € thousands, except share and per share data
	For the three months ended September 30,		For the nine months ended September 30,
	2017	2016	2017	2016
Numerator:
Net income attributable to shareholders of FMC-AG & Co. KGaA	309,276	304,262	886,136	781,151
Denominators:
Weighted average number of shares outstanding	306,572,494	305,972,432	306,447,106	305,602,983
Potentially dilutive shares	659,879	659,298	577,637	535,792
Basic earnings per share	1.01	0.99	2.89	2.56
Fully diluted earnings per share	1.01	0.99	2.89	2.55

       By resolution of the Company's annual general meeting on May 12, 2011, the Company was authorized to conduct a share buy-back program to repurchase ordinary shares. The buy-back program commenced on May 20, 2013 and was completed on August 14, 2013 after 7,548,951 shares had been repurchased in the amount of €384,966. On February 16, 2016, the Company retired 6,549,000 of the repurchased shares from the buy-back program at an average weighted price of €51 per share.

3.    Related Party Transactions

       Fresenius SE is also the Company's largest shareholder and owns 30.7% of the Company's outstanding shares, excluding treasury shares held by the Company, at September 30, 2017. The Company has entered into certain arrangements for services, leases and products with Fresenius SE or its subsidiaries and with certain of the Company's equity method investees as described in item a) below. The Company's terms related to the receivables or payables for these services, leases and products are generally consistent with the normal terms of the Company's ordinary course of business transactions with unrelated parties. Financing arrangements as described in item b) below have agreed upon terms which are determined at the time such financing transactions occur and reflect market rates at the time of the transaction. The relationship between the Company and its key management personnel who are considered to be related parties is described in item c) below. Our related party transactions are settled through Fresenius SE's cash management system where appropriate.

51

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

a)   Service Agreements, Lease Agreements and Products

       The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the "Fresenius SE Companies") to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. The Company also provides central purchasing services to the Fresenius SE Companies. These related party agreements generally have a duration of 1 - 5 years and are renegotiated on an as needed basis when the agreement comes due. The Company provides administrative services to one of its equity method investees.

       The Company is a party to real estate operating lease agreements with the Fresenius SE Companies, which mainly include leases for the Company's corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany. The majority of the leases expire at the end of 2026.

       In addition to the above mentioned service and lease agreements, the Company sold products to the Fresenius SE Companies and made purchases from the Fresenius SE Companies and equity method investees. In addition, Fresenius Medical Care Holdings, Inc. ("FMCH") purchases heparin supplied by Fresenius Kabi USA, Inc. ("Kabi USA"), through an independent group purchasing organization ("GPO"). Kabi USA is an indirect, wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. FMCH acquires heparin from Kabi USA, through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO.

       In December 2010, the Company formed the renal pharmaceutical company Vifor Fresenius Medical Care Renal Pharma Ltd., ("VFMCRP"), an equity method investee of which the Company owns 45%, with Galenica Ltd. (now known as Vifor Pharma Ltd). The Company has entered into exclusive supply agreements to purchase certain pharmaceuticals from VFMCRP.

       Below is a summary, including the Company's receivables from and payables to the indicated parties resulting from the above described transactions with related parties.

Service Agreements, Lease Agreements and Products
in € thousands
	For the nine months ended September 30, 2017		For the nine months ended September 30, 2016		September 30, 2017		December 31, 2016
	Sales of goods and services	Purchases of goods and services	Sales of goods and services	Purchases of goods and services	Accounts Receivables	Accounts Payables	Accounts Receivables	Accounts Payables
Service Agreements(1)
Fresenius SE	146	16,210	140	15,108	86	2,838	132	51
Fresenius SE affiliates	2,702	58,338	2,421	56,892	652	3,269	822	2,856
Equity method investees	13,970	-	12,677	-	1,064	-	2,506	-
Total	16,818	74,548	15,238	72,000	1,802	6,107	3,460	2,907
Lease Agreements
Fresenius SE	-	6,266	-	7,050	-	-	-	-
Fresenius SE affiliates	-	9,162	-	10,209	-	-	-	-
Total	-	15,428	-	17,259	-	-	-	-
Products
Fresenius SE	-	-	2	-	-	-	-	-
Fresenius SE affiliates	23,861	31,258	19,551	32,251	9,301	3,959	7,948	4,787
Equity method investees	-	316,027	-	292,422	-	87,366	-	55,329
Total	23,861	347,285	19,553	324,673	9,301	91,325	7,948	60,116

52

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

(1) In addition to the above shown Accounts Payable, Accrued Expenses for Service Agreements with related parties amounted to €3,552 and €3,359 at September 30, 2017 and December 31, 2016, respectively.

b)   Financing

       The Company receives short-term financing from and provides short-term financing to Fresenius SE. The Company also utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties. As of September 30, 2017 and December 31, 2016, the Company had accounts receivable from Fresenius SE related to short-term financing in the amount of €126,217 and €197,883, respectively. As of September 30, 2017 and December 31, 2016, the Company had accounts payable to Fresenius SE related to short-term financing in the amount of €123,453 and €186,350, respectively. The interest rates for these cash management arrangements are set on a daily basis and are based on the then-prevailing overnight reference rate for the respective currencies.

       On August 19, 2009, the Company borrowed €1,500 from the General Partner on an unsecured basis at 1.335%. The loan repayment has been extended periodically and is currently due August 22, 2018 with an interest rate of 1.100%. On November 28, 2013, the Company borrowed an additional €1,500 with an interest rate of 1.875% from the General Partner. The loan repayment has been extended periodically and is currently due on November 24, 2017 with an interest rate of 1.021%.

       At September 30, 2017 and December 31, 2016, a subsidiary of Fresenius SE held unsecured Senior Notes issued by the Company in the amount of €6,000 and €8,300, respectively. The Senior Notes were issued in 2011 and 2012, mature in 2021 and 2019, respectively, and each has a coupon rate of 5.25% with interest payable semiannually.

       At September 30, 2017 and December 31, 2016, the Company provided a cash advance to Fresenius SE in the amount of €10,900 and €36,245, respectively, on an unsecured basis at an interest rate of 1.100% and 0.771%, respectively. For further information on this loan agreement, see Note 7. "Short-Term Debt and Short-Term Debt from Related Parties – Short-Term Debt from Related Parties."

c)    Key Management Personnel

       Due to the Company's legal form as a German partnership limited by shares, the General Partner holds a key management position within the Company. In addition, as key management personnel, members of the Management Board and the Supervisory Board, as well as their close relatives, are considered related parties.

       The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the Management Board. The aggregate amount reimbursed to the General Partner was €15,995 and €13,846, respectively, for its management services during the nine months ended September 30, 2017 and 2016. As of September 30, 2017, the Company did not have any accounts receivable from the General Partner. As of December 31, 2016, the Company had accounts receivable from the General Partner in the amount of €174. As of September 30, 2017 and December 31, 2016, the Company had accounts payable to the General Partner in the amount of €2,919 and €14,696, respectively.

53

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

4.    Cash and Cash Equivalents

       At September 30, 2017 and December 31, 2016, cash and cash equivalents consisted of the following:

Cash and cash equivalents
in € thousands
	September 30, 2017	December 31, 2016
Cash	574,567	533,403
Securities and Time deposits (with a maturity of up to 90 days)	154,673	175,479
Cash and cash equivalents	729,240	708,882

5.    Trade Accounts Receivable

       At September 30, 2017 and December 31, 2016, trade accounts receivable consisted of the following:

Trade accounts receivable, less allowance for doubtful accounts
in € thousands
	September 30, 2017		December 31, 2016
Trade accounts receivable	3,701,884		3,826,280
less allowance for doubtful accounts	(529,384	)	(482,461	)
Trade accounts receivable, net	3,172,500		3,343,819

6.    Inventories

       At September 30, 2017 and December 31, 2016, inventories consisted of the following:

Inventories
in € thousands
	September 30, 2017	December 31, 2016
Finished goods	695,508	687,615
Health care supplies	348,932	362,307
Raw materials and purchased components	189,676	214,286
Work in process	74,829	73,269
Inventories	1,308,945	1,337,477

54

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

7.    Short-term Debt and Short-term Debt from Related Parties

       At September 30, 2017 and December 31, 2016, short-term debt and short-term debt from related parties consisted of the following:

Short-term Debt and Short-term Debt from Related Parties
in € thousands
	September 30, 2017	December 31, 2016
Commercial Paper Program	852,928	475,915
Borrowings under lines of credit	82,002	89,451
Other	1,073	6,644
Short-term debt	936,003	572,010
Short-term debt from related parties (see Note 3.b)	3,015	3,000
Short-term debt and short-term debt from related parties	939,018	575,010

       The Company and certain consolidated entities operate a multi-currency notional pooling cash management system. The Company met the conditions to offset balances within this cash pool for reporting purposes. At September 30, 2017 and December 31, 2016, cash and borrowings under lines of credit in the amount of €106,779 and €325,485 were offset under this cash management system.

Commercial Paper Program

       Commercial paper programs are flexible financing instruments to obtain short-term funding on the money market. Typically, commercial paper maturities range from a few days up to under two years. The Company established a commercial paper program on January 19, 2016 under which short-term notes of up to €1,000,000 can be issued. At September 30, 2017 and December 31, 2016, the outstanding commercial paper amounted to €853,000 and €476,000, respectively.

Other

       At September 30, 2017 and December 31, 2016, the Company had €1,073 and €6,644 of other debt outstanding related to fixed payments outstanding for acquisitions.

Short-term Debt from Related Parties

       The Company is party to an unsecured loan agreement with Fresenius SE under which the Company or its subsidiaries may request and receive one or more short-term advances up to an aggregate amount of $400,000 which matured on October 30, 2017.

55

FRESENIUS MEDICAL CARE AG & Co. KGaA


Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

8.    Long-term Debt and Capital Lease Obligations

       As of September 30, 2017 and December 31, 2016, long-term debt and capital lease obligations consisted of the following:

Long-term Debt and Capital Lease Obligations
in € thousands
	September 30, 2017		December 31, 2016
Amended 2012 Credit Agreement	2,068,885		2,244,115
Senior Notes	3,853,971		4,670,786
Convertible Bonds	385,422		380,735
Accounts Receivable Facility	168,643		165,037
Capital lease obligations	38,771		43,775
Other	207,606		52,656
Long-term debt and capital lease obligations	6,723,298		7,557,104
Less current portion	(890,949	)	(724,218	)
Long-term debt and capital lease obligations, less current portion	5,832,349		6,832,886

Amended 2012 Credit Agreement

       The Company originally entered into a syndicated credit facility of $3,850,000 and a 5 year tenor (the "2012 Credit Agreement") with a large group of banks and institutional investors (collectively, the "Lenders") on October 30, 2012. On November 26, 2014, the 2012 Credit Agreement was amended to increase the total credit facility to approximately $4,400,000 and extend the term for an additional two years until October 30, 2019 ("Amended 2012 Credit Agreement"). On July 11, 2017, the Company further amended and extended the Amended 2012 Credit Agreement resulting in a total credit facility of approximately $3,900,000 with maturities of 3 and 5 years on an unsecured basis. The Amended 2012 Credit Agreement now reflects a simplified structure consistent with the investment grade rating of the Company and lower tiered pricing.

       The current facilities under the Amended 2012 Credit Agreement now consist of the following:

•

A revolving credit facility of $900,000 which will be due and payable on July 31, 2022.

•

A revolving credit facility of €600,000 which will be due and payable on July 31, 2022.

•

A term loan facility of $1,500,000, also scheduled to mature on July 31, 2022. Quarterly repayments of $30,000 began on October 31, 2017 with the remaining balance outstanding due on the maturity date.

•

A term loan facility of €350,000 scheduled to mature on July 31, 2022. Quarterly repayments of €7,000 began on October 31, 2017 with the remaining balance outstanding due on the maturity date.

56

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

•

A non-amortizing term loan facility of €400,000 which is scheduled to mature on July 30, 2020.

       Interest on the credit facilities is floating at a rate equal to EURIBOR / LIBOR (as applicable) plus an applicable margin. The applicable margin is variable and depends on the Company's Consolidated Leverage Ratio which is a ratio of its consolidated funded debt less cash and cash equivalents held by the Consolidated Group to Consolidated EBITDA (as these terms are defined in the Amended 2012 Credit Agreement).

       The following table shows the available and outstanding amounts under the Amended 2012 Credit Agreement for September 30, 2017 and December 31, 2016:

Amended 2012 Credit Agreement – Maximum Amount Available and Balance Outstanding
in thousands
		Maximum Amount Available September 30, 2017				Balance Outstanding September 30, 2017(1)
Revolving Credit USD	$	900,000	€	762,324	$	68,361	€	57,904
Revolving Credit EUR	€	600,000	€	600,000	€	-	€	-
USD Term Loan 5-year	$	1,500,000	€	1,270,540	$	1,500,000	€	1,270,540
EUR Term Loan 5-year	€	350,000	€	350,000	€	350,000	€	350,000
EUR Term Loan 3-year	€	400,000	€	400,000	€	400,000	€	400,000
			€	3,382,864			€	2,078,444

	Maximum Amount Available December 31, 2016				Balance Outstanding December 31, 2016(1)
Revolving Credit USD	$	1,000,000	€	948,676	$	10,187	€	9,664
Revolving Credit EUR	€	400,000	€	400,000	€	-	€	-
USD Term Loan	$	2,100,000	€	1,992,221	$	2,100,000	€	1,992,221
EUR Term Loan	€	252,000	€	252,000	€	252,000	€	252,000
			€	3,592,897			€	2,253,885

(1) Amounts shown are excluding debt issuance costs.

       At September 30, 2017 and December 31, 2016, the Company had letters of credit outstanding in the amount of $2,050 and $3,550 (€1,736 and €3,368), respectively, under the USD revolving credit facility, which are not included above as part of the balance outstanding at those dates, but which reduce available borrowings under the applicable revolving credit facility.

57

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

Accounts Receivable Facility

       The following table shows the available and outstanding amounts under the Accounts Receivable Facility at September 30, 2017 and at December 31, 2016:

Accounts Receivable Facility – Maximum Amount Available and Balance Outstanding
in thousands
		Maximum Amount Available September 30, 2017(1)				Balance Outstanding September 30, 2017(2)
Accounts Receivable Facility	$	800,000	€	677,622	$	200,000	€	169,405

	Maximum Amount Available December 31, 2016(1)				Balance Outstanding December 31, 2016(2)
Accounts Receivable Facility	$	800,000	€	758,941	$	175,000	€	166,018

(1) Subject to availability of sufficient accounts receivable meeting funding criteria.

(2) Amounts shown are excluding debt issuance costs.

       The Company also had letters of credit outstanding under the Accounts Receivable Facility in the amount of $71,119 and $15,647 (€60,240 and €14,844) at September 30, 2017 and December 31, 2016, respectively. These letters of credit are not included above as part of the balance outstanding at September 30, 2017 and December 31, 2016; however, they reduce available borrowings under the Accounts Receivable Facility.

9.    Supplementary Information on Capital Management

       The principle objectives of the Company's capital management strategy are to optimize the weighted average cost of capital and to achieve a balanced mix of shareholders' equity and financial debt. The dialysis industry, in which the Company has a strong market position in global, growing and largely non-cyclical markets, is characterized by stable cash flows. Due to the Company's payors' mostly high credit quality, it is able to generate high, stable, predictable and sustainable cash flows.

       These generated cash flows allow the Company to utilize an extensive mix of financial liabilities.

58

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       As of September 30, 2017 and December 31, 2016 equity and debt were as follows:

Shareholders' Equity, Financial Liabilities and Total Assets
in € thousands, unless otherwise specified
	September 30, 2017	December 31, 2016
Shareholders' equity, including noncontrolling interests	10,673,021	11,051,132
Financial debt	7,662,316	8,132,114
Total assets	24,250,358	25,503,540
Financial debt in % of total assets	31.6%	31.9%
Total equity in % of total assets	44.0%	43.3%

       The Company is covered by the three leading rating agencies, Moody's, Standard & Poor's and Fitch. The Company currently has a BBB- rating from Standard & Poor's, a Baa3 rating from Moody's and a BBB– rating from Fitch.

Rating(1)
	Standard & Poor's	Moody's	Fitch
Corporate Credit Rating	BBB–	Baa3	BBB–
Outlook	stable	stable	stable

(1) A rating is not a recommendation to buy, sell or hold securities of the Company, and may be subject to suspension, change or withdrawal at any time by the assigning rating agency.

10    Share-based Plans

       On July 31, 2017 under the FMC-AG & Co. KGaA Long-Term Incentive Plan 2016, the Company awarded 604,484 performance shares, including 73,746 performance shares granted to members of the Management Board. The total fair value is €45,409, including a fair value of €5,540 to members of the Management Board. The fair value will be amortized over the four-year vesting period. The fair value per performance share at the grant date was €75.12.

11.    Employee Benefit Plans

       The Company currently has five principal pension plans, one for German employees, three for French employees and the other covering employees in the United States, the latter of which was curtailed in 2002. Plan benefits are generally based on years of service and final salary. As there is no legal requirement in Germany to fund defined benefit plans, the Company's pension obligations in Germany are unfunded. Each year FMCH contributes to the plan covering United States employees at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended. In 2017, FMCH did not have a minimum funding requirement. For the first nine months of 2017, the Company voluntarily provided €820 to the defined benefit plan. For the remaining period of 2017, the Company expects further voluntarily contributions of €176.

59

FRESENIUS MEDICAL CARE AG & Co. KGaA


Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       The following table provides the calculations of net periodic benefit cost for the three and nine months ended September 30, 2017 and 2016, respectively.

Net Periodic Benefit Cost
in € thousands
	For the three months ended September 30,		For the nine months ended September 30,
	2017	2016	2017	2016
Service cost	7,172	4,445	21,342	17,102
Net interest cost	2,818	4,065	8,356	12,199
Net periodic benefit costs	9,990	8,510	29,698	29,301

12.    Commitments and Contingencies

Legal and Regulatory Matters

       The Company is routinely involved in claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing health care services and products. Legal matters that the Company currently deems to be material or noteworthy are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.

       On February 15, 2011, a whistleblower (relator) action under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleged that the Company sought and received reimbursement from government payors for serum ferritin and multiple forms of hepatitis B laboratory tests that were medically unnecessary or not properly ordered by a physician. Discovery on the relator's complaint closed in May 2015. Although the United States initially declined to intervene in the case, the government subsequently changed position. On April 3, 2017, the court allowed the government to intervene with respect only to certain hepatitis B surface antigen tests performed prior to 2011, when Medicare reimbursement rules for such tests changed. The court rejected the government's request to conduct new discovery, but is allowing FMCH to take discovery against the government as if the government had intervened at the outset.

       The Company has received communications alleging conduct in countries outside the U.S. that may violate the U.S. Foreign Corrupt Practices Act ("FCPA") or other anti-bribery laws. The Company's Supervisory Board, through its Audit and Corporate Governance Committee, has been conducting

60

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

investigations with the assistance of independent counsel which are substantially complete. The Company voluntarily advised the U.S. Securities and Exchange Commission ("SEC") and the U.S. Department of Justice ("DOJ"). The Company's dialogue with the SEC and DOJ are ongoing. The Company continues to cooperate with the government investigations.

       The Company has identified and reported to the government, and has taken remedial actions including employee disciplinary actions with respect to, conduct that may result in monetary penalties or other sanctions under the FCPA or other anti-bribery laws. In addition, the Company's ability to conduct business in certain jurisdictions could be negatively impacted. The Company has recorded in prior periods a non-material accrual for an identified matter. The Company has substantially concluded its investigations and has entered into discussions toward a possible resolution with the government agencies. There is no timetable for a possible resolution. Given the current status of the resolution discussions and remediation activities, the Company cannot reasonably estimate the range of possible loss that may result from identified matters or from the resolution or remediation activities.

       The Company continues to implement enhancements to its anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws. The Company continues to be fully committed to FCPA and other anti-bribery law compliance.

       On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that the numerous lawsuits pending in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's acid concentrate products NaturaLyte® and GranuFlo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts. In Re: Fresenius GranuFlo/NaturaLyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. The Massachusetts state courts and the St. Louis City (Missouri) court subsequently established similar consolidated litigation for their cases. In Re: Consolidated Fresenius Cases, Case No. MICV 2013-03400-O (Massachusetts Superior Court, Middlesex County). Although similar cases were filed in other state courts, the Massachusetts federal and state courts and the St. Louis court were responsible, together, for more than 95% of all cases. The lawsuits alleged generally that inadequate labeling and warnings for these products caused harm to patients. On February 17, 2016, the Company reached with a committee of plaintiffs' counsel and reported to the courts an agreement in principle for settlement of potentially all cases. The agreement in principle calls for the Company to pay $250,000 into a settlement fund in exchange for releases of substantially all the plaintiffs' claims, subject to the Company's right to void the settlement under certain conditions.

       On October 12, 2017, the plaintiff committee and the Company determined that the condition of settlement related to minimum participation has been satisfied and are moving forward with implementation of the settlement. Funding of the settlement by the Company and its insurers is to be made on November 28, 2017. The Company believes that less than one percent (1%) of cases involved in the litigation will require any further substantive litigation activity for final resolution and that all such cases are pending in the U.S. District Court for Massachusetts (Boston); Los Angeles, California county court; or Birmingham, Alabama county court.

       The Company's affected insurers have agreed to fund $220,000 of the settlement fund, with a reservation of rights regarding certain coverage issues between and among the Company and its insurers. The Company has accrued a net expense of $60,000 for consummation of the settlement, including legal fees and other anticipated costs.

61

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       Following entry of the agreement in principle, the Company's insurers in the AIG group and the Company each initiated litigation against the other, in New York and Massachusetts state courts respectively, relating to the AIG group's coverage obligations under applicable policies. The affected carriers have confirmed that the coverage litigation does not impact their commitment to fund $220,000 of the settlement with plaintiffs. In the coverage litigation, the AIG group seeks to reduce its obligation to less than $220,000 and to be indemnified by the Company for a portion of its $220,000 outlay; the Company seeks to confirm the AIG group's $220,000 funding obligation, to recover defense costs already incurred by the Company, and to compel the AIG group to honor defense and indemnification obligations, if any, required for resolution of cases not participating in the settlement.

       Certain of the complaints in the GranuFlo®/NaturaLyte® litigation named combinations of FMC-AG & Co. KGaA, Management AG, Fresenius SE and Fresenius Management SE as defendants, in addition to FMCH and its domestic United States affiliates. The agreement in principle provides for dismissals and releases of claims encompassing the European defendants.

       Four institutional plaintiffs have filed complaints against FMCH or its affiliates under state deceptive practices statutes resting on certain background allegations common to the GranuFlo®/NaturaLyte® personal injury litigation, but seeking as remedy the repayment of sums paid to FMCH attributable to the GranuFlo®/NaturaLyte® products. These cases implicate different legal standards, theories of liability and forms of potential recovery from those in the personal injury litigation and their claims will not be extinguished by the personal injury litigation settlement described above. The four plaintiffs are the Attorneys General for the States of Kentucky, Louisiana and Mississippi and the commercial insurance company Blue Cross Blue Shield of Louisiana in its private capacity. State of Mississippi ex rel. Hood, v. Fresenius Medical Care Holdings, Inc., No. 14-cv-152 (Chancery Court, DeSoto County); State of Louisiana ex re. Caldwell and Louisiana Health Service & Indemnity Company v. Fresenius Medical Care Airline, 2016 Civ. 11035 (U.S.D.C. D. Mass.); Commonwealth of Kentucky ex rel. Beshear v. Fresenius Medical Care Holdings, Inc. et al., No. 16-CI-00946 (Circuit Court, Franklin County).

       In August 2014, FMCH received a subpoena from the United States Attorney for the District of Maryland inquiring into FMCH's contractual arrangements with hospitals and physicians, including contracts relating to the management of in-patient acute dialysis services. FMCH is cooperating in the investigation.

       In July 2015, the Attorney General for Hawaii issued a civil complaint under the Hawaii False Claims Act alleging a conspiracy pursuant to which certain Liberty Dialysis subsidiaries of FMCH overbilled Hawaii Medicaid for Liberty's Epogen® administrations to Hawaii Medicaid patients during the period from 2006 through 2010, prior to the time of FMCH's acquisition of Liberty. Hawaii v. Liberty Dialysis – Hawaii, LLC et al., Case No. 15-1-1357-07 (Hawaii 1^st Circuit). The State alleges that Liberty acted unlawfully by relying on incorrect and unauthorized billing guidance provided to Liberty by Xerox State Healthcare LLC, which acted as Hawaii's contracted administrator for its Medicaid program reimbursement operations during the relevant period. The amount of the overpayment claimed by the State is approximately $8,000, but the State seeks civil remedies, interest, fines, and penalties against Liberty and FMCH under the Hawaii False Claims Act substantially in excess of the overpayment. FMCH filed third-party claims for contribution and indemnification against Xerox. The State's False Claims Act complaint was filed after Liberty initiated an administrative action challenging the State's recoupment of alleged overpayments from sums currently owed to Liberty. The civil litigation and administrative action are proceeding in parallel.

62

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       On August 31 and November 25, 2015, respectively, FMCH received subpoenas under the False Claims Act from the United States Attorneys for the District of Colorado and the Eastern District of New York inquiring into FMCH's participation in and management of dialysis facility joint ventures in which physicians are partners. On March 20, 2017, FMCH received a subpoena in the Western District of Tennessee inquiring into certain of the operations of dialysis facility joint ventures with the University of Tennessee Medical Group, including joint ventures in which FMCH's interests were divested to Satellite Dialysis in connection with FMCH's acquisition of Liberty Dialysis in 2012. FMCH is cooperating in these investigations.

       On October 6, 2015, the Office of Inspector General of the United States Department of Health and Human Services ("OIG") issued a subpoena under the False Claims Act to the Company seeking information about utilization and invoicing by Fresenius Vascular Care, now known as Azura Vascular Care, facilities as a whole for a period beginning after the Company's acquisition of American Access Care LLC in October 2011 ("AAC"). On August 24, 2017, an additional and more detailed subpoena on the same topics was issued by the United States Attorney for the Eastern District of New York (Brooklyn), which has managed the Azura investigation from its outset. The Company is cooperating in the government's inquiry. Allegations against AAC arising in districts in Connecticut, Florida and Rhode Island relating to utilization and invoicing were settled in 2015.

       On June 30, 2016, FMCH received a subpoena from the United States Attorney for the Northern District of Texas (Dallas) seeking information under the False Claims Act about the use and management of pharmaceuticals including Velphoro® as well as FMCH's interactions with DaVita Healthcare Partners, Inc. The Company understands that the subpoena relates to an investigation previously disclosed by DaVita and that the investigation encompasses DaVita, Amgen, and Sanofi. FMCH is cooperating in the investigation.

       On November 18, 2016, FMCH received a subpoena under the False Claims Act from the United States Attorney for the Eastern District of New York (Brooklyn) seeking documents and information relating to the operations of Shiel Medical Laboratory, Inc., which FMCH acquired in October 2013. In the course of cooperating in the investigation and preparing to respond to the subpoena, FMCH identified falsifications and misrepresentations in documents submitted by a Shiel salesperson that relate to the integrity of certain invoices submitted by Shiel for laboratory testing for patients in long term care facilities. On February 21, 2017, FMCH terminated the employee and notified the United States Attorney of the termination and its circumstances. The terminated employee's conduct may subject the Company to liability for overpayments and penalties under applicable laws.

       On September 28, 2017, the Company announced its agreement to sell to Quest Diagnostics certain Shiel operations that are the subject of this Brooklyn subpoena, including the misconduct reported to the United States Attorney. Under the sale agreement, the Company retains responsibility for the Brooklyn investigation and its outcome. The Company continues to cooperate in the ongoing investigation.

       On December 14, 2016, the Center for Medicare & Medicaid Services ("CMS"), which administers the federal Medicare program, published an Interim Final Rule ("IFR") titled "Medicare Program; Conditions for Coverage for End-Stage Renal Disease Facilities-Third Party Payment." The IFR would have amended the Conditions for Coverage for dialysis providers, like FMCH and would have effectively enabled insurers to reject premium payments made by or on behalf of patients who received grants for individual market coverage from the American Kidney Fund ("AKF" or "the Fund"). The IFR could thus

63

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

have resulted in those patients losing individual insurance market coverage. The loss of coverage for these patients would have had a material and adverse impact on the operating results of FMCH.

       On January 25, 2017, a federal district court in Texas responsible for litigation initiated by a patient advocacy group and dialysis providers including FMCH preliminarily enjoined CMS from implementing the IFR. Dialysis Patient Citizens v. Burwell, 2017 Civ. 0016 (E.D. Texas, Sherman Div.). The preliminary injunction was based on CMS' failure to follow appropriate notice-and-comment procedures in adopting the IFR. The injunction remains in place and the court retains jurisdiction over the dispute.

       On June 22, 2017, CMS requested a stay of proceedings in the litigation pending further rulemaking concerning the IFR. CMS stated, in support of its request, that it expects to publish a Notice of Proposed Rulemaking in the Federal Register and otherwise pursue a notice-and-comment process. Plaintiffs in the litigation, including FMCH, consented to the stay, which was granted by the court on June 27, 2017.

       The operation of charitable assistance programs like that of the AKF is also receiving increased attention by state insurance regulators. The result may be a regulatory framework that differs from state to state. Even in the absence of the IFR or similar administrative actions, insurers are likely to continue efforts to thwart charitable premium assistance to our patients for individual market plans and other insurance coverages. If successful, these efforts would have a material adverse impact on the Company's operating results.

       On January 3, 2017, the Company received a subpoena from the United States Attorney for the District of Massachusetts under the False Claims Act inquiring into the Company's interactions and relationships with the AKF, including the Company's charitable contributions to the Fund and the Fund's financial assistance to patients for insurance premiums. FMCH is cooperating in the investigation, which the Company understands to be part of a broader investigation into charitable contributions in the medical industry.

       In early May 2017, the United States Attorney for the Middle District of Tennessee (Nashville) issued identical subpoenas to FMCH and two subsidiaries under the False Claims Act concerning the Company's retail pharmaceutical business. The investigation is exploring allegations of improper inducements to dialysis patients to fill oral prescriptions through FMCH's pharmacy service and of improper billing for returned pharmacy products. FMCH is cooperating in the investigation.

       In 2011, FMCH received a subpoena from the United States Attorney for the Eastern District of New York (Brooklyn) requesting information under the False Claims Act concerning an assay manufactured by Bayer Diagnostics. Bayer Diagnostics was later acquired by Siemens. The assay is used to test for the serum content of parathyroid hormone (PTH). The assay has been widely used by FMCH and others in the dialysis industry for assessment of bone mineral metabolism disorder, a common consequence of kidney failure. FMCH responded fully and cooperatively to the subpoena, but concluded that it was not the focus or target of the US Attorney's investigation. On March 16, 2017, the US Attorney elected not to intervene on a sealed relator (whistleblower) complaint first filed in January 2011 that underlay the investigation. After the US Attorney declined intervention, the United States District Court for the Eastern District unsealed the complaint and ordered the relator to serve and otherwise proceed on his own. On August 14, 2017, FMCH was dismissed with prejudice from the litigation on relator's motion. The litigation continued against other defendants Patriarca v. Bayer Diagnostics n/k/a Siemens et alia, 2011 Civ. 00181 (E.D.N.Y.).

64

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.

       The Company, like other healthcare providers, insurance plans and suppliers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories, dialysis clinics and other health care facilities, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the U.S. Food and Drug Administration ("FDA") and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls, injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. FMCH is currently engaged in remediation efforts with respect to one pending FDA warning letter. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law, the federal Civil Monetary Penalties Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence whistleblower actions. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of whistleblower actions, which are initially filed under court seal.

       The Company operates many facilities and handles protected health information ("PHI") of its patients and beneficiaries throughout the United States and other parts of the world, and engages with other business associates to help it carry out its health care activities. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies and its business associates. On occasion, the Company or its business associates may experience a breach under the Health Insurance Portability and Accountability Act ("HIPAA") Privacy Rule when there has been impermissible use, access, or disclosure of unsecured PHI, a breach under the HIPAA Security Rule when the Company or its business associates neglect to implement the required administrative, technical and physical safeguards of its electronic systems and devices, or a data breach that results in impermissible use, access or disclosure of personal identifying information of its employees, patients and beneficiaries. On those occasions, the Company must comply with state and federal breach notification requirements. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of its employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law.

65

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act, HIPAA, the Health Information Technology for Economic and Clinical Health Act and the Foreign Corrupt Practices Act, among other laws and comparable state laws or laws of other countries.

       Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.

       The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.

       The Company is also subject to ongoing and future tax audits in the U.S., Germany and other jurisdictions. With respect to other potential adjustments and disallowances of tax matters currently under review, the Company does not anticipate that an unfavorable ruling could have a material impact on its results of operations. The Company is not currently able to determine the timing of these potential additional tax payments.

       Other than those individual contingent liabilities mentioned above, the current estimated amount of the Company's other known individual contingent liabilities is immaterial.

13.    Financial Instruments

       The Company applies IFRS 7 (Financial Instruments: Disclosures). Thereby the following categories according to IAS 39 (Financial Instruments: Recognition and Measurement) are relevant: financial assets at fair value through profit or loss, loans and receivables, financial liabilities at fair value through profit or loss as well as financial liabilities recognized at amortized cost and available for sale financial assets.

66

FRESENIUS MEDICAL CARE AG & Co. KGaA


Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       The following table demonstrates the combination between categories and classes as well as the classes allocated to the balance sheet items:

(1) Excluding capital lease obligations

(2) Exclusively capital lease obligations

67

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

Valuation of Financial Instruments

       The carrying amounts of financial instruments at September 30, 2017 and December 31, 2016, classified into categories according to IAS 39, can be seen in the following table.

Carrying Amount of Financial Instrument Categories
in € thousands
	September 30, 2017		December 31, 2016
Loans and Receivables	3,547,069		3,835,800
Financial Liabilities recognized at amortized cost	(9,541,263	)	(10,210,287	)
Financial Assets at fair value through profit or loss	105,413		132,406
Financial Liabilities at fair value through profit or loss	(304,523	)	(339,701	)
Available for sale financial assets(1)	242,815		256,437
Not assigned to a category	7,846		(194,176	)

(1) The impact on the Consolidated Statements of Income and the Consolidated Statements of Shareholders' Equity is not material.

       The following table presents the carrying amounts and fair values of the Company's financial instruments at September 30, 2017 and December 31, 2016.

Carrying Amount and Fair Value of Financial Instruments
in € thousands
	September 30, 2017				December 31, 2016
	Carrying amount		Fair Value		Carrying amount		Fair Value
Non-derivative Financial Instruments
Cash and cash equivalents	729,240		729,240		708,882		708,882
Assets recognized at carrying amount(1)	3,692,065		3,692,065		3,987,806		3,987,806
Assets recognized at fair value	242,815		242,815		256,437		256,437
Liabilities recognized at carrying amount(2)	(9,580,034	)	(10,028,403	)	(10,254,062	)	(10,754,495	)
Liabilities recognized at fair value	(211,213	)	(211,213	)	(223,504	)	(223,504	)
Noncontrolling interests subject to put provisions	(827,606	)	(827,606	)	(1,007,733	)	(1,007,733	)
Derivative Financial Instruments
Derivatives not designated as hedging instruments	12,103		12,103		16,209		16,209
Derivatives designated as hedging instruments	(13	)	(13	)	(3,556	)	(3,556	)

(1) Not included are "Other current and non-current assets" that do not qualify as financial instruments (September 30, 2017: €926,213 and December 31, 2016: €850,630).

(2) Not included are "Current and non-current provisions and other current and non-current liabilities" that do not qualify as financial instruments (September 30, 2017: €1,461,079 and December 31, 2016: €1,429,344).

68

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

Non-derivative Financial Instruments

       The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows:

       Cash and cash equivalents are stated at nominal value which equals the fair value.

       Short-term financial instruments such as trade accounts receivable, accounts receivable from related parties, accounts payable, accounts payable to related parties and short-term debt as well as certain other financial instruments are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments.

       The fair value of available for sale financial assets quoted in an active market is based on price quotations at the period-end date (Level 1).

       Long-term debt is recognized at its carrying amount. The fair values of major long-term debt are calculated on the basis of market information (Level 2). Liabilities for which market quotes are available are measured using these quotes. The fair values of the other long-term debt are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.

       Variable payments outstanding for acquisitions are recognized at their fair value. The estimation of the individual fair values is based on the key inputs of the arrangement that determine the future contingent payment as well as the Company's expectation of these factors (Level 3). The Company assesses the likelihood and timing of achieving the relevant objectives. The underlying assumptions are reviewed regularly.

       Noncontrolling interests subject to put provisions are recognized at their fair value. The methodology the Company uses to estimate the fair values assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors (Level 3). Additionally, there are put provisions that are valued by an external valuation firm. The external valuation estimates the fair values using a combination of discounted cash flows and a multiple of earnings and/or revenue (Level 3). When applicable, the obligations are discounted at a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the liability. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate, and the discounted cash flows as well as the implicit multiple of earnings and/or revenue at which these noncontrolling interest obligations may ultimately be settled could vary significantly from the Company's current estimates depending upon market conditions.

69

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       Following is a roll forward of noncontrolling interests subject to put provisions at September 30, 2017 and December 31, 2016.

Noncontrolling interests subject to put provisions
in € thousands
	2017		2016
Beginning balance at January 1,	1,007,733		791,075
Contributions to noncontrolling interests	(123,461	)	(169,260	)
Purchase of noncontrolling interests	(111,959	)	(1,785	)
Sale of noncontrolling interests	63,098		53,919
Contributions from noncontrolling interests	11,684		29,144
Expiration of put provisions and other reclassifications	(6,180	)	(8,814	)
Changes in fair value of noncontrolling interests	(31,456	)	115,627
Net income	115,159		164,515
Foreign Currency Translation	(97,012	)	33,312
Ending balance as of September 30, 2017 and December 31, 2016	827,606		1,007,733

       Credit risk resulting from a decrease in the value of the Company's financing receivables and allowances on credit losses of financing receivables are immaterial.

Derivative Financial Instruments

Market Risk

       In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis, the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.

       In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes ("economic hedges"). The Company does not use financial instruments for trading purposes. The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other.

       To reduce the credit risk arising from derivatives the Company entered into Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.

70

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       These master netting agreements do not provide a basis for offsetting the fair values of derivative financial instruments in the statement of financial position as the offsetting criteria under IFRS are not satisfied.

       At September 30, 2017 and December 31, 2016, the Company had €19,176 and €24,312 of derivative financial assets subject to netting arrangements and €7,284 and €26,751 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of €13,099 and €13,673 as well as net liabilities of €1,207 and €16,112 at September 30, 2017 and December 31, 2016, respectively.

       In connection with the issuance of the Convertible Bonds in September 2014, the Company purchased share options. Any change in the Company's share price above the conversion price would be offset by a corresponding value change in the share options.

Foreign Exchange Risk Management

       The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes in accordance with Section 315e of the German Commercial Code ("HGB") the Company has chosen the euro as its reporting currency. Therefore, changes in the rate of exchange between the euro and the local currencies in which the financial statements of the Company's international operations are maintained, affect its results of operations and financial position as reported in its Consolidated Financial Statements.

       Additionally, individual subsidiaries are exposed to transactional risks mainly resulting from intercompany purchases between production sites and other subsidiaries with different functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing currencies and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At September 30, 2017 and December 31, 2016, the Company had no foreign exchange options.

       Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in Accumulated Other Comprehensive Income ("AOCI"). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps to assure that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenue for those contracts that hedge product purchases and sales or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totalled €117,255 and €103,358 at September 30, 2017 and December 31, 2016, respectively.

       The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currencies which do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these two cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for

71

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

hedge accounting totalled €638,137 and €1,407,611 at September 30, 2017 and December 31, 2016, respectively.

Interest Rate Risk Management

       The Company enters into derivatives, particularly interest rate swaps and, to a certain extent, interest rate options to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2019 and have a weighted average interest rate of 0.32%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense.

       The effective portion of gains and losses of derivatives designated as cash flow hedges is deferred in AOCI; the amount of gains and losses reclassified from AOCI are recorded in interest income and interest expenses.

       At September 30, 2017 and December 31, 2016, the notional amount of the euro-denominated interest rate swaps in place was €234,000 and €252,000.

       In addition, the Company also enters into interest rate hedges ("pre-hedges") in anticipation of future long-term debt issuance. These pre-hedges are used to hedge interest rate exposures with regard to interest rates which are relevant for the future long-term debt issuance and which could rise until the respective debt is actually issued. These pre-hedges were settled at the issuance date of the corresponding long-term debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the debt. At September 30, 2017 and December 31, 2016, the Company had €21,444 and €35,814, respectively, related to settlements of pre-hedges deferred in AOCI, net of tax.

72

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

Derivative Financial Instruments Valuation

       The following table shows the carrying amounts of the Company's derivatives at September 30, 2017 and December 31, 2016.

Derivative Financial Instrument Valuation
in € thousands
	September 30, 2017			December 31, 2016
	Assets(2)	Liabilities(2)		Assets(2)	Liabilities(2)
Derivatives in cash flow hedging relationships(1)
Current
Foreign exchange contracts	1,539	(376	)	2,018	(4,101	)
Non-current
Foreign exchange contracts	11	(58	)	17	(76	)
Interest rate contracts	-	(1,129	)	-	(1,414	)
Total	1,550	(1,563	)	2,035	(5,591	)
Derivatives not designated as hedging instruments(1)
Current
Foreign exchange contracts	17,824	(5,721	)	37,743	(21,415	)
Non-current
Foreign exchange contracts	-	-		-	(119	)
Derivatives embedded in the Convertible Bonds	-	(87,589	)	-	(94,663	)
Share options to secure the Convertible Bonds	87,589	-		94,663	-
Total	105,413	(93,310	)	132,406	(116,197	)

(1) At September 30, 2017 and December 31, 2016, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2).

(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.

       The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Current provisions and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other non-current assets or Non-current provisions and other non-current liabilities, respectively.

       The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows:

       The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To

73

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency. The fair value of the embedded derivative of the convertible bonds is calculated using the difference between the market value of the convertible bond and the market value of an adequate straight bond discounted with the market interest rates as of the reporting date.

       The Company's own credit risk is incorporated in the fair value estimation of derivatives that are liabilities. Counterparty credit risk adjustments are factored into the valuation of derivatives that are assets. The Company monitors and analyses the credit risk from derivative financial instruments on a regular basis. For the valuation of derivative financial instruments, the credit risk is considered in the fair value of every individual instrument. The default probability is based upon the credit default swap spreads of each counterparty appropriate for the duration. The calculation of the credit risk considered in the valuation is performed by multiplying the default probability appropriate for the duration with the expected discounted cash flows of the derivative financial instrument.

The Effect of Derivatives on the Consolidated Financial Statements

       The following table shows the effect of derivatives on the Consolidated Financial Statements:

The Effect of Derivatives on the Consolidated Financial Statements
				Location of (Gain)
in € thousands	Amount of Gain (Loss) recognized in AOCI			Loss reclassified from	Amount of (Gain) Loss reclassified from
Derivatives in Cash	on Derivatives (Effective Portion) for the			AOCI in Income	AOCI in Income (Effective Portion) for
Flow	nine months ended September 30,			(Effective Portion)	the nine months ended September 30,
Hedging Relationships	2017		2016		2017		2016
Interest rate contracts	(311	)	717	Interest income/expense	20,745		16,647
Foreign exchange contracts	4,577		1,249	Costs of Revenue	(1,999	)	(347	)
	4,266		1,966		18,746		16,300

		Amount of (Gain) Loss recognized in Income on Derivatives for the nine months ended September 30,
Derivatives not designated as Hedging Instruments	Location of (Gain) Loss recognized in Income on Derivatives
		2017			2016
Foreign exchange contracts	Selling, general and administrative expense		(7,536	)		24,714
Foreign exchange contracts	Interest income/expense		7,351			3,111
Derivatives embedded in the Convertible Bonds	Interest income/expense		(7,074	)		(11,867	)
Share options to secure the Convertible Bonds	Interest income/expense		7,074			11,867
			(185	)		27,825

       At September 30, 2017, the Company had foreign exchange derivatives with maturities of up to 17 months and interest rate swaps with maturities of up to 25 months.

74

FRESENIUS MEDICAL CARE AG & Co. KGaA


Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

14.    Segment and Corporate Information

       The Company's operating segments are the North America Segment, the EMEA Segment, the Asia-Pacific Segment and the Latin America Segment. The operating segments are determined based upon how the Company manages its businesses with geographical responsibilities. All segments are primarily engaged in providing health care services and the distribution of products and equipment for the treatment of ESRD and other extracorporeal therapies.

       Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate IFRS measures are revenue, operating income and operating income margin. The Company does not include income taxes as it believes this is outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs, which relate primarily to certain headquarters' overhead charges, including accounting and finance, because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement related to production are centrally managed at Corporate. The Company's global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment according to IFRS 8. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenue for the product transfers and their elimination are recorded as Corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but are accounted for as Corporate.

75

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

       Information pertaining to the Company's segment and Corporate activities for the three and nine months ended September 30, 2017 and 2016 is set forth below.

Segment and Corporate Information
in € thousands
	North America Segment		EMEA Segment		Asia- Pacific Segment		Latin America Segment		Segment Total		Corporate		Total
Three months ended September 30, 2017
Revenue external customers	3,115,071		632,097		410,714		174,723		4,332,605		3,097		4,335,702
Inter - segment revenue	293		2		223		118		636		(636	)	-
Revenue	3,115,364		632,099		410,937		174,841		4,333,241		2,461		4,335,702
Operating income	482,687		106,185		77,096		17,814		683,782		(75,201	)	608,581
Interest													(86,113	)
Earnings before taxes													522,468
Depreciation and amortization	(94,370	)	(29,252	)	(11,235	)	(4,234	)	(139,091	)	(38,692	)	(177,783	)
Income (loss) from equity method investees	15,886		(2,876	)	8		260		13,278		-		13,278
Capital expenditures, acquisitions and investments	170,037		47,109		13,334		9,197		239,677		65,079		304,756
Three months ended September 30, 2016
Revenue external customers	3,049,431		604,712		382,563		171,637		4,208,343		3,260		4,211,603
Inter - segment revenue	795		-		7		45		847		(847	)	-
Revenue	3,050,226		604,712		382,570		171,682		4,209,190		2,413		4,211,603
Operating income	489,586		112,354		76,180		17,859		695,979		(85,281	)	610,698
Interest													(89,558	)
Earnings before taxes													521,140
Depreciation and amortization	(97,118	)	(27,433	)	(11,121	)	(4,176	)	(139,848	)	(36,228	)	(176,076	)
Income (loss) from equity method investees	23,433		1,074		1,042		452		26,001		-		26,001
Capital expenditures, acquisitions and investments	172,184		37,496		18,475		12,281		240,436		49,874		290,310
Nine months ended September 30, 2017
Revenue external customers	9,714,927		1,887,510		1,205,640		534,819		13,342,896		11,947		13,354,843
Inter - segment revenue	1,465		3		245		270		1,983		(1,983	)	-
Revenue	9,716,392		1,887,513		1,205,885		535,089		13,344,879		9,964		13,354,843
Operating income	1,478,038		333,328		237,163		44,679		2,093,208		(250,047	)	1,843,161
Interest													(273,807	)
Earnings before taxes													1,569,354
Depreciation and amortization	(300,088	)	(90,001	)	(34,768	)	(13,278	)	(438,135	)	(115,629	)	(553,764	)
Income (loss) from equity method investees	53,166		(3,826	)	1,178		584		51,102		-		51,102
Total assets	15,572,667		3,609,233		2,066,100		668,863		21,916,863		2,333,495		24,250,358
thereof investments in equity method investees	326,439		184,964		97,587		24,290		633,280		-		633,280
Capital expenditures, acquisitions and investments(1)(2)	573,105		133,148		174,228		27,529		908,010		152,192		1,060,202
Nine months ended September 30, 2016
Revenue external customers	8,827,517		1,776,073		1,073,567		465,766		12,142,923		10,317		12,153,240
Inter - segment revenue	2,709		-		16		133		2,858		(2,858	)	-
Revenue	8,830,226		1,776,073		1,073,583		465,899		12,145,781		7,459		12,153,240
Operating income	1,347,816		354,060		202,269		41,995		1,946,140		(267,138	)	1,679,002
Interest													(275,762	)
Earnings before taxes													1,403,240
Depreciation and amortization	(284,603	)	(80,467	)	(32,169	)	(11,209	)	(408,448	)	(104,999	)	(513,447	)
Income (loss) from equity method investees	51,158		1,665		839		1,053		54,715		-		54,715
Total assets	16,087,336		3,272,763		1,747,920		673,484		21,781,503		2,052,958		23,834,461
thereof investments in equity method investees	277,501		191,551		95,946		24,752		589,750		-		589,750
Capital expenditures, acquisitions and investments(3)	664,647		130,488		34,476		26,456		856,067		160,426		1,016,493

(1) North America, EMEA, Asia-Pacific, Latin America acquisitions exclude €8,167, €4,441, €107,195 and €27 respectively of non-cash acquisitions for 2017.

(2) Acquisitions of the last twelve months decreased consolidated earnings in the amount of €1,285.

(3) North America, EMEA, Latin America and Asia-Pacific acquisitions exclude €8,180, €82,255, €4,479 and €4,354 respectively of non-cash acquisitions for 2016.

76

FRESENIUS MEDICAL CARE AG & Co. KGaA

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except share and per share data)

15.    Supplementary Cash Flow Information

       The following additional information is provided with respect to the Consolidated Statements of Cash Flows:

Supplementary Cash Flow Information
in € thousands
	For the nine months ended September 30,
	2017		2016
Details for acquisitions:
Assets acquired	(625,394	)	(416,700	)
Liabilities assumed	134,074		60,364
Noncontrolling interest subject to put provisions	61,738		39,327
Noncontrolling interest	11,424		13,545
Non-cash consideration	14,175		71,665
Cash paid	(403,983	)	(231,799	)
Less cash acquired	8,572		13,776
Net cash paid for acquisitions	(395,411	)	(218,023	)
Cash paid for investments	(16,780	)	(119,910	)
Cash paid for intangible assets	(15,681	)	(8,750	)
Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	(427,872	)	(346,683	)

16.    Events Occurring after the Balance Sheet Date

       No further significant activities have taken place subsequent to the balance sheet date September 30, 2017 that have a material impact on the key figures and earnings presented. Currently, there are no other significant changes in the Company's structure, management, legal form or personnel.

77

Quantitative and Qualitative Disclosures About Market Risk

       As of January 1, 2017, the Company migrated to reporting in accordance with International Financial Reporting Standards ("IFRS") as adopted by the International Accounting Standards Board ("IASB"). See Note 1, "The Company and Basis of Presentation – Basis of Presentation." During the period ended September 30, 2017, no material changes occurred to the information presented in Note 23 "Financial Instruments" of the Notes to the Company's Consolidated Financial Statements prepared in accordance with IFRS, as adopted in the European Union, for the year ended December 31, 2016. These financial statements are available on the Company's website.

78

Controls and Procedures

       The Company is a "foreign private issuer" within the meaning of Rule 3b-4(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). As such, the Company is not required to file quarterly reports with the Securities and Exchange Commission and is required to provide an evaluation of the effectiveness of its disclosure controls and procedures, to disclose significant changes in its internal control over financial reporting, and to provide certifications of its Chief Executive Officer and Chief Financial Officer under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 only in its Annual Report on Form 20-F. The Company furnishes quarterly financial information to the Securities and Exchange Commission (the "Commission") and such certifications under cover of Form 6-K on a voluntary basis and pursuant to the provisions of the Company's pooling agreement entered into for the benefit of the public holders of our shares. In connection with such voluntary reporting, the Company's management, including the Chief Executive Officer and the Chief Financial Officer of the Company's General Partner, has conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report, of the type contemplated by Securities Exchange Act Rule 13a-15. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded in connection with the furnishing of this report, that the Company's disclosure controls and procedures are designed to ensure that the information the Company is required to disclose in the reports filed or furnished under the Act is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms and are effective to ensure that the information the Company is required to disclose in its reports is accumulated and communicated to the General Partner's Management Board, including the General Partner's Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. During the past fiscal quarter, there have been no significant changes in internal controls, or in factors that could significantly affect internal controls.

       During the three-month period ended September 30, 2017, the Company substantially concluded its investigations into allegations of conduct outside the U.S. that may violate the U.S. Foreign Corrupt Practices Act or other anti-bribery laws and has entered into discussions toward a possible resolution with U.S. government agencies. For information with respect to compliance investigations, see Note 12 of the Notes to the Consolidated Financial Statements (unaudited), "Commitments and Contingencies" presented elsewhere in this Report. The Company continues to implement enhancements to its anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws.

79

OTHER INFORMATION

Legal and Regulatory Matters

       The information in Note 12 of the Notes to Consolidated Financial Statements (Unaudited), "Commitments and Contingencies" presented elsewhere in this report is incorporated by this reference.

80

Exhibits

Exhibit No.
2.34	Amendment No. 2 dated July 11, 2017 to the 2012 Credit Agreement (filed herewith)
2.35	Agreement and Plan of Merger, dated as of August 7, 2017, by and among Fresenius Medical Care Holdings, Inc., Broadway Renal Services, Inc., and NxStage Medical, Inc. ("NxStage") (incorporated by reference to Exhibit 2.21 to NxStage's Current Report on Form 8-K dated August 5, 2017, filed August 7, 2017).*
31.1	Certification of Chief Executive Officer and Chairman of the Management Board of the Company's General Partner Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer and member of the Management Board of the Company's General Partner Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chairman of the Management Board of the Company's General Partner and Chief Financial Officer and member of the Management Board of the Company's General Partner Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (this exhibit accompanies this report as required by the Sarbanes-Oxley Act of 2002 and is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended).

* The schedules to the Merger Agreement have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Copies of such schedules will be furnished to the SEC upon its request; provided, however, that confidential treatment may be requested pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.

81

SIGNATURES

       Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: November 2, 2017
	FRESENIUS MEDICAL CARE AG & Co. KGaA a partnership limited by shares, represented by:
	FRESENIUS MEDICAL CARE MANAGEMENT AG, its General Partner
	By:    /s/ RICE POWELL
	Name:	Rice Powell
	Title:	Chief Executive Officer and Chairman of the Management Board of the General Partner
	By:    /s/ MICHAEL BROSNAN
	Name:	Michael Brosnan
	Title:	Chief Financial Officer and member of the Management Board of the General Partner

82

EX-2.34

Exhibit 2.34

EXECUTION VERSION

AMENDMENT NO. 2

Dated as of July 11, 2017

among

FRESENIUS MEDICAL CARE AG & CO. KGAA

FRESENIUS MEDICAL CARE HOLDINGS, INC.

AND THE OTHER BORROWERS AND GUARANTORS IDENTIFIED HEREIN,

THE LENDERS PARTY HERETO,

BANK OF AMERICA, N.A.,

as Administrative Agent, Collateral Agent, an L/C Issuer and a Swingline Lender,

DEUTSCHE BANK SECURITIES INC.,

as Sole Syndication Agent,

COMMERZBANK AKTIENGESELLSCHAFT, FILIALE LUXEMBURG,

JPMORGAN CHASE BANK, N.A.,

THE BANK OF NOVA SCOTIA,

SUNTRUST BANK,

UNICREDIT BANK AG, NEW YORK BRANCH

and

WELLS FARGO BANK, NATIONAL ASSOCIATION,

as Co-Documentation Agents,

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED,

DEUTSCHE BANK SECURITIES INC.,

COMMERZBANK AKTIENGESELLSCHAFT, FILIALE LUXEMBURG,

J.P. MORGAN SECURITIES PLC,

THE BANK OF NOVA SCOTIA,

SUNTRUST ROBINSON HUMPHREY, INC.,

UNICREDIT BANK AG, NEW YORK BRANCH

and

WELLS FARGO SECURITIES, LLC,

as Mandated Lead Arrangers and Joint Book Runners

AMENDMENT NO. 2

THIS AMENDMENT NO. 2, dated as of July 11, 2017 (this “Amendment”), is by and among FRESENIUS MEDICAL CARE AG & Co. KGaA, a German partnership limited by shares (“FME”), FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation (“FMCH”), and the other Borrowers and Guarantors identified herein, the Lenders identified herein and BANK OF AMERICA, N.A., as Administrative Agent, Collateral Agent, an L/C Issuer and a Swingline Lender.  Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Existing Credit Agreement (as defined below) or the Credit Agreement (as defined below), as applicable.

W I T N E S S E T H

WHEREAS, approximately $4.2 billion in revolving credit and term loan facilities were established pursuant to the terms of that Credit Agreement date as of October 30, 2012 (as amended and modified prior to the date hereof, the “Existing Credit Agreement”) among FME, FMCH and certain subsidiaries and affiliates, as Borrowers and Guarantors, the Lenders identified therein and Bank of America, N.A., as Administrative Agent, Collateral Agent, a Swingline Lender and an L/C Issuer;

WHEREAS, the Borrowers have requested modification of certain provisions of the Existing Credit Agreement, including, among other things, the reconstitution, extension and increase of the revolving credit facilities and the term loan facilities thereunder; and

WHEREAS, the parties are willing to agree to the requested amendments to the Existing Credit Agreement on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of these premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

Section 1.General Description of Amendment and Extension Provisions.

1.1Reconstitution, Amendment and Extension of the Revolving Credit Facilities.  The Revolving Commitments will be reconstituted, consisting of $900 million in USD Revolving Commitments and €600 million in Euro Revolving Commitments, and the termination date therefor shall be extended as set forth in the Credit Agreement.  The appropriate Lenders acknowledge and agree to the reallocation of USD Revolving Commitments and Euro Revolving Commitments as shown on Schedule 2.01 attached hereto.

1.2Amendment and Replacement of the Term Loan Facilities.  The balance of the existing Tranche A-3 Term Loan and the existing Tranche A-4 Term Loan will be refinanced with the proceeds of a new $1,500 million Tranche A-5 Term Loan, a new €400 million Tranche A-6 Term Loan and a new €350 million Tranche A-7 Term Loan.  The maturity dates for the new Tranche A-5 Term Loan, the new Tranche A-6 Term Loan, and the new Tranche A-7 Term Loan shall be as set forth in the Credit Agreement.  The Lenders providing commitments for the Tranche A-5 Term Loan, the Tranche A-6 Term Loan and the Tranche A-7 Term Loan agree to the allocation of Tranche A-5 Term Loan Commitments, the Tranche A-6 Term Loan Commitments and Tranche A-7 Term Loan Commitments as shown on Schedule 2.01 attached hereto.

The proceeds of the Tranche A-5 Term Loan, the proceeds of the Tranche A-6 Term Loan and the proceeds of the Tranche A-7 Term Loan will be funded on a net basis after giving effect to the refinancing of the outstanding principal balance of the Tranche A-3 Term Loan and

1

the Tranche A-4 Term Loan, and the Lenders will fund their respective interests in the Tranche A-5 Term Loan, the Tranche A-6 Term Loan and the Tranche A-7 Term Loan, in each case, on a net basis after giving effect to the establishment and reconstitution of interests therein with existing Tranche A-3 Term Lenders and existing Tranche A-4 Term Lenders being allowed to “cashless” roll-over of their interests from the Tranche A-3 Term Loan and/or the Tranche A-4 Term Loan to the Tranche A-5 Term Loan, the Tranche A-6 Term Loan and/or the Tranche A-7 Term Loan, in each case, on a net basis.

1.3Amendment Generally.  The parties hereto agree that FME, the appropriate Lenders and the Administrative Agent shall effect such assignments, prepayments, borrowings and reallocations as are necessary to effectuate the modifications to the Commitments and Loans as contemplated in this Amendment and the Credit Agreement such that, after giving effect thereto, the Lenders shall hold each class of the Commitments and Loans and have the Applicable Percentages, in each case as set forth on Schedule 2.01 attached hereto.

Section 2.Amendment of the Existing Credit Agreement.

2.1Credit Agreement.  Effective upon satisfaction of the conditions precedent set forth in Section 3 below, the Existing Credit Agreement is hereby amended and restated in its entirety as set forth in Annex A attached hereto (as so amended, including the amendments set forth in Sections 2.2 and 2.3 below, the “Credit Agreement”).  As so amended, the Credit Agreement shall continue in full force and effect.

2.2Schedules to Credit Agreement.

(a)Schedule 2.01 to the Existing Credit Agreement is hereby amended and restated in its entirety to read as set forth on Schedule 2.01 attached hereto.

(b)Schedules 1.01(a), 6.14, 8.06 and 8.08 to the Existing Credit Agreement are hereby deleted in their entirety.

(c)Schedule 2.01(a)(ii) is hereby added to the Existing Credit Agreement to read as set forth on Schedule 2.01(a)(ii) attached hereto.

2.3Exhibits to Credit Agreement.

(a)Exhibits 2.02 and 11.06 to the Existing Credit Agreement are hereby amended and restated in their entirety to read as set forth on Exhibits 2.02 and 11.06 attached hereto, respectively.

(b)Exhibits 2.14-1, 2.14-2, 2.18-1, 2.18-2 and 7.12 to the Existing Credit Agreement are hereby deleted in their entirety.

(c)Exhibits 2.13-10, 2.13-11 and 2.13-12 are hereby added to the Existing Credit Agreement to read as set forth in Exhibits 2.13-10, 2.13-11 and 2.13-12 attached hereto, respectively.

Section 3.Conditions Precedent.  This Amendment shall become effective upon prior or simultaneous satisfaction of the following conditions, in each case in form and substance reasonably satisfactory to the Administrative Agent:

2

3.1Receipt by the Administrative Agent of executed signature pages to this Amendment (or, in the case of any Lender, and at such Lender’s direction, a written consent directing the Administrative Agent to enter into this Amendment on such Lender’s behalf) from (a) the Borrowers and the Guarantors, (b) the Administrative Agent, (c) the Collateral Agent, (d) each Swingline Lender, (e) each L/C Issuer and (f) the appropriate Lenders (together with any “cashless rollover” agreements as may be necessary or appropriate).

3.2Receipt by the Administrative Agent of legal opinions for the Borrowers and Guarantors, including local counsel, where appropriate, regarding, among other things, existence, due authorization, execution, delivery and enforceability of this Amendment and the other loan documentation, and no conflicts with organizational documents, material debt documents or applicable law.

3.3Receipt by the Administrative Agent of copies of supporting resolutions, Organization Documents (or confirmation that there has been no change to the Organization Documents delivered on the Amendment No. 1 Effective Date), certificates of good standing, incumbency certificates and other corporate documentation from the Borrowers and the Guarantors.

3.4Receipt by the Administrative Agent and the Lenders of all documentation and other information with respect to the Loan Parties required under applicable “know your customer” and anti-money laundering rules and regulations, including the PATRIOT Act, in each case, that has been requested by the Administrative Agent or any Lender.

3.5Payment of all fees and expenses owing in connection with this Amendment, including fees and expenses of counsel to the Administrative Agent, to the extent invoiced.

The Administrative Agent will promptly notify the Credit Parties and the Lenders when the conditions to the effectiveness of the amendment provisions of Section 3 of this Amendment have been met and will confirm that those provisions are effective.  The provisions of Sections 1 through 2 hereof shall not be effective until the Administrative Agent shall have given such confirmation.

Section 4.Representations and Warranties; New Lenders.

4.1Representations and Warranties.  Each Credit Party hereby represents and warrants that:

(a)it has full power and authority, and has taken all action necessary, to execute and deliver this Amendment and to consummate the transactions contemplated hereby;

(b)it has executed and delivered this Amendment and this Amendment is a legal, valid and binding obligation enforceable against it in accordance with its terms, except to the extent that the enforceability may be limited by applicable Debtor Relief Laws affecting creditors’ rights generally and by equitable principles of law (regardless whether enforcement is sought in equity or at law); and

(c)as of the date hereof, (i) the representations and warranties set forth in Article VI of the Credit Agreement or any other Credit Document, or that are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (except those which expressly relate to an earlier period, in which case they are

3

true and correct as of such earlier period) and (ii) no Default or Event of Default exists or will result herefrom.

4.2New Lenders.  Each Lender becoming a “Lender” under the Credit Agreement as of the date hereof, represents, warrants and agrees that (a) it has full power and authority, and has taken all action necessary, to execute and deliver this Amendment and to consummate the transactions contemplated hereby and become a Lender under the Credit Agreement, (b) it meets the requirements for an “Eligible Assignee” under the Credit Agreement, and if not a Lender or affiliate of a Lender, that it is a commercial lender or other financial institution or other “accredited” investor (as defined in SEC Regulation D) that makes or acquires loans in the ordinary course of business, (c) it has delivered herewith any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, including Sections 3.01 and 11.21 of the Credit Agreement, duly completed and executed, (d) it has received copies of the Credit Agreement and other Credit Documents, together with copies of the most recent financial statements delivered pursuant to the terms thereof and such other documents and information as it has deemed appropriate to make its own credit analysis and decision independently and without reliance on the Administrative Agent or any other Lender, (e) it will, independently without reliance on the Administrative Agent or any other Lender, and based on such documents and other information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Documents, and (f) from and after the date hereof, it shall be bound by the provisions of the Credit Agreement as a Lender for all purposes, and shall perform all obligations (including, for Lenders with Revolving Commitments, the purchase of participation interests in L/C Obligations and Swingline Loans as provided therein) and have all of the rights and benefits of a Lender thereunder.

Section 5.Release.

5.1The appropriate Lenders hereby authorize the Administrative Agent and the Collateral Agent to (a) release each of the entities listed on Annex B attached hereto (such released entities, collectively, the “Released Entities”) as Borrowers and/or Guarantors under the Credit Agreement (or, as applicable, as pledgors under the Pledge Agreements), and (b) release any Liens granted by or on the Released Entities and their property in favor of the Administrative Agent or the Collateral Agent pursuant to the Credit Documents (such collateral, collectively, the “Released Collateral”), in each case, upon satisfaction of the conditions precedent set forth in Section 3 above.

5.2The Administrative Agent and the Collateral Agent hereby agree and acknowledge that, upon satisfaction of the conditions precedent set forth in Section 3 above, without further action by any person and notwithstanding anything to the contrary in any Credit Document, (a) each of the Released Entities shall be irrevocably released as Borrowers and/or Guarantors under the Credit Agreement (or, as applicable, as pledgors under the Pledge Agreements), and (b) any Liens in favor of the Administrative Agent or the Collateral Agent on the Released Collateral shall be released.  The Administrative Agent and the Collateral Agent agree to execute and deliver to FME, at the sole expense of FME, all documents or instruments reasonably requested by FME to further evidence or effectuate the releases contemplated hereby and to return to the Released Entities any collateral of and in respect of the Released Entities that is in the Administrative Agent’s or the Collateral Agent’s possession upon satisfaction of the conditions precedent set forth in Section 3 above.

5.3Upon satisfaction of the conditions precedent set forth in Section 3 above, the Administrative Agent and the Collateral Agent hereby authorize FME (or any designee of FME)

4

to file the UCC-3 termination statements attached hereto as Annex C to evidence the release of the Administrative Agent’s and the Collateral Agent’s security interests pursuant to this Section 5.

5.4Without limiting the generality of Section 5.2 above, upon satisfaction of the conditions precedent set forth in Section 3 above, the Collateral Agent (acting in its own name and on behalf of the Administrative Agent and the Lenders) (a) hereby releases, pursuant to sec. 1255 para 1 of the German Civil Code (gibt auf im Sinne von § 1255 Abs. 1 Bürgerliches Gesetzbuch) the pledges over the Pledged Rights constituted under the German Share Pledge Agreements, without further action by any person and notwithstanding anything to the contrary in any Credit Document, (b) reassigns to the respective Released Entities any other rights which have been granted or assigned to it under the German Share Pledge Agreements and the Parallel Debt Agreements, (c) undertakes to provide written notice, in the form of Exhibit A attached hereto, to the Pledged Companies of the release of the pledges over the Pledged Rights, and (d) hereby terminates each of the German Share Pledge Agreements and the Parallel Debt Agreements.

For purposes of this Section 5.4:

(i)“German Share Pledge Agreements” means each of the following agreements: (A) German law governed share pledge agreement dated 30 October 2012 (roll of deeds no. 733/2012-S of the notary public Dr. Karl-Heinz Schmiegelt, Frankfurt am Main) and entered into between (1) FME, as pledgor, (2) the Pledged Companies, as pledged companies, (3) Bank of America, N.A., as collateral agent and pledgee, and (4) various institutions as pledgees; (B) German law governed share pledge confirmation and assumption agreement dated 16 October 2014 (roll of deeds no. 1338/2014 of the notary public Christoph Walther, Bad Homburg v.d.H.) and entered into between (1) FME, (2) Fresenius Medical Care Beteiligungsgesellschaft mbH as existing pledgor, (3) Fresenius Medical Care Investment GmbH as new shareholder, (4) Fresenius Medical Care Deutschland GmbH, as pledged company, (5) Bank of America, N.A., as collateral agent and pledgee, and (6) various institutions as pledgees; and (C) German law governed share pledge agreement dated 26 November 2014 (roll of deeds no. 94/2014-S of the notary public Dr. Kersten von Schenck, Frankfurt am Main) and entered into between (1) FME and Fresenius Medical Care Investment GmbH, as pledgors, (2) the Pledged Companies, as pledged companies, (3) Bank of America, N.A., as collateral agent and pledgee, and (4) various institutions as pledgees.

(ii)“Parallel Debt Agreements” means each of the following agreements: (A) the parallel debt agreement dated 30 October 2012 and entered into between (1) FME, (2) Bank of America, N.A., as collateral agent, and (3) various institutions as original finance parties; and (B) the confirmation of parallel debt agreement dated 26 November 2014 and entered into between (1) FME, (2) Bank of America, N.A., as collateral agent, and (3) various entities as obligors.

(iii)“Pledged Companies” means Fresenius Medical Care Beteiligungsgesellschaft mbH and Fresenius Medical Care Deutschland GmbH.

(iv)“Pledged Rights” has the meaning given to such term in the German Share Pledge Agreements and shall, in addition, include any other pledges created for the benefit of the pledgees pursuant to the German Share Pledge Agreements.

5

5.5The Collateral Agent hereby waives the receipt of the declaration of acceptance (verzichtet auf Zugang der Annahmeerklärung) pursuant to section 151 of the German Civil Code (Bürgerliches Gesetzbuch).

Section 6.Full Force and Effect; Affirmation.  Except as modified hereby, all of the terms and provisions of the Existing Credit Agreement and the other Credit Documents (including schedules and exhibits thereto, except as modified hereby) shall remain in full force and effect.  Each of the Credit Parties hereby (a) affirms all of its obligations under the Credit Documents to which it is party and (b) agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge their obligations under any Credit Document, except as expressly stated therein.

Section 7.Expenses.  FME agrees to pay all reasonable costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment, including the reasonable fees and expenses of Moore & Van Allen, PLLC.

Section 8.Counterparts.  This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, and it shall not be necessary in making proof of this Amendment to produce or account for more than one such counterpart.  Delivery by any party hereto of an executed counterpart of this Amendment by facsimile shall be effective as such party’s original executed counterpart.

Section 9.Credit Document.  Each of the parties hereto hereby agrees that this Amendment is a Credit Document.  The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender, any L/C Issuer, any Swingline Lender, the Administrative Agent or the Collateral Agent under any of the Credit Documents, nor, except as expressly provided herein, constitute a waiver or amendment of any provision of any of the Credit Documents.

Section 10.Governing Law; Jurisdiction.  This Amendment (except for Sections 5.4 and 5.5 hereof, which shall be governed by, and construed in accordance with, the laws of the Federal Republic of Germany) shall be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely within such state.  The courts of Frankfurt am Main, Germany, shall have non-exclusive jurisdiction to settle any dispute arising out of or in connection with Sections 5.4 or 5.5 hereof.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

6

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

BORROWER:	FRESENIUS MEDICAL CARE HOLDINGS, INC.,
	a New York corporation
	By:	/s/ Mark Fawcett
	Name:	Mark Fawcett
	Title:	Senior Vice President & Treasurer

BORROWER:
FRESENIUS MEDICAL CARE AG & Co. KGaA,
a German partnership limited by shares, represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner
By:	/s/ Michael Brosnan
Name:	Michael Brosnan
Title:	Member of the Management Board
By:	/s/ William J. Valle
Name:	William J. Valle
Title:	Member of the Management Board

BORROWERS:

NATIONAL MEDICAL CARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ALABAMA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF CALIFORNIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF GEORGIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF KENTUCKY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF LOUISIANA, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MINNESOTA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MISSISSIPPI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW HAMPSHIRE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW JERSEY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW MEXICO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NORTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF OHIO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF PENNSYLVANIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TENNESSEE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TEXAS, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF VIRGINIA, INC., a Delaware corporation

FRESENIUS USA MANUFACTURING, INC., a Delaware corporation

FRESENIUS USA MARKETING, INC., a Delaware corporation

FRESENIUS USA, INC., a Massachusetts corporation

SPECTRA LABORATORIES, INC., a Nevada corporation

WSKC DIALYSIS SERVICES, INC., an Illinois corporation

FRESENIUS MANAGEMENT SERVICES, INC., a Delaware corporation

RENAL CARE GROUP, INC., a Delaware corporation

DIALYSIS CENTERS OF AMERICA – ILLINOIS, INC., an Illinois corporation

RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation

RENAL ADVANTAGE HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WISCONSIN, INC., a Delaware corporation

FRESENIUS MEDICAL CARE VENTURES HOLDING COMPANY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF DELAWARE, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTH, INC., a Delaware corporation

RENAL CARE GROUP ALASKA, INC., an Alaska corporation

RENAL CARE GROUP EAST, INC., a Pennsylvania corporation

RCG MISSISSIPPI, INC., a Delaware corporation

RENAL CARE GROUP NORTHWEST, INC., a Delaware corporation

RCG UNIVERSITY DIVISION, INC., a Tennessee corporation

RENEX DIALYSIS CLINIC OF WOODBURY, INC., a New Jersey corporation

SPECTRA EAST, INC., a Delaware corporation

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF SOUTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

By:	/s/ Mark Fawcett
Name:	Mark Fawcett
Title:	Senior Vice President & Treasurer

GUARANTOR:	FRESENIUS MEDICAL CARE HOLDINGS, INC.,
	a New York corporation
	By:	/s/ Mark Fawcett
	Name:	Mark Fawcett
	Title:	Senior Vice President & Treasurer

GUARANTORS:

NATIONAL MEDICAL CARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ALABAMA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF CALIFORNIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF GEORGIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF KENTUCKY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF LOUISIANA, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MINNESOTA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MISSISSIPPI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW HAMPSHIRE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW JERSEY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW MEXICO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NORTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF OHIO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF PENNSYLVANIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TENNESSEE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TEXAS, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF VIRGINIA, INC., a Delaware corporation

FRESENIUS USA MANUFACTURING, INC., a Delaware corporation

FRESENIUS USA MARKETING, INC., a Delaware corporation

FRESENIUS USA, INC., a Massachusetts corporation

SPECTRA LABORATORIES, INC., a Nevada corporation

WSKC DIALYSIS SERVICES, INC., an Illinois corporation

FRESENIUS MANAGEMENT SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MARYLAND, INC., a Delaware corporation

RENAL CARE GROUP, INC., a Delaware corporation

DIALYSIS CENTERS OF AMERICA – ILLINOIS, INC., an Illinois corporation

RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation

RENAL ADVANTAGE HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE INC., a Delaware corporation

LIBERTY DIALYSIS, LLC, a Delaware limited liability company

AMERICAN ACCESS CARE HOLDINGS, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MISSOURI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WISCONSIN, INC., a Delaware corporation

DIALYSIS MANAGEMENT CORPORATION, a Texas corporation

FRESENIUS MEDICAL CARE VENTURES HOLDING COMPANY, INC., a Delaware corporation

NNA OF ALABAMA, INC., an Alabama corporation

BIO-MEDICAL APPLICATIONS OF DELAWARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF FAYETTEVILLE, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTH, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTHEAST, INC., a Florida corporation

RENAL CARE GROUP ALASKA, INC., an Alaska corporation

RENAL CARE GROUP EAST, INC., a Pennsylvania corporation

RCG MISSISSIPPI, INC., a Delaware corporation

RENAL CARE GROUP NORTHWEST, INC., a Delaware corporation

RENAL CARE GROUP TEXAS, INC., a Texas corporation

RCG UNIVERSITY DIVISION, INC., a Tennessee corporation

RENAL CARE GROUP SOUTHWEST HOLDINGS, INC., a Delaware corporation

RENAL RESEARCH INSTITUTE, LLC, a New York limited liability company

RENEX DIALYSIS CLINIC OF WOODBURY, INC., a New Jersey corporation

SPECTRA EAST, INC., a Delaware corporation

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF SOUTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

FRESENIUS MEDICAL CARE INTEGRATED CARE GROUP, LLC, a Delaware limited liability company

By:	/s/ Mark Fawcett
Name:	Mark Fawcett
Title:	Senior Vice President & Treasurer

GUARANTORS:	FRESENIUS MEDICAL CARE AG & Co.
	KGaA,
	a German partnership limited by shares, represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner
	By:	/s/ Michael Brosnan
	Name:	Michael Brosnan
	Title:	Member of the Management Board
	By:	/s/ William J. Valle
	Name:	William J. Valle
	Title:	Member of the Management Board
	FRESENIUS MEDICAL CARE
	DEUTSCHLAND GmbH,
	a German limited liability company
	By:	/s/ Olaf Schermeier
	Name:	Dr. Olaf Schermeier
	Title:	Managing Director
	By:	/s/ Marco Kiene
	Name:	Marco Kiene
	Title:	Managing Director
	FRESENIUS MEDICAL CARE
	BETEILIGUNGSGESELLSCHAFT mbH,
	a German limited liability company
	By:	/s/ Rice Powell
	Name:	Rice Powell
	Title:	Managing Director
	By:	/s/ Dominik Wehner
	Name:	Dominik Wehner
	Title:	Managing Director

GUARANTORS:	FRESENIUS MEDICAL CARE US
	BETEILIGUNGSGESELLSCHAFT mbH,
	a German limited liability company
	By:	/s/ Josef Dinger
	Name:	Josef Dinger
	Title:	Managing Director
	FRESENIUS MEDICAL CARE US ZWEI
	VERMÖGENSVERWALTUNGS GmbH & Co. KG, a German limited partnership
	By:	Fresenius Medical Care Vermögens-verwaltungs GmbH, a German limited liability company, its General Partner
		By:	/s/ Josef Dinger
		Name:	Josef Dinger
		Title:	Managing Director
	FRESENIUS MEDICAL CARE GmbH,
	a German limited liability company
	By:	/s/ Michael Mareth
	Name:	Michael Mareth
	Title:	Managing Director
	By:	/s/ Gunther Klotz
	Name:	Gunther Klotz
	Title:	Managing Director

GUARANTORS:	FMC FINANCE II S.à r.l.,
	a private limited company (société à responsabilité limitée) organized under the laws of Luxembourg
	By:	/s/ Gabriele Dux
	Name:	Gabriele Dux
	Title:	Manager
	By:	/s/ Armin Karch
	Name:	Armin Karch
	Title:	Manager
	FMC FINANCE VII S.A,
	a société anonyme organized under the laws of Luxembourg
	By:	/s/ Gabriele Dux
	Name:	Gabriele Dux
	Title:	Director
	By:	/s/ Ilka Fluhrer
	Name:	Ilka Fluhrer
	Title:	Director
	FMC FINANCE VIII S.A,
	a société anonyme organized under the laws of Luxembourg
	By:	/s/ Gabriele Dux
	Name:	Gabriele Dux
	Title:	Director
	By:	/s/ Ilka Fluhrer
	Name:	Ilka Fluhrer
	Title:	Director

GUARANTOR:	FRESENIUS MEDICAL CARE NORTH
	AMERICA HOLDINGS LIMITED
	PARTNERSHIP,
	a Delaware limited partnership
	By:	Fresenius Medical Care US Vermögensver-waltungs GmbH and Co. KG, a German limited partnership, its General Partner
		By:	Fresenius Medical Care Vermögensverwaltungs
			GmbH, a German limited liability company, its General Partner
			By:	/s/ Josef Dinger
			Name:	Josef Dinger
			Title:	Managing Director

GUARANTORS:	BIO-MEDICAL APPLICATIONS MANAGEMENT COMPANY, INC., a Delaware corporation
	BIO-MEDICAL APPLICATIONS OF MAINE, INC., a Delaware corporation
	EVEREST HEALTHCARE HOLDINGS, INC., a Delaware corporation
	FRESENIUS SECURITIES, INC., a California corporation
	SRC HOLDING COMPANY, INC., a Delaware corporation
	FRESENIUS MEDICAL CARE US FINANCE, INC., a Delaware corporation
	FRESENIUS MEDICAL CARE US FINANCE II, INC., a Delaware corporation
	FRESENIUS MEDICAL CARE B, LLC, a Delaware limited liability company
	STAT DIALYSIS CORPORATION, a Delaware corporation
	LIBERTY DIALYSIS HOLDINGS, INC., a Delaware corporation
	RENAL ADVANTAGE PARTNERS, LLC, a Delaware limited liability company
	RA ACQUISITION CO., LLC, a Delaware limited liability company
	RAI II, LLC, a Delaware limited liability company
	RAI CARE CENTERS HOLDINGS I, LLC, a Delaware limited liability company
	RAI CARE CENTERS HOLDINGS II, LLC, a Delaware limited liability company
	LIBERTY DIALYSIS, INC., a Delaware corporation
	AMERICAN ACCESS CARE INVESTMENT HOLDINGS, LLC, a Delaware limited liability company
	FRESENIUS VASCULAR CARE, INC., a Delaware corporation
	RENEX CORP., a Florida corporation
	By:	/s/ Mark Fawcett
	Name:	Mark Fawcett
	Title:	Senior Vice President & Treasurer

GUARANTOR:	NEW YORK DIALYSIS SERVICES, INC.,
	a New York corporation
	By:	/s/ Mark Fawcett
	Name:	Mark Fawcett
	Title:	Senior Vice President & Treasurer

GUARANTOR:	NCP Investment Holdings Inc.,
	a Delaware corporation
	By:	/s/ Bryan Mello
	Name:	Bryan Mello
	Title:	Assistant Treasurer

Acknowledged and agreed for purposes of Section 5.4 hereof:

FRESENIUS MEDICAL CARE INVESTMENT GmbH,
a German limited liability company
By:	/s/ Rice Powell
Name:	Rice Powell
Title:	Managing Director
By:	/s/ Dominik Wehner
Name:	Dominik Wehner
Title:	Managing Director

ADMINISTRATIVE AGENT:	BANK OF AMERICA, N.A.,
	as Administrative Agent
	By:	/s/ Maurice E. Washington
	Name:	Maurice E. Washington
	Title:	Vice President

COLLATERAL AGENT:	BANK OF AMERICA, N.A.,
	as Collateral Agent
	By:	/s/ Maurice E. Washington
	Name:	Maurice E. Washington
	Title:	Vice President

LENDERS:	BANK OF AMERICA, N.A.,
	as a Lender, an L/C Issuer and a Swingline Lender
	By:	/s/ Joseph L. Corah
	Name:	Joseph L. Corah
	Title:	Director

DEUTSCHE BANK AG NEW YORK BRANCH,
as a Lender and an L/C Issuer
By:	/s/ A. Scott Daniel
Name:	A. Scott Daniel
Title:	Managing Director
By:	/s/ Michael Busam
Name:	Michael Busam
Title:	Director

COMMERZBANK AKTIENGESELLSCHAFT,
FILIALE LUXEMBOURG,
as a Lender
By:	/s/ Dr. Kai Roderich Bringewald
Name:	Dr. Kai Roderich Bringewald
Title:	Vice President
By:	/s/ Jeanette Strupp
Name:	Jeanette Strupp
Title:	Associate

JPMORGAN CHASE BANK, N.A.,
as a Lender and an L/C Issuer
By:	/s/ Tasvir Hasan
Name:	Tasvir Hasan
Title:	Executive Director

SUNTRUST BANK, as a Lender and an L/C Issuer
By:	/s/ Philip VanFossan
Name:	Philip VanFossan
Title:	Vice President

THE BANK OF NOVA SCOTIA,
as a Lender and an L/C Issuer
By:	/s/ Michelle C. Phillips
Name:	Michelle C. Phillips
Title:	Execution Head & Director

UNICREDIT BANK AG,
as a Lender and an L/C Issuer
By:	/s/ Tom Taylor
Name:	Tom Taylor
Title:	Managing Director
By:	/s/ Thomas Petz
Name:	Thomas Petz
Title:	Director

WELLS FARGO BANK, NATIONAL ASSOCIATION,
as a Lender and an L/C Issuer
By:	/s/ Kirk Tesch
Name:	Kirk Tesch
Title:	Managing Director

TD BANK, N.A.,
as a Lender
By:	/s/ David Perlman
Name:	David Perlman
Title:	Senior Vice President

BBVA IRELAND PLC,
as a Lender
By:	/s/ Pablo Vallejo
Name:	Pablo Vallejo
Title:	Managing Director

BANCO SANTANDER, S.A.,
as a Lender
By:	/s/ Paloma Garcia
Name:	Paloma Garcia
Title:	Vice President
By:	/s/ Isabel Pastor
Name:	Isabel Pastor
Title:	Vice President

BANK OF CHINA, NEW YORK BRANCH,
as a Lender
By:	/s/ Raymond Qiao
Name:	Raymond Qiao
Title:	Chief Lending Officer

BANK OF CHINA LIMITED
ZWEIGNIEDERLASSUNG FRANKFURT AM MAIN
FRANKFURT BRANCH,
as a Lender
By:	/s/ Bernd Meist
Name:	Bernt Meist
Title:	Geschäftsleiter
By:	/s/ Fang Wang
Name:	Fang Wang
Title:	Vice President

BARCLAYS BANK PLC,
as a Lender
By:	/s/ Chris Bicheno
Name:	Chris Bicheno
Title:	Vice President
(Executed in London)

BAYERISCHE LANDESBANK,
as a Lender
By:	/s/ Ulrike Lann
Name:	Ulrike Lann
By:	/s/ Heidi Erhardt
Name:	Heidi Erhardt

BNP PARIBAS S.A. NIEDERLASSUNG
DEUTSCHLAND,
as a Lender
By:	/s/ Rene Höhnlein
Name:	Rene Höhnlein
Title:	Director
By:	/s/ Alexander Gutmann
Name:	Alexander Gutmann
Title:	Director

FIRST HAWAIIAN BANK,
as a Lender
By:	/s/ Dawn Hofmann
Name:	Dawn Hofmann
Title:	Executive Vice President

CITIBANK N.A., London Branch,
as a Lender
By:	/s/ Lucy Devlin
Name:	Lucy Devlin
Title:	Director

CREDIT AGRICOLE CORPORATE AND
INVESTMENT BANK DEUTSCHLAND,
as a Lender
By:	/s/ Femke Blancquaert
Name:	Femke Blancquaert
Title:	Chief Operating Officer
By:	/s/ Frederik Norrmann
Name:	Frederik Norrmann
Title:	Managing Director

CREDIT INDUSTRIEL ET COMMERCIAL,
LONDON BRANCH
as a Lender
By:	/s/ Ian Richardson
Name:	Ian Richardson
Title:	Director, Acquisition Finance
By:	/s/ Fabritzia Capurro
Name:	Fabritzia Capurro
Title:	Acquisition Finance, Director

CREDIT MUTUEL — BECM BANQUE
EUROPEENNE DU CREDIT MUTUEL SAS
NIEDERLASSUNG DEUTSCHLAND,
as a Lender
By:	/s/ Daniel Lorang
Name:	Daniel Lorang
By:	/s/ Walter Zweig
Name:	Walter Zweig

Credit Suisse AG, Cayman Islands Branch,
as a Lender
By:	/s/ William O’Daly
Name:	William O’Daly
Title:	Authorized Signatory
By:	/s/ Tino Schaufelberger
Name:	Tino Schaufelberger
Title:	Authorized Signatory

DNB Capital LLC,
as a Lender
By:	/s/ Christian Rynning
Name:	Christian Rynning
Title:	First Vice President
By:	/s/ Caroline Adams
Name:	Caroline Adams
Title:	First Vice President

DZ Bank AG,
Deutsche Zentral-Genossenschaftsbank,
Frankfurt am Main
as a Lender
By:	/s/ Brigitta Eugelhard
Name:	Brigitta Eugelhard
Title:	Vice President
By:	/s/ Christian Prellwitz
Name:	Christian Prellwitz
Title:	Senior Vice President

Goldman Sachs Bank USA,
as a Lender
By:	/s/ Lorraine Schmit
Name:	Lorraine Schmit
Title:	Authorized Signatory

HSBC Trinkaus & Burkhardt AG,
as a Lender
By:	/s/ Florian von Bodman
Name:	Florian von Bodman
Title:	Director
By:	/s/ Janis Eichenseher
Name:	Janis Eichenseher
Title:	Manager

HSBC Bank PLC,
as a Lender
By:	/s/ Colette Pithie
Name:	Colette Pithie
Title:	Associate Director

ING Bank, A Brach of ING-DIBA AG,
as a Lender
By:	/s/ Michael Hofmann
Name:	Michael Hofmann
Title:	Director
By:	/s/Olga Borovikov
Name:	Olga Borovikov
Title:	Vice President

Landesbank Baden-Württemberg, ACTING THROUHG ITS NEW YORK BRANCH,
as a Lender
By:	/s/ A. Bruns
Name:	A. Bruns
Title:	VP
By:	/s/ M. Breckheimer
Name:	M. Breckheimer
Title:	VP

Landesbank Hessen-Thüringen Girozentrale,
as a Lender
By:	/s/ Matthias Metzger
Name:	Matthias Metzger
Title:	SVP
By:	/s/ Claus Hemsteg
Name:	Claus Hemsteg
Title:	SVP

Mediobanca International (Luxembourg) S.A.,
as a Lender
By:	/s/ Stefano Biondi
Name:	Stefano Biondi
Title:	Chief Executive Officer
By:	/s/ Edoardo Reitano
Name:	Edoardo Reitano
Title:	Chief Financial Officer

MB Funding Lux S.A.,
as a Lender
By:	/s/ Alessandro Moro
Name:	Alessandro Moro
Title:	Managing Director
By:	/s/ Gaelle Attardo-Kontzler
Name:	Gaelle Attardo-Kontzler
Title:	Director

Mizuho Bank, Ltd,
as a Lender
By:	/s/ Henok Kifle
Name:	Henok Kifle
Title:	Senior Director
By:	/s/ Johannes Neuhauser
Name:	Johannes Neuhauser
Title:	Associate Director

PNC Bank, National Association,
as a Lender
By:	/s/ Christopher P. Kleczkowski
Name:	Christopher P. Kleczkowski
Title:	Senior Vice President

Royal Bank of Canada (New York Branch),
as a Lender
By:	/s/ Diana Lee
Name:	Diana Lee
Title:	Authorized Signatory

RBC Europe Limited,
as a Lender
By:	/s/ Carsten Metzger
Name:	Carsten Metzger
Title:	Director

City National Bank,
as a Lender
By:	/s/ Steven Sau
Name:	Steven Sau
Title:	VP

SEB AG,
as a Lender
By:	/s/ Irina Reichel
Name:	Irina Reichel
Title:
By:	/s/ Marion Haas
Name:	Marion Haas
Title:

Societe Generale,
as a Lender
By:	/s/ Shelley Guttman
Name:	Shelley Guttman
Title:	Director

Sumitomo Mitsui Banking Corporation,
as a Lender
By:	/s/ Michael Oellers
Name:	Michael Oellers
Title:	Managing Director
By:	/s/ Harald Wimmer
Name:	Harald Wimmer
Title:	Executive Director

U.S. Bank National Association,
as a Lender
By:	/s/ Joseph M. Schnorr
Name:	Joseph M. Schnorr
Title:	Senior Vice President

Danske Bank A/S
as a Lender
By:	/s/ Oliver Borchert
Name:	Oliver Borchert
Title:
By:	/s/ Bent Nielsen
Name:	Bent Nielsen
Title:

The Huntington National Bank,
as a Lender
By:	/s/ Josephine C. Wisniewski
Name:	Josephine C. Wisniewski
Title:	Vice President

Intesa Sanpaolo Bank Luxembourg
as a Lender
By:	/s/ Selji Amino
Name:	Selji Amino
Title:	Directeur-Adjoint
By:	/s/ Christiano Patalocchi
Name:	Christiano Patalocchi
Title:	Chief Risk Officer Directeur Agréé

Nord/LB Luxembourg S.A Covered Bond Bank,
as a Lender
By:	/s/ I. Sommerkamp-Brill
Name:	I. Sommerkamp-Brill
Title:
By:	/s/ A. Mohn
Name:	A. Mohn
Title:

The Bank of New York Mellon,
as a Lender
By:	/s/ Clifford A. Mull
Name:	Clifford A. Mull
Title:	Director

Arab Banking Corporation (B.S.C.), Grand Cayman branch,
as a Lender
By:	/s/ Richard Tull
Name:	Richard Tull
Title:	Vice President
	Head of Trade Finance
By:	/s/ Victoria Gale
Name:	Victoria Gale
Title:	Vice President

DBS Bank LTD.,
as a Lender
By:	/s/ Yeo How Ngee
Name:	Yeo How Ngee
Title:	Managing Director

Fifth Third Bank,
as a Lender
By:	/s/ Joshua N. Livingston
Name:	Joshua N. Livingston
Title:	Duly Authorized Signatory

First Tennessee Bank, N.A.,
as a Lender
By:	/s/ Cathy Wind
Name:	Cathy Wind
Title:	Senior Vice President

KfW IPEX Bank GmbH,
as a Lender
By:	/s/ Wolfgang Behler
Name:	Wolfgang Behler
Title:	Managing Director
By:	/s/ Sebastian Eberle
Name:	Sebastian Eberle
Title:	Director

The Bank of Tokyo-Mitsubishi UFJ, Ltd.
as a Lender
By:	/s/Stephan Stamm
Name:	Stephan Stamm
Title:	Managing Director
By:	/s/ Ed Langendam
Name:	Ed Langendam
Title:	Managing Director

Mercantil Bank, N.A.,
as a Lender
By:	/s/Daniel Ugarte
Name:	Daniel Ugarte
Title:	Vice-President, Syndications Portfolio Manager
By:	/s/ Carlos Iafigliola
Name:	Carlos Iafigliola
Title:	Sr. Vice-President, Treasury

People’s United Bank, N.A.,
as a Lender
By:	/s/ Amy LeBlanc Hackett
Name:	Amy LeBlanc Hackett
Title:	SVP

Raiffeisen Bank International AG,
as a Lender
By:	/s/Mag. Georg Lauringer
Name:	Mag. Georg Lauringer
Title:	Director
By:	/s/ Dr. Natalie Egger-Grunicke
Name:	Dr. Natalie Egger-Grunicke
Title:	Director

Synovus Bank,
as a Lender
By:	/s/ Michael Sawicki
Name:	Michael Sawicki
Title:	Director, Corporate Banking

Deutsche Apotheker — und Ärztebank eG,
as a Lender
By:	/s/ Bodo Büchler
Name:	Bodo Büchler
Title:	Abteilungsdirektor
By:	/s/Markus Wendel
Name:	Markus Wendel
Title:	Prokurist

Bank of Communications Co., Ltd, New York Branch,
as a Lender
By:	/s/ Shelley He
Name:	Shelley He
Title:	Deputy General Manager

Annex A

Credit Agreement

See attached.

CREDIT AGREEMENT

dated as of October 30, 2012

among

FRESENIUS MEDICAL CARE AG & CO. KGAA,
and

FRESENIUS MEDICAL CARE HOLDINGS, INC.

THE LENDERS PARTY HERETO,

BANK OF AMERICA, N.A.,
as Administrative Agent and L/C Issuer,

DEUTSCHE BANK SECURITIES INC.,
as Sole Syndication Agent,

COMMERZBANK AKTIENGESELLSCHAFT, FILIALE LUXEMBURG,
JPMORGAN CHASE BANK, N.A.,
THE BANK OF NOVA SCOTIA,
SUNTRUST BANK,

UNICREDIT BANK AG, NEW YORK BRANCH

and

WELLS FARGO BANK, NATIONAL ASSOCIATION,
as Co-Documentation Agents,

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED,
DEUTSCHE BANK SECURITIES INC.,
COMMERZBANK AKTIENGESELLSCHAFT, FILIALE LUXEMBURG,
J.P. MORGAN SECURITIES PLC,
THE BANK OF NOVA SCOTIA,
SUNTRUST ROBINSON HUMPHREY, INC.,

UNICREDIT BANK AG, NEW YORK BRANCH

and

WELLS FARGO SECURITIES, LLC
as Mandated Lead Arrangers and Joint Book Runners

TABLE OF CONTENTS

Article and Section		Page
Article I DEFINITIONS AND ACCOUNTING TERMS		1
1.01	Defined Terms	1
1.02	Interpretive Provisions	34
1.03	Accounting Terms and Provisions	34
1.04	Rounding	35
1.05	Exchange Rates; Currency Equivalents	35
1.06	Additional Alternative Currencies	36
1.07	Change of Currency	37
1.08	Times of Day	37
1.09	Letter of Credit Amounts	37
1.10	Anti-Boycott Rules	37
Article II COMMITMENTS AND CREDIT EXTENSIONS		38
2.01	Commitments	38
2.02	Borrowings, Conversions and Continuations	41
2.03	Additional Provisions with respect to Letters of Credit	44
2.04	Additional Provisions with respect to Swingline Loans	51
2.05	Repayment of Loans	54
2.06	Prepayments	55
2.07	Termination or Reduction of Commitments	56
2.08	Interest	57
2.09	Fees	57
2.10	Computation of Interest and Fees; Retroactive Adjustments of Applicable Rate	59
2.11	Payments Generally; Administrative Agent’s Clawback	59
2.12	Sharing of Payments By Lenders	61
2.13	Evidence of Debt	62
2.14	[Reserved]	62
2.15	[Reserved]	62
2.16	Cash Collateral	62
2.17	Defaulting Lenders	63
2.18	[Reserved]	65
Article III TAXES, YIELD PROTECTION AND ILLEGALITY		66
3.01	Taxes	66
3.02	Illegality	70
3.03	Inability to Determine Rates	70
3.04	Increased Cost; Capital Adequacy	71
3.05	Compensation for Losses	73
3.06	Mitigation Obligations; Replacement of Lenders	73
3.07	Survival Losses	74
Article IV GUARANTY		74
4.01	The Guaranty	74
4.02	Obligations Unconditional	75
4.03	Reinstatement	76
4.04	Certain Waivers	76
4.05	Remedies	76

i

4.06	Rights of Contribution	76
4.07	Guaranty of Payment; Continuing Guaranty	77
4.08	Keepwell	77
Article V CONDITIONS PRECEDENT TO CREDIT EXTENSIONS		77
5.01	Conditions of Effectiveness	77
5.02	Conditions to all Credit Extensions	79
Article VI REPRESENTATIONS AND WARRANTIES		79
6.01	Existence, Qualification and Power; Compliance with Laws	79
6.02	Authorization; No Contravention	80
6.03	Governmental Authorization; Other Consents	80
6.04	Binding Effect	80
6.05	Financial Statements	80
6.06	No Material Adverse Effect	80
6.07	Litigation	80
6.08	No Default	81
6.09	Ownership of Property; Liens	81
6.10	Environmental Compliance	81
6.11	Insurance	81
6.12	Taxes	81
6.13	ERISA Compliance	81
6.14	[Reserved]	82
6.15	Margin Regulations; Investment Company Act	82
6.16	Disclosure	82
6.17	Compliance with Laws	82
6.18	Intellectual Property; Licenses, Etc.	83
6.19	EEA Financial Institution	83
6.20	Reimbursement from Medical Reimbursement Programs	83
6.21	Anti-Corruption and Sanctions Compliance	83
Article VII AFFIRMATIVE COVENANTS		83
7.01	Financial Statements	84
7.02	Certificates; Other Information	84
7.03	Notification	85
7.04	Payment of Obligations	86
7.05	Preservation of Existence, Etc.	86
7.06	Maintenance of Properties	87
7.07	Maintenance of Insurance	87
7.08	Compliance with Laws	87
7.09	Books and Records	87
7.10	[Reserved]	88
7.11	Use of Proceeds	88
7.12	Ownership	88
Article VIII NEGATIVE COVENANTS		88
8.01	Indebtedness	88
8.02	Liens	89
8.03	[Reserved]	91
8.04	Fundamental Changes	91
8.05	[Reserved]	92

ii

8.06	[Reserved]	92
8.07	Change in Nature of Business	92
8.08	[Reserved]	92
8.09	Fiscal Year	92
8.10	Financial Covenants	92
Article IX EVENTS OF DEFAULT AND REMEDIES		93
9.01	Events of Default	93
9.02	Remedies Upon Event of Default	95
9.03	Application of Funds	95
Article X ADMINISTRATIVE AGENT		96
10.01	Appointment and Authorization of Administrative Agent	96
10.02	Rights as a Lender	96
10.03	Exculpatory Provisions	97
10.04	Reliance by Administrative Agent	97
10.05	Delegation of Duties	98
10.06	Resignation of the Administrative Agent	98
10.07	Non-Reliance on Administrative Agent and Other Lenders	99
10.08	No Other Duties	99
10.09	Administrative Agent May File Proofs of Claim	100
10.10	Collateral and Guaranty Matters	100
10.11	Swap Contracts	101
Article XI MISCELLANEOUS		101
11.01	Amendments, Etc.	101
11.02	Notices; Effectiveness; Electronic Communication	104
11.03	No Waiver; Cumulative Remedies; Enforcement	106
11.04	Expenses; Indemnity; Damage Waiver	106
11.05	Payments Set Aside	108
11.06	Successors and Assigns	108
11.07	Treatment of Certain Information; Confidentiality	113
11.08	Right of Setoff	114
11.09	Interest Rate Limitation	115
11.10	Counterparts; Integration; Effectiveness	115
11.11	Survival of Representations and Warranties	115
11.12	Severability	116
11.13	Replacement of Lenders	116
11.14	Lender Representations	117
11.15	Governing Law; Jurisdiction; Etc.	117
11.16	Waiver of Jury Trial	119
11.17	No Advisory or Fiduciary Responsibility	119
11.18	USA PATRIOT Act Notice	120
11.19	Judgment Currency	120
11.20	Electronic Execution of Assignments and Certain Other Documents	120
11.21	Acknowledgment and Consent to Bail-in of EEA Financial Institutions	121
11.22	Limitation of Liability for German Guarantors	121

iii

SCHEDULES

Schedule 2.01	Lenders and Commitments
Schedule 2.01(a)(ii)	USD L/C Commitments of USD L/C Issuers
Schedule 2.03	Existing Letters of Credit
Schedule 11.02	Notice Addresses

EXHIBITS

Exhibit 2.02	Form of Loan Notice
Exhibit 2.13-1	Form of USD Revolving Note
Exhibit 2.13-2	Form of USD Swingline Note
Exhibit 2.13-3	Form of Euro Revolving Note
Exhibit 2.13-6	Form of Tranche A-1 Term Note
Exhibit 2.13-7	Form of Tranche A-2 Term Note
Exhibit 2.13-8	Form of Tranche A-3 Term Note
Exhibit 2.13-9	Form of Tranche A-4 Term Note
Exhibit 2.13-10	Form of Tranche A-5 Term Note
Exhibit 2.13-11	Form of Tranche A-6 Term Note
Exhibit 2.13-12	Form of Tranche A-7 Term Note
Exhibit 7.02	Form of Compliance Certificate
Exhibit 11.06	Form of Assignment and Assumption

iv

CREDIT AGREEMENT

This CREDIT AGREEMENT (this “Credit Agreement”) is entered into as of October 30, 2012, among FRESENIUS MEDICAL CARE AG & Co. KGaA, a German partnership limited by shares, and FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation, as Borrowers and Guarantors hereunder, the Lenders party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.

The Borrowers have requested that the Lenders provide revolving credit facilities and term loan facilities, and the Lenders are willing to do so on the terms and conditions set forth herein.

In consideration of these premises and the mutual covenants and agreements contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties hereto covenant and agree as follows:

ARTICLE I

DEFINITIONS AND ACCOUNTING TERMS

1.01        Defined Terms.  As used in this Credit Agreement, the following terms have the meanings provided below:

“Acquisition” means a purchase or acquisition by any Person (a) that after giving effect thereto first results in such Person owning more than 50% of the Capital Stock with ordinary voting power of another Person or (b) of all or any substantial portion of the property (other than Capital Stock) of another Person, whether or not involving a merger or consolidation with such Person.  “Acquire” shall have a correlative meaning.  For the avoidance of doubt, once a Person owns more than 50% of the Capital Stock with ordinary voting power of another Person, additional purchases or acquisitions of additional Capital Stock of such other Person will be considered Investments and not Acquisitions.

“Administrative Agent” means Bank of America in its capacity as administrative agent for the Lenders under any of the Credit Documents, or any successor administrative agent.

“Administrative Agent’s Office” means, with respect to any currency, the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 11.02 (as may be updated from time to time) with respect to such currency, or such other address or account with respect to such currency as the Administrative Agent may from time to time notify the Borrowers and the Lenders.

“Administrative Questionnaire” means an administrative questionnaire for the Lenders in a form supplied by the Administrative Agent.

“Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with such Person.  Notwithstanding the foregoing, in relation to The Royal Bank of Scotland plc, the term “Affiliate” shall not include (i) the UK government or any member or instrumentality thereof, including Her Majesty’s Treasury and UK Financial Investments Limited (or any directors, officers, employees or entities thereof) or (ii) any persons or entities controlled by or under common control with the UK government or any member or instrumentality thereof (including Her Majesty’s Treasury and UK Financial Investments Limited) and which are not part of The Royal Bank of Scotland Group plc and its subsidiaries or subsidiary undertakings.

“Aggregate Commitments” means the aggregate principal amount of the Commitments.

“Aggregate Euro Revolving Commitment” means the Euro Revolving Commitments of all the Lenders.

“Aggregate Euro Revolving Committed Amount” has the meaning provided in Section 2.01(b)(i).

“Aggregate Revolving Commitment” means the Aggregate Euro Revolving Commitment and the Aggregate USD Revolving Commitment.

“Aggregate USD Revolving Commitment” means the USD Revolving Commitments of all the Lenders.

“Aggregate USD Revolving Committed Amount” has the meaning provided in Section 2.01(a)(i).

“Agreement Currency” has the meaning provided in Section 11.19.

“Alternative Currency” means Euros, British Pounds Sterling, Swiss francs, Japanese yen, Canadian dollars and any other currency that is approved by the Required Lenders.

“Alternative Currency Equivalent” means, at any time, with respect to any amount denominated in Dollars, the equivalent amount thereof in the applicable foreign currency as determined by the Administrative Agent or the L/C Issuer, as the case may be, at such time on the basis of the Spot Rate (determined in respect of the most recent Revaluation Date) for the purchase of such foreign currency with Dollars.

“Amendment No. 1” means that certain Amendment No. 1 to the Credit Agreement dated as of the Amendment No. 1 Effective Date.

“Amendment No. 1 Effective Date” means November 26, 2014.

“Amendment No. 2” means that certain Amendment No. 2 to the Credit Agreement dated as of the Amendment No. 2 Effective Date.

“Amendment No. 2 Effective Date” means July 11, 2017.

“Anti-Corruption Laws” shall have the meaning provided in Section 6.21(a).

“Applicable Currency” means Dollars or the applicable Alternative Currency.

“Applicable Percentage” means the following percentages per annum:

2

APPLICABLE PERCENTAGES FOR

USD REVOLVING LOANS AND TRANCHE A-5 TERM LOAN

Pricing Level	Consolidated Leverage Ratio		Fixed LIBOR Rate Loans and Letter of Credit Fee		Base Rate Loans		Commitment Fee
I	> 3.75:1.0		1.500	%	0.500	%	0.300	%
II	> 3.25:1.0 but < 3.75:1.0		1.375	%	0.375	%	0.250	%
III	> 2.75:1.0 but < 3.25:1.0		1.250	%	0.250	%	0.250	%
IV	> 2.25:1.0 but < 2.75:1.0		1.125	%	0.125	%	0.200	%
V	< 2.25:1.0		1.000	%	0.000	%	0.200	%
APPLICABLE PERCENTAGES FOR
EURO REVOLVING LOANS, TRANCHE A-6 TERM LOAN AND TRANCHE A-7 TERM LOAN
			Fixed LIBOR Rate Loans
Pricing Level		Consolidated Leverage Ratio	Euro Revolving Loans and Tranche A-7 Term Loan		Tranche A-6 Term Loan		Commitment Fee
I		> 3.75:1.0	1.375	%	1.250	%	0.500	%
II		> 3.25:1.0 but < 3.75:1.0	1.250	%	1.125	%	0.450	%
III		> 2.75:1.0 but < 3.25:1.0	1.125	%	1.000	%	0.400	%
IV		> 2.25:1.0 but < 2.75:1.0	1.000	%	0.875	%	0.350	%
V		< 2.25:1.0	0.875	%	0.750	%	0.300	%

Applicable Percentages for the Loan Obligations, the Letter of Credit Fee and the Commitment Fee will be based on the Consolidated Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to Section 7.02(b).  Any increase or decrease in such Applicable Percentage resulting from a change in the Consolidated Leverage Ratio shall become effective on the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to Section 7.02(b); provided, however, that if a Compliance Certificate is not delivered when due in accordance therewith, then Pricing Level I shall apply as of the first Business Day after the date on which such Compliance Certificate was required to have been delivered until the first Business Day immediately following delivery thereof.

Notwithstanding anything herein to the contrary, Pricing Level V shall be in effect from the Amendment No. 2 Effective Date until the first delivery date for a Compliance Certificate pursuant to Section 7.02(b) after such date.

The Applicable Percentages for any Incremental Loan Facility will be as provided in the Incremental Loan Facility Joinder Agreement relating thereto.

Determinations by the Administrative Agent of the appropriate Pricing Level shall be conclusive absent manifest error. Notwithstanding anything to the contrary contained in this definition, the determination of the Applicable Percentage for any period shall be subject to the provisions of Section 2.10(b).

3

“Applicable Required Lenders” means the Required USD Revolving Lenders, Required Euro Revolving Lenders, Required Tranche A-5 Term Lenders, the Required Tranche A-6 Term Lenders and/or the Required Tranche A-7 Term Lenders, as applicable.

“Applicable Time” means, with respect to any Borrowings and payments in any Alternative Currency, the local time in the place of settlement for such Alternative Currency as may be determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, to be necessary for timely settlement on the relevant date in accordance with normal banking procedures in the place of settlement, as previously notified in writing to FME and FMCH.

“Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.

“Arrangers” means MLPF&S, DBSI, Commerzbank Aktiengesellschaft, Filiale Luxemburg, J.P. Morgan Securities Plc, The Bank of Nova Scotia, SunTrust Robinson Humphrey, Inc., UniCredit Bank AG, New York Branch and Wells Fargo Securities, LLC, in their capacity as mandated lead arrangers and joint book runners.

“Assignee Group” means two or more Eligible Assignees that are Affiliates of one another or two or more Approved Funds managed by the same investment advisor.

“Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 11.06) and accepted by the Administrative Agent, in substantially the form of Exhibit 11.06 or any other form (including electronic documentation generated by MarkitClear or other electronic platform) approved by the Administrative Agent.

“Attributable Principal Amount” means (a) in the case of capital leases, the amount of capital lease obligations determined in accordance with IFRS, (b) in the case of Synthetic Leases, an amount determined by capitalization of the remaining lease payments thereunder as if it were a capital lease determined in accordance with IFRS, and (c) in the case of Securitization Transactions, the outstanding principal amount of such financing, after taking into account reserve amounts and making appropriate adjustments, determined by the Administrative Agent after consultation with the Lenders.

“Auto-Extension Letter of Credit” has the meaning provided in Section 2.03(b)(iii).

“Auto-Reinstatement Letter of Credit” has the meaning provided in Section 2.03(b)(iv).

“Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.

“Bail-In Legislation” means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.

“Bank of America” means Bank of America, N.A., together with its successors.

“Base Rate” means for any day a fluctuating rate per annum equal to, in the case of Loan Obligations denominated in Dollars, the highest of (a) the Federal Funds Rate plus one-half of one percent (0.5%), (b) the Prime Rate and (c) except during a Fixed LIBOR Rate Unavailability Period, the

4

Fixed LIBOR Rate for Dollars plus one-half of one percent (0.50%); provided that if the Base Rate shall be less than zero, such rate shall be deemed zero for purposes of this Credit Agreement.

“Base Rate Loan” means a Loan that bears interest based on the Base Rate.  All Base Rate Loans shall be denominated in Dollars.

“Borrowers” means:

(i)for Credit Extensions under the USD Revolving Commitments (other than USD Swingline Loans), (a) FME, and (b) FMCH;

(ii)for Credit Extensions under the Euro Revolving Commitments, (a) FME, and (b) FMCH;

(iii)for USD Swingline Loans, (a) FME and (b) FMCH;

(iv)for the Tranche A-1 Term Loan, FMCH and certain additional co-borrowers;

(v)for the Tranche A-2 Term Loan, FMCH and certain additional co-borrowers;

(vi)for the Tranche A-3 Term Loan, FMCH and certain additional co-borrowers;

(vii)for the Tranche A-4 Term Loan, FME;

(viii)for the Tranche A-5 Term Loan, FMCH;

(ix)for the Tranche A-6 Term Loan, FME; and

(x)for the Tranche A-7 Term Loan, FME.

and, in each case, including their successors and permitted assigns.

“Borrowing” means (a) a borrowing consisting of simultaneous Loans of the same Type, in the same currency and having the same Interest Period, or (b) a Swingline Borrowing, as appropriate.

“British Pounds Sterling”, “Sterling” and “£” means the lawful currency of the United Kingdom.

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the state where the Administrative Agent’s Office with respect to Obligations denominated in Dollars is located or in the State of New York, and:

(a)if such day relates to any interest rate settings as to a Fixed LIBOR Rate Loan denominated in Dollars, any fundings, disbursements, settlements and payments in Dollars in respect of any such Fixed LIBOR Rate Loan, or any other dealings in Dollars to be carried out pursuant to this Credit Agreement in respect of any such Fixed LIBOR Rate Loan, any such day that is also a London Banking Day;

(b)if such day relates to any interest rate settings as to a Fixed LIBOR Rate Loan denominated in Euro, any fundings, disbursements, settlements and payments in Euro in respect of any such Fixed LIBOR Rate Loan, or any other dealings in Euro to be carried out pursuant to this Credit Agreement in respect of any such Fixed LIBOR Rate Loan, a TARGET Day;

5

(c)if such day relates to any interest rate settings as to a Fixed LIBOR Rate Loan denominated in a currency other than Dollars or Euro, any such day on which dealings in deposits in the relevant currency are conducted by and between banks in the London or other applicable offshore interbank market for such currency; and

(d)if such day relates to any fundings, disbursements, settlements and payments in a currency other than Dollars or Euro in respect of a Fixed LIBOR Rate Loan denominated in a currency other than Dollars or Euro, or any other dealings in any currency other than Dollars or Euro to be carried out pursuant to this Credit Agreement in respect of any such Fixed LIBOR Rate Loan (other than any interest rate settings), any such day on which banks are open for foreign exchange business in the principal financial center of the country of such currency.

“Capital Stock” means (a) in the case of a corporation, capital stock, (b) in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of capital stock, (c) in the case of a partnership (including, without limitation, a KGaA (Kommanditgesellschaft auf Aktien)), partnership interests (whether general or limited) or other equivalents (however designated) of capital stock, (d) in the case of a limited liability company, membership interests and (e) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person.

“Captive Insurance Company” means any Affiliate of the Credit Parties primarily engaged in the business of providing insurance, reinsurance and insurance-related services to the Credit Parties, their Affiliates and associated healthcare practices.

“Cash Collateralize” means to pledge and deposit with or deliver to the Administrative Agent, for the benefit of one or more of the Administrative Agent, L/C Issuers or Swingline Lenders (as applicable) and the Lenders, as collateral for L/C Obligations, Obligations in respect of Swingline Loans, or obligations of the Lenders to fund participations in respect of either thereof (as the context may require), cash or deposit account balances or, if the applicable L/C Issuer or Swingline Lender benefitting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance reasonably satisfactory to (a) the Administrative Agent and (b) the applicable L/C Issuer or the applicable Swingline Lender (as applicable). “Cash Collateral” shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support.

“Cash Management Arrangements” means any arrangement arising in the ordinary course of business to provide cash management services, including cash pool, virtual cash pool, treasury, depository, overdraft, credit or debt card, electronic funds transfer and other cash management arrangements provided to FME or any of its Subsidiaries.

“Change in Law” means the occurrence, after the date of this Credit Agreement, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, implemented, adopted or issued.

6

“Change of Control” means if the general partner of the KGaA charged with management of FME shall at any time fail to be a Subsidiary of FSE, or if FSE shall fail at any time to own and control more than twenty-five percent (25%) of the Capital Stock with ordinary voting power in FME.

“Closing Date” means October 30, 2012, being the first date all conditions precedent in Section 5.01 are satisfied or waived in accordance with Section 11.01.

“CMS” means the Centers for Medicare and Medicaid Services, any successor thereof and any predecessor thereof, including the United States Health Care Financing Administration.

“Commitment Percentages” means the Revolving Commitment Percentage, the Tranche A-5 Term Loan Commitment Percentage, the Tranche A-6 Term Loan Commitment Percentage and/or the Tranche A-7 Term Loan Commitment Percentage, as context requires.

“Commitment Period” means the period from and including the Closing Date to (a) in the case of Revolving Loans and Swingline Loans, the Revolving Termination Date, and (b) in the case of Letters of Credit, the L/C Expiration Date, or, in any case, any earlier date on which the Revolving Commitments shall have been terminated.

“Commitments” means the Revolving Commitments, and the L/C Commitments and the Swingline Commitments, as applicable, thereunder, and the Term Loan Commitments.

“Commodity Exchange Act” means the Commodity Exchange Act (7 U.S.C. § 1 et seq.).

“Compliance Certificate” means a certificate substantially in the form of Exhibit 7.02.

“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

“Consolidated EBITDA” means, for any period for the Consolidated Group, the sum of (i) Consolidated Net Income, plus (ii) to the extent deducted in determining net income, (A) Consolidated Interest Expense, (B) tax expense based on income and (C) depreciation, amortization and other non-cash charges (but not including, for purposes hereof, restructuring charges which do not initially involve a cash payment but as for which there will be a subsequent cash payment), in each case on a consolidated basis determined in accordance with IFRS.  Except as otherwise expressly provided, the applicable period shall be the four consecutive fiscal quarters ending as of the date of determination.

“Consolidated Funded Debt” means, for the Consolidated Group, Funded Debt determined on a consolidated basis in accordance with IFRS.

“Consolidated Group” means FME and its Subsidiaries.

“Consolidated Interest Expense” means, for any period for the Consolidated Group, all interest expense, including the amortization of debt discount and premium, the interest component under capital leases and the implied interest component under Securitization Transactions, in each case on a consolidated basis determined in accordance with IFRS.  Except as expressly provided otherwise, the applicable period shall be the four consecutive fiscal quarters ending as of the date of determination.

“Consolidated Leverage Ratio” means, as of the last day of each fiscal quarter, the ratio of (i) the sum of Consolidated Funded Debt on such day minus the aggregate amount of cash and cash equivalents

7

held by members of the Consolidated Group on such day, to (ii) Consolidated EBITDA for the period of four consecutive fiscal quarters ending as of such day.

“Consolidated Net Income” means, for any period for the Consolidated Group, net income (or loss) determined on a consolidated basis in accordance with IFRS, but excluding for purposes of determining the Consolidated Leverage Ratio, extraordinary gains and losses and gains and losses from discontinued operations, and, in each such case, related tax effects thereon.  Except as otherwise expressly provided, the applicable period shall be the four consecutive fiscal quarters ending as of the date of determination.

“Contractual Obligation” means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.

“Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise.  “Controlling” and “Controlled” have meanings correlative thereto.  Without limiting the generality of the foregoing, a Person shall be deemed to be Controlled by another Person if such other Person possesses, directly or indirectly, power to vote ten percent (10%) or more of securities having ordinary voting power for the election of directors, managing general partners or the equivalent.

“Controlled JV Investments” means any Investment permitted under this Credit Agreement in minority interests in other entities that become Subsidiaries upon the consummation of such Investment.

“Covenant Holiday” shall have the meaning provided in Section 8.10(a).

“Credit Agreement” means this Credit Agreement, as defined in the preamble hereto, as the same may be amended and modified from time to time.

“Credit Documents” means this Credit Agreement, the Notes, the Fee Letters, the Issuer Documents, any Incremental Loan Facility Joinder Agreements, any agreement creating or perfecting rights in Cash Collateral pursuant to the provisions of Section 2.16 of this Credit Agreement and all other documents, instruments or agreements from time to time executed by any Responsible Officer or duly authorized signatory of a member of the Consolidated Group and delivered in connection with this Credit Agreement.

“Credit Extension” means each of the following: (a) a Borrowing, (b) the conversion or continuation of a Borrowing, and (c) an L/C Credit Extension.

“Credit Parties” means, collectively, the Borrowers and the Guarantors.

“Credit Party Materials” has the meaning specified in Section 7.02.

“Credit Support Party” shall have the meaning provided in the definition of Excluded Swap Obligation.

“DBSI” means Deutsche Bank Securities Inc., together with its successors.

“Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement,

8

receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.

“Default” means any event, act or condition that constitutes an Event of Default or that, with the giving of notice, the passage of time, or both, would constitute an Event of Default.

“Default Rate” means

(a)in the case of the Letter of Credit Fee, an interest rate equal to the sum of (i) the Applicable Percentage, plus (ii) two percent (2.0%) per annum;

(b)in the case of Fixed LIBOR Rate Loans, an interest rate equal to the sum of (i) the Fixed LIBOR Rate therefor, plus (ii) the Applicable Percentage, plus (iii) two percent (2.0%) per annum; and

(c)in all other cases, including Base Rate Loans, an interest rate equal to the sum of (i) the Base Rate, plus (ii) the Applicable Percentage, plus (iii) two percent (2.0%) per annum.

“Defaulting Lender” means, subject to Section 2.17(d), any Lender that (a) has failed to (i) fund all or any portion of its Loans within two Business Days of the date such Loans were required to be funded hereunder unless such failure is due to such Lender’s good faith determination that a condition precedent to funding has not been satisfied, or (ii) pay to the Administrative Agent, an L/C Issuer, a Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or Swingline Loans) within two Business Days of the date when due, (b) has notified the Borrowers, the Administrative Agent, an L/C Issuer or a Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect unless such failure is due to such Lender’s good faith determination that a condition precedent to funding has not been satisfied, (c) has failed, within three Business Days after written request by the Administrative Agent or the Borrowers, to confirm in writing to the Administrative Agent and the Borrowers that it will comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrowers), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity, or (iii) become the subject of a Bail-in Action; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender.  Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (a) through (d) above, and of the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.17(d)) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Borrower, the L/C Issuers, the Swingline Lenders and the other Lenders promptly following such determination.

“Defaulting Lender Account” has the meaning provided in Section 2.17(a)(iv).

9

“Designated Jurisdiction” means any country or territory that itself is the target of any comprehensive country-wide or territory-wide Sanction (at the time of the Amendment No. 2 Effective Date being Crimea, Cuba, Iran, North Korea, Sudan and Syria).

“Disposition” or “Dispose” means the sale, transfer or other disposition (including any Sale and Leaseback Transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith; provided, that for purposes of the definition of Pro Forma Basis, “Disposition” shall mean any Disposition to a Person that is not a member of the Consolidated Group of (i) more than 50% of the Capital Stock of any member of the Consolidated Group, (ii) all or any substantial portion of the property of any member of the Consolidated Group or (iii) any business unit.

“Dollar”, “U.S. Dollar”, “$” and “USD” mean the lawful currency of the United States.

“Dollar Equivalent” means, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in any other currency, the equivalent amount thereof in Dollars as determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, at such time on the basis of the Spot Rate (determined in respect of the most recent Revaluation Date) for the purchase of Dollars with such other currency.

“Domestic Credit Party” means any Credit Party that is organized under the laws of any State of the United States or the District of Columbia.

“Domestic Subsidiary” means any Subsidiary that is organized under the laws of any State of the United States or the District of Columbia.

“EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

“EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

“EEA Resolution Authority” means any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

“Eligible Assignee” means any Person that meets the requirements to be an assignee under Section 11.06(b)(iii), (v) and (vi) (subject to such consents, if any, as may be required under Section 11.06(b)(iii)).

“Environmental Laws” means any and all federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.

“ERISA” means the Employee Retirement Income Security Act of 1974.

10

“ERISA Affiliate” means any trade or business (whether or not incorporated) under common control with FMCH within the meaning of Section 414(b) or (c) of the Internal Revenue Code (and Sections 414(m) and (o) of the Internal Revenue Code for purposes of provisions relating to Section 412 of the Internal Revenue Code).

“ERISA Event” means (a) a Reportable Event with respect to a Pension Plan; (b) a withdrawal by FMCH or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (c) a complete or partial withdrawal by FMCH or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination under Sections 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e) an event or condition that would reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; or (f) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon FMCH or any ERISA Affiliate.

“EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.

“Euro”, “EUR” or “€” mean the single currency of the Participating Member States.

“Euro Equivalent” means, at any time, (a) with respect to any amount denominated in Euro, such amount, and (b) with respect to any amount denominated in any other currency, the equivalent amount thereof in Euro as determined by the Administrative Agent (or, with respect to Letters of Credit, as determined by the L/C Issuer) at such time on the basis of the Spot Rate (determined as of the most recent Revaluation Date) for the purchase of Euro with such Foreign Currency.

“Euro Revolving Commitment” means, for each Euro Revolving Lender, the commitment of such Lender to make Euro Revolving Loans (and to share in Euro Revolving Loan Obligations) hereunder.  The initial Euro Revolving Commitments as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“Euro Revolving Commitment Percentage” means, for each Euro Revolving Lender, a fraction (expressed as a percentage carried to the ninth decimal place), the numerator of which is such Lender’s Euro Revolving Committed Amount and the denominator of which is the Aggregate Euro Revolving Committed Amount.  The initial Euro Revolving Commitment Percentages as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“Euro Revolving Committed Amount” means, for each Euro Revolving Lender, the amount of such Lender’s Euro Revolving Commitment.  The initial Euro Revolving Committed Amounts as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“Euro Revolving Lenders” means those Lenders with Euro Revolving Commitments, together with their successors and permitted assigns.  The initial Euro Revolving Lenders as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“Euro Revolving Loans” has the meaning provided in Section 2.01(b)(i), including any additional loans and commitments established in respect thereof as Incremental Loan Facilities hereunder.

11

“Euro Revolving Loan Obligations” means the Euro Revolving Loans.

“Euro Revolving Notes” means the promissory notes, if any, given to evidence the Euro Revolving Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.  A form of Euro Revolving Note is attached as Exhibit 2.13-3.

“Event of Default” has the meaning provided in Section 9.01.

“Excluded Swap Obligation” means, with respect to any member of the Consolidated Group that provides a guaranty or security for the Obligations (each, a “Credit Support Party”), any Swap Obligation incurred after the date hereof, if, and to the extent that, all or a portion of the Guaranty of such Credit Support Party of, or the grant under a Credit Document by such Credit Support Party of a security interest to secure, such Swap Obligation (or any guarantee thereof) is or becomes illegal under the Commodity Exchange Act (or the application or official interpretation thereof) by virtue of such Credit Support Party’s failure for any reason to constitute an “eligible contract participant” as defined in the Commodity Exchange Act (determined after giving effect to Section 4.08 hereof and any and all guarantees of such Credit Support Party’s Swap Obligations by other Credit Support Parties) at the time the Guaranty of such Credit Support Party, or grant by such Credit Support Party of a security interest, becomes effective with respect to such Swap Obligation.  If a Swap Obligation arises under a Master Agreement governing more than one Swap Contract, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to Swap Contracts for which such Guaranty or security interest becomes illegal.

“Excluded Taxes” means any of the following Taxes imposed on or with respect to any Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrowers under Section 11.13) or (ii) such Lender changes its Lending Office, except in each case to the extent that, pursuant to Section 3.01(a)(ii), (a)(iii) or (c), amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its Lending Office, (c) Taxes attributable to such Recipient’s failure to comply with Section 3.01(e) and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA.

“Exclusion Event” means an event or events where (a) one or more members of the Consolidated Group other than any member of the Consolidated Group that either ceased operations or discontinued a material portion of its business or operations before September 30, 1999 are excluded from participation in any state or federal Medical Reimbursement Program and (b) in the prior fiscal year revenues from such excluded programs generated by the members of the Consolidated Group excluded from such programs represented more than five percent (5%) of consolidated revenues for the Consolidated Group.

“Existing Bank Credit Agreement” means that certain Bank Credit Agreement dated as of March 31, 2006 among FME, FMCH and certain of their subsidiaries and affiliates, as borrowers, certain subsidiaries and affiliates of FME, as guarantors, the lenders party thereto and Bank of America, N.A., as agent, as the same has been amended or modified from time to time, as in effect on the Closing Date immediately prior to the effectiveness of this Credit Agreement.

12

“Existing Letters of Credit” means those letters of credit outstanding on the Closing Date and identified as such on Schedule 2.03.

“Existing Term Loan Credit Agreement” means that certain Term Loan Credit Agreement dated as of March 31, 2006 among FME,  FMCH and certain of their subsidiaries and affiliates, as borrowers, certain subsidiaries and affiliates of FME, as guarantors, the lenders party thereto and Bank of America, N.A., as agent, as the same has been amended or modified from time to time, as in effect on the Closing Date immediately prior to the effectiveness of this Credit Agreement.

“FATCA” means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Credit Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code.

“Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that (a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average rate (rounded upward, if necessary, to a whole multiple of 1/100th of 1%) charged to Bank of America on such day on such transactions as determined by the Administrative Agent.

“Fee Letters” means those fee letters, in each case as amended, modified, extended, renewed and replaced between FME and FMCH, on the one hand, and the Arrangers and Lead Banks (as referenced and defined therein), on the other hand, including (i) the fee letters dated on or about September 27, 2012, consisting of a joint fee letter with MLPF&S and DBSI relating to arrangement and upfront fees, a separate fee letter with Bank of America relating to the administrative agency fee and letter of credit fronting fees and those separate fee letters with the other Arrangers relating to arrangement fees payable to them, (ii) the fee letter dated as of October 30, 2012 with Bank of America relating to letter of credit fronting fees, (iii) the fee letter dated as of July 1, 2014 with Wells Fargo Bank, National Association and Wells Fargo Securities, LLC relating to arrangement fees for establishment of the incremental Tranche A-2 Term Loan, (iv) the fee letters dated on or about November 12, 2014, consisting of a joint fee letter with MLPF&S and DBSI relating to arrangement and upfront fees, a separate fee letter with Bank of America relating to the administrative agency fee and letter of credit fronting fees and those separate fee letters with the other Arrangers relating to arrangement fees, and (v) the fee letters dated on or about June 28, 2017, (or otherwise dated prior to the Amendment No. 2 Effective Date) consisting of a joint fee letter with MLPF&S and DBSI relating to arrangement and upfront fees, a separate fee letter with Bank of America relating to the administrative agency fee and those separate fee letters with the other Arrangers relating to arrangement fees payable to them.

“Fixed LIBOR Rate” means:

(a)           with respect to any Credit Extension:

(i)            denominated in Euros, the rate per annum equal to the Euro interbank offered rate (“EURIBOR”) administered by the European Money Markets Institute (or any other person which takes over the administration of that rate) for such Interest Period as published by Bloomberg (or, in the event such rate is not published by Bloomberg, as published by any such other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion after consultation with FME) at or about 11:00 a.m. (Brussels time) two Business Days prior to

13

the commencement of such Interest Period (unless market practice differs in such market, then in accordance with prevailing market practice), for deposits in the relevant currency (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period;

(ii)           denominated in Dollars or another LIBOR Quoted Currency other than Euros, the rate per annum equal to the London Interbank Offered Rate or a comparable or successor thereto which is approved by the Administrative Agent (“LIBOR”), as published by Bloomberg (or such other commercially available source providing quotations as may be designated by the Administrative Agent from time to time) (in such case, the “LIBOR Rate”) at or about 11:00 a.m. (London time) two Business Days prior to the commencement of such Interest Period, for deposits in the relevant currency (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period;

(iii)          denominated in any Non-LIBOR Quoted Currency, the rate per annum designated with respect to such Alternative Currency at the time such Alternative Currency is approved by the Administrative Agent and the Lenders pursuant to Section 1.06(a) (or such other commercially available source providing quotations as may be designated by the Administrative Agent from time to time); and

(b)           for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the LIBOR Rate at or about 11:00 a.m. (London time) determined two Business Days prior to such date for Dollar deposits being delivered in the London interbank market for deposits in Dollars with a term of one month commencing that day;

provided that (x) if in any such instance the Fixed LIBOR Rate shall be less than zero, then such rate shall be deemed zero for purposes of this Credit Agreement, (y) to the extent a comparable or successor rate is approved by the Administrative Agent in connection with any rate set forth in this definition, the approved rate shall be applied in a manner consistent with market practices, except where and to the extent that such market practice is not administratively feasible for the Administrative Agent, such approved rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent, and (z) if the Borrowers shall request and the Administrative Agent shall approve any Fixed LIBOR Rate Loan having an Interest Period with a duration other than one, two, three or six months (but not longer than six months), the applicable interest rate for such period shall be the rate determined by the Administrative Agent by means of straight-line interpolation of (i) the rate that would be applicable for the next closest Interest Period otherwise available with a duration shorter than the requested period, and (ii) the rate that would be applicable for the next closest Interest Period otherwise available with a duration longer than the requested period, provided that if the requested period should extend over any year end, the higher of the two rates will apply.

“Fixed LIBOR Rate Loan” means a Loan that bears interest at a rate based on clause (a) of the definition of “Fixed LIBOR Rate”.  Fixed LIBOR Rate Loans may be denominated in Dollars or in an Alternative Currency.  All Loans denominated in an Alternative Currency must be Fixed LIBOR Rate Loans.

“Fixed LIBOR Rate Unavailability Period” means any period of time during which a notice delivered to any Borrower in accordance with Section 3.03 shall remain in force and effect.

“FMCH” means Fresenius Medical Care Holdings, Inc., a New York corporation.

14

“FME” means Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares (Kommanditgesellschaft auf Aktien).

“Foreign Currencies” means lawful currencies other than Dollars (including Alternative Currencies).

“Foreign Lender” means, with respect to any Borrower, (a) if such Borrower is a U.S. Person, a Lender that is not a U.S. Person, and (b) if such Borrower is not a U.S. Person, a Lender that is resident or organized under the laws of a jurisdiction other than that in which such Borrower is resident for tax purposes.  For purposes of this definition, the United States, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction.

“Foreign Subsidiary” means any Subsidiary that is not a Domestic Subsidiary.

“FRB” means the Board of Governors of the Federal Reserve System of the United States.

“Fronting Exposure” means, at any time there is a Defaulting Lender, (a) with respect to any L/C Issuer, such Defaulting Lender’s pro rata share of the outstanding L/C Obligations (with respect to Letters of Credit issued by such L/C Issuer) other than L/C Obligations as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof, and (b) with respect to any Swingline Lender, such Defaulting Lender’s pro rata share of Swingline Loans (with respect to the Swingline Loans issued by such Swingline Lender) other than Swingline Loans as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof.

“FSE” means Fresenius SE & Co. KGaA, a German partnership limited by shares (Kommanditgesellschaft auf Aktien).

“Fund” means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities.

“Funded Debt” means, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with IFRS:

(a)           all obligations for borrowed money, whether current or long-term (including the Obligations hereunder), and all obligations evidenced by bonds, debentures, notes, loan agreements or other similar instruments;

(b)           all purchase money indebtedness (including indebtedness and obligations in respect of conditional sales and title retention arrangements, except for customary conditional sales and title retention arrangements with suppliers that are entered into in the ordinary course of business) and all indebtedness and obligations in respect of the deferred purchase price of property or services (other than trade accounts payable incurred in the ordinary course of business and payable on customary trade terms and deferred compensation arrangements with employees);

(c)           the Attributable Principal Amount of capital leases and Synthetic Leases;

(d)           the Attributable Principal Amount of Securitization Transactions;

(e)           [Reserved];

15

(f)            Support Obligations in respect of Funded Debt of another Person; and

(g)           Funded Debt of any partnership or joint venture or other similar entity in which such Person is a general partner or joint venturer, and, as such, has personal liability for such obligations, but only to the extent there is recourse to such Person for payment thereof.

For purposes hereof, the amount of Funded Debt shall be determined based on the outstanding principal amount in the case of borrowed money indebtedness under clause (a) and purchase money indebtedness and the deferred purchase obligations under clause (b), and based on the amount of Funded Debt that is the subject of the Support Obligations in the case of Support Obligations under clause (f).

“GAAP” means generally accepted accounting principles in effect in the United States.

“Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).

“Governmental Reimbursement Program Costs” means with respect to and payable by members of the Consolidated Group the sum of:

(a)           all amounts (including punitive and other similar amounts) agreed to be paid in settlement or payable as a result of a final, non-appealable judgment, award or similar order relating to Medical Reimbursement Programs;

(b)           all final, non-appealable fines, penalties, forfeitures or other amounts rendered pursuant to criminal indictments or other criminal proceedings relating to Medical Reimbursement Programs; and

(c)           the amount of final, non-appealable recovery, damages, awards, penalties, forfeitures or similar amounts rendered in any litigation, suit, arbitration, investigation or other legal or administrative proceeding of any kind relating to Medical Reimbursement Programs;

provided, however, that Governmental Reimbursement Program Costs for purposes of this Credit Agreement shall not include any judgments, awards, fines, penalties or similar amounts that total less than €5 million in the aggregate.

“Guarantors” means (a) FME, (b) FMCH, and (c) any other Person that becomes a Guarantor after the Closing Date, in each case together with their successors and permitted assigns.

“Guaranty” means (a) the guaranty provided pursuant to Article IV hereof, and/or (b) any other guaranty agreement in respect of the Obligations given by any Person, in each case as the same may be amended and modified from time to time.

“Honor Date” has the meaning provided in Section 2.03(c)(i).

“IFRS” means international financial reporting standards as adopted by the International Accounting Standards Board and in effect from time to time.

16

“Immaterial Foreign Subsidiary” means a Foreign Subsidiary of FME that is not a Credit Party and owns assets with a fair market value of less than €50 million.

“Incremental Loan Facilities” has the meaning provided in Section 2.01(f).

“Incremental Loan Facility Joinder Agreement” means any joinder agreement entered into in connection with the Incremental Loan Facilities.

“Incremental Term Loan Closing Date” means July 1, 2014.

“Indebtedness” means, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with IFRS:

(a)           all Funded Debt;

(b)           all contingent obligations under letters of credit (including standby and commercial), bankers’ acceptances and similar instruments (including bank guaranties, surety bonds, comfort letters, keep-well agreements and capital maintenance agreements to the extent such instruments or agreements support financial, rather than performance, obligations);

(c)           net obligations under any Swap Contract;

(d)           Support Obligations in respect of Indebtedness of another Person; and

(e)           Indebtedness of any partnership or joint venture or other similar entity in which such Person is a general partner or joint venturer, and, as such, has personal liability for such obligations, but only to the extent there is recourse to such Person for payment thereof.

For purposes hereof, the amount of Indebtedness shall be determined (i) based on Swap Termination Value in the case of net obligations under Swap Contracts under clause (c) and (ii) based on the outstanding principal amount of the Indebtedness that is the subject of the Support Obligations in the case of Support Obligations under clause (d).

“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Credit Party under any Credit Document and (b) to the extent not otherwise described in clause (a), Other Taxes.

“Indemnitee” has the meaning provided in Section 11.04(b).

“Information” has the meaning specified in Section 11.07.

“Interest Payment Date” means, (a) as to any Base Rate Loan (including Swingline Loans), the last Business Day of each March, June, September and December, the Revolving Termination Date and the date of the final principal amortization payment on any Term Loan and, in the case of any Swingline Loan, any other dates as may be mutually agreed upon by the applicable Borrowers and the Swingline Lender, and (b) as to any Fixed LIBOR Rate Loan, the last Business Day of each Interest Period for such Loan, the date of repayment of principal of such Loan, the Revolving Termination Date and the date of the final principal amortization payment on any Term Loan, and in addition, where the applicable Interest Period exceeds three months, the date every three months after the beginning of such Interest Period.  If an Interest Payment Date falls on a date that is not a Business Day, such Interest Payment Date shall be deemed to be the next succeeding Business Day.

17

“Interest Period” means, as to each Fixed LIBOR Rate Loan, the period commencing on the date such Fixed LIBOR Rate Loan is disbursed or converted to or continued as a Fixed LIBOR Rate Loan and ending on (i) the date one, two, three or six months and, with the prior written consent of all applicable Lenders, nine or twelve months thereafter, as selected by the applicable Borrower in its Loan Notice, or (ii) such other date not more than six months from the commencement date thereof as requested by the Borrower in its Loan Notice and approved by the Administrative Agent; provided that:

(a)           any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;

(b)           any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period;

(c)           no Interest Period with respect to any Revolving Loan shall extend beyond the Revolving Termination Date; and

(d)           no Interest Period with respect to any Term Loan shall extend beyond any principal amortization payment date, except to the extent that the portion of such Loan comprised of Fixed LIBOR Rate Loans that is expiring prior to the applicable principal amortization payment date plus the portion comprised of Base Rate Loans equals or exceeds the principal amortization payment then due.

“Internal Revenue Code” means the Internal Revenue Code of 1986.

“Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of Capital Stock or other securities of another Person, (b) a loan, advance or capital contribution to, guaranty or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in (including by way of repurchase arrangements), another Person, including any partnership or joint venture interest in such other Person, or (c) the purchase or other acquisition (in one transaction or a series of transactions) of assets of another Person that constitute a business unit, but excluding, for the avoidance of doubt, any Investments made by any rabbi trust or other similar employee benefit or retirement arrangements of FMCH and its Subsidiaries.  For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment.

“IP Rights” has the meaning provided in Section 6.18.

“IRS” means the United States Internal Revenue Service.

“ISP” means, with respect to any Letter of Credit, the “International Standby Practices 1998” published by the Institute of International Banking Law & Practice, Inc. (or such later version thereof as may be in effect at the time of issuance of such Letter of Credit).

“Issuer Documents” means, with respect to any Letter of Credit, the L/C Application and any other document, agreement or instrument (including such Letter of Credit) entered into by a Borrower (or any Subsidiary) and the applicable L/C Issuer (or in favor of the applicable L/C Issuer), relating to such Letter of Credit.

18

“Judgment Currency” has the meaning provided in Section 11.19.

“Laws” means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.

“L/C Advance” means a USD L/C Advance.

“L/C Application” means a USD L/C Application.

“L/C Borrowing” means a USD L/C Borrowing.

“L/C Combined Sublimit” shall have the meaning provided in Section 2.01(a).

“L/C Commitment” means the USD L/C Commitment.

“L/C Credit Extension” means a USD L/C Credit Extension.

“L/C Expiration Date” means the day that is seven days prior to the Revolving Termination Date then in effect (or, if such day is not a Business Day, the immediately preceding Business Day).

“L/C Issuer” means the USD L/C Issuers.

“L/C Obligations” means the USD L/C Obligations.

“L/C Sublimit” means the USD L/C Sublimit.

“L/C Unreimbursed Amount” has the meaning provided in Section 2.03(c)(i).

“Lenders” means the USD Revolving Lenders, the Euro Revolving Lenders, the Tranche A-5 Term Loan Lenders, the Tranche A-6 Term Loan Lenders and/or the Tranche A-7 Term Lenders, as appropriate.

“Lending Office” means, as to any Lender, the office or offices of such Lender (or an Affiliate thereof) set forth in such Lender’s Administrative Questionnaire or such other office or offices as a Lender may from time to time notify the Borrowers and the Administrative Agent.

“Letter of Credit” means a USD Letter of Credit.

“Letter of Credit Fee” has the meaning provided in Section 2.09(b)(i).

“LIBOR Quoted Currency” means each of the following currencies:  Dollars, Euro, British pounds sterling, Japanese yen, Swiss franc, in each case as long as there is a published LIBOR Rate with respect thereto.

“Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement of any kind or nature whatsoever (including any conditional sale or other title

19

retention agreement, and any financing lease having substantially the same economic effect as any of the foregoing).

“Loan Notice” means a notice of (a) a Borrowing of Loans (including Swingline Loans), (b) a conversion of Loans from one Type to the other, or (c) a continuation of Fixed LIBOR Rate Loans, which, if in writing, shall be substantially in the form of Exhibit 2.02 or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the applicable Borrower.

“Loan Obligations” means the Revolving Loan Obligations and the Term Loans.

“Loans” means any Revolving Loan and/or any Term Loan, and the Fixed LIBOR Rate Loans and Base Rate Loans comprising such Loans.

“London Banking Day” means any day on which dealings in deposits in the Applicable Currency are conducted by and between banks in the London interbank eurodollar market.

“Master Agreement” has the meaning specified in the definition of “Swap Contract”.

“Material Adverse Effect” means (a) a material adverse change in, or a material adverse effect upon, the operations, business, properties, liabilities (actual or contingent), condition (financial or otherwise) or prospects of the Consolidated Group taken as a whole; (b) a material impairment of the ability of any Credit Party to perform its obligations under any Credit Document to which it is a party; or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against any Credit Party of any Credit Document to which it is a party.

“Maximum Rate” has the meaning specified in Section 11.09.

“Medicaid” means that means-tested entitlement program under Title XIX of the Social Security Act, which provides federal grants to states for medical assistance based on specific eligibility criteria, as set forth at Section 1396, et seq. of Title 42 of the United States Code, as amended, and any successor statute thereto.

“Medicaid Provider Agreement” means an agreement entered into between a state agency or other such entity administering the Medicaid program and a health care provider or supplier, under which the health care provider or supplier agrees to provide services for Medicaid patients in accordance with the terms of the agreement and Medicaid Regulations.

“Medicaid Regulations” means, collectively, (a) all federal statutes (whether set forth in Title XIX of the Social Security Act or elsewhere) affecting the medical assistance program established by Title XIX of the Social Security Act and any successor statutes thereto; (b) all applicable provisions of all federal rules, regulations, manuals and orders of all Governmental Authorities promulgated pursuant to or in connection with the statutes described in clause (a) above and all federal administrative, reimbursement and other guidelines of all Governmental Authorities having the force of law promulgated pursuant to or in connection with the statutes described in clause (a) above; (c) all state statutes and plans for medical assistance enacted in connection with the statutes and provisions described in clauses (a) and (b) above; and (d) all applicable provisions of all rules, regulations, manuals and orders of all Governmental Authorities promulgated pursuant to or in connection with the statutes described in clause (c) above and all state administrative, reimbursement and other guidelines of all Governmental Authorities having the force of law promulgated pursuant to or in connection with the statutes described

20

in clause (b) above, in each case as may be amended, supplemented or otherwise modified from time to time.

“Medical Reimbursement Programs” means a collective reference to the Medicare, Medicaid, CHAMPUS and TRICARE programs and any other health care program operated by or financed in whole or in part by any foreign or domestic federal, state or local government and any other non-government funded third party payor programs.

“Medicare” means that government-sponsored entitlement program under Title XVIII of the Social Security Act, which provides for a health insurance system for eligible elderly and disabled individuals, as set forth at Section 1395, et seq. of Title 42 of the United States Code, as amended, and any successor statute thereto.

“Medicare Provider Agreement” means an agreement entered into between CMS (or other such entity administering the Medicare program on behalf of the CMS) and a health care provider or supplier, under which the health care provider or supplier agrees to provide services for Medicare patients in accordance with the terms of the agreement and Medicare Regulations.

“Medicare Regulations” means, collectively, all federal statutes (whether set forth in Title XVIII of the Social Security Act or elsewhere) affecting the health insurance program for the aged and disabled established by Title XVIII of the Social Security Act and any successor statutes thereto; together with all applicable provisions of all rules, regulations, manuals and orders and administrative, reimbursement and other guidelines having the force of law of all Governmental Authorities (including CMS, the OIG, the United States Department of Health and Human Services, or any Person succeeding to the functions of any of the foregoing) promulgated pursuant to or in connection with any of the foregoing having the force of law, as each may be amended, supplemented or otherwise modified from time to time.

“Minimum Collateral Amount” means, at any time, (a) with respect to Cash Collateral consisting of cash or deposit account balances provided to reduce or eliminate Fronting Exposure during the existence of a Defaulting Lender, an amount equal to 103% of the Fronting Exposure of the L/C Issuers with respect to Letters of Credit issued and outstanding at such time, and (b) with respect to Cash Collateral consisting of cash or deposit account balances provided in accordance with the provisions of Section 2.16(a)(i), (a)(ii) or (a)(iii), an amount equal to 103% of the Outstanding Amount of all L/C Obligations.

“MLPF&S” means Merrill Lynch, Pierce, Fenner & Smith Incorporated (or any other registered broker-dealer wholly-owned by Bank of America Corporation to which all or substantially all of Bank of America Corporation’s or any of its subsidiaries’ investment banking, commercial lending services or related businesses may be transferred following the Amendment No. 2 Effective Date).

“Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which FMCH or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions.

“Non-Consenting Lender” has the meaning provided in Section 11.13.

“Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time.

“Non-Extension Notice Date” has the meaning provided in Section 2.03(b)(iii).

21

“Non-LIBOR Quoted Currency” means any currency other than a LIBOR Quoted Currency.

“Non-Reinstatement Deadline” has the meaning provided in Section 2.03(b)(iv).

“Notes” means the Revolving Notes, the Swingline Notes and the Term Notes.

“Obligations” means with respect to each of the Borrowers and Guarantors (a) all advances to, and debts, liabilities, obligations, covenants and duties of, any Credit Party arising under any Credit Document or otherwise with respect to any Loan or Letter of Credit, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Credit Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding, and (b) all obligations under any Swap Contract between FME or any of its Subsidiaries, on the one hand, and any Lender or Affiliate of a Lender, on the other hand, to the extent permitted hereunder; provided, however, that the “Obligations” of a Credit Party shall exclude any Excluded Swap Obligations with respect to such Credit Party.

“OFAC” means the United States Department of Treasury’s Office of Foreign Assets Control.

“OIG” means the Office of Inspector General of the United States Department of Health and Human Services or any other regulatory body which succeeds to the functions thereof.

“Organization Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Credit Document, or sold or assigned an interest in any Loan or Credit Document).

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Credit Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.06).

“Outstanding Amount” means, on any day,

(a)for USD Revolving Loan Obligations, (i) with respect to Revolving Loans and Swingline Loans thereunder, the Dollar Equivalent amount of the aggregate outstanding principal

22

amount thereof after giving effect to any Borrowings, prepayments and repayments on such date, and (ii) with respect to L/C Obligations thereunder, the Dollar Equivalent amount thereof after giving effect to any L/C Credit Extension, reimbursements and reductions in amounts available to be drawn under Letters of Credit thereunder;

(b)for Euro Revolving Loan Obligations, with respect to Revolving Loans thereunder, the Euro Equivalent amount of the aggregate outstanding principal amount thereof after giving effect to any Borrowings, prepayments and repayments on such date;

(c)with respect to the Tranche A-5 Term Loan, the Dollar Equivalent amount of the aggregate principal amount thereof after giving effect to any prepayments or repayments on such date;

(d)with respect to the Tranche A-6 Term Loan, the Euro Equivalent amount of the aggregate principal amount thereof after giving effect to any prepayments or repayments on such date; and

(e)with respect to the Tranche A-7 Term Loan, the Euro Equivalent amount of the aggregate principal amount thereof after giving effect to any prepayments or repayments on such date.

“Overnight Rate” means, for any day, (a) with respect to any amount denominated in Dollars, the greater of (i) the Federal Funds Rate and (ii) the overnight rate determined by the Administrative Agent, the L/C Issuer or the Swingline Lender, as the case may be, in accordance with banking industry rules on interbank compensation, and (b) with respect to any amount denominated in any other currency, the greater of (i) an overnight rate determined by the Administrative Agent, the L/C Issuer or the Swingline Lender, as the case may be, in accordance with banking industry rules on interbank compensation, and (ii) the rate of interest per annum at which overnight deposits in the applicable Alternative Currency, in an amount approximately equal to the amount with respect to which such rate is being determined, would be offered for such day by a branch or Affiliate of Bank of America in the applicable offshore interbank market for such currency to major banks in such interbank market.

“Participant” shall have the meaning provided in Section 11.06(d).

“Participant Register” shall have the meaning provided in Section 11.06(d).

“Participating Member State” means any member state of the European Union that has the euro as its lawful currency in accordance with legislation of the European Union relating to Economic and Monetary Union.

“Patriot Act” shall have the meaning provided in Section 11.18.

“PBGC” means the Pension Benefit Guaranty Corporation.

“Pension Plan” means any “employee pension benefit plan” (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by FMCH or any ERISA Affiliate or to which FMCH or any ERISA Affiliate contributes or has an obligation to contribute, or in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately preceding five plan years.

23

“Permitted Acquisitions” means any Acquisition that satisfies the following conditions:

(a)the Consolidated Group shall be in compliance with the financial covenants hereunder after giving effect thereto on a Pro Forma Basis;

(b)in the case of an Acquisition of Capital Stock, the board of directors (or other comparable governing body) of such other Person shall have approved the Acquisition; and

(c)(i) no Default or Event of Default shall then exist and be continuing immediately before or immediately after giving effect thereto on a Pro Forma Basis and (ii) with respect to any Acquisition (or series of related Acquisitions) for which cash consideration together with the principal amount of Indebtedness assumed in connection therewith exceeds €750 million in the aggregate, a Responsible Officer of FME shall provide a compliance certificate, in form and detail satisfactory to the Administrative Agent, affirming the matters under the foregoing subclauses.

“Permitted Receivables Financings” means (a) the accounts receivable facility established pursuant to the Seventh Amended and Restated Transfer and Administration Agreement dated as of November 24, 2014 by and among NMC Funding Corporation, as transferor, National Medical Care, Inc., as initial collection agent, Liberty Street Funding LLC and the other conduit investors party thereto, the financial institutions party thereto, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, Barclays Bank PLC, Credit Agricole Corporate and Investment Bank, New York, PNC Bank, National Association, and Royal Bank of Canada, as administrative agents, and The Bank of Nova Scotia, as administrative agent and as agent, as amended, modified, renewed, or supplemented from time to time, and any Permitted Receivables Financing entered into in replacement thereof and (b) other Securitization Transactions, in each case as amended and in effect from time to time; provided that (i) with respect to all such Securitization Transactions described in clause (b) that are entered into after the Closing Date, (A) each such Securitization Transaction relating to accounts receivable originating in or payable in the United States or any state thereof, and (B) each such Securitization Transaction exceeding €50 million in any instance or €150 million in the aggregate, the Administrative Agent and the Required Lenders shall be reasonably satisfied with the structure and documentation thereof and shall be reasonably satisfied that the terms thereof, including the discount applicable to the subject accounts receivable and the termination events, are (in the good faith understanding of the Administrative Agent and the Required Lenders) consistent with those prevailing in the market at the time of commitment thereto for similar transactions involving a receivables originator/servicer of similar credit quality and a receivables pool of similar characteristics; and (ii) with respect to all such Permitted Receivables Financings, the documentation therefor shall not be amended or modified in a way that is materially detrimental to the Lenders without the prior written approval of the Administrative Agent and the Required Lenders.

“Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.

“Plan” means any “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) established by FMCH or, with respect to any such plan that is subject to Section 412 of the Internal Revenue Code or Title IV of ERISA, any ERISA Affiliate.

“Platform” has the meaning provided in Section 7.02.

“Prime Rate” means the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate.”  The “prime rate” is a rate set by Bank of America based upon various factors including Bank of America’s costs and desired return, general economic conditions

24

and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate.  Any change in the “prime rate” announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change.

“Pro Forma Basis” means, for purposes of determining (a) the applicable Pricing Level under the definition of “Applicable Percentage,” (b) compliance with the covenants hereunder, (c) Permitted Acquisitions or Controlled JV Investments and (d) establishment of Incremental Loan Facilities, that the event or transaction relevant to the applicable calculation shall be deemed to have occurred as of the first day of the period of four consecutive fiscal quarters ending as of the end of the most recent fiscal quarter for which annual or quarterly financial statements shall have been delivered in accordance with the provisions hereof. Further, for purposes of making calculations on a “Pro Forma Basis” hereunder, (i) in the case of any Disposition, (A) income statement items (whether positive or negative) attributable to the property, entities or business units that are the subject of such Disposition shall be excluded to the extent relating to any period prior to the date of such Disposition, and (B) Indebtedness paid or retired in connection with such Disposition shall be deemed to have been paid and retired as of the first day of the applicable period; and (ii) in the case of any Acquisition or any Controlled JV Investments, (A) income statement items (whether positive or negative, but excluding transaction expenses and any one time expenses incurred in connection with the Acquisition or Investment) attributable to the property, entities or business units that are the subject of such Acquisition or Investment shall be included to the extent relating to any period prior to the date of such Acquisition or Investment, and (B) Indebtedness incurred in connection with the subject transaction shall be deemed to have been incurred as of the first day of the applicable period (and interest expense shall be imputed for the applicable period assuming prevailing interest rates hereunder); provided, that where the aggregate consideration paid or payable by any member of the Consolidated Group in connection with such Disposition or Acquisition or Controlled JV Investment is reasonably expected (taking the amount of cash and cash equivalents and the fair market value of any non cash consideration paid or payable and the amount of debt assumed, as reasonably determined by FME) to be €50 million or less, FME may elect whether or not to make the adjustments otherwise required pursuant to clauses (i) or (ii) hereof, as applicable.

“Property” means an interest of any kind in any property or asset, whether real, personal or mixed, and whether tangible or intangible.

“Public Lender” has the meaning specified in Section 7.02.

“Qualified ECP Guarantor” means, at any time, each Credit Party with total assets exceeding $10,000,000 at the time the relevant Guaranty or grant of security becomes effective with respect to such Swap Obligation or that qualifies at such time as an “eligible contract participant” under the Commodity Exchange Act and, in each case, can cause another Person to qualify as an “eligible contract participant” at such time by entering into a keepwell under Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.

“Recipient” means the Administrative Agent, any Lender, the L/C Issuer or any other recipient of any payment to be made by or on account of any obligation of any Credit Party hereunder.

“Register” has the meaning provided in Section 11.06(c).

“Related Parties” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates.

“Reportable Event” means any of the events set forth in Section 4043(c) of ERISA, other than events for which the thirty-day notice period has been waived.

25

“Request for Credit Extension” means (a) with respect to a Borrowing, conversion or continuation of Loans (including Swingline Loans) or the conversion or continuation of Loans, a Loan Notice and (b) with respect to an L/C Credit Extension, an L/C Application.

“Required Euro Revolving Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate Euro Revolving Commitments, or if the Euro Revolving Commitments have expired or been terminated, Lenders holding in the aggregate more than 50% of the Euro Revolving Loan Obligations; provided that the Commitments of, and the portion of the Euro Revolving Loan Obligations held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of “Required Euro Revolving Lenders”.

“Required Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate Commitments or, if the Commitments shall have expired or been terminated, Lenders holding in the aggregate more than 50% of the Loan Obligations (expressed in Dollar Equivalents at the applicable Spot Rate as of the most recent Revaluation Date for any Loan Obligations denominated in a currency other than Dollars) including, in each case, the aggregate amount of each Lender’s risk participation and funded participation in L/C Obligations and Swingline Loans; provided that the Commitments of, and the portion of the Loan Obligations held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders.

“Required Revolving Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate Revolving Commitments, or if the Revolving Commitments have expired or been terminated, Lenders holding in the aggregate more than 50% of the Revolving Loan Obligations (expressed in Dollar Equivalents at the applicable Spot Rate as of the most recent Revaluation Date for any Loan Obligations denominated in a currency other than Dollars) including, in each case, the aggregate amount of each Lender’s risk participation and funded participation in L/C Obligations; provided that the Commitments of, and the portion of the Revolving Loan Obligations held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of “Required Revolving Lenders”.

“Required Tranche A-3 Term Lenders” means, as of any date of determination, Lenders holding in the aggregate more than fifty percent (50%) of the Tranche A-3 Term Loan; provided that the portion of the Tranche A-3 Term Loan held by, or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Tranche A-3 Term Lenders.

“Required Tranche A-4 Term Lenders” means, as of any date of determination, Lenders holding in the aggregate more than fifty percent (50%) of the Tranche A-4 Term Loan; provided that the portion of the Tranche A-4 Term Loan held by, or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Tranche A-4 Term Lenders.

“Required Tranche A-5 Term Lenders” means, as of any date of determination, Lenders holding in the aggregate more than fifty percent (50%) of the Tranche A-5 Term Loan; provided that the portion of the Tranche A-5 Term Loan held by, or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Tranche A-5 Term Lenders.

“Required Tranche A-6 Term Lenders” means, as of any date of determination, Lenders holding in the aggregate more than fifty percent (50%) of the Tranche A-6 Term Loan; provided that the portion of the Tranche A-6 Term Loan held by, or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Tranche A-6 Term Lenders.

26

“Required Tranche A-7 Term Lenders” means, as of any date of determination, Lenders holding in the aggregate more than fifty percent (50%) of the Tranche A-7 Term Loan; provided that the portion of the Tranche A-7 Term Loan held by, or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Tranche A-7 Term Lenders.

“Required USD Revolving Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate USD Revolving Commitments, or if the USD Revolving Commitments have expired or been terminated, Lenders holding in the aggregate more than 50% of the USD Revolving Loan Obligations (including, in each case, the aggregate amount of each Lender’s risk participation and funded participation in USD L/C Obligations and USD Swingline Loans); provided that the commitments of, and the portion of the USD Revolving Loan Obligations held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of “Required USD Revolving Lenders”.

“Responsible Officer” means the chief executive officer, president, chief financial officer, senior vice president-finance, treasurer, assistant treasurer, managing director, management board member or director of a Credit Party (or in the case of a Credit Party that is a partnership, limited liability company or similarly organized entity, including without limitation FME, a Responsible Officer of its general partner, other managing entity or other person authorized to act on its behalf, and if such Person is also a partnership, limited liability company or similarly organized entity, a Responsible Officer of the entity that may be authorized to act on behalf of such Person), and, in the case of a company formed under Luxembourg law, any person(s) authorized under the relevant corporate body, and, solely for purposes of notices given pursuant to Article II, any other officer or employee of the applicable Credit Party so designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of the applicable Credit Party designated in or pursuant to an agreement between the applicable Credit Party and the Administrative Agent.  Any document delivered hereunder that is signed by a Responsible Officer of a Credit Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Credit Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Credit Party.

“Revaluation Date” means (a) with respect to any Loan, each of the following:  (i) each date of a Borrowing of a Fixed LIBOR Rate Loan denominated in a currency other than Dollars, (ii) each date of a continuation of a Fixed LIBOR Rate Loan denominated in a currency other than Dollars pursuant to Section 2.02, and (iii) such additional dates as the Administrative Agent shall determine or the respective Required Lenders shall require; and (b) with respect to any Letter of Credit, each of the following:  (i) each date of issuance of a Letter of Credit denominated in a currency other than Dollars, (ii) each date of an amendment of any such Letter of Credit having the effect of increasing the amount thereof, (iii) each date of any payment by the applicable L/C Issuer under any Letter of Credit denominated in a currency other than Dollars, and (iv) such additional dates as the Administrative Agent or the applicable L/C Issuer shall determine or the respective Required Lenders shall require.

“Revolving Commitment Percentage” means the USD Revolving Commitment Percentage and/or the Euro Revolving Commitment Percentage, as appropriate.

“Revolving Commitments” means the USD Revolving Commitments and the Euro Revolving Commitments.

“Revolving Committed Amount” means the USD Revolving Committed Amount and/or the Euro Revolving Committed Amount.

“Revolving Lenders” means the USD Revolving Lenders and/or the Euro Revolving Lenders, as appropriate.

27

“Revolving Loan Obligations” means the USD Revolving Loan Obligations and/or the Euro Revolving Loan Obligations, as appropriate.

“Revolving Loans” means the USD Revolving Loans and/or the Euro Revolving Loans, as appropriate.

“Revolving Notes” means the USD Revolving Notes and/or the Euro Revolving Notes.

“Revolving Termination Date” means July 31, 2022.

“Sale and Leaseback Transaction” means, with respect to any Borrower or any Subsidiary, any arrangement, directly or indirectly, with any Person (other than another member of the Consolidated Group) whereby such Borrower or such Subsidiary shall sell or transfer any property, real or personal, used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold or transferred.

“Same Day Funds” means (a) with respect to disbursements and payments in Dollars, immediately available funds, and (b) with respect to disbursements and payments in currencies other than Dollars, same day or other funds as may be determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, to be customary in the place of disbursement or payment for the settlement of international banking transactions in the relevant currency.

“Sanction(s)” means any economic or financial sanction or trade embargo administered or enforced by the United States Government (including without limitation, OFAC), the United Nations Security Council, the European Union and Her Majesty’s Treasury.

“SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.

“Securitization Subsidiary” has the meaning provided in the definition of “Securitization Transaction”.

“Securitization Transaction” means any financing or factoring or similar financing transaction (or series of such transactions) entered by any member of the Consolidated Group pursuant to which such member of the Consolidated Group may sell, convey or otherwise transfer, or grant a security interest in, accounts, payments, receivables, rights to future lease payments or residuals or similar rights to payment to a special purpose subsidiary or affiliate (a “Securitization Subsidiary”) or any other Person; provided, that, for the purposes of clarification, sales of accounts, payments, receivables and similar rights of payment on a non-recourse basis by Foreign Subsidiaries of FME to Persons that are not members of the Consolidated Group in an aggregate amount not to exceed $150 million in an fiscal year that are treated as Dispositions shall not constitute Securitization Transactions.

“Social Security Act” means the Social Security Act of 1965.

“Special Notice Currency” means at any time any currency other than (a) Dollars, (b) Euros and (c) currency of a country that is a member of the Organization of Economic Cooperation and Development at such time located in North America or Europe.

“Special Purpose Finance Subsidiary” means a Subsidiary of FME established for the exclusive purpose of issuing Indebtedness the proceeds from which are distributed, directly or indirectly, to FME or

28

one or more of its Subsidiaries and which itself has no Subsidiaries and no operations or material assets other than cash, cash equivalents, intercompany receivables and other assets relating to its financing activities.

“Specified Credit Party” has the meaning specified in Section 4.08.

“Spot Rate” for a currency means the rate determined by the Administrative Agent or the applicable L/C Issuer to be the rate quoted by the Person acting in such capacity as the spot rate for the purchase by such Person of such currency with another currency through its principal foreign exchange trading office at approximately 11:00 a.m. on the date two Business Days prior to the date as of which the foreign exchange computation is made; provided that the Administrative Agent or the applicable L/C Issuer may obtain such spot rate from another financial institution designated by the Administrative Agent or the applicable L/C Issuer if the Person acting in such capacity does not have as of the date of determination a spot buying rate for any such currency; and provided further that the applicable L/C Issuer may use such spot rate quoted on the date as of which the foreign exchange computation is made in the case of any Letter of Credit denominated in a currency other than Dollars.

“Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person.  Unless otherwise provided, all references herein to a “Subsidiary” or to “Subsidiaries” shall refer to a Subsidiary or Subsidiaries of FME.

“Support Obligations” means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the “primary obligor”) in any manner, whether directly or indirectly (other than endorsements in the ordinary course of business of negotiable instruments for deposit or collection), and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person.  The amount of any Support Obligations (subject to any limitations set forth therein) shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Support Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith.

“Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar

29

transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, that are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master Agreement”), including any such obligations or liabilities under any Master Agreement.

“Swap Obligation” means with respect to any Credit Party any obligation to pay or perform under any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act.

“Swap Termination Value” means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination values determined in accordance therewith, such termination values, and (b) for any date prior to the date referenced in clause (a), the amounts determined as the mark-to-market values for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender).

“Swingline Borrowing” means a borrowing of a Swingline Loan hereunder.

“Swingline Commitment” means the USD Swingline Commitment and/or any other commitments to make Swingline Loans established in respect of other Revolving Commitments hereunder.

“Swingline Lender” means the USD Swingline Lender and/or the lender identified as the swingline lender in the case of any other Swingline Loans established hereunder.

“Swingline Loans” means the USD Swingline Loans and/or any other swingline loan established in respect of the other Revolving Commitments hereunder.

“Swingline Notes” means the USD Swingline Note and/or any other promissory notes given to evidence Swingline Loans hereunder.

“Swingline Sublimit” means the USD Swingline Sublimit and/or any other sublimit for other swingline loans established hereunder.

“Synthetic Lease” means any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing arrangement that is considered borrowed money indebtedness for tax purposes but is classified as an operating lease under IFRS.

“TARGET Day” means any day on which TARGET2 (or, if such payment system ceases to be operative, such other payment system, if any, determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro.

“TARGET2” means the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which utilizes a single shared platform and which was launched on November 19, 2007.

30

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

“Term Loan” means any of the Tranche A-5 Term Loan, the Tranche A-6 Term Loan, the Tranche A-7 Term Loan or any other term loan established under the Incremental Loan Facilities.

“Term Loan Commitments” means the Tranche A-5 Term Loan Commitments, the Tranche A-6 Term Loan Commitments, the Tranche A-7 Term Loan Commitments and any term loan commitments established under the Incremental Loan Facilities; provided that, in any such case, after funding of the term loan determinations of “Required Lenders” shall be based on the outstanding principal amount thereof.

“Term Notes” means the Tranche A-5 Term Notes, the Tranche A-6 Term Notes, the Tranche A-7 Term Notes and Notes evidencing any other term loan that may be established under the Incremental Loan Facilities.

“Tranche A-1 Term Lenders” means those Lenders holding a portion of the Tranche A-1 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-1 Term Lenders were identified on the signature pages to this Credit Agreement and set forth on Schedule 2.01 on the Closing Date.

“Tranche A-1 Term Loan” means the term loan made on the Closing Date pursuant to Section 2.01(e).  The Tranche A-1 Term Loan was repaid on the Amendment No. 1 Effective Date.

“Tranche A-2 Term Lenders” means those Lenders holding a portion of the Tranche A-2 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-2 Term Lenders were set forth on Schedule 2.01, as amended, on the Incremental Term Loan Closing Date.

“Tranche A-2 Term Loan” means the incremental term loan made on the Incremental Term Loan Closing Date pursuant to Section 2.01(e-2).  The Tranche A-2 Term Loan was repaid on the Amendment No. 1 Effective Date.

“Tranche A-3 Term Lenders” means those Lenders holding a portion of the Tranche A-3 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-3 Term Lenders were set forth on Schedule 2.01, as amended, on the Amendment No. 1 Effective Date.

“Tranche A-3 Term Loan” means the term loan made on the Amendment No. 1 Effective Date pursuant to Section 2.01(e-3).  The Tranche A-3 Term Loan was repaid on the Amendment No. 2 Effective Date.

“Tranche A-4 Term Lenders” means those Lenders holding a portion of the Tranche A-4 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-4 Term Lenders were set forth on Schedule 2.01, as amended, on the Amendment No. 1 Effective Date.

“Tranche A-4 Term Loan” means the term loan made on the Amendment No. 1 Effective Date pursuant to Section 2.01(e-4).  The Tranche A-4 Term Loan was repaid on the Amendment No. 2 Effective Date.

“Tranche A-5 Term Lenders” means, prior to the funding of the initial Tranche A-5 Term Loan, those Lenders with Tranche A-5 Term Loan Commitments, and after funding of the Tranche A-5 Term

31

Loan, those Lenders holding a portion of the Tranche A-5 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-5 Term Lenders are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-5 Term Loan” means the term loan made on the Amendment No. 2 Effective Date pursuant to Section 2.01(e-5), including any increase thereto pursuant to any Incremental Loan Facility.

“Tranche A-5 Term Loan Commitment” means, for each Tranche A-5 Term Lender, the commitment of such Lender to make a portion of the Tranche A-5 Term Loan hereunder; provided that, at any time after funding of the Tranche A-5 Term Loan, determinations of “Required Lenders” and “Required Tranche A-5 Term Lenders” shall be based on the outstanding principal amount of the Tranche A-5 Term Loan.

“Tranche A-5 Term Loan Commitment Percentage” means, for each Tranche A-5 Term Lender, a fraction (expressed as a percentage carried to the ninth decimal place), the numerator of which is, prior to funding, such Lender’s Tranche A-5 Term Loan Committed Amount, and after funding, the principal amount of such Lender’s portion of the Tranche A-5 Term Loan, and the denominator of which is, prior to funding, the aggregate principal amount of the Tranche A-5 Term Loan Commitments, and after funding, is the Outstanding Amount of the Tranche A-5 Term Loan.  The initial Tranche A-5 Term Loan Commitment Percentages are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-5 Term Loan Committed Amount” means, for each Tranche A-5 Term Lender, the amount of such Lender’s Tranche A-5 Term Loan Commitment.  The initial Tranche A-5 Term Loan Committed Amounts are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-5 Term Loan Maturity Date” shall have the meaning provided in Section 2.05(d-5).

“Tranche A-5 Term Note” means the promissory notes substantially in the form of Exhibit 2.13-10, if any, given to evidence the Tranche A-5 Term Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.

“Tranche A-6 Term Lenders” means, prior to the funding of the initial Tranche A-6 Term Loan, those Lenders with Tranche A-6 Term Loan Commitments, and after funding of the Tranche A-6 Term Loan, those Lenders holding a portion of the Tranche A-6 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-6 Term Lenders are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-6 Term Loan” means the term loan made on the Amendment No. 2 Effective Date pursuant to Section 2.01(e-6), including any increase thereto pursuant to any Incremental Loan Facility.

“Tranche A-6 Term Loan Commitment” means, for each Tranche A-6 Term Lender, the commitment of such Lender to make a portion of the Tranche A-6 Term Loan hereunder; provided that, at any time after funding of the Tranche A-6 Term Loan, determinations of “Required Lenders” and “Required Tranche A-6 Term Lenders” shall be based on the outstanding principal amount of the Tranche A-6 Term Loan.

“Tranche A-6 Term Loan Commitment Percentage” means, for each Tranche A-6 Term Lender, a fraction (expressed as a percentage carried to the ninth decimal place), the numerator of which is, prior to funding, such Lender’s Tranche A-6 Term Loan Committed Amount, and after funding, the principal

32

amount of such Lender’s portion of the Tranche A-6 Term Loan, and the denominator of which is, prior to funding, the aggregate principal amount of the Tranche A-6 Term Loan Commitments, and after funding, is the Outstanding Amount of the Tranche A-6 Term Loan.  The initial Tranche A-6 Term Loan Commitment Percentages are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-6 Term Loan Committed Amount” means, for each Tranche A-6 Term Lender, the amount of such Lender’s Tranche A-6 Term Loan Commitment.  The initial Tranche A-6 Term Loan Committed Amounts are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-6 Term Loan Maturity Date” shall have the meaning provided in Section 2.05(d-6).

“Tranche A-6 Term Note” means the promissory notes substantially in the form of Exhibit 2.13-11, if any, given to evidence the Tranche A-6 Term Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.

“Tranche A-7 Term Lenders” means, prior to the funding of the initial Tranche A-7 Term Loan, those Lenders with Tranche A-7 Term Loan Commitments, and after funding of the Tranche A-7 Term Loan, those Lenders holding a portion of the Tranche A-7 Term Loan, together with their successors and permitted assigns.  The initial Tranche A-7 Term Lenders are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-7 Term Loan” means the term loan made on the Amendment No. 2 Effective Date pursuant to Section 2.01(e-7), including any increase thereto pursuant to any Incremental Loan Facility.

“Tranche A-7 Term Loan Commitment” means, for each Tranche A-7 Term Lender, the commitment of such Lender to make a portion of the Tranche A-7 Term Loan hereunder; provided that, at any time after funding of the Tranche A-7 Term Loan, determinations of “Required Lenders” and “Required Tranche A-7 Term Lenders” shall be based on the outstanding principal amount of the Tranche A-7 Term Loan.

“Tranche A-7 Term Loan Commitment Percentage” means, for each Tranche A-7 Term Lender, a fraction (expressed as a percentage carried to the ninth decimal place), the numerator of which is, prior to funding, such Lender’s Tranche A-7 Term Loan Committed Amount, and after funding, the principal amount of such Lender’s portion of the Tranche A-7 Term Loan, and the denominator of which is, prior to funding, the aggregate principal amount of the Tranche A-7 Term Loan Commitments, and after funding, is the Outstanding Amount of the Tranche A-7 Term Loan.  The initial Tranche A-7 Term Loan Commitment Percentages are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-7 Term Loan Committed Amount” means, for each Tranche A-7 Term Lender, the amount of such Lender’s Tranche A-7 Term Loan Commitment.  The initial Tranche A-7 Term Loan Committed Amounts are set forth on Schedule 2.01, as amended, on the Amendment No. 2 Effective Date.

“Tranche A-7 Term Loan Maturity Date” shall have the meaning provided in Section 2.05(d-7).

“Tranche A-7 Term Note” means the promissory notes substantially in the form of Exhibit 2.13-11, if any, given to evidence the Tranche A-7 Term Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.

33

“TRICARE” means the United States Department of Defense health care program for service families (including TRICARE Prime, TRICARE Extra and TRICARE Standard), and any successor or predecessor (including CHAMPUS) thereof.

“Type” means, with respect to any Revolving Loan or any Term Loan, its character as a Base Rate Loan or a Fixed LIBOR Rate Loan.

“UCC” means the Uniform Commercial Code in effect in any applicable jurisdiction from time to time.

“UCP” means, with respect to any Letter of Credit, the Uniform Customs and Practice for Documentary Credits, International Chamber of Commerce (“ICC”) Publication No. 600 (or such later version thereof as may be in effect at the time of issuance).

“United States” and “U.S.” mean the United States of America.

“USD L/C Advance” means, with respect to each USD Revolving Lender, such Lender’s funding of its participation in any USD L/C Borrowing.  All USD L/C Advances must be denominated in Dollars.

“USD L/C Application” means an application and agreement for the issuance or amendment of a USD Letter of Credit in the form from time to time in use by the USD L/C Issuer.

“USD L/C Borrowing” means any extension of credit resulting from a drawing under any USD Letter of Credit that has not been reimbursed or refinanced as a Borrowing of USD Revolving Loans.  All USD L/C Borrowings will be denominated in Dollars.

“USD L/C Commitment” means, with respect to the USD L/C Issuer, the commitment of the USD L/C Issuer to issue and to honor payment obligations under USD Letters of Credit, and, with respect to each USD Revolving Lender, the commitment of such Lender to purchase its pro rata share of participation interests in USD L/C Obligations.  The USD L/C Commitments of the USD L/C Issuers on the Amendment No. 2 Effective Date are set out on Schedule 2.01(a)(ii).  The USD L/C Commitment of the USD L/C Issuers may not be increased or extended without the prior written consent of such USD L/C Issuer.

“USD L/C Credit Extension” means, with respect to any USD Letter of Credit, the issuance thereof or extension of the expiry date thereof, or the increase of the amount thereof.

“USD L/C Issuer” means (a) Bank of America, (b) Deutsche Bank AG New York Branch, (c) JPMorgan Chase Bank, N.A., (d) The Bank of Nova Scotia, (e) SunTrust Bank, (f) UniCredit Bank AG, (g) Wells Fargo Bank, National Association and (h) any other USD Revolving Lender that shall agree to become a USD L/C Issuer and that the Administrative Agent may approve in its reasonable discretion, in each case in their capacity as issuer of USD Letters of Credit hereunder, together with their successors in such capacity.

“USD L/C Obligations” means, at any time, the sum of (a) the maximum amount available to be drawn under USD Letters of Credit then outstanding, assuming compliance with all requirements for drawings referenced therein, plus (b) the aggregate amount of all USD L/C Unreimbursed Amounts, including USD L/C Borrowings.  For purposes of computing the amount available to be drawn under any USD Letter of Credit, the amount of such USD Letter of Credit shall be determined in accordance with Section 1.09.  For all purposes of this Credit Agreement, if on any date of determination a USD Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation

34

of Rule 3.14 of the ISP, such USD Letter of Credit shall be deemed to be “outstanding” in the amount so remaining available to be drawn.

“USD L/C Sublimit” has the meaning provided in Section 2.01(a)(ii).

“USD L/C Unreimbursed Amount” means an L/C Unreimbursed Amount in respect of a USD Letter of Credit.

“USD Letter of Credit” means each standby letter of credit issued or existing under Section 2.01(a)(ii).  USD Letters of Credit will be issued in Dollars, Euros or other Alternative Currencies.

“USD Revolving Commitment” means, for each USD Revolving Lender, the commitment of such Lender to make USD Revolving Loans (and to share in USD Revolving Loan Obligations that are not USD Revolving Loans) hereunder.  The initial USD Revolving Commitments as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“USD Revolving Commitment Percentage” means, for each USD Revolving Lender, a fraction (expressed as a percentage carried to the ninth decimal place), the numerator of which is such Lender’s USD Revolving Committed Amount and the denominator of which is the Aggregate USD Revolving Committed Amount.  The initial USD Revolving Commitment Percentages as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“USD Revolving Committed Amount” means, for each USD Revolving Lender, the amount of such Lender’s USD Revolving Commitment.  The initial USD Revolving Committed Amounts as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“USD Revolving Lenders” means those Lenders with USD Revolving Commitments, together with their successors and permitted assigns.  The initial USD Revolving Lenders as of the Amendment No. 2 Effective Date are set out in Schedule 2.01.

“USD Revolving Loan” has the meaning provided in Section 2.01(a)(i), including any additional loans and commitments established in respect thereof as Incremental Loan Facilities hereunder.

“USD Revolving Loan Obligations” means the USD Revolving Loans, the USD L/C Obligations and the USD Swingline Loans.

“USD Revolving Notes” means the promissory notes, if any, given to evidence the USD Revolving Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.  A form of USD Revolving Note is attached as Exhibit 2.13-1.

“USD Swingline Commitment” means, with respect to each USD Revolving Lender, the commitment of such Lender to purchase its pro rata share of participation interests in USD Swingline Loans.

“USD Swingline Lender” means (a) Bank of America and (b) any other USD Revolving Lender that agrees to act as a USD Swingline Lender hereunder, in each case, in its capacity as such, together with any successor in such capacity.

“USD Swingline Loan” has the meaning provided in Section 2.01(a)(iii).

35

“USD Swingline Note” means the promissory note given to evidence the USD Swingline Loans, as amended, restated, modified, supplemented, extended, renewed or replaced.  A form of USD Swingline Note is attached as Exhibit 2.13-2.

“USD Swingline Sublimit” has the meaning provided in Section 2.01(a)(iii).  The USD Swingline Sublimit is a part of, and not in addition to, the Aggregate USD Revolving Commitments.

“U.S. Person” means any Person that is a “United States Person” as defined in Section 7701(a)(30) of the Internal Revenue Code.

“U.S. Tax Compliance Certificate” has the meaning provided in Section 3.01(e)(ii)(B)(III).

“Wholly Owned” means, with respect to any direct or indirect Subsidiary of any Person, that one hundred percent (100%) of the Capital Stock with ordinary voting power issued by such Subsidiary (other than directors’ qualifying shares and investments by foreign nationals mandated by applicable law) is beneficially owned, directly or indirectly, by such Person.

“Write-Down and Conversion Powers” means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.

1.02Interpretive Provisions.  With reference to this Credit Agreement and each other Credit Document, unless otherwise specified herein or in such other Credit Document:

(a)The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”.  The word “will” shall be construed to have the same meaning and effect as the word “shall”.  Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Credit Document), (ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words “hereto”, “herein”, “hereof” and “hereunder”, and words of similar import when used in any Credit Document, shall be construed to refer to such Credit Document in its entirety and not to any particular provision thereof, (iv) all references in a Credit Document to “Articles”, “Sections”, “Exhibits” and “Schedules” shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Credit Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory provisions, rules, regulations, and orders consolidating, amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, and (vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all assets and property of whatever kind, real and personal, tangible and intangible, including cash, securities, accounts and contract rights.

36

(b)In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including;” the words “to” and “until” each mean “to but excluding;” and the word “through” means “to and including.”

(c)Section headings herein and in the other Credit Documents are included for convenience of reference only and shall not affect the interpretation of this Credit Agreement or any other Credit Document.

1.03Accounting Terms and Provisions.

(a)All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Credit Agreement shall be prepared in conformity with, IFRS applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the audited financial statements for the fiscal year ending December 31, 2016, except as otherwise specifically prescribed herein.  Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness shall be based on the carrying amount of the financial liabilities and the effects of IAS 39 or IFRS 9 or similar positions under IFRS on financial liabilities shall be disregarded, in this respect.

(b)Notwithstanding any provision herein to the contrary, determinations of (i) the applicable Pricing Level under the definition of “Applicable Percentage” and (ii) compliance with the financial covenants shall be made on a Pro Forma Basis.

(c)To the extent not otherwise described in the financial statements delivered pursuant to Section 7.01(a) or (b) or the other materials and information provided pursuant to Section 7.02, FME will provide a written summary of material changes in IFRS or in the consistent application thereof to the extent that either affects the numeric value of any financial ratio or requirement herein or in any other Credit Document and material changes in accounting policies or financial reporting practices with each annual and quarterly Compliance Certificate delivered in accordance with Section 7.02(b).  If there is any change in IFRS or in the consistent application thereof after the date hereof that would affect the computation of any financial covenant, ratio or requirement set forth in any Credit Document, and either FME or the Required Lenders shall so request, then the Administrative Agent, the Required Lenders and FME agree to endeavor, in good faith, to agree upon an amendment to this Credit Agreement that would adjust such financial covenants, ratio or requirement in a manner that would preserve the original intent thereof in light of such change in IFRS (subject to the approval of the Required Lenders), but would allow compliance therewith to be determined in accordance with the most recent financial statements delivered pursuant to Section 7.01(a) or (b), provided that, until so amended (i) such financial covenants, ratio or requirement shall continue to be computed in accordance with IFRS prior to such change therein and (ii) the Borrowers shall provide the Administrative Agent and the Lenders financial statements and other documents required under this Credit Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement before and after giving effect to such change in IFRS.  Notwithstanding anything contained herein to the contrary, it is understood and agreed that for purposes of this Credit Agreement, operating leases (as determined in accordance with IFRS on the Amendment No. 2 Effective Date) will not be recharacterized as a capital lease or other obligation that would constitute Funded Debt hereunder, except for purposes of financial statement deliveries under Section 7.01.

(d)(i) for the purposes of any determination of the Consolidated Leverage Ratio hereunder (including as used in the determination of the applicable Pricing Level under Applicable Percentage hereunder and in the financial covenant set forth in Section 8.10), any Dollar denominated amounts of

37

Funded Debt, cash and cash equivalents as of the last day of any fiscal quarter shall be converted into Euros using the average rate of exchange for conversion for the period of four consecutive fiscal quarters ending as of the date of determination, rather than the spot rate therefor on such date, whether or not in conformity with the rules and requirements of IFRS, and (ii) otherwise, for purposes of determining compliance with any levels and tests set forth in Articles VII, VIII and/or IX, amounts shall be converted into Euros on the basis of the exchange rates (as shown on Reuters ECB page 37 or other exchange rates used in preparing the annual audited financial statements under Section 7.01(a), as appropriate) as in effect on the date of the measurement.

(e)FME elected to apply IFRS accounting principles in lieu of GAAP on or about December 1, 2016, as permitted by the terms of this Credit Agreement.

1.04Rounding.  Any financial ratios required to be maintained pursuant to this Credit Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).

1.05Exchange Rates; Currency Equivalents.

(a)The Administrative Agent or the applicable L/C Issuer shall determine the Spot Rates as of each Revaluation Date to be used for calculating Dollar Equivalent amounts of Credit Extensions and Outstanding Amounts denominated in currencies other than Dollars.  Such Spot Rates shall become effective as of such Revaluation Date and shall be the Spot Rates employed in converting any amounts between the applicable currencies until the next Revaluation Date to occur.

(b)Wherever in this Credit Agreement in connection with a Borrowing, conversion, continuation or prepayment of a Fixed LIBOR Rate Loan or the issuance, amendment or extension of a Letter of Credit, an amount, such as a required minimum or multiple amount, is expressed in Dollars, but such Borrowing, Fixed LIBOR Rate Loan or Letter of Credit is denominated in currencies other than Dollars, such amount shall be the relevant Alternative Currency Equivalent of such Dollar amount (rounded to the nearest unit of such Alternative Currency, with 0.5 of a unit being rounded upward), as determined by the Administrative Agent or the applicable L/C Issuer, as the case may be.

1.06Additional Alternative Currencies.

(a)FME may from time to time request that Fixed LIBOR Rate Loans be made and/or Letters of Credit be issued in a currency other than those specifically listed in the definition of “Alternative Currency;” provided that such requested currency is a lawful currency (other than Dollars) that is readily available and freely transferable and convertible into Dollars.  In any such case, the request shall be subject to the approval of the Administrative Agent and the respective Lenders, and the L/C Issuer and Swingline Lender, as applicable, in their discretion.

(b)Any such request shall be made to the Administrative Agent not later than 11:00 a.m., ten (10) Business Days prior to the date of the desired Credit Extension (or such other time or date as may be agreed by the Administrative Agent and, in the case of any such request pertaining to Letters of Credit or Swingline Loans, the applicable L/C Issuer or Swingline Lender, in any such case, in its or their sole discretion).  In the case of any such request pertaining to Fixed LIBOR Rate Loans, the Administrative Agent shall promptly notify each Lender thereof; and in the case of any such request pertaining to Letters of Credit or Swingline Loans, the Administrative Agent shall promptly notify the applicable L/C Issuer or Swingline Lender, respectively, thereof.  Each Lender (in the case of any such request pertaining to Fixed LIBOR Rate Loans) or the applicable L/C Issuer (in the case of a request pertaining to Letters of Credit)

38

or Swingline Lender (in the case of a request pertaining to Swingline Loans) shall notify the Administrative Agent, not later than 11:00 a.m., seven Business Days after receipt of such request whether it consents, in its sole discretion, to the making of Fixed LIBOR Rate Loans, the issuance of Letters of Credit or Swingline Loans, as the case may be, in such requested currency.

(c)Any failure by a Lender, the applicable L/C Issuer or the applicable Swingline Lender, as the case may be, to respond to such request within the time period specified in the preceding sentence shall be deemed to be a refusal by such Lender, the applicable L/C Issuer or the applicable Swingline Lender, as the case may be, to permit Fixed LIBOR Rate Loans to be made, Letters of Credit to be issued or Swingline Loans to be made in such requested currency.  If the Administrative Agent and all the Lenders consent to making Fixed LIBOR Rate Loans in such requested currency, the Administrative Agent shall so notify FME and such currency shall thereupon be deemed for all purposes to be an Alternative Currency hereunder for purposes of any Borrowings of Fixed LIBOR Rate Loans; if the Administrative Agent and the applicable L/C Issuer consent to the issuance of Letters of Credit in such requested currency, the Administrative Agent shall so notify FME and such currency shall thereupon be deemed for all purposes to be an Alternative Currency hereunder for purposes of any Letter of Credit issuances, and if the Administrative Agent and the applicable Swingline Lender shall consent to making Swingline Loans in the requested currency, the Administrative Agent shall notify FME and such currency shall thereupon be deemed for all purposes to be an Alternative Currency for any such Swingline Loan Borrowings. If the Administrative Agent shall fail to obtain consent to any request for an additional currency under this Section 1.06, the Administrative Agent shall promptly so notify FME.

1.07Change of Currency.

(a)Each obligation of the Borrowers to make a payment denominated in the national currency unit of any member state of the European Union that adopts the Euro as its lawful currency after the date hereof shall be redenominated into Euro at the time of such adoption.  If, in relation to the currency of any such member state, the basis of accrual of interest expressed in this Credit Agreement in respect of that currency shall be inconsistent with any convention or practice in the London interbank market for the basis of accrual of interest in respect of the Euro, such expressed basis shall be replaced by such convention or practice with effect from the date on which such member state adopts the Euro as its lawful currency; provided that if any Borrowing in the currency of such member state is outstanding immediately prior to such date, such replacement shall take effect, with respect to such Borrowing, at the end of the then current Interest Period.

(b)Each provision of this Credit Agreement shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect the adoption of the Euro by any member state of the European Union and any relevant market conventions or practices relating to the Euro.

(c)Each provision of this Credit Agreement also shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect a change in currency of any other country and any relevant market conventions or practices relating to the change in currency.

1.08Times of Day.  Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight savings or standard, as applicable).

1.09Letter of Credit Amounts.  Unless otherwise specified herein (including, without limitation, as otherwise specified in Sections 1.05(a) and (b)), the amount of a Letter of Credit at any time shall be deemed to be the Dollar Equivalent of the stated amount of such Letter of Credit in effect at such

39

time; provided, however, that with respect to any Letter of Credit that, by its terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the Dollar Equivalent of the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time.

1.10Anti-Boycott Rules.  The representations and warranties in Section 6.21(b) and the undertakings in Section 7.11(b):

(a)are made or given by, and shall apply to, a Credit Party or member of the Consolidated Group that qualifies as a resident party domiciled, incorporated or established in Germany (Inländer) within the meaning of section 2 para. 15 of the German Foreign Trade Act (Außenwirtschaftsgesetz) only to the extent that the making or giving of, and compliance with (or undertaking to comply with), such representations, warranties and undertakings do not result in any violation of, conflict with, or liability under, section 7 of the German Foreign Trade Regulations (Außenwirtschaftsverordnung), EU Regulation (EC) 2271/96 (as amended by Council Regulation (EC) No 807/2003 of 14 April 2003) or any similar anti-boycott laws or regulations (the “Anti-Boycott Rules”); and

(b)shall, with respect to any Lender or any L/C Issuer which has notified the Administrative Agent that it wishes be treated as a “Restricted Finance Party” for the purposes of those Sections and has not subsequently notified the Administrative Agent that it no longer wishes to be treated as such (or, with respect to the Administrative Agent, for so long as it wishes to be so treated) (a “Restricted Finance Party”), be made or given to, or apply for the benefit of, such Restricted Finance Party only to the extent (as notified by such Restricted Finance Party to the Administrative Agent (or, in the case of the Administrative Agent, as determined by it) from time to time) that such making, giving and application would not result in any violation of, conflict with, or liability under, any Anti-Boycott Rules.

In ascertaining the Required Lenders, the Required Euro Revolving Lenders, the Required Revolving Lenders, the Required Tranche A-5 Term Lenders, the Required Tranche A-6 Term Lenders, the Required Tranche A-7 Term Lenders or the Required USD Revolving Lenders, or whether any given percentage (including, for the avoidance of doubt, unanimity) of the Aggregate Commitments or the agreement of any specified group of Lenders has been obtained to approve any request for a consent, waiver, amendment or other vote under the Credit Documents in relation to Section 6.21(b) or Section 7.11(b) (including any request pursuant to Section 9.02) or any other provision of the Credit Documents relating to a Default or Event of Default arising from a breach of any of those Sections) the Commitments of each Restricted Finance Party shall be deemed to be zero and each Restricted Finance Party shall be deemed not to be a Lender.  Any amendment or waiver that has the effect of changing or which relates to this Section 1.10 shall not be effected without the consent of each Restricted Finance Party.

ARTICLE II

COMMITMENTS AND CREDIT EXTENSIONS

2.01Commitments.

(a)USD Revolving Commitments.  During the Commitment Period,

(i)USD Revolving Loans.  The USD Revolving Lenders severally agree to make revolving credit loans (the “USD Revolving Loans”) to the applicable Borrowers in Dollars, from time to time, on any Business Day, in an aggregate principal amount of up to NINE HUNDRED

40

MILLION DOLLARS ($900,000,000) (as such amount may be increased or decreased in accordance with the provisions hereof, the “Aggregate USD Revolving Committed Amount”);

(ii)USD Letters of Credit.  The USD L/C Issuers, in reliance upon the commitments of the USD Revolving Lenders set forth herein, agrees(I) to issue USD Letters of Credit denominated in Dollars, Euros or other Alternative Currencies for the account of the applicable Borrowers and other members of the Consolidated Group on any Business Day, (II) to amend or extend USD Letters of Credit previously issued hereunder, and (III) to honor drawings under USD Letters of Credit in an aggregate principal amount up to TWO HUNDRED FIFTY MILLION DOLLARS ($250,000,000) (as such amount may be decreased in accordance with the provisions hereof, the “USD L/C Sublimit”), provided that (i) the Outstanding Amount of USD L/C Obligations shall not exceed the USD L/C Sublimit, (ii) the Outstanding Amount of all L/C Obligations shall not exceed the L/C Sublimit, and (iii) for any USD L/C Issuer, the Outstanding Amount of USD L/C Obligations shall not exceed the amount of such USD L/C Issuer’s USD L/C Commitment;

(iii)USD Swingline Loans.  Subject to the terms and conditions set forth herein and in reliance on the agreements of the other USD Revolving Lenders set forth herein, the USD Swingline Lender agrees to make revolving credit loans (the “USD Swingline Loans”) to the applicable Borrowers in Dollars on any Business Day in an aggregate principal amount of up to TWO HUNDRED FIFTY MILLION DOLLARS ($250,000,000) (as such amount may be decreased in accordance with the provisions hereof, the “USD Swingline Sublimit”), provided that (A) that the Outstanding Amount of USD Swingline Loans shall not exceed the USD Swingline Sublimit, and (B) the USD Swingline Lender shall not be under any obligation to make any USD Swingline Loan if it shall determine (which determination shall be conclusive and binding absent manifest error) that it has, or may have, Fronting Exposure;

and, provided further that, in each case, (A) the Outstanding Amount of USD Revolving Loan Obligations shall not exceed the Aggregate USD Revolving Committed Amount, and (B) with regard to each USD Revolving Lender individually, the Outstanding Amount of such Lender’s USD Revolving Commitment Percentage of USD Revolving Loan Obligations shall not exceed its respective USD Revolving Committed Amount.

(iv)Additional Provisions Relating to USD Revolving Loans.  USD Revolving Loans may consist of Base Rate Loans and Fixed LIBOR Rate Loans, or a combination thereof, as the applicable Borrowers may request, and may be repaid and reborrowed in accordance with the provisions hereof.

(v)Additional Provisions Relating to USD Letters of Credit.  Subject to the terms and conditions hereof, each applicable Borrower’s ability to obtain USD Letters of Credit for itself or for other members of the Consolidated Group shall be fully revolving, and accordingly each such applicable Borrower may obtain USD Letters of Credit to replace USD Letters of Credit that have expired or that have been drawn upon and reimbursed.

(vi)Additional Provisions Relating to USD Swingline Loans.  USD Swingline Loans shall be comprised solely of Base Rate Loans and may be repaid and reborrowed in accordance with the provisions hereof.  Immediately upon the making of a USD Swingline Loan, each USD Revolving Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the USD Swingline Lender a participation interest in such USD Swingline Loan in an amount equal to the product of such Lender’s USD Revolving Commitment Percentage thereof.

41

(b)Euro Revolving Commitments.  During the Commitment Period,

(i)the Euro Revolving Lenders severally agree to make revolving credit loans (the “Euro Revolving Loans”) to the applicable Borrowers in Euros, from time to time, on any Business Day, in an aggregate principal amount of up to SIX HUNDRED MILLION EUROS (€600,000,000) (as such amount may be increased or decreased in accordance with the provisions hereof, the “Aggregate Euro Revolving Committed Amount”);

and, provided that, in each case, (A) the Outstanding Amount of Euro Revolving Loan Obligations shall not exceed the Aggregate Euro Revolving Committed Amount, and (B) with regard to each Euro Revolving Lender individually, the Outstanding Amount of such Lender’s Euro Revolving Commitment Percentage of Euro Revolving Loan Obligations shall not exceed its respective Euro Revolving Committed Amount.

(ii)Additional Provisions Relating to Euro Revolving Loans.  Euro Revolving Loans shall consist of Fixed LIBOR Rate Loans, as the applicable Borrowers may request, and may be repaid and reborrowed in accordance with the provisions hereof.

(c)[Reserved].

(d)[Reserved].

(e)Tranche A-1 Term Loan.  A term loan (the “Tranche A-1 Term Loan”) in the aggregate principal amount of Two Billion Six Hundred Million Dollars ($2,600,000,000) was made on the Closing Date.  The outstanding principal balance of the Tranche A-1 Term Loan on the Amendment No. 1 Effective Date was Two Billion Three Hundred Million Dollars ($2,300,000,000).  The Tranche A-1 Term Loan was repaid in full and refinanced on the Amendment No. 1 Effective Date, in whole or in part, with proceeds from the Tranche A-3 Term Loan.

(e-2)Tranche A-2 Term Loan.  An incremental term loan (the “Tranche A-2 Term Loan”) in the aggregate principal amount of Six Hundred Million Dollars ($600,000,000) was made on July 1, 2014 (the “Incremental Term Loan Closing Date”).  The Tranche A-2 Term Loan was repaid in full and refinanced prior to the Amendment No. 1 Effective Date, in whole or in part, with proceeds from the issuance of senior notes.

(e-3)Tranche A-3 Term Loan.  A term loan (the “Tranche A-3 Term Loan”) in the aggregate principal amount of Two Billion Five Hundred Million Dollars ($2,500,000,000) was made on the Amendment No. 1 Effective Date.  The outstanding principal balance of the Tranche A-3 Term Loan on the Amendment No. 2 Effective Date was Two Billion Dollars ($2,000,000,000).  The Tranche A-3 Term Loan was repaid in full and refinanced on the Amendment No. 2 Effective Date, in whole or in part, with proceeds from the Tranche A-5 Term Loan.

(e-4)Tranche A-4 Term Loan.  A term loan (the “Tranche A-4 Term Loan”) in the aggregate principal amount of Three Hundred Million Euro (€300,000,000) was made on the Amendment No. 1 Effective Date.  The outstanding principal balance of the Tranche A-4 Term Loan on the Amendment No. 2 Effective Date was Two Hundred Forty Million Euro (€240,000,000).  The Tranche A-4 Term Loan was repaid in full and refinanced on the Amendment No. 2 Effective Date, in whole or in part, with proceeds from the Tranche A-6 Term Loan and the Tranche A-7 Term Loan.

(e-5)Tranche A-5 Term Loan.  On the Amendment No. 2 Effective Date, each of the Tranche A-5 Term Lenders severally agrees to make its portion of a term loan (in the amount of its respective

42

Tranche A-5 Term Loan Committed Amount) in a single advance in Dollars, in an aggregate principal amount of ONE BILLION FIVE HUNDRED MILLION DOLLARS ($1,500,000,000) (the “Tranche A-5 Term Loan”), to FMCH, as Borrower therefor.  The Tranche A-5 Term Loan may consist of Base Rate Loans, Fixed LIBOR Rate Loans or a combination thereof, as such Borrower may request.  Amounts repaid on the Tranche A-5 Term Loan may not be reborrowed.

(e-6)Tranche A-6 Term Loan.  On the Amendment No. 2 Effective Date, each of the Tranche A-6 Term Lenders severally agrees to make its portion of a term loan (in the amount of its respective Tranche A-6 Term Loan Committed Amount) in a single advance in Euros, in an aggregate principal amount of FOUR HUNDRED MILLION EUROS (€400,000,000) (the “Tranche A-6 Term Loan”), to FME, as Borrower therefor.  The Tranche A-6 Term Loan shall be comprised solely of Fixed LIBOR Rate Loans.  Amounts repaid on the Tranche A-6 Term Loan may not be reborrowed.

(e-7)Tranche A-7 Term Loan.  On the Amendment No. 2 Effective Date, each of the Tranche A-7 Term Lenders severally agrees to make its portion of a term loan (in the amount of its respective Tranche A-7 Term Loan Committed Amount) in a single advance in Euros, in an aggregate principal amount of THREE HUNDRED FIFTY MILLION EUROS (€350,000,000) (the “Tranche A-7 Term Loan”), to FME, as Borrower therefor.  The Tranche A-7 Term Loan shall be comprised solely of Fixed LIBOR Rate Loans.  Amounts repaid on the Tranche A-7 Term Loan may not be reborrowed.

(f)Incremental Loan Facilities.  At any time on or after the Amendment No. 2 Effective Date, the Borrowers may, on written notice to the Administrative Agent, establish additional credit facilities (collectively, the “Incremental Loan Facilities”) by increasing the aggregate commitments under the existing revolving credit facilities, increasing the amount of existing term loans or establishing new revolving credit and term loan facilities; provided that:

(i)the aggregate principal amount of loans and commitments for all the Incremental Loan Facilities established after the Amendment No. 2 Effective Date will not exceed an amount equal to $1,000 million in loans and commitments in U.S. dollars and €1,000 million in loans and commitments in Euro;

(ii)no Default or Event of Default shall exist immediately before or immediately after giving effect thereto (assuming, for purposes of any increase in the aggregate commitments under the existing revolving credit facilities, that such incremental revolving commitments are fully drawn) and the conditions to the making of Credit Extensions under Section 5.02 have been satisfied;

(iii)the lenders providing commitments for the Incremental Loan Facilities must be Eligible Assignees and otherwise reasonably acceptable to the Administrative Agent and will provide lender joinder agreements or other agreements reasonably satisfactory to the Administrative Agent giving effect to the Incremental Loan Facilities;

(iv)if loans are outstanding under a respective credit facility at the time of any such increase, the Borrowers will make such payments and adjustments on the subject Loans (including payment of any break-funding amounts owing under Section 3.05) as may be necessary and appropriate to give effect to the revised commitment amounts and percentages, it being agreed that the Administrative Agent shall, in consultation with the Borrowers, manage the allocation of the revised Commitment Percentages to the existing Fixed LIBOR Rate Loans in such a manner as to minimize the amounts so payable by the Borrowers;

43

(v)in the case of an increase in a term loan amount after the first principal amortization payment date, adjustments will be made to the schedule of amortization payments provided therefor, as appropriate, to give effect thereto such that the interest of Lenders in such principal amortization payments will not be less than would have been received if the Incremental Loan Facilities had not been established;

(vi)the Borrowers will provide supporting resolutions, legal opinions, promissory notes and other items as may be reasonably required by the Administrative Agent and the Lenders providing commitments for the Incremental Loan Facilities; and

(vii)payment by the Borrowers of upfront fees, arrangement fees and other fees, if any, payable in respect of the Incremental Loan Facilities.

In connection with the establishment of any Incremental Loan Facility, (A) none of the Lenders, nor any of the Arrangers, shall have any obligation to provide commitments or loans for any Incremental Loan Facility without their prior written approval, (B) Schedule 2.01 hereto will be revised to reflect the Lenders, Loans, Commitments, committed amounts and Commitment Percentages after giving effect to the establishment of any Incremental Loan Facility, and (C) notwithstanding anything to the contrary contained herein, a Lender may, upon the establishment of an Incremental Loan Facility in connection with a refinancing, extension, loan modification or other similar transaction permitted hereunder, exchange, continue or rollover all or a portion of its Loans in connection therewith, pursuant to a cashless settlement mechanism acceptable to FME, the Administrative Agent and such Lender.

2.02Borrowings, Conversions and Continuations.

(a)Each Borrowing, each conversion of Loans from one Type to the other, and each continuation of Fixed LIBOR Rate Loans shall be made upon a Borrower’s irrevocable notice to the Administrative Agent which may be given by (A) telephone or (B) a written Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a written Loan Notice. Each such irrevocable notice must be received by the Administrative Agent not later than:

(i)USD Revolving Loans.  (A) 1:00 p.m. on the day of the requested Borrowing, in the case of a Borrowing of, or conversion into, USD Revolving Loans that are Base Rate Loans; and (B) 11:30 a.m. three Business Days prior to the requested date of a Borrowing of, or conversion into, USD Revolving Loans that are Fixed LIBOR Rate Loans.

(ii)Euro Revolving Loans.  11:30 a.m. four Business Days prior to the requested date of a Borrowing of, or conversion into, Euro Revolving Loans that are Fixed LIBOR Rate Loans.

(iii)[Reserved].

(iv)Term Loans.  (A) 1:00 p.m. on the day of the requested Borrowing, in the case of a Borrowing of, or conversion into, the Tranche A-5 Term Loan (or any other term loan established under the Incremental Loan Facilities in Dollars) that are Base Rate Loans; and (B) 11:30 a.m. (1) three Business Days prior to the requested date of a Borrowing of, or conversion into, the Tranche A-5 Term Loan (or any other term loan established under the Incremental Loan Facilities in Dollars) that are Fixed LIBOR Rate Loans and (2) four Business Days prior to the requested date of a Borrowing of, or

44

conversion into, the Tranche A-6 Term Loan and the Tranche A-7 Term Loan (or any other term loan established under the Incremental Loan Facilities in an Alternative Currency) that are Fixed LIBOR Rate Loans.

(b)Except as provided in Sections 2.03(c) and 2.04(a), each Borrowing, conversion or continuation shall be a minimum principal amount of:

(i)USD Revolving Loans.  (A) $500,000 and whole multiples of $100,000 in excess thereof in the case of USD Revolving Loans that are Base Rate Loans, and (B) $2 million and whole multiples of $1 million in excess thereof in the case of USD Revolving Loans that are Fixed LIBOR Rate Loans.

(ii)Euro Revolving Loans.  €5 million and whole multiples of €500,000 in excess thereof in the case of Euro Revolving Loans.

(iii)[Reserved].

(iv)Term Loans.  (A) $5 million and whole multiples of $1 million in excess thereof in the case of the Tranche A-5 Term Loan (or any other term loan established under the Incremental Loan Facilities in Dollars) and (B) €5 million and whole multiples of €1 million in excess thereof in the case of the Tranche A-6 Term Loan and the Tranche A-7 Term Loan (or any other term loan established under the Incremental Loan Facilities in an Alternative Currency).

Each Loan Notice (whether telephonic or written) shall specify (i) whether the applicable Borrower’s request is with respect to Revolving Loans or Term Loans, and, in each case, the particular kinds and types, (ii) whether such request is for a Borrowing, conversion, or continuation, (iii) the requested date of such Borrowing, conversion or continuation (which shall be a Business Day), (iv) the principal amount of Loans to be borrowed, converted or continued, (v) the Type of Loans to be borrowed, converted or continued, (vi) if applicable, the duration of the Interest Period with respect thereto and (vii) the currency of the Loans to be borrowed.  If a Borrower fails to specify a currency in a Loan Notice for Loans (other than Euro Revolving Loans, the Tranche A-6 Term Loan or the Tranche A-7 Term Loan) requesting a Borrowing, then the Loans so requested shall be made in Dollars.  If a Borrower fails to specify a Type of Loan in a Loan Notice or if a Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Loans shall be made as, or converted to, Base Rate Loans; provided, however, that in the case of a failure to timely request a continuation of Loans denominated in currencies other than Dollars, such Loans shall be continued as Fixed LIBOR Rate Loans in their original currency with an Interest Period of one month.  Any automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Fixed LIBOR Rate Loans.  If a Borrower requests a Borrowing of, conversion to, or continuation of Fixed LIBOR Rate Loans in any Loan Notice, but fails to specify an Interest Period, the Interest Period will be deemed to be one month.  No Loan may be converted into or continued as a Loan denominated in a different currency, but instead must be repaid in the original currency of such Loan and reborrowed in the other currency.

(c)Following receipt of a Loan Notice, the Administrative Agent shall promptly notify each applicable Lender of the amount (and currency) of its pro rata share of the applicable Loans, and if no timely notice of a conversion or continuation is provided by a Borrower, the Administrative Agent shall notify each Lender of the details of any automatic conversion to Base Rate Loans or continuation of Loans denominated in a currency other than Dollars, in each case as described in the preceding subsection.  In the case of a Borrowing, each Lender shall make the amount of its Loan available to the Administrative Agent in Same Day Funds at the Administrative Agent’s Office for the Applicable Currency not later than 1:00 p.m. (or 2 hours after delivery of the Loan Notice by the Borrower as

45

provided above, if later), in the case of any Loan denominated in Dollars, and not later than the Applicable Time specified by the Administrative Agent in the case of any Loan in currencies other than Dollars, in each case on the Business Day specified in the applicable Loan Notice.  Upon satisfaction of the applicable conditions set forth in Section 5.02 (and, if such Borrowing is the initial Credit Extension, Section 5.01), the Administrative Agent shall make all funds so received available to the applicable Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the applicable Borrower on the books of Bank of America with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by such Borrower; provided, however, that if, on the date of such Borrowing denominated in Dollars there are L/C Borrowings outstanding, then the proceeds of such Borrowing, first, shall be applied to the payment in full of any such L/C Borrowings, and second, shall be made available to such Borrower as provided above.

(d)Except as otherwise provided herein, without the consent of the Applicable Required Lenders, (i) a Fixed LIBOR Rate Loan may be continued or converted only on the last day of an Interest Period for such Fixed LIBOR Rate Loan and (ii) any conversion into, or continuation as, a Fixed LIBOR Rate Loan denominated in Dollars may be made only if the conditions to Credit Extensions in Section 5.02 have been satisfied.  During the existence of a Default or Event of Default, without the consent of the Applicable Required Lenders, (i) Base Rate Loans may not be converted into Fixed LIBOR Rate Loans, and (ii) Fixed LIBOR Rate Loans denominated in Dollars may not be requested, and may not be continued as Fixed LIBOR Rate Loans, and any such Fixed LIBOR Rate Loans denominated in Dollars shall be converted to Base Rate Loans on the last date of the Interest Period with respect thereto.

(e)The Administrative Agent shall promptly notify the Borrowers and the Lenders of the interest rate applicable to any Interest Period for Fixed LIBOR Rate Loans upon determination of such interest rate.  The determination of the Fixed LIBOR Rate by the Administrative Agent shall be conclusive in the absence of manifest error.  At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrowers and the Lenders of any change in Bank of America’s prime rate used in determining the Base Rate promptly following the public announcement of such change.

(f)After giving effect to all Borrowings, all conversions of Revolving Loans from one Type to the other, and all continuations of Revolving Loans as the same Type, at any time there shall not be more than (i) ten (10) Interest Periods in effect, in the case of USD Revolving Loans, (ii) ten (10) Interest Periods in effect, in the case of Euro Revolving Loans, (iii) ten (10) Interest Periods in effect for any particular Term Loan, unless otherwise agreed by the Administrative Agent, and (iv) the number of Interest Periods for any Incremental Loan Facility provided in the joinder agreement therefor, or if not provided, five Interest Periods.

Each Lender, at its option, may make any Loans by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan.

2.03Additional Provisions with respect to Letters of Credit.

(a)Obligation to Issue or Amend.

(i)The L/C Issuers shall not issue any Letter of Credit if:

(A)subject to Section 2.03(b)(iii), the expiry date of such requested Letter of Credit would occur more than twelve months after the date of issuance or last extension, unless the Applicable Required Lenders have approved such expiry date; or

46

(B)the expiry date of the requested Letter of Credit would occur after the L/C Expiration Date, unless all the respective Lenders have approved such expiry date;

(ii)The L/C Issuers shall not be under any obligation to issue any Letter of Credit if:

(A)any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain the applicable L/C Issuer from issuing the Letter of Credit, or any Law applicable to applicable L/C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over the applicable L/C Issuer shall prohibit, or request that the applicable L/C Issuer refrain from, the issuance of letters of credit generally or the Letter of Credit in particular or shall impose upon the applicable L/C Issuer with respect to the Letter of Credit any restriction, reserve or capital requirement (for which the applicable L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon the applicable L/C Issuer any unreimbursed loss, cost or expense that was not applicable on the Closing Date and that the applicable L/C Issuer in good faith deems material to it;

(B)the issuance of the Letter of Credit would violate any Law or one or more policies of the applicable L/C Issuer applicable to letters of credit generally;

(C)except as otherwise agreed by the Administrative Agent and the L/C Issuer, the Letter of Credit is in an initial stated amount less than $500,000;

(D)[Reserved];

(E)the applicable L/C Issuer does not as of the issuance date of the requested Letter of Credit issue Letters of Credit in the requested currency; or

(F)any Lender is at such time a Defaulting Lender, unless the L/C Issuer has entered into arrangements, including delivery of Cash Collateral, satisfactory to the L/C Issuer in (its sole discretion) with the Borrowers or such Defaulting Lender to eliminate L/C Issuer’s actual or potential Fronting Exposure (after giving effect to Section 2.17(b)) with respect to the Defaulting Lender arising from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L/C Obligations as to which the applicable L/C Issuer has actual or potential Fronting Exposure, as it may elect in its sole discretion.

(iii)The L/C Issuers shall not be under any obligation to amend any Letter of Credit if:

(A)the applicable L/C Issuer would have no obligation at such time to issue the Letter of Credit in its amended form under the terms hereof; or

(B)the beneficiary of the Letter of Credit does not accept the proposed amendment to the Letter of Credit.

(iv)The L/C Issuers shall act on behalf of the Lenders with respect to any Letters of Credit issued by them and the documents associated therewith, and the L/C Issuers shall have all of the benefits and immunities (A) provided to the Administrative Agent in Article X with respect to any acts taken or omissions suffered by the L/C Issuers in connection with Letters of Credit

47

issued by them or proposed to be issued by them and Issuer Documents pertaining to such Letters of Credit as fully as if the term “Administrative Agent” as used in Article X included the L/C Issuers with respect to such acts or omissions, and (B) as additionally provided herein with respect to the L/C Issuers.

(b)Procedures for Issuance and Amendment; Auto-Extension Letters of Credit.

(i)Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the applicable Borrower delivered to the applicable L/C Issuer (with a copy to the Administrative Agent) in the form of a L/C Application, appropriately completed and signed by a Responsible Officer.  L/C Applications may be sent by facsimile, by United States mail, by overnight courier, by electronic transmission using the system provided by the L/C Issuer, by personal delivery or by any other means acceptable to the L/C Issuer.  Such L/C Application must be received by the applicable L/C Issuer and the Administrative Agent not later than (A) 11:00 a.m. at least two Business Days prior to the proposed date of the issuance, extension or amendment, in the case of Letters of Credit denominated in Dollars, and (B) 11:00 a.m. at least five Business Days prior to the proposed date of the issuance, extension or amendment, in the case of Letters of Credit denominated in currencies other than Dollars (or, in each case, such later date and time as the applicable L/C Issuer and the Administrative Agent may agree in a particular instance in their sole discretion).  In the case of a request for an initial issuance of a Letter of Credit, such L/C Application shall specify in form and detail satisfactory to the applicable L/C Issuer:  (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day); (B) the amount and currency thereof; (C) the expiry date thereof; (D) the name and address of the beneficiary thereof; (E) the documents to be presented by such beneficiary in case of any drawing thereunder; (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder; (G) the purpose and nature of the requested Letter of Credit and (H) such other matters as the applicable L/C Issuer may require.  In the case of a request for an amendment of any outstanding Letter of Credit, such L/C Application shall specify in form and detail satisfactory to the applicable L/C Issuer (A) the Letter of Credit to be amended; (B) the proposed date of amendment thereof (which shall be a Business Day); (C) the nature of the proposed amendment; and (D) such other matters as the applicable L/C Issuer may require.  Additionally, such Borrower shall furnish to the applicable L/C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as the applicable L/C Issuer or the Administrative Agent may require.

(ii)Promptly after receipt of any L/C Application, the applicable L/C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such L/C Application from the applicable Borrower and, if not, the applicable L/C Issuer will provide the Administrative Agent with a copy thereof.  Unless the applicable L/C Issuer has received written notice from the Administrative Agent, any Lender or any Credit Party, at least one Business Day prior to the requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in Article V shall not then be satisfied, then, subject to the terms and conditions hereof, the applicable L/C Issuer shall, on the requested date, issue a Letter of Credit for the account of the applicable Borrower (or Subsidiary) or enter into the applicable amendment, as the case may be, in each case in accordance with the applicable L/C Issuer’s usual and customary business practices.  Immediately upon the issuance of each Letter of Credit, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the applicable L/C Issuer a risk participation in such Letter of Credit in an amount equal to such Lender’s pro rata share thereof.

48

(iii)If a Borrower so requests in any applicable L/C Application, the applicable L/C Issuer may, in its sole and absolute discretion, agree to issue a Letter of Credit that has automatic extension provisions (each, an “Auto-Extension Letter of Credit”); provided that any such Auto-Extension Letter of Credit must permit the applicable L/C Issuer to prevent any such extension at least once in each twelve-month period (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in each such twelve-month period to be agreed upon at the time such Letter of Credit is issued.  Unless otherwise directed by the applicable L/C Issuer, such Borrower shall not be required to make a specific request to such L/C Issuer for any such extension.  Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the applicable L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not later than the L/C Expiration Date; provided, however, that the applicable L/C Issuer shall not permit any such extension if (A) the applicable L/C Issuer has determined that it would not be permitted or would have no obligation at such time to issue such Letter of Credit in its revised form (as extended) under the terms hereof (by reason of the provisions of Section 2.03(a) or otherwise), or (B) it has received notice (which may be by telephone or in writing) on or before the day that is seven Business Days before the Non-Extension Notice Date (1) from the Administrative Agent that the Required USD Revolving Lenders have elected not to permit such extension or (2) from the Administrative Agent, any USD Revolving Lender or any Borrower that one or more of the applicable conditions specified in Section 5.02 is not then satisfied, and in each case directing the applicable L/C Issuer not to permit such extension.

(iv)If a Borrower so requests in any applicable L/C Application, the applicable L/C Issuer may, in its sole and absolute discretion, agree to issue a Letter of Credit that permits the automatic reinstatement of all or a portion of the stated amount thereof after any drawing thereunder (each, an “Auto-Reinstatement Letter of Credit”).  Unless otherwise directed by the applicable L/C Issuer, such Borrower shall not be required to make a specific request to the applicable L/C Issuer to permit such reinstatement.  Once an Auto-Reinstatement Letter of Credit has been issued, except as provided in the following sentence, the Lenders shall be deemed to have authorized (but may not require) the applicable L/C Issuer to reinstate all or a portion of the stated amount thereof in accordance with the provisions of such Letter of Credit.  Notwithstanding the foregoing, if such Auto-Reinstatement Letter of Credit permits the applicable L/C Issuer to decline to reinstate all or any portion of the stated amount thereof after a drawing thereunder by giving notice of such non-reinstatement within a specified number of days after such drawing (the “Non-Reinstatement Deadline”), the applicable L/C Issuer shall not permit such reinstatement if it has received a notice (which may be by telephone or in writing) on or before the day that is seven Business Days before the Non-Reinstatement Deadline (A) from the Administrative Agent that the Required USD Revolving Lenders have elected not to permit such reinstatement or (B) from the Administrative Agent, any USD Revolving Lender or any Borrower that one or more of the applicable conditions specified in Section 5.02 is not then satisfied (treating such reinstatement as an L/C Credit Extension for purposes of this clause) and, in each case, directing the applicable L/C Issuer not to permit such reinstatement.

(v)Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the applicable L/C Issuer will also deliver to the applicable Borrower and the Administrative Agent a true and complete copy of such Letter of Credit or amendment.

49

(c)Drawings and Reimbursements; Funding of Participations.

(i)Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under any Letter of Credit, the applicable L/C Issuer shall notify the applicable Borrower and the Administrative Agent thereof.  In the case of a Letter of Credit denominated in a currency other than Dollars, the applicable Borrower shall reimburse the applicable L/C Issuer in the same such currency, unless (A) such L/C Issuer (at its option) shall have specified in such notice that it will require reimbursement in Dollars, or (B) in the absence of any such requirement for reimbursement in Dollars, such Borrower shall have notified such L/C Issuer promptly following receipt of the notice of drawing that such Borrower will reimburse such L/C Issuer in Dollars.  In the case of any such reimbursement in Dollars of a drawing under a Letter of Credit denominated in a currency other than Dollars, the applicable L/C Issuer shall notify the applicable Borrower of the Dollar Equivalent of the amount of the drawing promptly following the determination thereof.  Not later than 11:00 a.m. on the date of any payment by the applicable L/C Issuer under a Letter of Credit to be reimbursed in Dollars, or the Applicable Time on the date of any payment by the applicable L/C Issuer under a Letter of Credit to be reimbursed in a currency other than Dollars (each such date, an “Honor Date”), the applicable Borrower shall reimburse the applicable L/C Issuer through the Administrative Agent in an amount equal to the amount of such drawing and in the Applicable Currency.  If the applicable Borrower fails to so reimburse the applicable L/C Issuer by such time, the Administrative Agent shall promptly notify each applicable Lender of the Honor Date, the amount of the unreimbursed drawing (expressed in Dollars in the amount of the Dollar Equivalent thereof in the case of a Letter of Credit denominated in an Alternative Currency) (the “L/C Unreimbursed Amount”), and the amount of such Lender’s pro rata share thereof.  In such event, the applicable Borrower shall be deemed to have requested a Borrowing of Base Rate Loans or Fixed LIBOR Rate Loans with an Interest Period of one month, as appropriate, to be disbursed on the Honor Date in an amount equal to the L/C Unreimbursed Amount, without regard to the minimum and multiples specified in Section 2.02 for such Loans, but subject to the amount of the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 5.02 (other than the delivery of a Loan Notice).  Any notice given by an L/C Issuer or the Administrative Agent pursuant to this Section 2.03(c)(i) may be given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice.

(ii)Each Lender shall upon any notice pursuant to Section 2.03(c)(i) make funds available (and the Administrative Agent may apply Cash Collateral provided for this purpose) for the account of the applicable L/C Issuer at the Administrative Agent’s Office in an amount equal to its pro rata share of the L/C Unreimbursed Amount not later than 1:00 p.m. on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.03(c)(iii), each of the respective Lenders that so makes funds available shall be deemed to have made a Revolving Loan that is a Base Rate Loan or Fixed LIBOR Rate Loan with an Interest Period of one month, as appropriate, to the respective Borrower in such amount.  The Administrative Agent shall remit the funds so received to the applicable L/C Issuer in the Applicable Currency (or, if requested by the applicable L/C Issuer, the equivalent amount thereof in Dollars as determined by the Administrative Agent at such time on the basis of the Spot Rate as of the funding date).

(iii)With respect to any L/C Unreimbursed Amount that is not fully refinanced by a Borrowing because the conditions set forth in Section 5.02 cannot be satisfied or for any other reason, the applicable Borrower shall be deemed to have incurred from the applicable L/C Issuer an L/C Borrowing in the amount of the L/C Unreimbursed Amount that is not so refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the applicable Default Rate.  In such event, each Lender’s payment to the Administrative Agent for the account of the applicable L/C Issuer pursuant to

50

Section 2.03(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such Lender in satisfaction of its participation obligation under this Section 2.03.

(iv)Until each respective Lender funds its Revolving Loan or L/C Advance pursuant to this Section 2.03(c) to reimburse the applicable L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lender’s pro rata share of such amount shall be solely for the account of the applicable L/C Issuer.

(v)Each Lender’s obligation to make Revolving Loans or L/C Advances to reimburse the L/C Issuers for amounts drawn under Letters of Credit, as contemplated by this Section 2.03(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right that such Lender may have against any L/C Issuer, any Borrower or any other Person for any reason whatsoever; (B) the occurrence or continuance of a Default or Event of Default, or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing; provided, however, that each Lender’s obligation to make Revolving Loans pursuant to this Section is subject to the conditions set forth in Section 5.02 (other than delivery of a Loan Notice).  No such making of an L/C Advance shall relieve or otherwise impair the obligation of the applicable Borrowers to reimburse the applicable L/C Issuer for the amount of any payment made by the applicable L/C Issuer under any Letter of Credit, together with interest as provided herein.

(vi)If any Lender fails to make available to the Administrative Agent for the account of the applicable L/C Issuer any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.03(c) by the time specified in Section 2.03(c)(ii), then, without limiting the other provisions of this Credit Agreement, the applicable L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the applicable L/C Issuer at a rate per annum equal to the applicable Overnight Rate from time to time in effect, plus any administrative, processing or similar fees customarily charged by the applicable L/C Issuer in connection with the foregoing.  If such Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s Revolving Loan included in the relevant Borrowing or L/C Advance in respect of the relevant L/C Borrowing, as the case may be.  A certificate of the applicable L/C Issuer submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (vi) shall be conclusive absent manifest error.

(d)Repayment of Participations.

(i)At any time after an L/C Issuer has made a payment under any Letter of Credit and has received from any Lender such Lender’s L/C Advance in respect of such payment in accordance with Section 2.03(c), if the Administrative Agent receives for the account of the applicable L/C Issuer any payment in respect of the related L/C Unreimbursed Amount or interest thereon (whether directly from a Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Lender its pro rata share thereof (appropriately adjusted, in the case of interest payments, to reflect the period of time during which such Lender’s L/C Advance was outstanding) in the same funds as those received by the Administrative Agent.

(ii)If any payment received by the Administrative Agent for the account of an L/C Issuer pursuant to Section 2.03(c)(i) is required to be returned under any of the circumstances

51

described in Section 11.05 (including pursuant to any settlement entered into by the applicable L/C Issuer in its discretion), each Lender shall pay to the Administrative Agent for the account of the applicable L/C Issuer its pro rata share thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Lender, at a rate per annum equal to the Overnight Rate from time to time in effect.  The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Credit Agreement.

(e)Obligations Absolute.  The obligation of each Borrower to reimburse the applicable L/C Issuer for each drawing under each Letter of Credit and to repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Credit Agreement under all circumstances, including the following:

(i)any lack of validity or enforceability of such Letter of Credit, this Credit Agreement or any other Credit Document;

(ii)the existence of any claim, counterclaim, setoff, defense or other right that a Borrower or any Subsidiary may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), any L/C Issuer or any other Person, whether in connection with this Credit Agreement, the transactions contemplated hereby or by such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction;

(iii)any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit;

(iv)waiver by the L/C Issuer of any requirement that exists for the L/C Issuer’s protection and not the protection of the Borrower or any waiver by the L/C Issuer which does not in fact materially prejudice the Borrower;

(v)honor of a demand for payment presented electronically even if such Letter of Credit requires that demand be in the form of a draft;

(vi)any payment made by the L/C Issuer in respect of an otherwise complying item presented after the date specified as the expiration date of, or the date by which documents must be received under such Letter of Credit if presentation after such date is authorized by the UCC, the ISP or the UCP, as applicable;

(vii)any payment by an L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does not comply with the terms of such Letter of Credit; or any payment made by an L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law;

(viii)any adverse change in the relevant exchange rates or in the availability of the relevant currency to the Borrowers or any Subsidiary or in the relevant currency markets generally; or

52

(ix)any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Borrower or any Subsidiary.

Each Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to such Borrower and, in the event of any claim of noncompliance with such Borrower’s instructions or other irregularity, such Borrower will immediately notify the applicable L/C Issuer.  A Borrower shall be conclusively deemed to have waived any such claim against the applicable L/C Issuer and its correspondents unless such notice is given as aforesaid.

(f)Role of the L/C Issuers in such Capacity.  Each of the Lenders and the Borrowers agrees that, in paying any drawing under a Letter of Credit, the L/C Issuers shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document.  None of the L/C Issuers, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of any L/C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Applicable Required Lenders, as applicable; (ii) any action taken or omitted in the absence of gross negligence or willful misconduct; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer Document.  Each Borrower hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to such Borrower’s use of any Letter of Credit; provided, however, that this assumption is not intended to, and shall not, preclude such Borrower from pursuing such rights and remedies as such Borrower may have against the beneficiary or transferee at law or under any other agreement.  None of the L/C Issuers, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of any L/C Issuer, shall be liable or responsible for any of the matters described in clauses (i) through (ix) of Section 2.03(e); provided, however, that anything in such clauses to the contrary notwithstanding, a Borrower may have a claim against an L/C Issuer, and the applicable L/C Issuer may be liable to such Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by such Borrower that such Borrower proves were caused by the applicable L/C Issuer’s willful misconduct or gross negligence.  In furtherance and not in limitation of the foregoing, the L/C Issuers may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuers shall not be responsible for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, that may prove to be invalid or ineffective for any reason.  The L/C Issuer may send a Letter of Credit or conduct any communication to or from the beneficiary via the Society for Worldwide Interbank Financial Telecommunication (“SWIFT”) message or overnight courier, or any other commercially reasonable means of communicating with a beneficiary.

(g)Applicability of ISP.  Unless otherwise expressly agreed by the L/C Issuer and a Borrower when a Letter of Credit is issued (including any such agreement applicable to an Existing Letter of Credit), the rules of the ISP shall apply to each standby Letter of Credit.  Notwithstanding the foregoing, the L/C Issuer shall not be responsible to the Borrower for, and the L/C Issuer’s rights and remedies against the Borrowers shall not be impaired by, any action or inaction of the L/C Issuer required or permitted under any law, order, or practice that is required or permitted to be applied to any Letter of Credit or this Credit Agreement, including the Law or any order of a jurisdiction where the L/C Issuer or the beneficiary is located, the practice stated in the ISP or UCP, as applicable, or in the decisions, opinions, practice statements or official commentary of the ICC Banking Commission, the Bankers Association for Finance and Trade International Financial Services Association (BAFT IFSA), or the

53

Institute of International Banking Law & Practice, whether or not any Letter of Credit chooses such law or practice.

(h)Letters of Credit Issued for Members of Consolidated Group.  Notwithstanding that a Letter of Credit issued or outstanding hereunder is in support of any obligations of, or is for the account of, any Subsidiary, the applicable Borrower shall be obligated to reimburse the applicable L/C Issuer for any and all drawings under such Letter of Credit.  Each applicable Borrower hereby acknowledges that the issuance of Letters of Credit for the account of any Subsidiary inures to the benefit of such applicable Borrower, and that such applicable Borrower’s business derives substantial benefits from the businesses of such Subsidiary.

(i)Letter of Credit Fees.  The Borrowers shall pay Letter of Credit fees as set forth in Section 2.09(b).

(j)Conflict with Issuer Documents.  In the event of any conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control.

2.04Additional Provisions with respect to Swingline Loans.

(a)Borrowing Procedures.

(i)USD Swingline Loans.  Each USD Swingline Borrowing shall be made in Dollars upon a Borrower’s irrevocable notice to the USD Swingline Lender and the Administrative Agent, which may be given by telephone. Each such notice must be received by the USD Swingline Lender and the Administrative Agent not later than 2:00 p.m. on the requested borrowing date, and shall specify (i) the amount to be borrowed, which shall be a minimum principal amount of $100,000, and (ii) the requested borrowing date, which shall be a Business Day.  Each such telephonic notice must be confirmed promptly by delivery to the USD Swingline Lender and the Administrative Agent of a written Loan Notice, appropriately completed and signed by a Responsible Officer of such Borrower.  Promptly after receipt by the USD Swingline Lender of any telephonic Loan Notice, the USD Swingline Lender will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Loan Notice and, if not, the USD Swingline Lender will notify the Administrative Agent (by telephone or in writing) of the contents thereof.  Unless the USD Swingline Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any USD Revolving Lender) prior to 3:00 p.m. on the date of the proposed USD Swingline Borrowing (A) directing the USD Swingline Lender not to make such USD Swingline Loan as a result of the limitations set forth in this Article II, or (B) that one or more of the applicable conditions specified in Article V is not then satisfied, then, subject to the terms and conditions hereof, the USD Swingline Lender will, not later than 4:00 p.m. on the borrowing date specified in such Loan Notice, make the amount of its USD Swingline Loan available to the applicable Borrower at its office by crediting the account of such Borrower on the books of the USD Swingline Lender in immediately available funds.

(ii)[Reserved].

(b)Refinancing.

(i)USD Swingline Loans.

54

(A)The USD Swingline Lender at any time in its sole and absolute discretion may request, on behalf of the applicable Borrowers (which hereby irrevocably authorizes the USD Swingline Lender to so request on its behalf), that each USD Revolving Lender make a USD Revolving Loan that is a Base Rate Loan or a Fixed LIBOR Rate Loan with an Interest Period of one month, as appropriate, in an amount equal to such Lender’s pro rata share of USD Swingline Loans then outstanding.  Such request shall be made in writing (which written request shall be deemed to be a Loan Notice for purposes hereof) and in accordance with the requirements of Section 2.02, without regard to the minimum and multiples specified therein, but subject to the unutilized portion of the Aggregate USD Revolving Commitments and the conditions set forth in Section 5.02.  The USD Swingline Lender shall furnish the applicable Borrowers with a copy of the applicable Loan Notice promptly after delivering such notice to the Administrative Agent.  Each USD Revolving Lender shall make an amount equal to its pro rata share of the amount specified in such Loan Notice available to the Administrative Agent in Same Day Funds (and the Administrative Agent may apply for Cash Collateral available with respect to the applicable Swingline Loan) for the account of the USD Swingline Lender at the Administrative Agent’s Office not later than 2:00 p.m. on the day specified in such Loan Notice, whereupon, subject to Section 2.04(c)(i)(B), each USD Revolving Lender that so makes funds available shall be deemed to have made a USD Revolving Loan that is a Base Rate Loan or a Fixed LIBOR Rate Loan with an Interest Period of one month, as appropriate, in such amount.  The Administrative Agent shall remit the funds so received to the USD Swingline Lender.

(B)If for any reason any USD Swingline Loan cannot be refinanced by such a Borrowing of USD Revolving Loans in accordance with Section 2.04(b)(i)(A), the request for USD Revolving Loans submitted by the USD Swingline Lender as set forth herein shall be deemed to be a request by the USD Swingline Lender that each of the USD Revolving Lenders fund its risk participation in the relevant USD Swingline Loan and each USD Revolving Lender’s payment to the Administrative Agent for the account of the USD Swingline Lender pursuant to Section 2.04(c)(i)(A) shall be deemed payment in respect of such participation.

(C)If any USD Revolving Lender fails to make available to the Administrative Agent for the account of the USD Swingline Lender any amount required to be paid by such USD Revolving Lender pursuant to the foregoing provisions of this Section 2.04(b)(i) by the time specified in Section 2.04(b)(i)(A), the USD Swingline Lender shall be entitled to recover from such USD Revolving Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the USD Swingline Lender at a rate per annum equal to the applicable Overnight Rate from time to time in effect, plus any administrative, processing or similar fees customarily charged by the USD Swingline Lender in connection with the foregoing.  If such USD Revolving Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s USD Revolving Loan included in the relevant Borrowing or funded participation in the relevant USD Swingline Loan, as the case may be.  A certificate of the USD Swingline Lender submitted to any USD Revolving Lender (through the Administrative Agent) with respect to any amounts owing under this clause (C) shall be conclusive absent manifest error.

(D)Each USD Revolving Lender’s obligation to make USD Revolving Loans or to purchase and fund risk participations in USD Swingline Loans pursuant to

55

this Section 2.04(b)(i) shall be absolute and unconditional and shall not be affected by any circumstance, including (1) any setoff, counterclaim, recoupment, defense or other right that such Lender may have against the USD Swingline Lender, any Borrower or any other Person for any reason whatsoever, (2) the occurrence or continuance of a Default or Event of Default, (3) non-compliance with the conditions set forth in Section 5.02, or (4) any other occurrence, event or condition, whether or not similar to any of the foregoing; provided however, that each USD Revolving Lender’s obligation to make Loans pursuant to this Section 2.04(b)(i) is subject to the conditions set forth in Section 5.02.  No such purchase or funding of risk participations shall relieve or otherwise impair the obligation of the Borrowers to repay USD Swingline Loans, together with interest as provided herein.

(ii)[Reserved].

(c)Repayment of Participations.

(i)USD Swingline Loans.

(A)At any time after any USD Revolving Lender has purchased and funded a risk participation in a USD Swingline Loan, if the USD Swingline Lender receives any payment on account of such USD Swingline Loan, the USD Swingline Lender will distribute to such Lender its pro rata share of such payment (appropriately adjusted, in the case of interest payments, to reflect the period of time during which such Lender’s risk participation was funded) in the same funds as those received by the USD Swingline Lender.

(B)If any payment received by the USD Swingline Lender in respect of principal or interest on any USD Swingline Loan is required to be returned by the USD Swingline Lender under any of the circumstances described in Section 11.05 (including pursuant to any settlement entered into by the USD Swingline Lender in its discretion), each USD Revolving Lender shall pay to the USD Swingline Lender its pro rata share thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the Overnight Rate.  The Administrative Agent will make such demand upon the request of the USD Swingline Lender.  The obligations of the USD Revolving Lenders under this clause shall survive the payment in full of the USD Revolving Loan Obligations and the termination of this Credit Agreement.

(ii)[Reserved].

(d)Interest for Account of Swingline Lender.  The Swingline Lender shall be responsible for invoicing the Borrowers for interest on the Swingline Loans.  Until each Lender funds its Revolving Loan or risk participation pursuant to this Section 2.04 to refinance such Lender’s pro rata share of any Swingline Loan, interest in respect thereof shall be solely for the account of the Swingline Lender.

(e)Payments Directly to Swingline Lender.  The Borrowers shall make all payments of principal and interest in respect of the Swingline Loans directly to the Swingline Lender.

56

2.05Repayment of Loans.

(a)Revolving Loans.  The Outstanding Amount of Revolving Loans shall be repaid in full on the Revolving Termination Date.

(b)USD Swingline Loans.  The Outstanding Amount of USD Swingline Loans shall be repaid in full on the earlier to occur of (i) the date of demand by the USD Swingline Lender, and (ii) the Revolving Termination Date.

(c)[Reserved].

(d)Tranche A-1 Term Loan.  [Reserved — the Tranche A-1 Term Loan has been repaid.]

(d-2)Tranche A-2 Term Loan.  [Reserved — the Tranche A-2 Term Loan has been repaid.]

(d-3)Tranche A-3 Term Loan.  [Reserved — the Tranche A-3 Term Loan has been repaid.]

(d-4)Tranche A-4 Term Loan.  [Reserved — the Tranche A-4 Term Loan has been repaid.]

(d-5)Tranche A-5 Term Loan.  The principal amount of the Tranche A-5 Term Loan shall be repaid in twenty (20) consecutive quarterly installments on the last Business Day of each January, April, July and October, beginning October 31, 2017 and ending on July 31, 2022 (the “Tranche A-5 Term Loan Maturity Date”) when the remaining principal amount will be due and payable in full.  The first nineteen (19) installments will each be in the principal amount of Thirty Million Dollars ($30,000,000) and the twentieth (20th) and final installment on the Tranche A-5 Term Loan Maturity Date will be in the remaining principal amount of the Tranche A-5 Term Loan.

(d-6)Tranche A-6 Term Loan.  The Tranche A-6 Term Loan is a non-amortizing term loan.  The principal amount of the Tranche A-6 Term Loan shall be repaid in full in a single installment on July 30, 2020 (the “Tranche A-6 Term Loan Maturity Date”).

(d-7)Tranche A-7 Term Loan.  The principal amount of the Tranche A-7 Term Loan shall be repaid in twenty (20) consecutive quarterly installments on the last Business Day of each January, April, July and October, beginning October 31, 2017 and ending on July 31, 2022 (the “Tranche A-7 Term Loan Maturity Date”) when the remaining principal amount will be due and payable in full.  The first nineteen installments will each be in the principal amount of Seven Million Euro (€7,000,000) and the twentieth (20th) and final installment on the Tranche A-7 Term Loan Maturity Date will be in the remaining principal amount of the Tranche A-7 Term Loan.

(e)Incremental Loan Facilities.  The principal amount of any Incremental Loan Facility established hereunder shall be as provided in the Incremental Loan Facility Joinder Agreement pursuant to which such loan is established.

2.06Prepayments.

(a)Voluntary Prepayments.  The Loans may be repaid in whole or in part without premium or penalty (except, in the case of Loans other than Base Rate Loans, amounts payable pursuant to Section 3.05); provided that:

(i)in the case of Loans other than Swingline Loans, (A) notice thereof must be received by 12:00 noon by the Administrative Agent at least

57

(1)three Business Days prior to the date of prepayment of Fixed LIBOR Rate Loans denominated in Dollars, and shall be in a minimum principal amount of $1 million and whole multiples of $1 million;

(2)four Business Days prior to the date of prepayment of Fixed LIBOR Rate Loans denominated in currencies other than Dollars and Special Notice Currencies, and shall be a minimum principal amount of the equivalent of €1 million and whole multiples of €1 million;

(3)five Business Days prior to the date of prepayment of Fixed LIBOR Rate Loans denominated in Special Notice Currencies, and shall be in a minimum principal amount of the equivalent of €1 million and whole multiples of €1 million;

(4)one Business Day prior to of the date of prepayment of Base Rate Loans, and shall be in a minimum principal amount of $1 million and whole multiples of $1 million; and

or, in any such case, the entire remaining principal amount thereof, if less;

(ii)in the case of USD Swingline Loans, (A) notice thereof must be received by the USD Swingline Lender by 2:00 p.m. on the date of prepayment (with a copy to the Administrative Agent), and (B) any such prepayment shall be in the same minimum principal amounts as for advances thereof (or any lesser amount that may be acceptable to the USD Swingline Lender); and

(iii)[Reserved];

Each such notice of voluntary prepayment hereunder shall be irrevocable and shall specify the date and amount of prepayment and the Loans and Type(s) of Loans that are being prepaid and, if Fixed LIBOR Rate Loans are to be prepaid, the Interest Period(s) of such Loans.  The Administrative Agent will give prompt notice to the applicable Lenders of any prepayment on the Loans and the Lender’s interest therein.  If such notice is given by a Borrower, such Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.  Prepayments of Fixed LIBOR Rate Loans hereunder shall be accompanied by accrued interest on the amount prepaid and breakage or other amounts due, if any, under Section 3.05.

(b)Mandatory Prepayments.

(i)Revolving Commitments.  If at any time (A) the Outstanding Amount of USD Revolving Loan Obligations shall exceed the Aggregate USD Revolving Committed Amount, (B) the Outstanding Amount of USD L/C Obligations shall exceed the USD L/C Sublimit, (C) the Outstanding Amount of USD Swingline Loans shall exceed the USD Swingline Sublimit, or (D) the Outstanding Amount of Euro Revolving Loan Obligations shall exceed the Aggregate Euro Revolving Committed Amount, then the applicable Borrowers shall make an immediate prepayment on or in respect of the respective Revolving Loan Obligations in an amount equal to the difference; provided, however, that, except with respect to clause (B) above, L/C Obligations will not be Cash Collateralized hereunder until the Revolving Loans and Swingline Loans in respect thereof have been paid in full.

(ii)[Reserved].

58

(iii)[Reserved].

(iv)[Reserved].

(c)Application.  Within each Loan, prepayments will be applied first to Base Rate Loans, then to Fixed LIBOR Rate Loans in direct order of Interest Period maturities.  In addition:

(i)Voluntary Prepayments.  Voluntary prepayments on the Term Loans may be applied to the Tranche A-5 Term Loan, the Tranche A-6 Term Loan, the Tranche A-7 Term Loan or any other Term Loan established hereunder as the Borrower may direct; provided that any such prepayment on a Term Loan will be applied to such Term Loan, first, in forward order of maturity to the principal amortization payments coming due within the next twelve months in direct order of maturity and, second, pro rata to the remaining principal amortization installments on such Term Loan, as the case may be.  Voluntary prepayments will be paid by the Administrative Agent to the Lenders ratably in accordance with their respective interests therein.

(ii)Mandatory Prepayments.  Mandatory prepayments on the Loan Obligations will be paid by the Administrative Agent to the Lenders ratably in accordance with their respective interests therein; provided that:

(A)Mandatory prepayments in respect of the Revolving Commitments under subsection (b)(i) above shall be applied to the respective Revolving Loan Obligations as appropriate.

(B)[Reserved].

(C)[Reserved].

2.07Termination or Reduction of Commitments.

(a)Voluntary Reductions.  The Borrowers may, upon notice to the Administrative Agent, terminate or permanently reduce, in whole or in part, the aggregate amount of USD Revolving Commitments and/or Euro Revolving Commitments hereunder by notice to the Administrative Agent; provided that (i) any such notice thereof must be received by 11:00 a.m. at least three Business Days prior to the date of termination or reduction and any such prepayment shall be in a minimum principal amount of $5 million or €5 million, as appropriate, and integral multiples of $1 million or €1 million, as appropriate in excess thereof; (ii) the aggregate amount of the respective Revolving Commitments may not be reduced to an amount less than the Revolving Loan Obligations in respect thereof then outstanding, and (iii) if, after giving effect to any reduction of the aggregate amount of the applicable Revolving Commitments, the L/C Sublimit or the Swingline Sublimit shall exceed the aggregate amount of the Revolving Commitments in respect thereof, such sublimit shall be automatically reduced by the amount of the difference.  The Administrative Agent will give prompt notice to the applicable Lenders of any such termination or reduction in the aggregate amount of such Revolving Commitments.  Any reduction of the aggregate amount of USD Revolving Commitments and/or Euro Revolving Commitments shall be applied ratably to the applicable Revolving Commitments of the respective Lenders, as appropriate.  All commitment or other fees accrued with respect thereto through the effective date of any termination of the aggregate amount of USD Revolving Commitments and/or Euro Revolving Commitments shall be paid on the effective date of such termination.

(b)Mandatory Reductions.  The Revolving Commitments will not be reduced by the amounts paid on the Revolving Loan Obligations under Section 2.06(b).

59

2.08Interest.

(a)Subject to the provisions of subsection (b) below, (i) each Fixed LIBOR Rate Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Fixed LIBOR Rate for such Interest Period plus the Applicable Percentage; and (ii) each Loan that is a Base Rate Loan (including USD Swingline Loans) shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Percentage.

(b)(i)If any amount of principal of any Loan or L/C Borrowing is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Law.

(ii)If any amount (other than principal of any Loan) payable under any Credit Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Law.

(iii)Upon the occurrence and during the continuation of an Event of Default, then upon the request of the Required Lenders, the principal amount of all outstanding Obligations hereunder shall bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Law.

(iv)Accrued and unpaid interest on past due amounts (including interest on past due amounts) shall be due and payable upon demand.

(c)Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein.  Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.

2.09Fees.

(a)Commitment Fees.  The Borrowers shall pay to the Administrative Agent for the account of each of the Revolving Lenders their respective pro rata share of a commitment fee (the “Commitment Fee”) equal to the product of (i) the Applicable Percentage times (ii) the actual daily amount by which the aggregate amount of the respective Revolving Commitments exceed the Outstanding Amount of the Revolving Loan Obligations in respect thereof, subject, in each case, to adjustment for Defaulting Lenders as provided in Section 2.17.  For the avoidance of doubt, the Outstanding Amount of Swingline Loans shall not be counted towards or considered usage of the respective Revolving Commitments for purposes of determining the Commitment Fee.  The Commitment Fee shall accrue at all times during the Commitment Period, including at any time during which one or more of the conditions in Article V shall not have been met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date (and on the last day of the Commitment Period).  The Commitment Fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Percentage during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Percentage separately for each period during such quarter that the Applicable Percentage was in effect.  The Commitment Fee payable in respect of the

60

USD Revolving Commitments will be payable in Dollars, and the Commitment Fee payable in respect of the Euro Revolving Commitments will be payable in Euro.

(b)Letter of Credit Fees.

(i)Letter of Credit Fees.  The Borrowers shall pay to the Administrative Agent for the account of each of the Revolving Lenders their pro rata share of a fee in respect of Letters of Credit under the respective Revolving Commitments, as applicable (the “Letter of Credit Fee”) equal to the product of (i) the Applicable Percentage times (ii) the daily amount available to be drawn under such Letters of Credit, subject, in each case, to adjustment for Defaulting Lenders under Section 2.17.  For purposes of determining the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.09.  The Letter of Credit Fee shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date (and on the last day of the L/C Expiration Date).  The Letter of Credit Fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Percentage during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Percentage separately for each period during such quarter that the Applicable Percentage was in effect.  Notwithstanding anything to the contrary contained herein, the Letter of Credit Fee shall accrue at the Default Rate after the occurrence and during the continuation of an Event of Default whenever the Default Rate shall be in effect for Loan Obligations under Section 2.08(b).  The Letter of Credit Fee payable in respect of the USD Revolving Commitments will be payable in Dollars.

(ii)Fronting Fee and Documentary and Processing Charges Payable to L/C Issuers.  The Borrowers shall pay directly to each L/C Issuer for its own account a fronting fee (the “Fronting Fee”) with respect to each Letter of Credit issued by it at the rate and at the times specified in the applicable Fee Letter or as otherwise separately agreed between the Borrowers and any L/C Issuer, computed on the daily amount available to be drawn under such Letters of Credit.  For purposes of determining the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.09.  Unless otherwise agreed, the Fronting Fee shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date (and on the last day of the L/C Expiration Date).  In addition, the Borrowers shall pay directly to the L/C Issuer for its own account the customary issuance, presentation, amendment and other processing fees, and other standard costs and charges, of such L/C Issuer relating to letters of credit as from time to time in effect.  Such customary fees and standard costs and charges are due and payable on demand and are nonrefundable.  Unless otherwise provided, Fronting Fees and other amounts payable hereunder in respect of the USD Revolving Commitments will be payable in Dollars.

(c)Other Fees.

(i)The Borrowers shall pay to the Arrangers and the Administrative Agent for their own respective accounts fees in the amounts and at the times specified in the Fee Letters.  Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever.

(ii)[Reserved].

(iii)The Borrowers shall pay to the Lenders such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified.  Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever.

61

2.10Computation of Interest and Fees; Retroactive Adjustments of Applicable Rate.

(a)All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to the Fixed LIBOR Rate) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed.  All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year), or, in the case of interest in respect of Loans denominated in (x) British Pounds Sterling, on the basis of a year of 365 or 366 days, as the case may be and (y) currencies other than Dollars and British Pounds Sterling, as to which market practice differs from the foregoing, in accordance with such market practice.  Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to Section 2.11(a), bear interest for one day.  Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.  With respect to all Non-LIBOR Quoted Currencies, the calculation of the applicable interest rate shall be determined in accordance with market practice.

(b)If, as a result of any restatement of or other adjustment to the financial statements of the Borrowers or for any other reason, the Borrowers or the Lenders determine that (i) the Consolidated Leverage Ratio as calculated by the Borrowers as of any applicable date was inaccurate and (ii) a proper calculation of the Consolidated Leverage Ratio would have resulted in higher pricing for such period, the Borrowers shall immediately and retroactively be obligated to pay to the Administrative Agent for the account of the applicable Lenders or the applicable L/C Issuer, as the case may be, promptly on demand by the Administrative Agent (or, after the occurrence of an actual or deemed entry of an order for relief with respect to any Borrower under the Bankruptcy Code of the United States, automatically and without further action by the Administrative Agent, any Lender or any L/C Issuer), an amount equal to the excess of the amount of interest and fees that should have been paid for such period over the amount of interest and fees actually paid for such period.  This paragraph shall not limit the rights of the Administrative Agent, any Lender or any L/C Issuer, as the case may be, under Section 2.03(c)(iii), 2.03(j), 2.08(b), 2.09 or under Article IX.  The Borrowers’ obligations under this paragraph shall survive the termination of the Aggregate Commitments and the repayment of all other Obligations hereunder.

2.11Payments Generally; Administrative Agent’s Clawback.

(a)General.  All payments to be made by the Borrowers shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff.  Except as otherwise expressly provided herein and except with respect to principal of and interest on Loans denominated in currencies other than Dollars, all payments by the Borrowers hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative Agent’s Office in Dollars and in Same Day Funds not later than 2:00 p.m. on the date specified herein.  Except as otherwise expressly provided herein, all payments by the Borrowers hereunder with respect to principal and interest on Loans denominated in a currency other than Dollars shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative Agent’s Office in such other currency and in Same Day Funds not later than the Applicable Time specified by the Administrative Agent on the dates specified herein.  Without limiting the generality of the foregoing, the Administrative Agent may require that any payments due under this Credit Agreement be made in the United States.  If, for any reason, a Borrower is prohibited by any Law from making any required payment hereunder in the Applicable Currency, such Borrower shall make such payment in Dollars in the Dollar Equivalent thereof.  The Administrative Agent will promptly distribute to each Lender its pro rata share of such payment in like funds as received by wire transfer to such Lender’s Lending Office.  All payments received by the Administrative Agent (i) after 2:00 p.m., in the case of payments in Dollars, or

62

(ii) after the Applicable Time specified by the Administrative Agent in the case of payments in currencies other than Dollars, shall in each case be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue.  Subject to the definition of “Interest Period”, if any payment to be made by a Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be.

(b)(i)Funding by Lenders; Presumption by Administrative Agent.  Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing of Fixed LIBOR Rate Loans (or, in the case of any Borrowing of Base Rate Loans, prior to the time such Borrowing is to be made) that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.02 (or, in the case of a Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.02) and may, in reliance upon such assumption, make available to the applicable Borrower a corresponding amount.  In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the applicable Borrowers severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount in Same Day Funds with interest thereon, for each day from and including the date such amount is made available to such Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the Overnight Rate, plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by a Borrower, the interest rate applicable to Base Rate Loans.  If such Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to such Borrower the amount of such interest paid by such Borrower for such period.  If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s Loan included in such Borrowing.  Any payment by a Borrower shall be without prejudice to any claim such Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.

(ii)Payments by Borrowers; Presumptions by Administrative Agent.  Unless the Administrative Agent shall have received notice from a Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or any L/C Issuer hereunder that such Borrower will not make such payment, the Administrative Agent may assume that such Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or any L/C Issuer, as the case may be, the amount due.  In such event, if such Borrower has not in fact made such payment, then each of the Lenders or the applicable L/C Issuer, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or L/C Issuer, in Same Day Funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the Overnight Rate.

A notice of the Administrative Agent to any Lender or any Borrower with respect to any amount owing under this subsection (b) shall be conclusive, absent manifest error.

(c)Failure to Satisfy Conditions Precedent.  If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender to a Borrower as provided in the foregoing provisions of this Article II, and such funds are not made available to such Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in Article V are

63

not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.

(d)Obligation of the Lenders Several.  The obligations of the Lenders hereunder to make Loans, to fund participations in Letters of Credit and Swingline Loans and to make payments pursuant to Section 11.04(c) are several and not joint.  The failure of any Lender to make any Loan, to fund any such participation or to make any payment under Section 11.04(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to make its payment under Section 11.04(c).

(e)Funding Source.  Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.

2.12Sharing of Payments By Lenders.  If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of the Loans made by it, or the participations in L/C Obligations or in Swingline Loans held by it resulting in such Lender’s receiving payment of a proportion of the aggregate amount of such Loans or participations and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater proportion shall (a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans and subparticipations in L/C Obligations and Swingline Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing them, provided that:

(i)if any such participations or subparticipations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and

(ii)the provisions of this Section shall not be construed to apply to (x) any payment made by or on behalf of a Borrower pursuant to and in accordance with the express terms of this Credit Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) the application of Cash Collateral provided for in Section 2.16, or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or subparticipations in L/C Obligations or Swingline Loans to any assignee or participant, other than as assignment to a Borrower or any Subsidiary thereof (as to which the provisions of this Section shall apply).

Each Credit Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against such Credit Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Credit Party in the amount of such participation.

2.13Evidence of Debt.

(a)The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business.  The accounts or records maintained by the Administrative Agent and each Lender shall be conclusive

64

absent manifest error of the amount of the Credit Extensions made by the Lenders to the Borrowers and the interest and payments thereon.  Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrowers hereunder to pay any amount owing with respect to the Obligations.  In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.  Upon the request of any Lender made through the Administrative Agent, each applicable Borrower shall execute and deliver to the Administrative Agent a Note for such Lender, which shall evidence such Lender’s Loans in addition to such accounts or records.  Each Lender may attach schedules to its Note and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto.

(b)In addition to the accounts and records referred to in subsection (a), each Lender and the Administrative Agent shall maintain in accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit and Swingline Loans.  In the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.

2.14[Reserved].

2.15[Reserved] .

2.16Cash Collateral.

(a)Certain Credit Support Events.  If (i) the L/C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in an L/C Borrowing, (ii) as of the L/C Expiration Date, any L/C Obligation for any reason remains outstanding, (iii) the Borrower shall be required to provide Cash Collateral pursuant to Section 9.02(c), or (iv) there shall exist a Defaulting Lender, the Borrowers shall immediately (in the case of clause (iii) above) or within one Business Day (in all other cases) following any request by the Administrative Agent or the L/C Issuer, provide Cash Collateral in an amount not less than the applicable Minimum Collateral Amount (determined in the case of Cash Collateral provided pursuant to clause (iv) above, after giving effect to Section 2.17(b) and any Cash Collateral provided by the Defaulting Lender) or such lesser amount as may be agreed with the L/C Issuer, in its sole discretion.

(b)Grant of Security Interest.  The Borrowers, and to the extent provided by any Defaulting Lender, such Defaulting Lender, hereby grant to the Administrative Agent, for the benefit of the Administrative Agent, the L/C Issuer and the Lenders, and agrees to maintain, subject to any lien of the Administrative Agent as depository bank for unpaid fees and similar charges, a first priority security interest in all such Cash Collateral, and in all proceeds of the foregoing, all as security for the obligations to which such Cash Collateral may be applied pursuant to Section 2.16(c).  If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent or the L/C Issuer as herein provided or that the total amount of such Cash Collateral is less than the Minimum Collateral Amount, the Borrower will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency.  All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in blocked, non-interest bearing deposit accounts with, and subject to the control of, the Administrative Agent. The Borrower shall pay on demand therefor from time to time all customary account opening, activity and other administrative fees and charges in connection with the maintenance and disbursement of Cash Collateral.

65

(c)Application.  Notwithstanding anything to the contrary contained in this Credit Agreement, Cash Collateral provided under any of this Section 2.16 or 9.02 in respect of Letters of Credit or Swingline Loans shall be held and applied to the satisfaction of the specific L/C Obligations, Swingline Loans, obligations to fund participations therein (including, as to Cash Collateral provided by a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided.

(d)Release.  Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or to secure other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender (or, as appropriate, its assignee following compliance with Section 11.06(b)(vi))) or (ii) the determination by the Administrative Agent and the L/C Issuer that there exists excess Cash Collateral; provided, however, (x) any such release shall be without prejudice to, and any disbursement or other transfer of Cash Collateral shall be and remain subject to, any other Lien conferred under the Credit Documents and the other applicable provisions of the Credit Documents, and (y) the Person providing Cash Collateral and the L/C Issuer may agree that Cash Collateral shall not be released but instead held to support future anticipated Fronting Exposure or other obligations.

2.17Defaulting Lenders.

(a)Adjustments.  Notwithstanding anything to the contrary contained in this Credit Agreement, if any Lender becomes a Defaulting Lender, then, until such time as such Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:

(i)A Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent, and to participate in the process of any such amendment, waiver or consent, with respect to this Credit Agreement and the other Credit Documents shall be suspended as provided in the definition of “Required Lenders” and in Section 11.01.

(ii)A Defaulting Lender may be replaced and its interests assigned or Commitments terminated as provided in Section 11.13.

(iii)The L/C Issuers and Swingline Lender may require Cash Collateral or other assurance in respect of Fronting Exposure as a condition to Credit Extensions.

(iv)all payments of principal, interest and other amounts owing to a Defaulting Lender will be paid into an account or subaccount with the Administrative Agent (collectively, the “Defaulting Lender Account”) to secure the Defaulting Lender’s obligations under this Credit Agreement.  Amounts held in the Defaulting Lender Account shall be applied at such time or times as may be determined by the Administrative Agent as follows:  first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the L/C Issuers or Swingline Lenders hereunder; third, if so determined by the Administrative Agent or requested by an L/C Issuer or a Swingline Lender, to be held as Cash Collateral for future funding obligations of that Defaulting Lender of any participation in any Swingline Loan or Letter of Credit; fourth, as the Borrowers may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Credit Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrowers, to be held in a deposit account and released pro rata in order to (x) satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Credit Agreement and (y) Cash Collateralize the L/C

66

Issuer’s future Fronting Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Credit Agreement in accordance with Section 2.16; sixth, to the payment of any amounts owing to the Lenders, the L/C Issuers or Swingline Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, an L/C Issuer or a Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Credit Agreement; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrowers as a result of any judgment of a court of competent jurisdiction obtained by the Borrowers against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Credit Agreement; and eighth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which such Defaulting Lender has not fully funded its appropriate share and (y) such Loans or L/C Borrowings were made or the related Letters of Credit were issued at a time when the conditions set forth in Section 5.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Borrowings owed to, all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Borrowings owed to, such Defaulting Lender.

(v)Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.17(a)(v) shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto;

(A)No Defaulting Lender shall be entitled to receive any Commitment Fees under Section 2.09(a) for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).

(B)Each Defaulting Lender shall be entitled to receive Letter of Credit Fees under Section 2.09(b) for any period during which that Lender is a Defaulting Lender only to the extent allocable to its pro rata share of the stated amount of Letters of Credit for which it has provided Cash Collateral as provided in Section 2.16.

(C)With respect to any Letter of Credit Fee under Section 2.09(b) not required to be paid to any Defaulting Lender pursuant to clause (B) above, the Borrowers shall (x) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting Lender’s participation in L/C Obligations or Swingline Loans that have been reallocated to such Non-Defaulting Lender pursuant to clause (b) below, (y) pay to the L/C Issuer and Swingline Lender, as applicable, the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to such L/C Issuer’s or Swingline Lender’s Fronting Exposure to such Defaulting Lender, and (z) not required to pay the remaining amount of any such fee.

(vi)So long as no Event of Default shall exist immediately before or immediately after giving affect thereto, the Borrowers may with the consent of the Administrative Agent elect to terminate the Commitments of the Defaulting Lender, and repay its share of outstanding Revolving Loan Obligations on a non-pro rata basis.

(b)Reallocation of Pro Rata Share to Reduce Fronting Exposure.  All or any part of such Defaulting Lender’s participation in L/C Obligations and Swingline Loans shall be reallocated among the

67

Non-Defaulting Lenders in accordance with their respective pro rata shares (calculated without regard to such Defaulting Lender’s Commitment) but only to the extent that such reallocation does not cause the aggregate amount of any Non-Defaulting Lender’s share of Revolving Loan Obligations to exceed such Non-Defaulting Lender’s Commitment in respect thereof.  Subject to Section 11.21, no reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender’s increased exposure following such reallocation.

(c)Cash Collateral, Repayment of Swingline Loans.  If the reallocation described in Section 2.17(b) above cannot, or can only partially, be effected, the Borrowers shall, without prejudice to any right or remedy available to it hereunder or under applicable Law, (x) first, prepay Swingline Loans in an amount equal to the Swingline Lenders’ Fronting Exposure, and (y) second, Cash Collateralize the L/C Issuers’ Fronting Exposure in accordance with the procedures set forth in Section 2.16.

(d)Defaulting Lender Cure.  If the Borrowers, the Administrative Agent, Swingline Lenders and the L/C Issuers agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit and Swingline Loans to be held on a pro rata basis by the Lenders in accordance with their respective pro rata shares (without giving effect to Section 2.17(b)), whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrowers while that Lender was a Defaulting Lender; and provided; further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.

(e)New Swingline Loans and Letters of Credit.  So long as any Lender is a Defaulting Lender (i) the Swingline Lender shall not be required to fund any Swingline Loans unless it is satisfied that there will be no Fronting Exposure after giving effect to such Swingline Loans, and (ii) no L/C Issuer shall be required to issue, extend, renew or increase any Letter of Credit unless it is satisfied that it will have no Fronting Exposure after giving effect thereto.

2.18[Reserved] .

ARTICLE III

TAXES, YIELD PROTECTION AND ILLEGALITY

3.01Taxes.

(a)Payments Free of Taxes; Obligation to Withhold; Payments on Account of Taxes.

(i)Any and all payments by or on account of any obligation of any Credit Party under any Credit Document shall be made without deduction or withholding for any Taxes, except as required by applicable Laws.  If any applicable Laws (as determined in the good faith discretion of the Administrative Agent) require the deduction or withholding of any Tax from any such payment by the Administrative Agent or a Credit Party, then the Administrative Agent or

68

such Credit Party shall be entitled to make such deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to subsection (e) below.

(ii)If any Credit Party or the Administrative Agent shall be required by the Internal Revenue Code to withhold or deduct any Taxes, including both United States federal backup withholding and withholding taxes, from any payment, then (A) the Administrative Agent shall withhold or make such deductions as are determined by the Administrative Agent to be required based upon the information and documentation it has received pursuant to subsection (e) below, (B) the Administrative Agent shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with the Internal Revenue Code, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Credit Parties shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the applicable Recipient, receives an amount equal to the sum it would have received had no such withholding or deduction been made.

(iii)If any Credit Party or the Administrative Agent shall be required by any applicable Laws other than the Internal Revenue Code to withhold or deduct any Taxes from any payment, then (A) such Credit Party or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as are determined by it to be required based upon the information and documentation it has received pursuant to subsection (e) below, (B) such Credit Party or the Administrative Agent, to the extent required by such Laws, shall timely pay the full amount so withheld or deducted by it to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Credit Party shall be increased as  necessary so that after any required withholding or the making of all required deductions (including deductions applicable to additional sums payable under this Section 3.01) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made.

(b)Payment of Other Taxes by the Credit Parties.  Without limiting the provisions of subsection (a) above, the Credit Parties shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.

(c)Tax Indemnifications.

(i)Each of the Credit Parties shall, and does hereby, jointly and severally indemnify each Recipient, and shall make payment in respect thereof within ten days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 3.01) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender or L/C Issuer (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or L/C Issuer, shall be conclusive absent manifest error.  Each of the Credit Parties shall, and does hereby, jointly and severally indemnify the Administrative Agent, and shall make payment in respect thereof within ten days after demand therefor, for any amount which a Lender or L/C Issuer for any reason fails to pay indefeasibly to the Administrative Agent as required pursuant to Section 3.01(c)(ii) below.

69

(ii)Each Lender and L/C Issuer shall, and does hereby, severally indemnify, and shall make payment in respect thereof within ten days after demand therefor, (x) the Administrative Agent against any Indemnified Taxes attributable to such Lender or L/C Issuer (but only to the extent that any Credit Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Credit Parties to do so), (y) the Administrative Agent and the Credit Parties, as applicable, against any Taxes attributable to such Lender’s failure to comply with the provisions of Section 11.06(d) relating to the maintenance of a Participant Register and (z) the Administrative Agent and the Credit Parties, as applicable, against any Excluded Taxes attributable to such Lender or L/C Issuer, in each case, that are payable or paid by the Administrative Agent or a Credit Party in connection with any Credit Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error.  Each Lender and L/C Issuer hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender or L/C Issuer, as the case may be, under this Credit Agreement or any other Credit Document against any amount due to the Administrative Agent under this clause (ii).

(d)Evidence of Payments.  Upon request by the Borrowers or the Administrative Agent, as the case may be, after any payment of Taxes by any Credit Party or by the Administrative Agent to a Governmental Authority as provided in this Section 3.01, the Borrowers shall deliver, or cause to be delivered, to the Administrative Agent or the Administrative Agent shall deliver to the Borrowers, as the case may be, the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return required by Law to report such payment or other evidence of such payment reasonably satisfactory to the Borrowers or the Administrative Agent, as the case may be.

(e)Status of Lenders; Tax Documentation.

(i)Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Credit Document shall deliver to the Borrowers and the Administrative Agent, at the time or times reasonably requested by the Borrowers or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Borrowers or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrowers or the Administrative Agent as will enable the Borrowers or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 3.01(e)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.

(ii)Without limiting the generality of the foregoing, in the event that a Borrower is a U.S. Person,

(A)any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender

70

under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;

(B)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:

(I)in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Credit Document, executed copies of IRS Form W-8BENE (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Credit Document, IRS Form W-8BENE (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;

(II)executed copies of IRS Form W-8ECI;

(III)in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate substantially in the form of Exhibit H-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Internal Revenue Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Internal Revenue Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BENE (or W-8BEN, as applicable); or

(IV)to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BENE (or W-8BEN, as applicable), a U.S. Tax Compliance Certificate substantially in the form of Exhibit H-2 or Exhibit H-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit H-4 on behalf of each such direct and indirect partner;

(C)any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Credit Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such

71

supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and

(D)if a payment made to a Lender under any Credit Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment.  Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Credit Agreement.

(iii)Each Lender agrees that if any form or certification it previously delivered pursuant to this Section 3.01 expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrowers and the Administrative Agent in writing of its legal inability to do so.

(f)Treatment of Certain Refunds.  Unless required by applicable Law, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender or L/C Issuer, or have any obligation to pay to any Lender or L/C Issuer, any refund of Taxes withheld or deducted from funds paid for the account of such Lender or L/C Issuer, as the case may be.  If any Recipient determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified by any Credit Party or with respect to which any Credit Party has paid additional amounts pursuant to this Section 3.01, it shall pay to the Credit Party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by a Credit Party under this Section 3.01 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Recipient, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that the Credit Party, upon the request of the Recipient, agrees to repay the amount paid over to the Credit Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Recipient in the event the Recipient is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this subsection, in no event will the applicable Recipient be required to pay any amount to the Credit Party pursuant to this subsection the payment of which would place the Recipient in a less favorable net after-Tax position than such Recipient would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This subsection shall not be construed to require any Recipient to make available its tax returns (or any other information relating to its taxes that it deems confidential) to any Credit Party or any other Person.

(g)Survival.  Each party’s obligations under this Section 3.01 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender or L/C Issuer, the termination of the Commitments and the repayment, satisfaction or discharge of all other Obligations.

72

3.02Illegality.  If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable Lending Office to perform any of its obligations hereunder or make, maintain or fund Loans whose interest is determined by reference to the Fixed LIBOR Rate (whether denominated in Dollars or an Alternative Currency), or to determine or charge interest rates based upon the Fixed LIBOR Rate, or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars or any Alternative Currency in the applicable interbank market, then, on notice thereof by such Lender to the applicable Borrower through the Administrative Agent, (a) any obligation of such Lender to issue, maintain or fund or to make or continue Fixed LIBOR Rate Loans in the affected currency or currencies or, in the case of Fixed LIBOR Rate Loans in Dollars, to convert Base Rate Loans to Fixed LIBOR Rate Loans shall be suspended and (b) if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by reference to the Fixed LIBOR Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Fixed LIBOR Rate component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the applicable Borrower that the circumstances giving rise to such determination no longer exist.  Upon receipt of such notice, (x) the applicable Borrower shall, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable and such Loans are denominated in Dollars, convert all of such Lender’s Fixed LIBOR Rate Loans to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Fixed LIBOR Rate component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Fixed LIBOR Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Fixed LIBOR Rate Loans and (y) if such notice asserts the illegality of such Lender determining or charging interest rates based upon the Fixed LIBOR Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Fixed LIBOR Rate component thereof until the Administrative Agent is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Fixed LIBOR Rate.  Upon any such prepayment or conversion, the applicable Borrower shall also pay accrued interest on the amount so prepaid or converted.

3.03Inability to Determine Rates.  If the Required Lenders determine that for any reason in connection with any request for a Fixed LIBOR Rate Loan or a conversion to or continuation thereof that

(a)(i) deposits in the Applicable Currency are not being offered to banks in the applicable offshore interbank market for the Applicable Currency, the applicable amount or the applicable Interest Period for such Fixed LIBOR Rate Loan, or (ii) adequate and reasonable means do not exist for determining the Fixed LIBOR Rate for any requested Interest Period with respect to a proposed Fixed LIBOR Rate Loan (whether denominated in Dollars or another currency or in connection with an existing or proposed Base Rate Loan that is determined by reference to the Fixed LIBOR Rate, the “Impacted Loans”), or

(b)the Fixed LIBOR Rate for the Applicable Currency for any requested Interest Period with respect to a proposed Fixed LIBOR Rate Loan, or in connection with an existing or proposed Base Rate Loan which is based on the Fixed LIBOR Rate, does not adequately and fairly reflect the cost to such Lenders of funding such Loan,

(c)the Administrative Agent will promptly notify the affected Borrowers and Lenders.  Thereafter, (x) the obligation of the Lenders to make or maintain such Fixed LIBOR Rate Loans in the affected currency or currencies shall be suspended and (y) in the event of a determination described in the preceding sentence with respect to the Fixed LIBOR Rate component of the Base Rate, the utilization of

73

the Fixed LIBOR Rate component in determining the Base Rate shall be suspended (to the extent of the affected Fixed LIBOR Rate Loans or Interest Periods), in each case until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice.  Upon receipt of such notice, the Borrowers may revoke any pending request for a Borrowing of, conversion to or continuation of Fixed LIBOR Rate Loans in the affected currency or currencies (to the extent of the affected Fixed LIBOR Rate Loans or Interest Periods) in respect thereof or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Loans or unaffected Fixed LIBOR Rate Loans, as appropriate, in the amount specified therein.

Notwithstanding the foregoing, if the Administrative Agent has made the determination described in this section, the Administrative Agent, in consultation with the Borrower and the Required Lenders for the affected class of Impacted Loans, may establish an alternative interest rate for the Impacted Loans,  in which case, such alternative rate of interest shall apply with respect to the Impacted Loans until (1) the Administrative Agent revokes the notice delivered with respect to the Impacted Loans under clause (a) of the first sentence of this section, (2) the Administrative Agent or the Required Lenders for the affected class of Impacted Loans notify the Administrative Agent and the Borrower that such alternative interest rate does not adequately and fairly reflect the cost to such Lenders of funding the Impacted Loans, or (3) any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for such Lender or its applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to such alternative rate of interest or to determine or charge interest rates based upon such rate or any Governmental Authority has imposed material restrictions on the authority of such Lender to do any of the foregoing and provides the Administrative Agent and the Borrower written notice thereof.

3.04Increased Cost; Capital Adequacy.

(a)Increased Costs Generally.  If any Change in Law shall:

(i)impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the Fixed LIBOR Rate or contemplated by Section 3.04(e) hereof);

(ii)subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or

(iii)impose on any Lender or L/C Issuer or the London interbank market any other condition, cost or expense (other than Taxes) affecting this Credit Agreement or Fixed LIBOR Rate Loans made by such Lender or any Letter of Credit or participation therein;

and the result of any of the foregoing shall be to increase the cost to such Lender or other Recipient of making, converting to, continuing or maintaining any Loan, the interest on which is determined by reference to the Fixed LIBOR Rate (or of maintaining its obligation to make any such Loan), or to increase the cost to such Lender, L/C Issuer or other Recipient of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender, L/C Issuer or other Recipient hereunder (whether of principal, interest or any other amount) then, upon request of such Lender, L/C Issuer or other Recipient, the applicable Borrower will pay, or cause to be paid, to such Lender, L/C Issuer or other Recipient, as the case may be, such additional amount or amounts as will compensate such

74

Lender, L/C Issuer or other Recipient, as the case may be, for such additional costs incurred or reduction suffered.

(b)Capital Requirements.  If any Lender or L/C Issuer determines that any Change in Law affecting such Lender or L/C Issuer or any Lending Office of such Lender or such Lender’s or L/C Issuer’s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender’s or L/C Issuer’s capital or on the capital of such Lender’s or L/C Issuer’s holding company, if any, as a consequence of this Credit Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by L/C Issuer, to a level below that which such Lender or L/C Issuer or such Lender’s or L/C Issuer’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s or L/C Issuer’s policies and the policies of such Lender’s or L/C Issuer’s holding company with respect to capital adequacy), then from time to time the applicable Borrower will pay or cause to be paid to such Lender or L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or L/C Issuer or such Lender’s or L/C Issuer’s holding company for any such reduction suffered.

(c)Certificates for Reimbursement.  A certificate of a Lender or L/C Issuer setting forth the amount or amounts necessary to compensate such Lender or L/C Issuer or its holding company, as the case may be, as specified in subsection (a) or (b) of this Section and delivered to the Borrowers shall be conclusive absent manifest error.  The Borrowers shall pay such Lender or L/C Issuer, as the case may be, the amount shown as due on any such certificate within ten days after receipt thereof.

(d)Delay in Requests.  Failure or delay on the part of any Lender or L/C Issuer to demand compensation pursuant to the foregoing provisions of this Section shall not constitute a waiver of such Lender’s or L/C Issuer’s right to demand such compensation, provided that the Borrowers shall not be required to compensate a Lender or L/C Issuer pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than six months prior to the date that such Lender or L/C Issuer, as the case may be, notifies the Borrowers of the Change in Law giving rise to such increased costs or reductions and of such Lender’s or L/C Issuer’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof).

(e)Reserves on Fixed LIBOR Rate Loans.  The Borrowers shall pay, or cause to be paid, to each Lender, (i) as long as such Lender shall be required to maintain reserves with respect to liabilities or assets consisting of or including Eurocurrency funds or deposits (currently known as “Eurocurrency liabilities”), additional interest on the unpaid principal amount of each Fixed LIBOR Rate Loan equal to the actual costs of such reserves allocated to such Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive absent manifest error), and (ii) as long as such Lender shall be required to comply with any reserve ratio requirement or analogous requirement of any other central banking or financial regulatory authority imposed in respect of the maintenance of the Commitments or the funding of the Fixed LIBOR Rate Loans, such additional costs (expressed as a percentage per annum and rounded upwards, if necessary, to the nearest five decimal places) equal to the actual costs thereof allocated to such Commitment or Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive absent manifest error), which, in each case, shall be due and payable on each date on which interest is payable on such Loan, provided the Borrowers shall have received at least fifteen days’ prior notice (with a copy to the Administrative Agent) of such additional interest or costs from such Lender.  If a Lender fails to give notice fifteen days prior to the relevant Interest Payment Date, such additional interest or costs shall be due and payable fifteen days from receipt of such notice.

75

3.05Compensation for Losses.  Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrowers shall promptly compensate, or cause to be compensated, such Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of:

(a)any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise);

(b)any failure by any Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by such Borrower;

(c)any failure by any Borrower to make payment of any Loan or drawing under any Letter of Credit (or interest due thereon) denominated in an Alternative Currency on its scheduled due date or any payment thereof in a different currency; or

(d)any assignment of a Fixed LIBOR Rate Loan on a day other than the last day of the Interest Period therefor as a result of a request by any Borrower pursuant to Section 11.13;

including any foreign exchange losses and any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained or from the performance of any foreign exchange contract.  The Borrowers shall also pay, or cause to be paid, any customary administrative fees charged by such Lender in connection with the foregoing.

For purposes of calculating amounts payable by the Borrowers to the Lenders under this Section 3.05, each Lender shall be deemed to have funded each Fixed LIBOR Rate Loan made by it at the Fixed LIBOR Rate used in determining the Fixed LIBOR Rate for such Loan by a matching deposit or other borrowing in the offshore interbank market for such currency for a comparable amount and for a comparable period, whether or not such Fixed LIBOR Rate Loan was in fact so funded.

3.06Mitigation Obligations; Replacement of Lenders.

(a)Designation of a Different Lending Office.  If any Lender requests compensation under Section 3.04, or any Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender, L/C Issuer or any Governmental Authority for the account of any Lender or L/C Issuer pursuant to Section 3.01, or if any Lender or L/C Issuer gives a notice pursuant to Section 3.02, then at the request of the Borrower such Lender or L/C Issuer, as applicable, shall use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender or L/C Issuer, as applicable, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.01 or 3.04, as the case may be, in the future, or eliminate the need for the notice pursuant to Section 3.02, as applicable, and (ii) in each case, would not subject such Lender or L/C Issuer, as the case may be, to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender or L/C Issuer, as the case may be.  The Borrowers hereby agree to pay, or cause to be paid, all reasonable costs and expenses incurred by any Lender or L/C Issuer in connection with any such designation or assignment.

(b)Replacement of Lenders.  If any Lender requests compensation under Section 3.04, or if any Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any

76

Governmental Authority for the account of any Lender pursuant to Section 3.01 and, in each case, such Lender has declined or is unable to designate a different Lending Office in accordance with Section 3.06(a), the Borrowers may replace such Lender in accordance with Section 11.13.

3.07Survival Losses.  All of the Credit Parties’ obligations under this Article III shall survive termination of the Commitments hereunder and repayment of the Loan Obligations and resignation of the Administrative Agent.

ARTICLE IV

GUARANTY

4.01The Guaranty.

(a)Each of the Guarantors hereby jointly and severally irrevocably guarantees to the Administrative Agent and each of the holders of the Obligations as hereinafter provided, as primary obligor and not as surety, the prompt payment of the Obligations in full when due (whether at stated maturity, as a mandatory prepayment, by acceleration, as a mandatory Cash Collateralization or otherwise) strictly in accordance with the terms thereof.  The Guarantors hereby further agree that if any of the Obligations are not paid in full when due (whether at stated maturity, as a mandatory prepayment, by acceleration, as a mandatory Cash Collateralization or otherwise), the Guarantors will, jointly and severally, promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Obligations, the same will be promptly paid in full when due (whether at extended maturity, as a mandatory prepayment, by acceleration, as a mandatory Cash Collateralization or otherwise) in accordance with the terms of such extension or renewal.

(b)Notwithstanding any provision to the contrary contained herein or in any other of the Credit Documents, Swap Contracts or other agreements or documents relating to the Obligations, (i) the obligations of each Guarantor under this  Credit Agreement and the other Credit Documents shall not exceed an aggregate amount equal to the largest amount that would not render such obligations subject to avoidance under the Debtor Relief Laws or any comparable provisions of any applicable state law, and (ii) the Obligations of a Guarantor shall exclude any Excluded Swap Obligations with respect to such Guarantor.

(c)The liability of a German Guarantor shall be subject to the limitations set forth in Section 11.22 hereof.

(d)The liability of any entity incorporated under the laws of the Grand Duchy of Luxembourg (a “Luxembourg Guarantor”) for obligations of any entity of which such Luxembourg Guarantor is a Subsidiary and/or for obligations of any of such Luxembourg Guarantor’s Affiliates (other than its own Subsidiaries) in respect of the guaranty set forth in this Article IV shall be limited at any time to an aggregate amount not exceeding ninety five percent (95%) of the greater of the sum of such Luxembourg Guarantor’s own funds (capitaux propres) and the debt owed bythe Luxembourg Guarantor to its direct and indirect shareholders as determined by Article 34 of the Luxembourg Law of 19 December 2002 on the register of commerce and companies, accounting and companies annual accounts, as amended, (i) as set forth in its most recently approved financial statements or (ii) existing as of the Closing Date.  This limitation does not apply to any amounts borrowed under any facility and in each case made available, in any form whatsoever, to such Luxembourg Guarantor or its Subsidiaries.

77

4.02Obligations Unconditional.

(a)The obligations of the Guarantors under Section 4.01 are joint and several, absolute and unconditional, irrespective of the value, genuineness, validity, regularity or enforceability of any of the Credit Documents or other documents relating to the Obligations, or any substitution, compromise, release, impairment or exchange of any other guarantee of or security for any of the Obligations, and, to the fullest extent permitted by applicable Law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this Section 4.02 that the obligations of the Guarantors hereunder shall be absolute and unconditional under any and all circumstances.  Each Guarantor agrees that it shall have no right of subrogation, indemnity, reimbursement or contribution against the Borrowers or any other Guarantor for amounts paid under this Article IV until such time as the Obligations have been irrevocably paid in full and the Commitments relating thereto have expired or terminated.

(b)Without limiting the generality of the foregoing subsection, it is agreed that, to the fullest extent permitted by Law, the occurrence of any one or more of the following shall not alter or impair the liability of any Guarantor hereunder, which shall remain absolute and unconditional as described above:

(i)at any time or from time to time, without notice to any Guarantor, the time for any performance of or compliance with any of the Obligations shall be extended, or such performance or compliance shall be waived;

(ii)any of the acts mentioned in any of the provisions of any of the Credit Documents, or other documents relating to the Obligations or any other agreement or instrument referred to therein shall be done or omitted;

(iii)the maturity of any of the Obligations shall be accelerated, or any of the Obligations shall be modified, supplemented or amended in any respect, or any right under any of the Credit Documents or any other document relating to the Obligations or any other agreement or instrument referred to therein shall be waived or any other guarantee of any of the Obligations or any security therefor shall be released, impaired or exchanged in whole or in part or otherwise dealt with;

(iv)any Lien granted to, or in favor of, the Administrative Agent or any holder of the Obligations as security for any of the Obligations shall fail to attach or be perfected; or

(v)any of the Obligations shall be determined to be void or voidable (including for the benefit of any creditor of any Guarantor) or shall be subordinated to the claims of any Person (including any creditor of any Guarantor).

(c)With respect to its obligations hereunder, each Guarantor hereby expressly waives diligence, presentment, demand of payment, protest, notice of acceptance of the guaranty given hereby and of extensions of credit that may constitute obligations guaranteed hereby, notices of amendments, waivers, consents and supplements to the Credit Documents and other documents relating to the Obligations, or the compromise, release or exchange of collateral or security, and all other notices whatsoever, and any requirement that the Administrative Agent or any holder of the Obligations exhaust any right, power or remedy or proceed against any Person under any of the Credit Documents or any other document relating to the Obligations or any other agreement or instrument referred to therein, or against any other Person under any other guarantee of, or security for, any of the Obligations.

4.03Reinstatement.  Neither the Guarantors’ obligations hereunder nor any remedy for the enforcement thereof shall be impaired, modified, changed or released in any manner whatsoever by an impairment, modification, change, release or limitation of the liability of the Borrowers, by reason of any

78

Borrower’s bankruptcy or insolvency or by reason of the invalidity or unenforceability of all or any portion of the Obligations.  In addition, the obligations of each Guarantor under this Article IV shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of any Person in respect of the Obligations is rescinded or must be otherwise restored by any holder of any of the Obligations, whether as a result of any Debtor Relief Law or otherwise, and each Guarantor agrees that it will indemnify the Administrative Agent and each holder of the Obligations on demand for all reasonable costs and expenses (including reasonable attorneys’ fees and disbursements) incurred by the Administrative Agent or such holder of the Obligations in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any Debtor Relief Law.

4.04Certain Waivers.  Each Guarantor acknowledges and agrees that (a) the guaranty given hereby may be enforced without the necessity of resorting to or otherwise exhausting remedies in respect of any other security or collateral interests, and without the necessity at any time of having to take recourse against the Borrowers hereunder or against any collateral securing the Obligations or otherwise, and (b) it will not assert any right to require the action first be taken against the Borrowers or any other Person (including any co-guarantor) or pursuit of any other remedy or enforcement any other right, and (c) nothing contained herein shall prevent or limit action being taken against the Borrowers hereunder, under the other Credit Documents or the other documents and agreements relating to the Obligations or from foreclosing on any security or collateral interests relating hereto or thereto, or from exercising any other rights or remedies available in respect thereof, if neither the Borrowers nor the Guarantors shall timely perform their obligations, and the exercise of any such rights and completion of any such foreclosure proceedings shall not constitute a discharge of the Guarantors’ obligations hereunder unless as a result thereof, the Obligations shall have been paid in full and the Commitments relating thereto shall have expired or terminated, it being the purpose and intent that the Guarantors’ obligations hereunder be absolute, irrevocable, independent and unconditional under all circumstances.  Each Guarantor agrees that it shall have no right of recourse to security for the Obligations, except through the exercise of rights of subrogation pursuant to Section 4.02 and through the exercise of rights of contribution pursuant to Section 4.06.

4.05Remedies.  The Guarantors agree that, to the fullest extent permitted by Law, as between the Guarantors, on the one hand, and holders of the Obligations, on the other hand, the Obligations may be declared to be forthwith due and payable as provided in Section 9.02 (and shall be deemed to have become automatically due and payable in the circumstances specified in Section 9.02) for purposes of Section 4.01 notwithstanding any stay, injunction or other prohibition preventing such declaration (or preventing the Obligations from becoming automatically due and payable) as against any other Person and that, in the event of such declaration (or the Obligations being deemed to have become automatically due and payable), the Obligations (whether or not due and payable by any other Person) shall forthwith become due and payable by the Guarantors for purposes of Section 4.01.

4.06Rights of Contribution.  The Guarantors hereby agree as among themselves that, in connection with payments made hereunder, each Guarantor shall have a right of contribution from each other Guarantor in accordance with applicable Law.  Such contribution rights shall be subordinate and subject in right of payment to the Obligations until such time as the Obligations have been irrevocably paid in full and the Commitments relating thereto shall have expired or been terminated, and none of the Guarantors shall exercise any such contribution rights until the Obligations have been irrevocably paid in full and the Commitments relating thereto shall have expired or been terminated.

4.07Guaranty of Payment; Continuing Guaranty.  The guarantee given by the Guarantors in this Article IV is a guaranty of payment and not of collection, is a continuing guarantee, and shall apply to all Obligations whenever arising.

79

4.08Keepwell.    At the time the Guaranty in this Article IV by any Credit Party that is not then an “eligible contract participant” under the Commodity Exchange Act (a “Specified Credit Party”) or the grant of a security interest under the Credit Documents by any such Specified Credit Party, in either case, becomes effective with respect to any Swap Obligation, FME, in the case a Specified Credit Party that is not a Domestic Subsidiary, and FMCH, in the case a Specified Credit Party that is the Domestic Subsidiary hereby, absolutely, unconditionally and irrevocably undertakes to provide, or to cause Subsidiary to provide, such funds or other support to each Specified Credit Party with respect to such Swap Obligation as may be needed by such Specified Credit Party from time to time to honor all of its obligations under the Credit Documents in respect of such Swap Obligation (but, in each case, only up to the maximum amount of such liability that can be hereby incurred without rendering such Qualified ECP Guarantor’s obligations and undertakings under this Article IV, or otherwise under this Credit Agreement, voidable under applicable Debtor Relief Laws, and not for any greater amount). The obligations and undertakings of FME and FMCH under this Section shall remain in full force and effect until the guaranteed Obligations have been paid in full and the commitments relating thereto have expired or terminated. Each Credit Party intends this Section to constitute, and this Section shall be deemed to constitute, “keepwell, support, or other agreement” for the benefit of, each Specified Credit Party for all purposes of Section 1a(18)(A)(v)(II) of the Commodity Exchange Act.

ARTICLE V

CONDITIONS PRECEDENT TO CREDIT EXTENSIONS

5.01Conditions of Effectiveness.  This Credit Agreement shall be effective upon satisfaction of the following conditions precedent in each case in a manner satisfactory to the Administrative Agent and each Lender1:

(a)Executed Credit Documents.  Receipt by the Administrative Agent of (i) multiple counterparts of this Credit Agreement, and (ii) executed Notes for those Lenders requesting them, in each case properly executed by a Responsible Officer or duly authorized signatory.

(b)Financial Information.  Receipt by the Administrative Agent of, with respect to FME and its subsidiaries on a consolidated basis, (A) unaudited company-prepared financial statements, including a balance sheet, income statement, and statement of cash flows (excluding notes) for the fiscal period ending June 30, 2012, and (B) audited financial statements, including balance sheet, income statement and statement of cash flows (excluding notes) for the fiscal year ending December 31, 2011.

(c)[Reserved].

(d)Corporate Documents.  Receipt by the Administrative Agent of a certificate of a Responsible Officer or duly authorized signatory of each Credit Party attaching each of the following documents and certifying that each is true and correct and complete and in full force and effect as of the Closing Date:

(i)Charter Documents.  Copies of its certificate of organization or equivalent, certified to be true and correct as of a recent date by the appropriate Governmental Authority of the state or other jurisdiction of its organization.

1  Draft Note:  These were conditions to the effectiveness of the 2012 credit agreement which included certain collateral pledges that have been released on the Amendment No. 2 Effective Date.  Changes are shown to this Section 5.01 in an attempt to help avoid a mistaken impression that collateral pledges might still exist.

80

(ii)Bylaws.  Copies of its bylaws, operating agreement or partnership agreement or the equivalent.

(iii)Resolutions.  Copies of its resolutions approving and adopting the Credit Documents to which it is a party, the transactions contemplated herein and therein, and authorizing the execution and delivery thereof.

(iv)Incumbency.  Original incumbency certificates identifying the officers thereof authorized to act on its behalf in connection with the Credit Documents (if available from the applicable jurisdiction).

(v)Good Standing.  Certificates of good standing or the equivalent (if available from the applicable jurisdiction), certified as of a recent date by the appropriate Governmental Authorities from the state or other jurisdiction of its organization, and such other states or jurisdictions as the Administrative Agent may reasonably request and, in relation to a Luxembourg Guarantor, a confirmation by a manager that the company is not (A) subject to bankruptcy, insolvency, voluntary or judicial liquidation, composition with creditors, reprieve from payment, controlled management or (B) on the date of the confirmation, in a state of cessation or payments and has not lost its commercial creditworthiness except if otherwise provided for in the relevant charter documents.

(e)Legal Opinions.  Receipt by the Administrative Agent of favorable legal opinions from counsel to FME and FMCH in form and substance reasonably satisfactory to the Administrative Agent regarding, among other things, existence and due authorization, execution, delivery and enforceability of the Credit Documents, no violations of Organization Documents, certain material agreements or applicable Law caused by the execution, delivery and performance of the Credit Documents.

(f)Replacement of the Existing Credit Agreements.  Evidence of repayment of the loans and obligations owing by FME, FMCH and the other Borrowers and Guarantors under the Existing Bank Credit Agreement and the Existing Term Loan Credit Agreement, and, in each case, termination of the commitments thereunder and release of the security interests relating thereto.

(g)Fees.  Payment of all fees and expenses required to be paid on or before the Closing Date, including the reasonable and documented fees and expenses of counsel for the Administrative Agent and Arrangers.  As used herein, “documented” means such documentation as may be customary, reasonable and appropriate in light of the circumstances, but which, for purposes of closing, may include a summary statement with estimates of fees and expenses through a reasonable post-closing period.

Without limiting the generality of the provisions of Section 10.04, for purposes of determining compliance with the conditions specified in this Section 5.01, each Lender that has signed this Credit Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.

5.02Conditions to all Credit Extensions.  The obligation of each Lender to honor any Request for Credit Extension is subject to the following conditions precedent:

81

(a)The representations and warranties of each Credit Party contained in Article VI or any other Credit Document, or that are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects on and as of the date of such Credit Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects as of such earlier date, and except that for purposes of this Section 5.02, the representations and warranties contained in subsections (A) and (B) of Section 6.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 7.01.

(b)No Default or Event of Default shall exist, or would result from such proposed Credit Extension.

(c)The Administrative Agent and, if applicable, the L/C Issuer or the Swingline Lender shall have received a Request for Credit Extension in accordance with the requirements hereof.

Each Borrowing pursuant to any Request for Credit Extension (other than a Loan Notice requesting only a conversions or continuations) submitted by the Borrowers shall be deemed to be a representation and warranty by such Borrowers that the conditions specified in Section 5.02(a) and (b) have been satisfied on and as of the date of the applicable Credit Extension.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES

Each Borrower and each other Credit Party represents and warrants to the Administrative Agent and the Lenders the following (provided, only the Borrowers (and not the other Credit Parties) represent and warrant as to the representations and warranties set forth in Section 6.21(b)):

6.01Existence, Qualification and Power; Compliance with Laws.  Each Credit Party (a) is a corporation, partnership, limited liability company or other entity duly organized or formed, validly existing and in good standing (to the extent such concept exists in the applicable jurisdiction and except to the extent that the failure to be in good standing could not reasonably be expected to have a Material Adverse Effect) under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Credit Documents to which it is a party, (c) is duly qualified and is licensed and in good standing (to the extent such concept exists in the applicable jurisdiction) under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license, (d) is in compliance with all Laws and (e) has, to the extent applicable: (i) entered into and maintains in good standing its Medicare Provider Agreements and Medicaid Provider Agreements and (ii) ensured that all such required licenses are in full force and effect on the date hereof and have not been revoked or suspended or otherwise limited; except in the case of clauses (b)(i), (b)(ii), (c), (d) and (e), to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect.

6.02Authorization; No Contravention.  The execution, delivery and performance by each Credit Party of each Credit Document to which such Person is party, have been duly authorized by all necessary corporate or other organizational action, and do not (a) contravene the terms of any of such Person’s Organization Documents; (b) materially conflict with or result in any material breach or

82

contravention of, or the creation of any Lien under, (i) any material Contractual Obligation to which such Person is a party or (ii) any material order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; (c) violate any Law; or (d) except to the extent it would not have a Material Adverse Effect, result in a limitation on any licenses, permits, certificates or determinations of need or other approvals applicable to the business, operations or properties of any Credit Party or adversely affect the ability of any Credit Party to participate in any Medical Reimbursement Programs.

6.03Governmental Authorization; Other Consents.  No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Credit Party of this Credit Agreement or any other Credit Document other than those that have already been obtained and are in full force and effect.

6.04Binding Effect.  This Credit Agreement and each other Credit Document has been duly executed and delivered by each Credit Party that is party thereto.  This Credit Agreement and the other Credit Documents constitute legal, valid and binding obligations of such Credit Party, enforceable against such Credit Party in accordance with its terms, except to the extent that the enforceability thereof may be limited by applicable Debtor Relief Laws affecting creditors’ rights generally and by equitable principles of law (regardless of whether enforcement is sought in equity or at law).

6.05Financial Statements.  The audited consolidated balance sheets of the Consolidated Group for the fiscal year ended December 31, 2016, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year, including the notes thereto (A) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; (B) fairly present the financial condition of the Consolidated Group as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein; and (C) reflect all material indebtedness and other material liabilities, direct or contingent, as of the date thereof, including liabilities for taxes, material commitments and Indebtedness of the Consolidated Group.

6.06No Material Adverse Effect.  Since December 31, 2016, there has been no event or circumstance, either individually or in the aggregate, that has had or would reasonably be expected to have a Material Adverse Effect.

6.07Litigation.  There are no actions, suits, investigations, criminal prosecutions, civil investigative demands, imposition of criminal or civil fines or penalties, proceedings, claims or disputes pending or, to the knowledge of the Borrowers after due and diligent investigation, threatened, at law, in equity, in arbitration or before any Governmental Authority, by or against any member of the Consolidated Group or against any of their respective properties or revenues that (a) purport to affect or pertain to this Credit Agreement or any other Credit Document, or (b) would reasonably be expected to have a Material Adverse Effect.

6.08No Default.  No member of the Consolidated Group is in default under or with respect to any Contractual Obligation that would reasonably be expected to have a Material Adverse Effect. No Default or Event of Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Credit Agreement or any other Credit Document.

6.09Ownership of Property; Liens.  Each member of the Consolidated Group has good record and marketable title to, or valid leasehold interests in, all real property necessary or used in the ordinary

83

conduct of its business, except for such defects in title as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  The property of the Consolidated Group is subject to no Liens, other than Liens permitted by Section 8.02.

6.10Environmental Compliance.  No member of the Consolidated Group has any liability or responsibility under any claim in respect of the violation of any Environmental Laws, except for such claims that would not reasonably be expected to have a Material Adverse Effect.

6.11Insurance.  The properties of the Consolidated Group are insured pursuant to self-insurance arrangements or with financially sound and reputable insurance companies that are not Affiliates of the Borrowers or with Captive Insurance Companies, in each case in such kinds, types, amounts and with such deductibles and self-insurance retentions as are in accordance with sound business practice.

6.12Taxes.  Each member of the Consolidated Group has filed all material federal, state and other tax returns and reports required to be filed, and have paid all taxes shown thereon to be due and has paid all other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those that are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP or IFRS, as appropriate.  There is no proposed tax assessment against the Borrowers or any Subsidiary that would, if made, have a Material Adverse Effect.

6.13ERISA Compliance.

(a)Each Plan of such Credit Party and its Subsidiaries is in compliance with the applicable provisions of ERISA, the Internal Revenue Code and other federal or state Laws, except where a failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  Each Plan of such Credit Party and its Subsidiaries that is intended to qualify under Section 401(a) of the Internal Revenue Code has received a favorable determination letter from the IRS or an application for such a letter is currently pending before the IRS with respect thereto and, to the best knowledge of Responsible Officers of the Credit Parties, nothing has occurred that would prevent, or cause the loss of, such qualification.  Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, such Credit Party and each of its ERISA Affiliates have made all required contributions to each Plan of such Credit Party and its Subsidiaries subject to Section 412 of the Internal Revenue Code, and no application for a funding waiver or an extension of any amortization period pursuant to Section 412 of the Internal Revenue Code has been made with respect to such Plan.

(b)There are no pending or, to the best knowledge of the Borrowers, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan of such Credit Party and its Subsidiaries that would reasonably be expected to have a Material Adverse Effect.  There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan of such Credit Party and its Subsidiaries that has resulted or would reasonably be expected to result in a Material Adverse Effect.

(c)Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) no ERISA Event has occurred or is reasonably expected to occur with respect to such Credit Party and its Subsidiaries; (ii) no Pension Plan of such Credit Party and its Subsidiaries is in “at risk” status under Section 430(i)(4) of the Internal Revenue Code or Section 303(i)(4) of ERISA; (iii) neither such Credit Party nor any of its ERISA Affiliates has incurred, or reasonably expects to incur, any liability under Title IV of ERISA with respect to any Pension Plan of such Credit Party and its Subsidiaries (other than premiums due and not delinquent under Section 4007 of ERISA); (iv) neither

84

such Credit Party nor any of its ERISA Affiliates has incurred, or reasonably expects to incur, any liability (and no event has occurred that, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Sections 4201 or 4243 of ERISA with respect to a Multiemployer Plan of such Credit Party and its Subsidiaries; and (v) neither such Credit Party nor any of its ERISA Affiliates has engaged in a transaction that would reasonably be expected to subject such Credit Party and its Subsidiaries to Sections 4069 or 4212(c) of ERISA.

(d)Neither of the Borrowers is, as of the Amendment No. 2 Effective Date, (i) an employee benefit plan subject to Title I of ERISA, (ii) a plan or account subject to Section 4975 of the Internal Revenue Code, (iii) an entity deemed to hold “plan assets” of any such plans or accounts for purposes of ERISA or the Internal Revenue Code, or (iv) a “governmental plan” within the meaning of ERISA.

6.14[Reserved] .

6.15Margin Regulations; Investment Company Act.

(a)The Credit Parties are not engaged and will not engage, principally or as one of their important activities, in the business of purchasing or carrying “margin stock” (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock.  Following the application of the proceeds of each Borrowing or drawing under each Letter of Credit, not more than twenty-five percent (25%) of the value of the assets subject to the provisions of Section 8.02 or subject to any restriction contained in any agreement or instrument between a Borrower and any Lender or any Affiliate of any Lender relating to Indebtedness will be margin stock.

(b)None of the Credit Parties, any Person Controlling a Credit Party, or any Subsidiary is or is required to be registered as an “investment company” under the Investment Company Act of 1940.

6.16Disclosure.    Each Credit Party has disclosed to the Administrative Agent and the Lenders all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that could reasonably be expected to result in a Material Adverse Effect.  No report, financial statement, certificate or other information (other than information of a general economic nature) furnished (whether in writing or orally) by or on behalf of any Credit Party to the Administrative Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Credit Agreement or delivered hereunder or under any other Credit Document (in each case, as modified or supplemented by other information so furnished) taken as a whole contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that, with respect to projected financial information, the Borrowers represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time, it being understood that projections are subject to uncertainties and contingencies beyond the control of the Credit Parties and that no assurance can be given that such projections will be realized.

6.17Compliance with Laws.  Each member of the Consolidated Group is in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions, settlements or other agreements with any Governmental Authority and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

85

6.18Intellectual Property; Licenses, Etc.  Except to the extent it would not reasonably be expected to have a Material Adverse Effect, (a) the Consolidated Group owns, or possesses the right to use, all of the trademarks, service marks, trade names, copyrights, patents, patent rights, franchises, licenses and other intellectual property rights (collectively, “IP Rights”) that are reasonably necessary for the operation of their respective businesses, without conflict with the rights of any other Person, (b) to the best knowledge of the Credit Parties, no slogan or other advertising device, product, process, method, substance, part or other material now employed, or now contemplated to be employed, by any member of the Consolidated Group infringes upon any rights held by any other Person, and (c) no claim or litigation regarding any of the foregoing is pending or, to the best knowledge of the Credit Parties, threatened.

6.19EEA Financial Institution.  Neither FME nor any of its Subsidiaries is an EEA Financial Institution.

6.20Reimbursement from Medical Reimbursement Programs.  The accounts receivable of each of the Domestic Credit Parties have been and will continue to be adjusted in all material respects to reflect the reimbursement policies (both those most recently published in writing as well as those not in writing that have been verbally communicated) of any Medical Reimbursement Program (including Medicare, Medicaid, Blue Cross/Blue Shield, private insurance companies, health maintenance organizations, preferred provider organizations, alternative delivery systems, managed care systems, government contracting agencies and other third party payors) applicable to such Credit Party.  In particular, such accounts receivable relating to any Medical Reimbursement Program do not and shall not exceed amounts any obligee is entitled to receive under any capitation arrangement, fee schedule, discount formula, cost-based reimbursement or other adjustment or limitation to its usual charges, in each case to the extent it would not reasonably be expected to have a Material Adverse Effect.

6.21Anti-Corruption and Sanctions Compliance.

(a)Except to the extent disclosed in its filings with the SEC, the Borrowers and their Subsidiaries have conducted their businesses in compliance in all material respects with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar applicable anti-corruption legislation in other jurisdictions where they have operations (“Anti-Corruption Laws”), and have instituted and maintained policies and procedures reasonably designed to promote compliance with such laws.

(b)Subject to Section 1.10, neither the Borrowers nor any of their Subsidiaries, nor to the knowledge of the foregoing, any of their respective directors or officers, is an individual or entity (for purposes hereof, “Person”) that is (i) the target of Sanctions, or (ii) organized or domiciled in a Designated Jurisdiction.

ARTICLE VII

AFFIRMATIVE COVENANTS

Until the Loan Obligations hereunder shall have been paid in full or otherwise satisfied, and the Commitments hereunder shall have expired or been terminated, the Credit Parties will, and will cause members of the Consolidated Group to:

7.01Financial Statements.  Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the Required Lenders:

86

(a)Within ninety-five (95) days after the last day of each fiscal year of FME, the audited consolidated balance sheet of FME and its Subsidiaries, in each case as at the end of such fiscal year and (beginning with the fiscal year ending December 31, 2016), and the related consolidated statements of income or operations, and the related statements of shareholders’ equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with IFRS, audited and accompanied by a report and opinion of an independent certified public accountant of nationally recognized standing reasonably acceptable to the Required Lenders, which report and opinion shall state that such accountants conducted their audit of such financial statements in accordance with generally accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception or any qualification or exception as to the scope of such audit or other material qualification or exception of any kind; and

(b)Within fifty (50) days after the last day of each of the first three fiscal quarters of FME, the unaudited consolidated balance sheet of FME and its Subsidiaries, as at the end such fiscal quarter, and the related consolidated statements of income or operations, and the related statements of shareholders’ equity and cash flows for such fiscal quarter and for the portion of the fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and certified by a Responsible Officer thereof as fairly presenting the financial condition, results of operations, shareholders’ equity and cash flows in accordance with IFRS, subject only to normal year-end audit adjustments and the absence of footnotes.

As to any information contained in materials furnished pursuant to Section 7.02(c), the Borrowers shall not be separately required to furnish such information under subsections (a) or (b) above, but the foregoing shall not be in derogation of the obligation of the Borrowers to furnish the information and materials described in subsections (a) and (b) above at the times specified therein.

7.02Certificates; Other Information.  Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the Required Lenders:

(a)concurrently with the delivery of the financial statements referred to in Section 7.01(a), a certificate of its independent certified public accountants certifying such financial statements and stating that in making the examination necessary therefor no knowledge was obtained of any Default or Event of Default or, if any such Default or Event of Default shall exist, stating the nature and status of such event;

(b)concurrently with the delivery of the financial statements referred to in Sections 7.01(a) and (b), a duly completed Compliance Certificate signed by a Responsible Officer (i) setting forth computations in reasonable detail satisfactory to the Administrative Agent demonstrating compliance with the financial covenant, (ii) certifying that no Default or Event of Default exists as of the date thereof (or the nature and extent thereof and proposed actions with respect thereto) and (iii) to the extent necessary pursuant to Section 1.03, including a summary of all material changes in or the consistent application of IFRS affecting the numeric value of the financial covenants, and a reconciliation between calculation of the financial covenants (and determination of the applicable pricing level under the definition of “Applicable Percentage”) before and after giving effect to such changes;

(c)promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of FME, and copies

87

of all annual, regular, periodic and special reports and registration statements that FME may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, and not otherwise required to be delivered to the Administrative Agent pursuant hereto; and

(d)promptly, such additional information regarding the business, financial or corporate affairs of members of the Consolidated Group, or compliance with the terms of the Credit Documents, as the Administrative Agent or any Lender may from time to time reasonably request.

Documents required to be delivered pursuant to Section 7.01(a) or (b) or Section 7.02(c) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which FME posts such documents at sec.gov/edaux/searches.htm, or provides a link thereto on FME’s website on the internet at the website address listed on Schedule 11.02; or (ii) on which such documents are posted on FME’s behalf on SyndTrak or another relevant website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent); provided that: (i) FME shall deliver paper copies of such documents to the Administrative Agent or any Lender that requests FME to deliver such paper copies until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (ii) FME shall notify (which may be by facsimile or electronic mail) the Administrative Agent and each Lender of the posting of any such documents and provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents.  The Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by FME with any such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents.

The Borrowers hereby acknowledge that (A) the Administrative Agent and the Arrangers will make available to the Lenders materials and/or information provided by or on behalf of the Borrowers hereunder (collectively, the “Credit Party Materials”) by posting the Credit Party Materials on SyndTrak or another similar electronic system (the “Platform”) and (B) certain of the Lenders may be “public-side” Lenders (i.e., Lenders that do not wish to receive material non-public information with respect to the Borrowers or their securities) (each, a “Public Lender”).  The Borrowers hereby further agree that (1) all Credit Party Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (2) by marking Credit Party Materials “PUBLIC,” the Borrowers shall be deemed to have authorized the Administrative Agent, the Arrangers and the Lenders to treat such Credit Party Materials as not containing any material non-public information (although it may be sensitive and proprietary) with respect to the Borrowers or their securities for purposes of United States federal and state securities laws (provided that to the extent such Credit Party Materials constitute Information, they shall be treated as set forth in Section 11.07); (3) all Credit Party Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated as “Public Investor”; and (4) the Administrative Agent and the Arrangers shall be entitled to treat and shall treat any Credit Party Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not marked as “Public Investor”.

7.03Notification.  Promptly notify the Administrative Agent and each Lender party to this Credit Agreement:

(a)after any Credit Party knows or has reason to know of the occurrence of any Default or Event of Default;

88

(b)of any matter that has resulted or would reasonably be expected to result in a Material Adverse Effect, including as a result of (i) breach or non-performance of, or any default under, a Contractual Obligation of the Borrowers or any Subsidiary; (ii) any dispute, litigation, investigation, proceeding or suspension between the Borrowers or any Subsidiary and any Governmental Authority; or (iii) the commencement of, or any material development in, any litigation or proceeding affecting the Borrowers or any Subsidiary, including pursuant to any applicable Environmental Laws;

(c)of the occurrence of any ERISA Event;

(d)of any material change in accounting policies or financial reporting practices by members of the Consolidated Group to the extent such change affects compliance with the financial covenants hereunder;

(e)of any notice of intent to exclude or any other Exclusion Event that would reasonably be expected to result in a Material Adverse Effect;

(f)of (i) the institution of any investigation, review or proceeding against any Credit Party to suspend, revoke or terminate (or that may result in the termination of) any Medicaid Provider Agreement or Medicare Provider Agreement, or any such investigation or proceeding that may result in an Exclusion Event or (ii) any notice of loss or threatened loss of accreditation by the Joint Commission or any other accrediting entity, loss of participation under any Medical Reimbursement Program or loss of applicable health care license, in each case, that would reasonably be expected to result in a Material Adverse Effect;

(g)[Reserved]; and

(h)of the issuance of any material indictment or the initiation of other material criminal proceedings against any member of the Consolidated Group and provide a certificate, signed by a Responsible Officer, setting forth a detailed description of the nature of the proceedings and the relevant facts in connection therewith together with an estimation of the fines, penalties and damages sought in connection therewith.

Each notice pursuant to this Section shall be accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to therein and stating what action the Borrowers have taken and proposes to take with respect thereto.  Each notice pursuant to Section 7.03(a) shall describe with particularity any and all provisions of this Credit Agreement and any other Credit Document that have been breached.

7.04Payment of Obligations.  Pay and discharge as the same shall become due and payable, all its material obligations and liabilities, including (a) all material tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with IFRS are being maintained; (b) all lawful claims that, if overdue and unpaid, would by law become a Lien upon its property (other than Liens permitted hereunder); and (c) all Indebtedness, as and when due and payable, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.

89

7.05Preservation of Existence, Etc.

(a)Preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 8.04 or in a liquidation, dissolution, winding-up or other termination of existence not prohibited by Section 8.04; (b) take all reasonable action to maintain all rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect; and (c) preserve or renew all of its registered patents, trademarks, trade names and service marks, the non-preservation of which could reasonably be expected to have a Material Adverse Effect.

7.06Maintenance of Properties.

(a)Maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear excepted; (b) make all necessary repairs thereto and renewals and replacements thereof except where the failure to do so could not reasonably be expected to have a Material Adverse Effect; and (c) use the standard of care typical in the industry in the operation and maintenance of its facilities.

7.07Maintenance of Insurance.  Maintain in full force and effect, self-insurance arrangements or insurance with financially sound and reputable insurance companies that are not Affiliates or with Captive Insurance Companies, with respect to its properties and business against loss or damage of the kinds, of such types, in such amounts and with such deductibles and self-insurance retentions as are in accordance with sound business practice.

7.08Compliance with Laws.

(a)Except to the extent the failure to do so would not reasonably be expected to have a Material Adverse Effect, cause each member of the Consolidated Group to (i) comply with all the requirements of Law (including Titles XVIII and XIX of the Social Security Act, Medicare Regulations, Medicaid Regulations), and all restrictions and requirements imposed by any Governmental Authority, applicable to it and its property (including Environmental Laws and ERISA), (ii) obtain and maintain all licenses, permits, certifications and approvals of all applicable Governmental Authorities as are required for the conduct of its business as currently conducted and herein contemplated (including professional licenses, certificates or determinations of need, Medicare Provider Agreements and Medicaid Provider Agreements), (iii) ensure that billing policies, arrangements, protocols and instructions will comply with reimbursement requirements under Medicare, Medicaid and other Medical Reimbursement Programs and will be administered by properly trained personnel and (iv) make commercially reasonable efforts to implement policies that are consistent with the regulations implementing the privacy requirements of the Administrative Simplification subtitle of HIPAA set forth at 45 CFR Parts 160, 162 and 164.

(b)FMCH has in place and shall maintain a compliance program for its Subsidiaries that is reasonably consistent with publicly available OIG guidelines and is reasonably designed to provide effective internal controls that promote adherence to, prevent and detect material violations of, Laws applicable to its Subsidiaries, including any Medicaid Regulations and Medicare Regulations applicable to its Subsidiaries, which compliance program includes the implementation of internal audits and monitoring on a regular basis to monitor compliance therewith, with such regulations.

7.09Books and Records.  (a) Maintain proper books of record and account, in which full, true and correct entries in conformity with IFRS (or, with respect to any foreign entity, the equivalent) shall be made of all financial transactions and matters involving the assets and business of the Borrowers or such Subsidiary, as the case may be; and (b) maintain such books of record and account in material conformity

90

with all applicable requirements of any Governmental Authority having regulatory jurisdiction over the Borrowers or such Subsidiary, as the case may be.

7.10[Reserved].

7.11Use of Proceeds.

(a)Use the proceeds of the Credit Extensions to refinance certain existing indebtedness and for general corporate purposes not in contravention of any Law or of any Credit Document.

(b)Subject to Section 1.10, not knowingly use, directly or indirectly, any proceeds from the Credit Extensions, or knowingly lend, contribute or otherwise make available such proceeds to fund any activities or business that would result in a violation of Sanctions applicable to them.

(c)Not knowingly use, directly or indirectly, the proceeds of any Credit Extension for any purpose in violation of any Anti-Corruption Laws.

7.12Ownership. At all times FMCH shall be a Wholly-Owned Subsidiary of FME.

ARTICLE VIII

NEGATIVE COVENANTS

Until the Loan Obligations hereunder shall have been paid in full or otherwise satisfied, and until the Commitments hereunder shall have expired or been terminated, the Credit Parties will not, and will not permit members of the Consolidated Group to:

8.01Indebtedness.  Create, incur, assume or suffer to exist any Indebtedness, except:

(a)unsecured or secured intercompany Indebtedness between and among members of the Consolidated Group;

(b)unsecured Indebtedness of FME owing to FSE and any of its Subsidiaries (other than FME and its Subsidiaries) in an aggregate principal amount not to exceed €600 million at any time outstanding;

(c)Indebtedness and obligations (contingent or otherwise) owing under Swap Contracts, provided that such obligations are (or were) entered into by such Person in the ordinary course of business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets or property held or reasonably anticipated by such Person, or changes in the value of securities issued by such Person, and not for the purposes of speculation or taking a “market view”;

(d)Indebtedness under capital leases, Synthetic Lease obligations and purchase money obligations incurred to provide all or a portion of the purchase price (or cost of construction or acquisition), in each case, for additions to plant, property and equipment and refinancings, refundings, renewals or extensions thereof, provided that (i) such Indebtedness when incurred shall not exceed the purchase price or cost of construction of such property, (ii) no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance

91

outstanding thereon at the time of such refinancing, and (iii) for the Consolidated Group taken as a whole, the total amount of all such Indebtedness shall not exceed €500 million in the aggregate at any time;

(e)Indebtedness and obligations under Permitted Receivables Financings, provided that the Attributable Principal Amount of all such Permitted Receivables Financings shall not exceed €1,700 million in the aggregate at any time;

(f)customer deposits and advance payments received from customers for goods purchased in the ordinary course of business;

(g)Indebtedness assumed or incurred by members of the Consolidated Group that are not Wholly Owned Subsidiaries of up to €750 million outstanding, including joint ventures and other entities in which FME, directly or indirectly, does not own all of the Capital Stock with ordinary voting power;

(h)Indebtedness in connection with a Permitted Acquisition or a Controlled JV Investment consisting of (i) purchase money obligations and deferred purchase obligations assumed in connection therewith, and (ii) other Indebtedness of up to €750 million assumed or incurred by members of the Consolidated Group in connection therewith and any related costs, fees and expenses;

(i)Indebtedness pursuant to any Cash Management Arrangement;

(j)unsecured Indebtedness of (x) the Borrowers, (y) other Credit Parties and (z) Special Purpose Finance Subsidiaries whose Indebtedness is guaranteed by FME; and

(k)in addition to the Indebtedness permitted hereinabove, (i) secured Indebtedness of (x) the Borrowers, (y) other Credit Parties and (z) Special Purpose Finance Subsidiaries whose Indebtedness is guaranteed by FME, in each case under Section 8.02(w); and (ii) all Indebtedness of Subsidiaries that are not Credit Parties or Special Purpose Finance Subsidiaries whose Indebtedness is guaranteed by FME, whether or not secured; provided, that the aggregate principal amount of Indebtedness under this Section 8.01(k) shall not exceed the greater of €1,000 million and 25% of Consolidated EBITDA (determined on a Pro Forma basis for the period of four consecutive fiscal quarters most recently ended for which financial statements have been delivered pursuant hereto).

8.02Liens.  Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than the following:

(a)[Reserved];

(b)Liens securing obligations of up to €75 million under Swap Contracts permitted hereunder in other collateral, including cash collateral, whether or not the counterparties thereto are Lenders or Affiliates of Lenders;

(c)Liens for taxes, assessments or governmental charges or levies not yet due or payable or that are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with IFRS;

92

(d)carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s, supplier’s or other like Liens arising in the ordinary course of business that are not overdue for a period of more than thirty days or that are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person;

(e)pledges or deposits in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA, or to secure the performance of tenders, statutory obligations, bids, leases, government contracts, performance and return-of-money bonds and other similar obligations (exclusive of obligations for the payment of borrowed money);

(f)deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business;

(g)easements, rights-of-way, restrictions, minor defects or irregularities in title and other similar encumbrances affecting real property that, in the aggregate, are not substantial in amount, and that do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person;

(h)Liens securing attachments or judgments for the payment of money not constituting an Event of Default under Section 9.01(h) or securing appeal or other surety bonds related to such judgments or pending a judicial determination of a dispute in an amount that would not constitute an Event of Default under Section 9.01(h) if judgment were granted in such amount;

(i)Liens securing, or in respect of, obligations under capital leases or Synthetic Leases and purchase money obligations for additions to plant, property and equipment permitted hereunder, provided that (i) such Liens do not at any time encumber any property other than the property financed by such Indebtedness and (ii) the Indebtedness secured thereby does not exceed the cost or fair market value, whichever is lower, of the property being acquired on the date of acquisition;

(j)Liens on the property or assets of any Credit Party granted in connection with Sale and Leaseback Transactions;

(k)Liens on the property or assets granted in connection with Permitted Receivables Financings (including any related filings of financing statements), provided that such Liens shall extend only to those accounts receivable and related property that are the subject of the Permitted Receivables Financing;

(l)leases and subleases of real property granted to others not interfering in any material respect with the business of any member of the Consolidated Group;

(m)any interest of title of a lessor under, and Liens arising under UCC financing statements (or equivalent filings, registrations or agreements in foreign jurisdictions) relating to, leases permitted by this Credit Agreement;

93

(n)normal and customary rights of setoff and other liens on deposits of cash in favor of banks and other depository institutions arising as a matter of law or under customary general terms and conditions governing such deposits;

(o)Liens in favor of customs and revenue authorities required as a matter of law to secure payment of customs duties in connection with the importation of goods;

(p)Liens created or deemed to exist by the establishment of trusts for the purpose of satisfying (i) Governmental Reimbursement Program Costs and (ii) other actions or claims pertaining to the same or related matters or other Medical Reimbursement Programs, provided in each case that (A) adequate reserves for such claims or actions have been established and (B) contributions to such trusts in respect of such actions or claims shall not exceed €60 million at any time;

(q)Liens on the property of, and ownership interests in, members of the Consolidated Group that are not Wholly Owned Subsidiaries, including joint ventures and other entities in which FME, directly or indirectly, does not own all of the Capital Stock with ordinary voting power, to secure Indebtedness permitted under Section 8.01(a) or Section 8.01(g);

(r)Liens arising out of the refinancing, extension, renewal or refunding of any Indebtedness secured by any Lien otherwise permitted by this Section 8.02, provided that (i) such Indebtedness is not secured by any additional assets of the Consolidated Group and (ii) the amount of such Indebtedness secured by any such Lien is not increased;

(s)Liens securing Indebtedness assumed or incurred in connection with a Permitted Acquisition or a Controlled JV Investment as permitted under Section 8.01(h) on (i) property that is acquired in connection with such Acquisition or Investment or subject to the Lien of an existing security agreement assumed in connection with such Acquisition or Investment, and (ii) ownership interests in the entity, joint venture or investment that is the subject of such Acquisition or Investment;

(t)Liens on cash and Investments of Captive Insurance Companies and their Subsidiaries in connection with insurance arrangements subject to customary and prevailing market standards;

(u)Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by members of the Consolidated Group in the ordinary course of business;

(v)Liens relating to any Cash Management Arrangement; and

(w)in addition to other Liens permitted under this Section 8.02, Liens securing Indebtedness of the Borrowers and their Subsidiaries permitted under Section 8.01(k).

8.03[Reserved].

8.04Fundamental Changes.  FME and its Subsidiaries will not enter into transactions of merger or consolidation with another Person, or dissolve or liquidate, or Dispose of all or substantially all of their assets, except that:

94

(a)in the case of mergers and consolidations, (i) members of the Consolidated Group may enter into transactions of merger or consolidation with other members of the Consolidated Group, and (ii) members of the Consolidated Group may enter into transactions of merger or consolidation with other parties, provided that where such a transaction is related to an Acquisition the cost of which is in excess of €750 million, FME will provide an officer’s certificate in form and detail satisfactory to the Administrative Agent confirming that no Default or Event of Default shall exist immediately before or immediately after giving effect to the transaction on a Pro Forma Basis, and provided, further, that, in all cases, if FME or FMCH is a party to the transaction, it shall be the surviving entity;

(b)in the case of dissolutions and liquidations, the Subsidiaries of FME (other than FMCH) may be dissolved or liquidated; and

(c)in the case of Dispositions, FME and its Subsidiaries, taken as a whole, shall not Dispose of all or substantially all of their assets.

8.05[Reserved].

8.06[Reserved].

8.07Change in Nature of Business.  Engage in any material line of business substantially different from those lines of business conducted by the Consolidated Group on the date hereof or any business substantially related or incidental thereto.

8.08[Reserved].

8.09Fiscal Year.  Change its fiscal year without the prior written consent of the Required Lenders.

8.10Financial Covenants.

(a)Consolidated Leverage Ratio.  As of the end of each fiscal quarter, the Consolidated Leverage Ratio will not exceed:

Fiscal Quarters Ending	Maximum Consolidated Leverage Ratio
From the Amendment No. 1 Effective Date through December 30, 2017	4.00:1.00
December 31, 2017 and thereafter	3.75:1.00

; provided that the foregoing limits may be increased, from time to time, by notice from FME in connection with one or a series of acquisitions and investments in any period of four consecutive fiscal quarters for which financial statements are available (plus the period extending until the next quarterly or annual financial statements shall be due) where the acquisition consideration (including assumed indebtedness) is in excess of €1,000 million, to 4.25:1.0 for a period of up to four consecutive fiscal quarters (the “Covenant Holiday”).  Thereafter the Covenant Holiday will not be available again until the original financial covenant levels have been complied with for at least one fiscal quarter.

(b)[Reserved].

95

ARTICLE IX

EVENTS OF DEFAULT AND REMEDIES

9.01Events of Default.  Any of the following shall constitute an Event of Default:

(a)Non-Payment.  The Borrowers or any other Credit Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan or any L/C Obligation, or (ii) within five Business Days after the same becomes due, any interest on any Loan or on any L/C Obligation, or any commitment or other fee due hereunder, or (iii) within five Business Days after the same becomes due, any other amount payable hereunder or under any other Credit Document; or

(b)Specific Covenants.  The Borrowers fails to perform or observe any term, covenant or agreement contained in any of Section 7.02 or 7.03, or Article VIII; or

(c)Other Defaults.  Any Credit Party fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above) contained in any Credit Document on its part to be performed or observed (subject to applicable grace or cure periods, if any) and such failure continues unremedied for a period of at least thirty days after the earlier of a Responsible Officer of a Credit Party becoming aware of such default or notice thereof by the Administrative Agent; or

(d)Representations and Warranties.  Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Borrowers or any other Credit Party herein, in any other Credit Document, or in any document delivered in connection herewith or therewith shall prove to be false or misleading in any material respect when made or deemed made; or

(e)Cross-Default.  (i) Any member of the Consolidated Group (A) fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Support Obligations (other than Indebtedness hereunder and Indebtedness under Swap Contracts) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than €200 million, or (B) fails to observe or perform any other agreement or condition relating to any such Indebtedness or Support Obligations or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such Support Obligations (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Support Obligations to become payable or cash collateral in respect thereof to be demanded (unless the event causing the delivery of cash collateral solely results from an event relating to a defaulting lender (or such other similar concept)); or (ii) there occurs under any Swap Contract an Early Termination Date (as defined in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which the Borrowers or any Subsidiary is the Defaulting Party (as defined in such Swap Contract) or (B) any Termination Event (as so defined) under such Swap Contract as to which the Borrowers or any Subsidiary is

96

an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by the Borrowers or such Subsidiary as a result thereof is greater than €200 million; or

(f)Insolvency Proceedings, Etc.  Any member of the Consolidated Group (other than any Immaterial Foreign Subsidiary) institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for sixty calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for sixty calendar days, or an order for relief is entered in any such proceeding; or

(g)Inability to Pay Debts; Attachment.  (i) Any member of the Consolidated Group (other than any Immaterial Foreign Subsidiary) becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of any such Person and is not released, vacated or fully bonded within thirty days after its issue or levy; or

(h)Judgments.  There is entered against member of the Consolidated Group (i) a final judgment or order for the payment of money in an aggregate amount exceeding €200 million (to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage) or (ii) any one or more non-monetary final judgments that have, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and, in either case, (A) such judgment or order is not paid, bonded or otherwise discharged within thirty days of entry thereof and enforcement proceedings are commenced by any creditor upon such judgment or order, or (B) there is a period of thirty consecutive days during which a stay of enforcement of such judgment, by reason of a pending appeal or otherwise, is not in effect (it being understood and agreed for the purposes of clarification that any judgment or order entered into in connection with the W.R. Grace bankruptcy that relates to the settlement of the fraudulent transfer and related claims against members of the Consolidated Group is not included within the scope of this provision); or

(i)ERISA.  (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan that has resulted or would reasonably be expected to result in liability of the Borrowers under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of €200 million, or (ii) the Borrowers or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of €200 million; or

(j)Invalidity of Credit Documents.  Any Credit Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or satisfaction in full of all the Obligations, ceases to be in full force and effect; or any Credit Party or any other Person contests in any manner the validity or enforceability of any Credit Document; or any Credit Party denies that it has any or further liability or obligation under any Credit Document, or purports to revoke, terminate or rescind any Credit Document;

97

(k)Exclusion Event.  There occurs any Exclusion Event that has, or could reasonably be expected to have, a Material Adverse Effect; or

(l)Change of Control.  There occurs any Change of Control.

9.02Remedies Upon Event of Default.  If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions:

(a)declare the commitments of the Lenders to make Loans and the obligation of the L/C Issuers to make L/C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated;

(b)declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Credit Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Borrowers;

(c)require that the Borrowers Cash Collateralize their respective L/C Obligations (in each case, in an amount equal to the then Outstanding Amount thereof); and

(d)exercise on behalf of itself and the Lenders all rights and remedies available to it or to the Lenders under the Credit Documents or applicable Law;

provided, however, that upon the occurrence of an Event of Default under Section 9.01(f), the obligation of each Lender to make Loans and any obligation of each L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrowers to Cash Collateralize the L/C Obligations as aforesaid shall automatically become effective, in each case without further act of the Administrative Agent or any Lender.

9.03Application of Funds.  After the exercise of remedies provided for in Section 9.02 (or after the Loans have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso to Section 9.02), any amounts received on account of the Obligations shall be applied by the Administrative Agent in the following order:

First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including all reasonable fees, expenses and disbursements of any law firm or other counsel to the Administrative Agent and amounts payable under Article III) payable to the Administrative Agent in its capacity as such;

Second, to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal and interest and Letter of Credit Fees) payable to the Lenders and the L/C Issuers (including all reasonable fees, expenses and disbursements of any law firm or other counsel to the respective Lenders and the respective L/C Issuers and amounts payable under Article III), ratably among the Lenders in proportion to the amounts described in this clause Second payable to them;

Third, to payment of that portion of the Obligations constituting accrued and unpaid Letter of Credit Fees and interest on the Loans, L/C Borrowings and other Obligations, ratably

98

among the Lenders, the Swingline Lender and the L/C Issuers in proportion to the respective amounts described in this clause Third payable to them;

Fourth, to (a) payment of that portion of the Obligations constituting unpaid principal of the Loans and L/C Borrowings, (b) payment of breakage, termination or other amounts owing in respect of any Swap Contract between any Credit Party and any Lender, or any Affiliate of a Lender, to the extent such Swap Contract is permitted hereunder, and (c) the Administrative Agent for the account of the applicable L/C Issuers, to Cash Collateralize that portion of the L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit, ratably among such parties in proportion to the respective amounts described in this clause Fourth payable to them; and

Last, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrowers or as otherwise required by Law.

Subject to Section 2.03(c) and 2.16, amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause Fourth above shall be applied to satisfy drawings under such Letters of Credit as they occur.  If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the other Obligations, if any, in the order set forth above.  Excluded Swap Obligations with respect to any Credit Party shall not be paid with amounts received from such Credit Party or such Credit Party’s assets, but appropriate adjustments shall be made with respect to payments from other Credit Parties to preserve the allocation to Obligations otherwise set forth above in this Section.

ARTICLE X

ADMINISTRATIVE AGENT

10.01Appointment and Authorization of Administrative Agent.

(a)Each of the Lenders and the L/C Issuers hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Credit Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.  The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuers, and neither any Borrower nor any other Credit Party shall have rights as a third party beneficiary of any of such provisions.

(b)[Reserved].

(c)It is understood and agreed that the use of the term “agent” herein or in any other Credit Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law.  Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between the contracting parties.

10.02Rights as a Lender.  The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept

99

deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrowers or any of their Subsidiaries or Affiliates as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

10.03Exculpatory Provisions.  The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Credit Documents, and its duties hereunder shall be administrative in nature.  Without limiting the generality of the foregoing, the Administrative Agent:

(a)shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;

(b)shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Credit Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Credit Documents), provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Credit Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and

(c)shall not, except as expressly set forth herein and in the other Credit Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any of the Credit Parties or their Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.

The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 11.01 and 9.02) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment.  The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given in writing to the Administrative Agent by a Borrower, a Lender or an L/C Issuer.

The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Credit Agreement or any other Credit Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Credit Agreement, any other Credit Document or any other agreement, instrument or document, or the creation, perfection or priority of any Lien purported to be created by any collateral documents, (v) the value or sufficiency of any collateral, or (vi) the satisfaction of any condition set forth in Article V or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.

10.04Reliance by Administrative Agent.  The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement,

100

instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon.  In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or an L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or L/C Issuer unless the Administrative Agent shall have received notice to the contrary from such Lender or L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit.  The Administrative Agent may consult with legal counsel (who may be counsel for the Credit Parties), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.

10.05Delegation of Duties.  The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Credit Document by or through any one or more sub-agents appointed by the Administrative Agent.  The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties.  The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent.  The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.

10.06Resignation of the Administrative Agent.

(a)The Administrative Agent may at any time give notice of its resignation to the Lenders, the L/C Issuers and the Borrowers.  Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrowers, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be obligated to) on behalf of the Lenders and the L/C Issuers, appoint a successor Administrative Agent meeting the qualifications set forth above.  Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.

(b)If the Person serving as the Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, the Required Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrowers and such Person remove such Person as Administrative Agent and, in consultation with the Borrowers, appoint a successor.  If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty days (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.

(c)With effect from the Resignation Effective Date or the Removal Effective Date (as applicable), (i) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Credit Documents (except that in the case of any collateral

101

security held by the Administrative Agent on behalf of the Lenders or the L/C Issuers under any of the Credit Documents, the retiring or removed Administrative Agent shall continue to hold such collateral security until such time as a successor Administrative Agent is appointed) and (ii) except for any indemnity payments or other amounts then owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and L/C Issuer directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above.  Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or removed) Administrative Agent (other than as provided in Section 3.01(g) and other than any rights to indemnity payments or other amounts owed to the retiring or removed Administrative Agent as of the Resignation Effective Date or the Removal Effective Date, as applicable), and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Credit Documents (if not already discharged therefrom as provided above in this Section).  The fees payable by the Borrowers to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrowers and such successor.  After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Credit Documents, the provisions of this Article and Section 11.04 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent.

(d)Any resignation by Bank of America as Administrative Agent pursuant to this Section shall also constitute its resignation as L/C Issuer and Swingline Lender.  If Bank of America resigns as an L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L/C Issuer and all L/C Obligations with respect thereto, including the right to require the Lenders to make Loans or fund risk participations in L/C Unreimbursed Amounts pursuant to Section 2.03(b).  If Bank of America resigns as Swingline Lender, it shall retain all the rights of a Swingline Lender provided for hereunder with respect to Swingline Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Revolving Loans or to fund risk participations in outstanding Swingline Loans pursuant to Section 2.04(b).  Upon the appointment by the Borrowers of a successor L/C Issuer or Swingline Lender hereunder (which successor shall in all cases be a Lender other than a Defaulting Lender), (i) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer and Swingline Lender, as applicable, (ii) the retiring L/C Issuer and Swingline Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Credit Documents, and (iii) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume its obligations with respect to such Letters of Credit.

10.07Non-Reliance on Administrative Agent and Other Lenders.  Each of the Lenders and the L/C Issuers acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Credit Agreement.  Each of the Lender and the L/C Issuers also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Credit Agreement, any other Credit Document or any related agreement or any document furnished hereunder or thereunder.

102

10.08No Other Duties.  Anything herein to the contrary notwithstanding, none of the Mandated Lead Arrangers, Joint Book Running Managers, Sole Syndication Agent or Co-Documentation Agents listed on the cover page hereof shall have any powers, duties or responsibilities under this Credit Agreement or any of the other Credit Documents, except in their respective capacities, as applicable, as Administrative Agent, Lender or L/C Issuer hereunder.

10.09Administrative Agent May File Proofs of Claim.  In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to any Credit Party, the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrowers) shall be entitled and empowered, by intervention in such proceeding or otherwise:

(a)to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations and all other Obligations  that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuers and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L/C Issuers and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuers and the Administrative Agent under Sections 2.09 and 11.04) allowed in such judicial proceeding; and

(b)to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the L/C Issuers, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under Sections 2.09 and 11.04.

Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or L/C Issuer to authorize the Administrative Agent to vote in respect of the claim of any Lender or L/C Issuer in any such proceeding.

10.10Collateral and Guaranty Matters.

(a)The Lenders and the L/C Issuers irrevocably authorize and direct the Administrative Agent, at its option and in its discretion,

(i)[Reserved];

(ii)[Reserved];

(iii)to release any Guarantor from its obligations under the Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted hereunder; and

103

(iv)[Reserved].

Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the authority of the Administrative Agent to release or subordinate its interests in particular types of items of property or to release any Guarantor from its guaranty obligations hereunder pursuant to this Section 10.10.

(b)The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of any collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by any Credit Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any collateral, or portion thereof, in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment.

10.11Swap Contracts.  No Lender or any Affiliate of a Lender that is party to any Swap Contract permitted hereunder that obtains the benefits of Section 9.03 or the guaranties hereunder or any collateral by virtue of the provisions hereof or any collateral document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Credit Document or otherwise in respect of any collateral (including the release or impairment of any collateral) (or to notice of or to consent to any amendment, waiver or modification of the provisions hereof or of the guaranties provided hereunder or any collateral document) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Credit Documents.  Notwithstanding any other provision of this Article X to the contrary, the Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Obligations arising under Swap Contracts unless the Administrative Agent has received written notice of such Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Lender or Affiliate of a Lender that is party to such Swap Contract, as the case may be.

ARTICLE XI

MISCELLANEOUS

11.01Amendments, Etc.  Except as expressly provided herein below, no amendment or waiver of, or any consent to deviation from, any provision of this Credit Agreement or any other Credit Document shall be effective unless in writing and signed by the Required Lenders (or by the Administrative Agent on behalf of the Required Lenders upon receipt of a consent and direction letter from the Required Lenders) and the applicable Borrowers and Credit Parties, as the case may be, and acknowledged by the Administrative Agent, and each such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which it is given; provided, however, that:

(a)no such amendment, waiver or consent (however characterized) shall be effective without the written consent of each Lender directly affected thereby (whose consent shall be sufficient therefor without the consent of the Required Lenders) to:

(i)extend or increase the Commitment of any Lender (or reinstate any Commitment terminated pursuant to Section 9.02), without the written consent of such Lender (it being understood and agreed that amendment or waiver of any condition precedent set forth in Section 5.02 or of any Default or Event of Default or

104

a mandatory reduction in Commitments shall not be considered an extension or increase in Commitments for purposes hereof);

(ii)waive non-payment or postpone any date fixed by this Credit Agreement or any other Credit Document for any payment (excluding mandatory prepayments) of principal, interest, fees or other amount due to the Lenders (or any of them) or any scheduled reduction of Commitments hereunder or under any other Credit Document without the written consent of each Lender entitled to receive such payment or whose Commitments are to be reduced;

(iii)reduce the principal of, or the rate of interest specified herein on, any Loan or L/C Borrowing, or (subject to clause (v) of the last proviso of this Section 11.01) any fees or other amounts payable hereunder or under any other Credit Document without the written consent of each Lender entitled to receive such amount; provided, however, that only the consent of the Required Lenders shall be necessary (A) to amend the definition of “Default Rate” or to waive any obligation of the Borrowers to pay interest or Letter of Credit Fees at the Default Rate or (B) to amend any financial covenant hereunder (or any defined term used therein) even if the effect of such amendment would be to reduce the rate of interest on any Loan or L/C Borrowing or to reduce any fee payable hereunder;

(iv)amend Section 1.06 or the definition of “Alternative Currency”;

(v)change any provision of this Section 11.01(a) or the definitions of “Required Lenders”, “Required USD Revolving Lenders”, “Required Euro Revolving Lenders”, “Required Tranche A-5 Term Lenders”, “Required Tranche A-6 Term Lenders” or “Required Tranche A-7 Term Lenders” or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder without the written consent of each Lender directly affected thereby;

(vi)release FME or FMCH from their obligations as Guarantors under the Credit Documents (other than as provided herein or as appropriate in connection with transactions permitted hereunder) without the written consent of each Lender directly affected thereby;

(vii)[Reserved]; or

(viii)[Reserved];

(b)unless also signed by the Required USD Revolving Lenders, no such amendment, waiver or consent shall:

(i)waive any Default or Event of Default for purposes of Section 5.02,

(ii)amend or waive any mandatory prepayment on USD Revolving Loan Obligations under Section 2.06(b) or the manner of application thereof to the USD Revolving Loan Obligations under Section 2.06(c), or

105

(iii)amend or waive the definition of “Required USD Revolving Lenders”;

(c)unless also signed by the Required Euro Revolving Lenders, no such amendment, waiver or consent shall:

(i)waive any Default or Event of Default for purposes of Section 5.02,

(ii)amend or waive any mandatory prepayment on Euro Revolving Loan Obligations under Section 2.06(b) or the manner of application thereof to the Euro Revolving Loan Obligations under Section 2.06(c), or

(iii)amend or waive the definition of “Required Euro Revolving Lenders”;

(d)unless also signed by each Restricted Finance Party, no such amendment, waiver or consent shall change Section 1.10;

(e)unless also signed by the Required Revolving Lenders, no such amendment, waiver or consent shall amend or waive the provisions of Section 5.02 (Conditions to all Credit Extensions), Article VIII (Negative Covenants), Article IX (Events of Default and Remedies), this Section 11.01(e) or the definition of “Required Revolving Lenders”;

(f)unless also consented to in writing by the affected L/C Issuer, no such amendment, waiver or consent shall affect the rights or duties of such L/C Issuer under this Credit Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it;

(g)unless also consented to in writing by the affected Swingline Lender, no such amendment, waiver or consent shall affect the rights or duties of such Swingline Lender under this Credit Agreement;

(h)unless also consented to in writing by the Administrative Agent, no such amendment, waiver or consent shall affect the rights or duties of the Administrative Agent under this Credit Agreement or any other Credit Document;

(i)unless also signed by the Required Tranche A-5 Term Lenders, no such amendment, waiver or consent shall amend or waive the provisions of this Section 11.01(i) or the definition of “Required Tranche A-5 Term Lenders”;

(j)unless also signed by the Required Tranche A-6 Term Lenders, no such amendment, waiver or consent shall amend or waive the provisions of this Section 11.01(j) or the definition of “Required Tranche A-6 Term Lenders”;

(k)unless also signed by the Required Tranche A-7 Term Lenders, no such amendment, waiver or consent shall amend or waive the provisions of this Section 11.01(k) or the definition of “Required Tranche A-7 Term Lenders”;

(l)unless also signed by Lenders holding in the aggregate more than fifty percent (50%) of each other term loan established under the Incremental Loan Facilities (excluding for the purposes of such determination the amounts held by any Defaulting Lender), no amendment, waiver or consent shall amend or waive the provisions of this Section 11.01(k);

106

provided however, that notwithstanding anything to the contrary contained herein, (i) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (A) the Commitment of such Lender may not be increased or extended without the consent of such Lender and (B) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender, (ii) each Lender is entitled to vote as such Lender sees fit on any bankruptcy or insolvency reorganization plan that affects the Loans, (iii) each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code supersedes the unanimous consent provisions set forth herein, (iv) the Required Lenders may consent to allow a Credit Party to use cash collateral in the context of a bankruptcy or insolvency proceeding and any such determination shall be binding on all the Lenders, (v) the Fee Letters may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto, (vi) a Lender may, in connection with an amendment or modification in connection with a refinancing, extension, loan modification or similar transaction permitted hereunder, exchange, continue or rollover all or a portion of its Loans in connection therewith, pursuant to a cashless settlement mechanism acceptable to FME, the Administrative Agent and such Lender, and (vii) the definition of “USD L/C Commitment” and Schedule 2.01(a)(ii) may be amended by FME, the Administrative Agent and each L/C Issuer to reflect the USD L/C Commitments of the L/C Issuers in effect from time to time.

Notwithstanding any provision herein to the contrary, this Credit Agreement may be amended (or amended and restated) with the written consent of the Credit Parties and the Administrative Agent for the Incremental Loan Facilities established hereunder, and otherwise, with the written consent of the Required Lenders, the Administrative Agent and the Credit Parties (i) to add one or more additional revolving credit or term loan facilities to this Credit Agreement and to permit the extensions of credit and all related obligations and liabilities arising in connection therewith from time to time outstanding to share ratably (or on a basis subordinated to the existing facilities hereunder) in the benefits of this Credit Agreement and the other Credit Documents with the obligations and liabilities from time to time outstanding in respect of the existing facilities hereunder, and (ii) in connection with the foregoing, to permit, as deemed appropriate by the Administrative Agent and approved by the Required Lenders, the Lenders providing such additional credit facilities to participate in any required vote or action required to be approved by the Required Lenders or by any other number, percentage or class of Lenders hereunder.

Further, notwithstanding anything herein to the contrary, if following the Closing Date, the Administrative Agent and FME shall have agreed in their sole and absolute discretion that there is an ambiguity, inconsistency, manifest error or any error or omission of a technical or immaterial nature, in each case, in any provision of the Credit Documents, then the Administrative Agent and FME shall be permitted to amend such provision and such amendment shall become effective without any further action or consent of any other party to any Credit Documents if the same is not objected to in writing by the Required Lenders within ten Business Days following receipt of notice thereof (it being understood that the Administrative Agent has no obligation to agree to any such amendment).

11.02Notices; Effectiveness; Electronic Communication.

(a)Notices Generally.  Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in subsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows:

107

(i)if to any Credit Party, the Administrative Agent, any L/C Issuer or the Swingline Lender, to the address, facsimile number, electronic mail address or telephone number specified for such Person on Schedule 11.02; and

(ii)if to any other Lender, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public information relating to the Credit Parties).

Notices and other communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices and other communications sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient).  Notices and other communications delivered through electronic communications to the extent provided in subsection (b) below, shall be effective as provided in such subsection (b).

(b)Electronic Communications.  Notices and other communications to the Lenders and the L/C Issuers hereunder may be delivered or furnished by electronic communication (including unencrypted e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply to notices to any Lender or any L/C Issuer pursuant to Article II if such Lender or L/C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication.  The Administrative Agent, the Swingline Lender, the L/C Issuers and the Borrowers may, in their discretion, agree to accept notices and other communications hereunder by electronic communications pursuant to procedures approved by them, provided that approval of such procedures may be limited to particular notices or communications.

Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor provided that, for both clauses (i) and (ii), if such notice, e-mail or other communication is not sent during the normal business hours of the recipient, such notice, e-mail or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient.

(c)The Platform.  THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.”  THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE CREDIT PARTY MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE CREDIT PARTY MATERIALS.  NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE CREDIT PARTY MATERIALS OR THE PLATFORM.  In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to any Credit Party, Lender, L/C Issuer or other Person for losses, claims, damages, liabilities or expenses

108

of any kind (whether in tort, contract or otherwise) arising out of any Credit Party’s or the Administrative Agent’s transmission of Credit Party Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to any Borrower or any other Credit Party, any Lender, any L/C Issuer or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages).

(d)Change of Address, Etc.  Each of the Borrowers, the Administrative Agent, the L/C Issuers and the Swingline Lender may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the other parties hereto.  Each other Lender may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the Credit Parties, the Administrative Agent, the L/C Issuers and the Swingline Lender.  In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, facsimile number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender.  Furthermore, each Public Lender agrees to cause at least one individual at or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public Lender’s compliance procedures and applicable Law, including United States Federal and state securities Laws, to make reference to Credit Party Materials that are not made available through the “Public Side Information” portion of the Platform and that may contain material non-public information with respect to the Borrowers or their securities for purposes of United States Federal or state securities laws.

(e)Reliance by Administrative Agent, L/C Issuers and Lenders.  The Administrative Agent, the L/C Issuers and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic Loan Notices and L/C Applications) purportedly given by or on behalf of any Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof.  The Credit Parties shall indemnify each of the Administrative Agent, L/C Issuers, the Lenders and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of a Credit Party.  All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

11.03No Waiver; Cumulative Remedies; Enforcement.  No failure by any Lender, L/C Issuer, Swingline Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other Credit Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder or under any other Credit Document (including the imposition of the Default Rate) preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.  The rights, remedies, powers and privileges herein provided and provided under each of the other Credit Documents are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.

Notwithstanding anything to the contrary contained herein or in any other Credit Document, the authority to enforce rights and remedies hereunder and under the other Credit Documents against the Credit Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 9.02 for the benefit of all the Lenders and the L/C Issuers; provided,

109

however, that the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Credit Documents, (b) the L/C Issuers or the Swingline Lenders from exercising the rights and remedies that inure to their benefit (solely in their capacity as L/C Issuer or Swingline Lender, as the case may be) hereunder and under the other Credit Documents, (c) any Lender from exercising setoff rights in accordance with Section 11.08 (subject to the terms of Section 2.12), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Credit Party under any Debtor Relief Law; and provided further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Credit Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to Section 9.02 and (ii) in addition to the matters set forth in clauses (b), (c) and (d) of the preceding proviso and subject to Section 2.12, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.

11.04Expenses; Indemnity; Damage Waiver.

(a)Costs and Expenses.  The Borrowers shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent, and its Affiliates (including the reasonable fees, charges and disbursements of Moore & Van Allen, PLLC, as counsel for the Administrative Agent and the Lenders and of special and local counsel to the Administrative Agent and the Lenders), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Credit Agreement and the other Credit Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by any L/C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket expenses incurred by the Administrative Agent, any Lender or any L/C Issuer (including the fees, charges and disbursements of any counsel for the Administrative Agent, any Lender or any L/C Issuer), in connection with the enforcement or protection of its rights (A) in connection with this Credit Agreement and the other Credit Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or related negotiations in respect of such Loans or Letters of Credit.

(b)Indemnification by the Borrowers.  The Borrowers shall indemnify the Administrative Agent (and any sub-agent thereof), the Arrangers, each Lender and each L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the reasonable fees, charges and disbursements of any counsel for any Indemnitee), incurred by any Indemnitee or asserted against any Indemnitee by any Person (including the Borrower or any other Credit Party) other than such Indemnitee and its Related Parties arising out of, in connection with, or as a result of (i) the execution or delivery of this Credit Agreement, any other Credit Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Credit Agreement and the other Credit Documents Person (including in respect of any matters addressed in Section 3.01), (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by an L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), or (iii) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by any Borrower or any other Credit Party, and regardless of

110

whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by the Borrowers or any other Credit Party against an Indemnitee for breach in bad faith of such Indemnitee’s obligations hereunder or under any other Credit Document, if the Borrowers or such Credit Party has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction.  Without limiting the provisions of Section 3.01(c), this Section 11.04(b) shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.

(c)Reimbursement by Lenders.  To the extent that any Borrower for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), an L/C Issuer, Swingline Lender or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), such L/C Issuer, Swingline Lender or such Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender’s share of the total Loans and Commitments hereunder at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on such Lender’s pro rata share as of the time that the applicable unreimbursed expense or indemnity payment is sought, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent or any such sub-agent or such L/C Issuer or Swingline Lender in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) or an L/C Issuer or Swingline Lender in connection with such capacity.  The obligations of the Lenders under this subsection (c) are subject to the provisions of Section 2.11(d).

(d)Waiver of Consequential Damages, Etc.  To the fullest extent permitted by applicable law, the Credit Parties shall not assert, and hereby waive, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Credit Agreement, any other Credit Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof.  No Indemnitee referred to in subsection (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed to such unintended recipients by such Indemnitee through telecommunications, electronic or other information transmission systems in connection with this Credit Agreement or the other Credit Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the gross negligence or willful misconduct of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction.

(e)Payments.  All amounts due under this Section shall be payable not later than thirty Business Days after demand therefor.

(f)Survival.  The agreements in this Section and the indemnity provisions of Section 11.02(e) shall survive the resignation of the Administrative Agent, any L/C Issuer and the Swingline Lender, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other obligations hereunder or under any of the other Credit Documents.

111

11.05Payments Set Aside.  To the extent that any payment by or on behalf of any Borrower is made to the Administrative Agent, any L/C Issuer or any Lender, or the Administrative Agent, any L/C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, such L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender and each L/C Issuer severally agrees to pay to the Administrative Agent on demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the applicable Overnight Rate from time to time in effect, in the applicable currency of such recovery or payment.  The obligations of the Lenders and the L/C Issuers under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Credit Agreement.

11.06Successors and Assigns.

(a)Successors and Assigns Generally.  The provisions of this Credit Agreement and the other Credit Documents shall be binding upon and inure to the benefit of the parties hereto and thereto and their respective successors and assigns permitted hereby, except that neither any Borrower nor any other Credit Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an Eligible Assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void).  Nothing in this Credit Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent, the L/C Issuers and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Credit Agreement.

(b)Assignments by Lenders.  Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Credit Agreement and the other Credit Documents (including all or a portion of its Commitment and the Loans (including for purposes of this subsection (b), participations in L/C Obligations and in Swingline Loans) at the time owing to it); provided that (in each case with respect to any credit facility) any such assignment shall be subject to the following conditions:

(i)Minimum Amounts.

(A)in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment under any credit facility provided hereunder and/or the related Loans at the time owing to it (in each case with respect to any credit facility provided hereunder) or contemporaneous assignments to related Approved Funds that equal at least the amount specified in paragraph (b)(i)(B) of this Section in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and

112

(B)in any case not described in subsection (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if a “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $5 million or €5 million, as appropriate, in the case of an assignment of Revolving Commitments (and the Revolving Loans relating thereto), and $1 million or €1 million, as appropriate, in the case of an assignment of a Term Loan, unless (x) the Revolving Commitments (and the Revolving Loans relating thereto) and the Term Loan subject to such assignment is the full amount of the assignor’s interest therein, as applicable, or (y) each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, FME otherwise consents (each such consent not to be unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single Eligible Assignee (or to an Eligible Assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met; and

(ii)Proportionate Amounts.  Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Credit Agreement with respect to the Loans or the Commitment assigned, except that this clause (ii) shall not (A) apply to the Swingline Lender’s rights and obligations in respect of Swingline Loans or (B) prohibit any Lender from assigning all or a portion of its rights and obligations among its separate Revolving Commitments (and the Revolving Loans relating thereto) and Term Loans (and the Commitments relating thereto) on a non-pro rata basis;

(iii)Required Consents.  No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition:

(A)the consent of FME (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment, (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that FME shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five Business Days after having received notice thereof or (3) such assignment is assigned by the Lenders that are the Administrative Agent, Sole Syndication Agent or Co-Documentation Agents during the primary syndication of the Loans and Commitments;

(B)the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of (1) any unfunded Term Loan Commitment or any Revolving Commitment, if such assignment is to a Person that is not a Lender with a Commitment in respect of the applicable credit facility, an Affiliate of such Lender or an Approved Fund with respect to such Lender, or (2) any Term Loan to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund;

113

(C)the consent of the applicable L/C Issuer (such consent not to be unreasonably withheld or delayed) shall be required for any assignment in respect of a USD Revolving Loan or a USD Revolving Commitment relating thereto; and

(D)the consent of the applicable Swingline Lender (such consent not to be unreasonably withheld or delayed) shall be required for any assignment in respect of a USD Revolving Loan or a USD Revolving Commitment relating thereto.

(iv)Assignment and Assumption.  The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $2,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment.  The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire.

(v)No Assignment to Certain Persons.  No such assignment shall be made to (A) any Borrower or any of their Affiliates or Subsidiaries, (B) any Defaulting Lender or any of its Affiliates or Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (B), or (C) a natural person.

(vi)Certain Additional Payments.  In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrowers and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent, each L/C Issuer, each Swingline Lender or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swingline Loans in accordance with its pro rata share.  Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Credit Agreement until such compliance occurs.

Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the Eligible Assignee thereunder shall be a party to this Credit Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Credit Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Credit Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Credit Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05, and 11.04 with respect to facts and circumstances occurring prior to the effective date of such assignment; provided that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from the Lender’s having been a Defaulting Lender.  Upon request, each applicable Borrower (at its expense) shall execute and deliver a Note to the assignee Lender. 

114

Any assignment or transfer by a Lender of rights or obligations under this Credit Agreement that does not comply with this subsection shall be treated for purposes of this Credit Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section.

(c)Register.  The Administrative Agent, acting solely for this purpose as an agent of the Borrowers (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the “Register”).  The entries in the Register shall be conclusive absent manifest error, and the Borrowers, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Credit Agreement.  In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender.  The Register shall be available for inspection by any of the Borrowers, the L/C Issuers and the Lenders, at any reasonable time and from time to time upon reasonable prior notice.

(d)Participations.  Any Lender may at any time, without the consent of, or notice to, FME or the other Credit Parties or the Administrative Agent, sell participations to any Person (other than a natural person, a Defaulting Lender, any Borrower or any of their respective Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Credit Agreement (including all or a portion of its Commitment and/or the Loans (including such Lender’s participations in L/C Obligations and/or Swingline Loans) owing to it); provided that (i) such Lender’s obligations under this Credit Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrowers, the Administrative Agent, the Lenders and the L/C Issuers shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Credit Agreement.  For the avoidance of doubt, each Lender shall be responsible for the indemnity under Section 11.04(c) without regard to the existence of any participation.

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Credit Agreement and to approve any amendment, modification or waiver of any provision of this Credit Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification that extends the time for, reduces the amount or alters the application of proceeds with respect to such obligations and payments required thereon that directly affects such Participant.  The Borrowers agree that each Participant shall be entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this Section (it being understood that the documentation required under Section 3.01(e) shall be delivered to the Lender who sells the participation) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of Sections 3.06 and 11.13 as if it were an assignee under paragraph (b) of this Section and (B) shall not be entitled to receive any greater payment under Sections 3.01 or 3.04, with respect to any participation, than the Lender from whom it acquired the applicable participation would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation.  Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 3.06 with respect to any Participant.  To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 11.08 as though it were a Lender; provided that such Participant agrees to be subject to Section 2.12 as though it were a Lender.  Each Lender that sells a participation

115

shall, acting solely for this purpose as a non-fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Credit Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under any Credit Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Credit Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.

(e)Limitations on Participant Rights.  A Participant shall not be entitled to receive any greater payment under Section 3.01 or 3.04 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with each applicable Borrower’s prior written consent.  A Participant that would be a Foreign Lender if it were a Lender shall not be entitled to the benefits of Section 3.01 unless each applicable Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of each such Borrower, to comply with Sections 3.01(e) and 3.06 as though it were a Lender.

(f)Certain Pledges.  Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Credit Agreement (including under its Note(s), if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank or other central bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

(g)Resignation as L/C Issuer or Swingline Lender after Assignment.  Notwithstanding anything to the contrary contained herein, if at any time Bank of America assigns all of its Revolving Commitments (and the Revolving Loans relating thereto) pursuant to subsection (b) above, Bank of America may, (i) upon thirty days’ notice to the Borrowers and the Lenders, resign as L/C Issuer and/or (ii) upon thirty days’ notice to the Borrowers, resign as Swingline Lender.  In the event of any such resignation as L/C Issuer or Swingline Lender, the Borrowers shall be entitled to appoint from among the Lenders a successor L/C Issuer or Swingline Lender hereunder; provided, however, that no failure by the Borrowers to appoint any such successor shall affect the resignation of Bank of America as L/C Issuer or Swingline Lender, as the case may be.  If Bank of America resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of an L/C Issuer hereunder with respect to all Letters of Credit issued by it outstanding as of the effective date of its resignation as L/C Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Loans or fund risk participations in L/C Unreimbursed Amounts pursuant to Section 2.03(c)).  If Bank of America resigns as Swingline Lender, it shall retain all the rights of the Swingline Lender provided for hereunder with respect to Swingline Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Base Rate Loans or fund risk participations in outstanding Swingline Loans pursuant to Section 2.04(c).  Upon the appointment of a successor L/C Issuer and/or Swingline Lender, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer or Swingline Lender, as the case may be, and (b) any successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any,

116

outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit.

11.07Treatment of Certain Information; Confidentiality.  Each of the Administrative Agent, the Lenders and the L/C Issuers agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ Related Parties (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Credit Document or any action or proceeding relating to this Credit Agreement or any other Credit Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights and obligations under this Credit Agreement or any Eligible Assignee invited to become a Lender pursuant to Section 2.01(d), or (ii) any actual or prospective party (or its Related Parties) to any swap, derivative, credit insurance or other transaction under which payments are to be made by reference to the Borrowers and their obligations, this Credit Agreement or payments hereunder, (g) to Numbering Service Providers as provided hereinbelow, (h) on a confidential basis to (i) any rating agency in connection with rating the Borrowers or their Subsidiaries or the credit facilities provided hereunder or (ii) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, (i) with the consent of the applicable Borrower or (j) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, any L/C Issuer or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrowers.

For purposes of this Section, “Information” means all information received from the Borrowers or any Subsidiary relating to the Borrowers or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or any L/C Issuer on a nonconfidential basis prior to disclosure by the Borrowers or any Subsidiary.  Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

Each of the Administrative Agent, the Lenders and the L/C Issuers acknowledges that (a) the Information may include material non-public information concerning any of the Borrowers or their Subsidiaries, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including United States federal and state securities Laws.

Any Lender may disclose to any national or international numbering service provider (a “Numbering Service Provider”) appointed by any Credit Party to provide identification numbering services in respect of this Credit Agreement, the credit facilities established hereunder and/or one or more of the Credit Parties the following information; provided that such information is not price-sensitive information which has not otherwise been published or is available in the public domain:

(i) names of the Credit Parties; (ii) country of domicile of the Credit Parties, (iii) place of incorporation of the Credit Parties, (iv) date of this Credit Agreement, (v) the names of the

117

Administrative Agent and Arrangers, (vi) the date of each amendment and restatement of this Credit Agreement, (vii) the amount of total loans and commitments under this Credit Agreement, (viii) the currencies of the credit facilities under this Credit Agreement, (ix)  the type of credit facilities under this Credit Agreement, (x) the ranking of the credit facilities under this Credit Agreement, (xi) the termination and maturity dates for credit facilities under this Credit Agreement, (xii) changes to any of the information previously supplied pursuant to the foregoing clauses (i) through (xii) hereof, and (xiii) such other information as may be agreed between such Lenders and FME,

to enable such Numbering Service Provider to provide its usual syndicated loan numbering identification services.  The parties acknowledge and agree that each identification number assigned to this Credit Agreement, the credit facilities established hereunder and/or one or more of the Credit Parties by a Numbering Service Provider and the information associated with each such number may be disclosed to users of its services in accordance with the standard terms and conditions of that Numbering Service Provider.  Each Credit Party represents that none of the information set out above is, nor will be at any time be, unpublished price-sensitive information.  The Administrative Agent shall notify FME of (A) the name of any Numbering Service Provider appointed by the Administrative Agent in respect of this Credit Agreement, the credit facilities established hereunder and/or one or more of the Credit Parties, and (B) the number or, as the case may be, numbers assigned to the Credit Agreement, the credit facilities established hereunder and/or one or more of the Credit Parties by such Numbering Service Provider.

11.08Right of Setoff.  If an Event of Default shall have occurred and be continuing, each Lender, each L/C Issuer and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, such L/C Issuer or any such Affiliate to or for the credit or the account of any Borrower or any other Credit Party against any and all of the obligations of such Borrower or such Credit Party now or hereafter existing under this Credit Agreement or any other Credit Document to such Lender or L/C Issuer or their respective Affiliates, irrespective of whether or not such Lender or L/C Issuer or Affiliate shall have made any demand under this Credit Agreement or any other Credit Document and although such obligations of such Borrower or such Credit Party may be contingent or unmatured or are owed to a branch, office or Affiliate of such Lender or L/C Issuer different from the branch, office or Affiliate  holding such deposit or obligated on such indebtedness; provided that in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.17 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent the L/C Issuer and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff.  The rights of each Lender, L/C Issuer and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender, such L/C Issuer or their respective Affiliates may have.  Each Lender and L/C Issuer agrees to notify each applicable Borrower and the Administrative Agent promptly after any such setoff and application, provided that the failure to give such notice shall not affect the validity of such setoff and application.

11.09Interest Rate Limitation.  Notwithstanding anything to the contrary contained in any Credit Document, the interest paid or agreed to be paid under the Credit Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”).  If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal,

118

refunded to the applicable Borrower.  In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.

11.10Counterparts; Integration; Effectiveness.  This Credit Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  This Credit Agreement, the other Credit Documents and any separate letter agreements with respect to fees payable to the Administrative Agent and the L/C Issuer constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.  Except as provided in Section 5.01, this Credit Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto.  Delivery of an executed counterpart of a signature page of this Credit Agreement by facsimile or other electronic imaging means (e.g., “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Credit Agreement.

11.11Survival of Representations and Warranties.  All representations and warranties made hereunder and in any other Credit Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof.  Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding.

11.12Severability.  If any provision of this Credit Agreement or the other Credit Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Credit Agreement and the other Credit Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  Without limiting the foregoing provisions of this Section 11.12, if and to the extent that the enforceability of any provisions in this Credit Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, an L/C Issuer or a Swingline Lender, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited.

11.13Replacement of Lenders.  If (a) any Lender requests compensation under Section 3.04, (b) any Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, and, in each case, such Lender has declined to or is unable to designate a different Lending Office in accordance with Section 3.06(a), (c) a Lender (a “Non-Consenting Lender”) does not consent to a proposed amendment, consent, change, waiver, discharge or termination with respect to any Credit Document that has been approved by the Required Lenders, the Required Revolving Lenders, the Required Tranche A-5 Term Lenders, the Required Tranche A-6 Term Lenders or the Required Tranche A-7 Term Lenders (or the required lenders for any other term loan established under the Incremental Loan Facilities), as appropriate

119

(including, without limitation, by a failure to respond in writing to a proposed amendment by the date and time specified by the Administrative Agent) as provided in Section 11.01 but requires unanimous consent of all Lenders or all Lenders of a particular class of loans, or (d) any Lender is a Defaulting Lender, then the Borrowers may, at their sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 11.06), all of its interests, rights (other than its existing rights to payments pursuant to Sections 3.01 and 3.04) and obligations under this Credit Agreement and the related Credit Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that:

(i)the respective Borrower shall have paid to the Administrative Agent the assignment fee (if any) specified in Section 11.06(b)(iv);

(ii)such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and, with respect to Revolving Lenders, L/C Borrowings, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Credit Documents (including any amounts under Section 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the applicable Borrower (in the case of all other amounts);

(iii)in the case of any such assignment resulting from a claim for compensation under Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter;

(iv)such assignment does not conflict with applicable Laws; and

(v)in the case of any such assignment from a Non-Consenting Lender, the applicable assignee shall have consented to the applicable amendment, waiver or consent;

provided that the failure by a Non-Consenting Lender to execute and deliver an Assignment and Assumption shall not impair the validity of the removal of such Non-Consenting Lender and the mandatory assignment of such Non-Consenting Lender’s Commitments and outstanding Loans and, with respect to the Revolving Lenders, participations in L/C Obligations pursuant to this Section 11.13 shall nevertheless be effective without the execution by such Non-Consenting Lender of an Assignment and Assumption.

A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrowers to require such assignment and delegation cease to apply.

11.14Lender Representations .

(a)Each of the Lenders party to this Credit Agreement hereby represents and warrants to the Borrowers that at least one of the following statements is an accurate representation as to the source of funds to be used by such Lender in connection with the financing hereunder:

120

(i)no part of such funds constitutes assets allocated to any separate account maintained by such Lender in which any employee benefit plan (or its related trust) has any interest;

(ii)to the extent that any part of such funds constitutes assets allocated to any separate account maintained by such Lender, such Lender has disclosed to the Borrowers the name of each employee benefit plan whose assets in such account exceed ten percent (10%) of the total assets of such account as of the date of such purchase (and, for purposes of this subsection (b), all employee benefit plans maintained by the same employer or employee organization are deemed to be a single plan);

(iii)to the extent that any part of such funds constitutes assets of an insurance company’s general account, such insurance company has complied with all of the requirements of the regulations issued under Section 401(c)(1)(A) of ERISA; or

(iv)such funds constitute assets of one or more specific benefit plans that such Lender has identified in writing to the Borrowers.

As used in this Section, the terms “employee benefit plan” and “separate account” shall have the respective meanings provided in Section 3 of ERISA.

(b)Each Lender represents and warrants to the Administrative Agent and the Arrangers and their respective Affiliates (and not, for the avoidance of doubt, for the benefit of the Borrowers or any other Credit Party), that such Lender is not, as of the Amendment No. 2 Effective Date, (i) an employee benefit plan subject to Title I of ERISA, (ii) a plan or account subject to Section 4975 of the Internal Revenue Code, (iii) an entity deemed to hold “plan assets” of any such plans or accounts for purposes of ERISA or the Internal Revenue Code, or (iv) a “governmental plan” within the meaning of ERISA.

11.15Governing Law; Jurisdiction; Etc.

(a)GOVERNING LAW.  THIS CREDIT AGREEMENT AND THE OTHER CREDIT DOCUMENTS AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER CREDIT DOCUMENT (EXCEPT, AS TO ANY OTHER CREDIT DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

(b)SUBMISSION TO JURISDICTION.  EACH OF THE BORROWERS AND OTHER CREDIT PARTIES  IRREVOCABLY AND UNCONDITIONALLY AGREES THAT IT WILL NOT COMMENCE ANY ACTION, LITIGATION OR PROCEEDING OF ANY KIND OR DESCRIPTION, WHETHER IN LAW OR EQUITY, WHETHER IN CONTRACT OR IN TORT OR OTHERWISE, AGAINST THE ADMINISTRATIVE AGENT, ANY LENDER, ANY L/C ISSUER, THE SWINGLINE LENDER OR ANY RELATED PARTY OF THE FOREGOING IN ANY WAY RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER CREDIT DOCUMENT OR THE TRANSACTIONS RELATING HERETO OR THERETO IN ANY FORUM OTHER THAN THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK AND ANY APPELLATE COURT FROM ANY THEREOF, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE JURISDICTION OF SUCH COURTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION, LITIGATION OR PROCEEDING

121

MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT.  EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION, LITIGATION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW.  NOTHING IN THIS CREDIT AGREEMENT OR IN ANY OTHER CREDIT DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER OR ANY L/C ISSUER OR SWINGLINE LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER CREDIT DOCUMENT AGAINST ANY CREDIT PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c)WAIVER OF VENUE.  EACH OF THE BORROWERS AND OTHER CREDIT PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER CREDIT DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d)SERVICE OF PROCESS.  EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 11.02.  NOTHING IN THIS CREDIT AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

IF ANY CREDIT PARTY THAT IS NOT ORGANIZED IN THE UNITED STATES DOES NOT HAVE A PRINCIPAL PLACE OF BUSINESS IN THE UNITED STATES OR ANY STATE OR OTHER POLITICAL SUBDIVISION THEREOF (EACH, A “FOREIGN CREDIT PARTY”), SUCH FOREIGN CREDIT PARTY HEREBY IRREVOCABLY DESIGNATES AND APPOINTS FMCH (IN SUCH CAPACITY, THE “PROCESS AGENT”), AS ITS AUTHORIZED AGENT, TO ACCEPT AND ACKNOWLEDGE ON ITS BEHALF, SERVICE OF ANY AND ALL PROCESS WHICH MAY BE SERVED IN ANY SUIT, ACTION OR PROCEEDING OF THE NATURE REFERRED TO IN THIS SECTION 11.15 IN ANY FEDERAL OR NEW YORK STATE COURT, AND HEREBY CONSENTS TO PROCESS BEING SERVED UPON THE PROCESS AGENT IN ANY SUCH SUIT, ACTION OR PROCEEDING.  EACH FOREIGN CREDIT PARTY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ALL CLAIM OF ERROR BY REASON OF ANY SUCH SERVICE AND AGREES THAT SUCH SERVICE SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON SUCH BORROWER IN ANY SUCH SUIT, ACTION OR PROCEEDING AND SHALL, TO THE FULLEST EXTENT PERMITTED BY LAW, BE TAKEN AND HELD TO BE VALID AND PERSONAL SERVICE UPON AND PERSONAL DELIVERY TO SUCH FOREIGN CREDIT PARTY.  NOTHING IN THIS PROVISION SHALL AFFECT THE RIGHT OF THE ADMINISTRATIVE AGENT OR ANY LENDER TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR LIMIT THE RIGHT OF THE ADMINISTRATIVE AGENT OR ANY LENDER TO BRING PROCEEDINGS AGAINST A FOREIGN CREDIT PARTY IN THE COURTS OF ANY JURISDICTION OR JURISDICTIONS.  THE DESIGNATION AND APPOINTMENT OF THE PROCESS AGENT SHALL BE IRREVOCABLE UNTIL ALL PRINCIPAL AND INTEREST AND ALL OTHER AMOUNTS PAYABLE BY ANY FOREIGN CREDIT PARTY UNDER THIS CREDIT AGREEMENT AND ANY OTHER CREDIT DOCUMENT SHALL HAVE BEEN PAID IN FULL IN ACCORDANCE WITH THE PROVISIONS HEREOF AND THEREOF.  IF

122

SUCH AGENT SHALL CEASE SO TO ACT, EACH FOREIGN CREDIT PARTY COVENANTS AND AGREES TO DESIGNATE IRREVOCABLY AND APPOINT WITHOUT REASONABLE DELAY ANOTHER SUCH AGENT REASONABLY SATISFACTORY TO THE ADMINISTRATIVE AGENT.

11.16Waiver of Jury Trial.  EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS CREDIT AGREEMENT OR ANY OTHER CREDIT DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS CREDIT AGREEMENT AND THE OTHER CREDIT DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

11.17No Advisory or Fiduciary Responsibility.  In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Credit Document), each of the Credit Parties acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (i) (A) the arranging and other services regarding this Credit Agreement provided by the Administrative Agent, the Arrangers, the Lenders and the L/C Issuers are arm’s-length commercial transactions between the Credit Parties and their respective Affiliates, on the one hand, and the Administrative Agent, the Arrangers, the Lenders and the L/C Issuers, on the other hand, (B) each of the Credit Parties has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C) each of the Credit Parties is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Credit Documents; (ii) (A) each of the Administrative Agent, the Arrangers, the Lenders and the L/C Issuers is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Credit Parties or any of their respective Affiliates, or any other Person and (B) none of the Administrative Agent, the Arrangers, the Lenders nor the L/C Issuers has any obligation to the Credit Parties or any of their respective Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Credit Documents; and (iii) the Administrative Agent, the Arrangers, the Lenders and the L/C Issuers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Credit Parties and their respective Affiliates, and neither the Administrative Agent, the Arrangers, any Lender or any L/C Issuer has any obligation to disclose any of such interests to any Borrower, any other Credit Party or any of their respective Affiliates.  To the fullest extent permitted by Law, each of the Borrowers and the other Credit Parties hereby waives and releases any claims that it may have against the Administrative Agent, the Arrangers, the Lenders and the L/C Issuers with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.

11.18USA PATRIOT Act Notice.  Each Lender that is subject to the Patriot Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Credit Parties that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot Act”), it is required to obtain, verify and record information that identifies the Credit Parties, which information includes the name and address of the Credit Parties and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Credit Parties in accordance with the Act.  The Credit Parties shall, promptly

123

following a request by the Administrative Agent or any Lender, provide all documentation and other information that the Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act.

11.19Judgment Currency.  If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder or any other Credit Document in one currency into another currency, the rate of exchange used shall be that at which in accordance with normal banking procedures the Administrative Agent could purchase the first currency with such other currency on the Business Day preceding that on which final judgment is given.  The obligation of each Credit Party in respect of any such sum due from it to the Administrative Agent or any Lender hereunder or under the other Credit Documents shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than that in which such sum is denominated in accordance with the applicable provisions of this Credit Agreement (the “Agreement Currency”), be discharged only to the extent that on the Business Day following receipt by the Administrative Agent or such Lender, as the case may be, of any sum adjudged to be so due in the Judgment Currency, the Administrative Agent or such Lender, as the case may be, may in accordance with normal banking procedures purchase the Agreement Currency with the Judgment Currency.  If the amount of the Agreement Currency so purchased is less than the sum originally due to the Administrative Agent or any Lender from any Borrower in the Agreement Currency, such Borrower agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent or such Lender, as the case may be, against such loss.  If the amount of the Agreement Currency so purchased is greater than the sum originally due to the Administrative Agent or any Lender in such currency, the Administrative Agent or such Lender, as the case may be, agrees to return the amount of any excess to such Borrower (or to any other Person who may be entitled thereto under applicable law).

11.20Electronic Execution of Assignments and Certain Other Documents.   The words “execute,” “execution,” “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Credit Agreement and the transactions contemplated hereby (including without limitation Assignment and Assumptions, amendments or other modifications, Loan Notices, including those for Swingline Loans, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it.

11.21Acknowledgment and Consent to Bail-in of EEA Financial Institutions.  Solely to the extent any Lender or L/C Issuer that is an EEA Financial Institution is a party to this Credit Agreement and notwithstanding anything to the contrary in any Credit Documents or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Lender that is an EEA Financial Institution arising under any Credit Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:

(a)the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender that is an EEA Financial Institution; and

124

(b)the effects of any Bail-In Action on any such liability, including, if applicable:

(i)a reduction in full or in part or cancellation of any such liability;

(ii)a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Credit Agreement or any other Credit Documents; or

(iii)the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any EEA Resolution Authority.

11.22Limitation of Liability for German Guarantors.  With respect to the liability of a Guarantor existing and/or incorporated in the Federal Republic of Germany in the form of a company with limited liability (GmbH) or a German limited partnership having a GmbH as general partner (GmbH & Co. KG) (“German Guarantor”), and in each case only to the extent such German Guarantor secures the Indebtedness of FME or any of its Subsidiaries (other than such German Guarantor and its Subsidiaries), the following provisions apply:

(a)Nothing herein shall lead to an obligation of a Guarantor to make a payment under a Guaranty or an indemnity under the Credit Documents and the Administrative Agent agrees not to enforce any obligation to render such payments to the extent that the application of the proceeds would cause (i) a German Guarantor’s (or in the case of a GmbH & Co. KG, its general partner’s) net assets (Reinvermögen - calculated as the sum of the balance sheet positions shown under § 266(2)(A), (B) and (C) German Commercial Code (Handelsgesetzbuch)) less the sum of the liabilities (shown under the balance sheet positions pursuant to § 266(3)(B), (C) and (D) German Commercial Code) - to fall below such German Guarantor’s (or in the case of a GmbH & Co. KG, its general partner’s) registered share capital (Stammkapital) or (ii) (if the amount of the net assets is already less than the registered share capital) cause such amount to be further reduced and, in either case, thereby affecting the assets required for the obligatory preservation of its registered share capital according to section 30, 31 of the German Limited Liability Company Act (GmbHG) (such event a “Capital Impairment”). For the purpose of calculating the Capital Impairment, the following adjustments will be made:

(i)the amount of any increase of the registered share capital out of retained earnings (Kapitalerhöhung aus Gesellschaftsmitteln) after the date of this Credit Agreement that has been effected without the prior consent of the Administrative Agent shall be deducted from the registered share capital; and

(ii)liabilities incurred in violation of the provisions of any of the Credit Documents shall be disregarded.

(b)In the event such German Guarantor’s (or in the case of a GmbH & Co. KG, its general partner’s) net assets fall below its registered share capital, such German Guarantor, upon request of the Administrative Agent, will realize in due course, to the extent legally permitted, any and all of its assets that are shown in the balance sheet with a book value (Buchwert) that is significantly lower than the market value of the assets if the relevant assets are not necessary for such German Guarantor’s business (nicht betriebsnotwendiges Vermögen).

125

(c)If such German Guarantor objects to the amount demanded by the Administrative Agent under a Guaranty or an indemnity under the Credit Documents within twenty Business Days after the Administrative Agent has submitted to the relevant Guarantor a payment demand, the German Guarantor shall appoint within five Business Days a reputable international auditor to determine the exact amount up to which payment can be made under the Guaranty or indemnity under the Credit Documents without causing a Capital Impairment. The auditor shall notify the German Guarantor and the Administrative Agent of the maximum amount payable under the Guaranty or indemnity under the Credit Documents within forty Business Days after its appointment. The costs of such auditor’s determination shall be borne by the German Guarantor. The determination of the auditor shall be binding for such German Guarantor, the Administrative Agent and the Lenders (except for manifest error). To the extent that any payment has been made under a Guaranty or an indemnity under the Credit Documents by the relevant Guarantor that would be necessary for the German Guarantor (or in the case of a GmbH & Co. KG, its general partner) to be able to cure any Capital Impairment or Liquidity Impairment (as defined below) such payment shall immediately — upon such German Guarantor’s demand — be returned to the German Guarantor by any Person receiving such payment, provided, however, in no event shall the Administrative Agent have any responsibility or liability for the return of any such payment distributed to any Lender by the Administrative Agent, including, without limitation, any obligation to seek return of such amounts from such Lender.

(d)The maximum amount payable under a Guaranty or an indemnity under the Credit Documents shall be limited to the extent and as long as the German Guarantor as a consequence of the payment would be unable to pay its debts when due (zahlungsunfähig) within the meaning of section 64 GmbHG (such event a “Liquidity Impairment”). For the purpose of establishing whether a Liquidity Impairment would occur, payments made by the German Guarantor after the Administrative Agent has notified the German Guarantor of its intention to enforce the Guaranty or any indemnity under the Credit Documents with respect to payment obligations that are not due at the time of the payment shall be disregarded, unless the Administrative Agent has consented to such payments (at the direction of the Required Lenders). From the time the Administrative Agent has notified the German Guarantor and FME of its intention to enforce the Guaranty or any indemnity under the Credit Documents, FME may not make any payment demands against such German Guarantor under shareholder loans and all such payment obligations of such German Guarantor towards FME shall be deferred, subordinated or waived as FME sees fit, until the Administrative Agent notifies such German Guarantor that it is no longer enforcing the Guaranty or indemnity under the Credit Documents or the Administrative Agent consents (at the direction of the Required Lenders) to the payments to be made to FME. Such notice may be delivered by the Administrative Agent at any time and, if not previously delivered, will be delivered by the Administrative Agent after the Loans under the Credit Documents have been repaid in full.

(e)If (i) the German Guarantor does not object to the payment amount within the twenty Business Days period or (ii) if the German Guarantor does not appoint the auditor within the five Business Days period or (iii) if the auditor fails to notify the amount payable within the forty Business Days period, then the Administrative Agent shall be entitled to enforce the Guaranty or indemnity under the Credit Documents without further delay. The burden of demonstration and proof (Darlegungs- und Beweislast) regarding the Capital Impairment and the maximum amount payable under the Credit Documents shall remain with the German Guarantor.

(f)The limitations in this Section 11.22 as to the Capital Impairment shall not apply in each of the following cases: (i) if and to the extent a German Guarantor secures any amounts borrowed under the Credit Documents which are lent or on-lent to the German Guarantor or any of its subsidiaries from time to time, (ii) while control or profit pooling agreements exist between such German Guarantors and FME, and (iii) to the extent the German Guarantor has an adequate compensation claim (vollwertiger Gegenleistungs- oder Rückgewähranspruch) against its parent company or FME that compensates for any

126

loss incurred due to any payment by the German Guarantor (or in the case of a GmbH & Co. KG, its general partner) under the Guaranty or any indemnity under the Credit Documents.

(g)[Reserved].

[SIGNATURES PAGES OMITTED]

127

Annex B

Released Entities

Borrowers:

NATIONAL MEDICAL CARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ALABAMA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF CALIFORNIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF GEORGIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF KENTUCKY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF LOUISIANA, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MINNESOTA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MISSISSIPPI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW HAMPSHIRE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW JERSEY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW MEXICO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NORTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF OHIO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF PENNSYLVANIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TENNESSEE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TEXAS, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF VIRGINIA, INC., a Delaware corporation

FRESENIUS USA MANUFACTURING, INC., a Delaware corporation

FRESENIUS USA MARKETING, INC., a Delaware corporation

FRESENIUS USA, INC., a Massachusetts corporation

SPECTRA LABORATORIES, INC., a Nevada corporation

WSKC DIALYSIS SERVICES, INC., an Illinois corporation

FRESENIUS MANAGEMENT SERVICES, INC., a Delaware corporation

RENAL CARE GROUP, INC., a Delaware corporation

DIALYSIS CENTERS OF AMERICA — ILLINOIS, INC., an Illinois corporation

RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation

RENAL ADVANTAGE HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WISCONSIN, INC., a Delaware corporation

FRESENIUS MEDICAL CARE VENTURES HOLDING COMPANY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF DELAWARE, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTH, INC., a Delaware corporation

RENAL CARE GROUP ALASKA, INC., an Alaska corporation

RENAL CARE GROUP EAST, INC., a Pennsylvania corporation

RCG MISSISSIPPI, INC., a Delaware corporation

RENAL CARE GROUP NORTHWEST, INC., a Delaware corporation

RCG UNIVERSITY DIVISION, INC., a Tennessee corporation

RENEX DIALYSIS CLINIC OF WOODBURY, INC., a New Jersey corporation

SPECTRA EAST, INC., a Delaware corporation

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF SOUTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

Guarantors

NATIONAL MEDICAL CARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ALABAMA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF CALIFORNIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF GEORGIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF KENTUCKY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF LOUISIANA, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MINNESOTA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MISSISSIPPI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW HAMPSHIRE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW JERSEY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NEW MEXICO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF NORTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF OHIO, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF PENNSYLVANIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TENNESSEE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF TEXAS, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WEST VIRGINIA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF VIRGINIA, INC., a Delaware corporation

FRESENIUS USA MANUFACTURING, INC., a Delaware corporation

FRESENIUS USA MARKETING, INC., a Delaware corporation

FRESENIUS USA, INC., a Massachusetts corporation

SPECTRA LABORATORIES, INC., a Nevada corporation

WSKC DIALYSIS SERVICES, INC., an Illinois corporation

FRESENIUS MANAGEMENT SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MARYLAND, INC., a Delaware corporation

RENAL CARE GROUP, INC., a Delaware corporation

DIALYSIS CENTERS OF AMERICA — ILLINOIS, INC., an Illinois corporation

RENAL CARE GROUP OF THE MIDWEST, INC., a Kansas corporation

RENAL ADVANTAGE HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE INC., a Delaware corporation

LIBERTY DIALYSIS, LLC, a Delaware limited liability company

AMERICAN ACCESS CARE HOLDINGS, LLC, a Delaware limited liability company

BIO-MEDICAL APPLICATIONS OF MISSOURI, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF WISCONSIN, INC., a Delaware corporation

DIALYSIS MANAGEMENT CORPORATION, a Texas corporation

FRESENIUS MEDICAL CARE VENTURES HOLDING COMPANY, INC., a Delaware corporation

NNA OF ALABAMA, INC., an Alabama corporation

BIO-MEDICAL APPLICATIONS OF DELAWARE, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF FAYETTEVILLE, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTH, INC., a Delaware corporation

RENAL CARE GROUP OF THE SOUTHEAST, INC., a Florida corporation

RENAL CARE GROUP ALASKA, INC., an Alaska corporation

RENAL CARE GROUP EAST, INC., a Pennsylvania corporation

RCG MISSISSIPPI, INC., a Delaware corporation

RENAL CARE GROUP NORTHWEST, INC., a Delaware corporation

RENAL CARE GROUP TEXAS, INC., a Texas corporation

RCG UNIVERSITY DIVISION, INC., a Tennessee corporation

RENAL CARE GROUP SOUTHWEST HOLDINGS, INC., a Delaware corporation

RENAL RESEARCH INSTITUTE, LLC, a New York limited liability company

RENEX DIALYSIS CLINIC OF WOODBURY, INC., a New Jersey corporation

SPECTRA EAST, INC., a Delaware corporation

FRESENIUS MEDICAL CARE DEUTSCHLAND GmbH, a German limited liability company

FRESENIUS MEDICAL CARE BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company

FRESENIUS MEDICAL CARE US BETEILIGUNGSGESELLSCHAFT mbH, a German limited liability company

FRESENIUS MEDICAL CARE US ZWEI VERMÖGENSVERWALTUNGS GmbH & Co. KG, a German limited partnership

FRESENIUS MEDICAL CARE GmbH, a German limited liability company

FMC FINANCE II S.à r.l., a private limited company (société à responsabilité limitée) organized under the laws of Luxembourg

FMC FINANCE VII S.A, a société anonyme organized under the laws of Luxembourg

FMC FINANCE VIII S.A, a société anonyme organized under the laws of Luxembourg

FRESENIUS MEDICAL CARE NORTH AMERICA HOLDINGS LIMITED PARTNERSHIP, a Delaware limited partnership

BIO-MEDICAL APPLICATIONS MANAGEMENT COMPANY, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF MAINE, INC., a Delaware corporation

EVEREST HEALTHCARE HOLDINGS, INC., a Delaware corporation

FRESENIUS SECURITIES, INC., a California corporation

SRC HOLDING COMPANY, INC., a Delaware corporation

FRESENIUS MEDICAL CARE US FINANCE, INC., a Delaware corporation

FRESENIUS MEDICAL CARE US FINANCE II, INC., a Delaware corporation

FRESENIUS MEDICAL CARE B, LLC, a Delaware limited liability company

STAT DIALYSIS CORPORATION, a Delaware corporation

LIBERTY DIALYSIS HOLDINGS, INC., a Delaware corporation

RENAL ADVANTAGE PARTNERS, LLC, a Delaware limited liability company

RA ACQUISITION CO., LLC, a Delaware limited liability company

RAI II, LLC, a Delaware limited liability company

RAI CARE CENTERS HOLDINGS I, LLC, a Delaware limited liability company

RAI CARE CENTERS HOLDINGS II, LLC, a Delaware limited liability company

LIBERTY DIALYSIS, INC., a Delaware corporation

AMERICAN ACCESS CARE INVESTMENT HOLDINGS, LLC, a Delaware limited liability company

FRESENIUS VASCULAR CARE, INC., a Delaware corporation

RENEX CORP., a Florida corporation

NEW YORK DIALYSIS SERVICES, INC., a New York corporation

FRESENIUS MEDICAL CARE RX, LLC, a Delaware limited liability company

FRESENIUS MEDICAL CARE PHARMACY SERVICES, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF SOUTH CAROLINA, INC., a Delaware corporation

BIO-MEDICAL APPLICATIONS OF ILLINOIS, INC., a Delaware corporation

FMS NEW YORK SERVICES, LLC, a Delaware limited liability company

NNA MANAGEMENT COMPANY OF KENTUCKY, INC., a Kentucky corporation

FRESENIUS MEDICAL CARE INTEGRATED CARE GROUP, LLC, a Delaware limited liability company

NCP INVESTMENT HOLDINGS, INC., a Delaware corporation

Pledgors

FRESENIUS MEDICAL CARE INVESTMENT GmbH, a German limited liability company

FRESENIUS MEDICAL CARE US VERMÖGENSVERWALTUNGS GmbH & Co. KG, a German limited partnership

Annex C

UCC-3 Termination Statements

See attached.

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4179760 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: AMERICAN ACCESS CARE INVESTMENT HOLDINGS, LLC (017625.004786) F#363397 A#808444 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174670 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: BIO-MEDICAL APPLICATIONS MANAGEMENT COMPANY, INC. (017625.004786) f#363360 a#808445 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174787 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: BIO-MEDICAL APPLICATIONS OF MARYLAND, INC. (017625.004786) F#363361 A#808446 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4175784 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: EVEREST HEALTHCARE HOLDINGS, INC. (017625.004786) F#363369 A#808447 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116893 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE BETEILIGUNGSGESELLSCHAFT MBH (017625.004786) F#363421 A#808448 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 201210300615066 10/30/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: check only one box. ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE HOLDINGS (017625.004786) F#363355 A#808449 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2014 5150149 12/18/2014 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE INTEGRATED CARE GROUP, LLC (017625.004786) F#452936 A#808450 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174621 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE NORTH AMERICA HOLDINGS LIMITED PARTNERSHIP (017625.004786) F#362538 A#808451 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116897 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#364122 A#808452 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116896 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#364121 A#808453 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116894 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#363422 A#808454 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116899 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#364124 A#808455 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116898 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#364123 A#808456 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012116895 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS MEDICAL CARE US VERMOEGENSVERWALTUNGS GMBH & CO. KG (017625.004786) F#363423 A#808457 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 127335293308 10/30/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS SECURITIES,INC. (017625.004786) F#363370 A#808458 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4179018 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: FRESENIUS VASCULAR CARE, INC. (017625.004786) F#363398 A#808459 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4179075 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY ACQUISITIONS LLC (017625.004786) F#363400 A#808460 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176014 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY DIALYSIS HOLDINGS, INC. (017625.004786) F#363376 A#808461 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176097 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY DIALYSIS INTERMEDIATE HOLDINGS II INC. (017625.004786) F#363378 A#808462 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176568 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY DIALYSIS INTERMEDIATE HOLDINGS, INC. (017625.004786) F#363383 A#808463 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176618 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY DIALYSIS, INC. (017625.004786) F#363384 A#808464 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174944 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY DIALYSIS, LLC (017625.004786) F#363367 A#808465 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4178580 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY IGNITION II, (017625.004786) F#363393 A#808466 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4178630 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY IGNITION III, INC. (017625.004786) F#363394 A#808467 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4178531 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY IGNITION, INC. (017625.004786) F#363390 A#808468 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176659 10/30/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: check only one box. ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY II, INC. (017625.004786) F#363385 A#808469 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4178424 12/18/2014 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY III, INC. (017625.004786) F#363387 A#808470 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4178499 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: LIBERTY IV, INC. (017625.004786) F#363388 A#808471 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174654 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: NATIONAL MEDICAL CARE, INC. (017625.004786) F#363359 A#808472 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176386 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RA ACQUISITION CO., LLC (017625.004786) F#363382 A#808473 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174852 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENAL ADVANTAGE HOLDINGS, INC. (017625.004786) F#363363 A#808474 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174886 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENAL ADVANTAGE INC. (017625.004786) F#363365 A#808475 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4176352 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENAL ADVANTAGE PARTNERS, LLC (017625.004786) F#363380 A#808476 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4174829 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENAL CARE GROUP, INC. (017625.004786) F#363362 A#808477 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 87 10/30/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENEX CORP (017625.004786) F#363399 A#808478 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 07797187 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: RENEX CORP. (017625.004786) F#363399 A#808478 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

UCC FINANCING STATEMENT AMENDMENT FOLLOW INSTRUCTIONS A. NAME & PHONE OF CONTACT AT FILER (optional) Julie Allen 704-331-3745 B. E-MAIL CONTACT AT FILER (optional) julieallen@mvalaw.com C. SEND ACKNOWLEDGMENT TO: (Name and Address) Moore & Van Allen, PLLC 100 North Tryon Street Suite 4700 Charlotte, NC 28202 THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY 1a. INITIAL FINANCING STATEMENT FILE NUMBER 2012 4175925 10/31/2012 1b. This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor’s name in item 13 2. TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement 3. ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9 For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8 4. CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law 5. PARTY INFORMATION CHANGE: Check one of these two boxes: This Change affects Debtor or Secured Party of record AND Check one of these three boxes to: CHANGE name and/or address: Complete ADD name: Complete item DELETE name: Give record name item 6a or 6b; and item 7a or 7b and item 7c 7a or 7b, and item 7c to be deleted in item 6a or 6b 6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b) 6a. ORGANIZATION’S NAME OR 6b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor’s name) 7a. ORGANIZATION’S NAME OR 7b. INDIVIDUAL’S SURNAME INDIVIDUAL’S FIRST PERSONAL NAME INDIVIDUAL’S ADDITIONAL NAME(S)/INITlAL(S) SUFFIX 7c. MAILING ADDRESS STATE POSTAL CODE COUNTRY 8. COLLATERAL CHANGE: Also check one of these four boxes: ADD collateral DELETE collateral RESTATE covered collateral ASSIGN collateral Indicate collateral: 9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment) If this is an Amendment authorized by a DEBTOR, check here and provide name of authorizing Debtor OR 9a. ORGANIZATION’S NAME Bank of America, N.A., as Collateral Agent 9b. INDIVIDUAL’S SURNAME FIRST PERSONAL NAME ADDITIONAL NAME(S)/INITIAL(S) SUFFIX 10. OPTIONAL FILER REFERENCE DATA: Filed with: DE - Secretary of State; Debtor: SRC HOLDING COMPANY, INC. (017625.004786) F#363374 A#808479 International Association of Commercial Administrators (IACA) FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

Schedule 2.01

Lenders and Commitments

See attached.

Schedule 2.01(a)(ii)

USD L/C Commitments of USD L/C Issuers

USD L/C Issuer	USD L/C Commitments
Bank of America, N.A.	$	50,000,000.00
Deutsche Bank AG New York Branch	$	50,000,000.00
The Bank of Nova Scotia	$	50,000,000.00
JPMorgan Chase Bank, N.A.	$	20,000,000.00
SunTrust Bank	$	20,000,000.00
UniCredit Bank AG, New York Branch	$	20,000,000.00
Wells Fargo Bank, National Association	$	20,000,000.00
Total	$	230,000,000.00

Exhibit A

FORM OF NOTICE OF RELEASE

To:Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care Beteiligungsgesellschaft mbH

Fresenius Medical Care Investment GmbH

Fresenius Medical Care Deutschland GmbH

BANK OF AMERICA, N.A. as Collateral Agent (acting in its own name and on behalf of the Administrative Agent and the Lenders) hereby notifies Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care Beteiligungsgesellschaft mbH, Fresenius Medical Care Investment GmbH and Fresenius Medical Care Deutschland GmbH of the release of all pledges created pursuant to (A) the German law governed share pledge agreement dated 30 October 2012 (roll of deeds no. 733/2012-S of the notary public Dr. Karl-Heinz Schmiegelt, Frankfurt am Main), (B) the German law governed share pledge confirmation and assumption agreement dated 16 October 2014 (roll of deeds no. 1338/2014 of the notary public Christoph Walther, Bad Homburg v.d.H.) and (C) the German law governed share pledge agreement dated 26 November 2014 (roll of deeds no. 94/2014-S of the notary public Dr. Kersten von Schenck, Frankfurt am Main).

Sincerely,

BANK OF AMERICA, N.A.,

as Collateral Agent

By:

Name:

Title:

Exhibit 2.02

FORM OF LOAN NOTICE

Date: __________ __, 20__

To:Bank of America, N.A., as Administrative Agent

Re:Credit Agreement, dated as of October 30, 2012 (as amended, restated, increased, supplemented or otherwise modified from time to time, the “Credit Agreement” among, inter alios, FRESENIUS MEDICAL CARE AG & Co. KGaA, a German partnership limited by shares, FRESENIUS MEDICAL CARE HOLDINGS, INC., a New York corporation, the Guarantors identified therein, the Lenders party thereto, and BANK OF AMERICA, N.A., as Administrative Agent.  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.

Ladies and Gentlemen:

1.The undersigned hereby requests the following:

o  a USD Revolving Loan Borrowing

o  a USD Revolving Loan continuation

o  a USD Revolving Loan conversion

o  a USD Swingline Loan Borrowing

o  a Euro Revolving Loan Borrowing

o  a Euro Revolving Loan continuation

o  a Euro Revolving Loan conversion

o  a Tranche A-5 Term Loan Borrowing

o  a Tranche A-5 Term Loan continuation

o  a Tranche A-5 Term Loan conversion

o  a Tranche A-6 Term Loan Borrowing

o  a Tranche A-6 Term Loan continuation

o  a Tranche A-6 Term Loan conversion

o  a Tranche A-7 Term Loan Borrowing

o  a Tranche A-7 Term Loan continuation

o  a Tranche A-7 Term Loan conversion

2.Date of Borrowing, conversion or continuation (which shall be a Business Day): ____________________________

3.Amount and Currency of Borrowing, conversion or continuation: _________________________________________

4.Type of Loan requested: _________________________________________________________________________

5.Interest Period (if applicable): _____________________________________________________________________

The undersigned hereby represents and warrants that (a) this Loan Notice complies with the requirements, as applicable, of Section 2.01(a) of the Credit Agreement, with respect to USD Swingline

Loans and USD Revolving Loans, Section 2.01(b) of the Credit Agreement, with respect to Euro Revolving Loans, Section 2.01(e-5) of the Credit Agreement, with respect to the Tranche A-5 Term Loan, Section 2.01(e-6) of the Credit Agreement, with respect to the Tranche A-6 Term Loan, Section 2.01(e-7) of the Credit Agreement, with respect to the Tranche A-7 Term Loan, and with the requirements of Section 2.02 of the Credit Agreement [and (b) the representations and warranties contained in Sections 5.02(a) and (b) of the Credit Agreement have been satisfied on and as of the date of the requested Credit Extension]1.

BORROWER:	[APPLICABLE BORROWER]
	By:
	Name:
	Title:

1  Bracketed text not applicable if Loan Notice pertains only to continuations and/or conversions.

Exhibit 11.06

FORM OF ASSIGNMENT AND ASSUMPTION

This Assignment and Assumption (this “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into by and between [the][each] Assignor identified in item 1 below ([the][each, an] “Assignor”) and [the][each] Assignee identified in item 2 below ([the][each, an] “Assignee”).  [It is understood and agreed that the rights and obligations of [the Assignors][the Assignees] hereunder are several and not joint.]  Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by the Assignee.  The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.

For an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective Assignees], and [the][each] Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of [the Assignor’s][the respective Assignors’] rights and obligations in [its capacity as a Lender][their respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor][the respective Assignors] under the respective facilities identified below (including, without limitation, the [Multi-Currency Letters of Credit] [USD Swingline Loans and the USD Letters of Credit] included in such facilities) and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of [the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by [the][any] Assignor to [the][any] Assignee pursuant to clauses (i) and (ii) above being referred to herein collectively as [the][an] “Assigned Interest”).  Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by [the][any] Assignor.

1.Assignor[s]:
2.Assignee[s]:		[is an [Affiliate][Approved Fund] of [identify Lender]]
		[is an [Affiliate][Approved Fund] of [identify Lender]]
3.Borrower(s):	Fresenius Medical Care AG & Co. KGaA and Fresenius Medical Care Holdings, Inc.
4.Administrative Agent: Bank of America, N.A., as the administrative agent under the Credit Agreement

5.Credit Agreement:Credit Agreement dated as of October 30, 2012 among, inter alios, Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, Fresenius Medical Care Holdings, Inc., a New York corporation, the Guarantors identified therein, the Lenders party thereto and the Administrative Agent (as such agreement shall be amended, restated, supplemented or otherwise modified from time to time).

6.Assigned Interest[s]:

Assignor[s]	Assignee[s]	Facility Assigned2	Aggregate Amount of Commitment/Loans for all Lenders3	Amount of Commitment/ Loans Assigned	Percentage Assigned of Commitment/ Loans4		CUSIP Number
			[$][€]	[$][€]		%
			[$][€]	[$][€]		%
			[$][€]	[$][€]		%

[7.Trade Date:_______________________]5

Effective Date: _______________, 20__ [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]

The terms set forth in this Assignment and Assumption are hereby agreed to:

ASSIGNOR
[NAME OF ASSIGNOR]
By:
	Name:
	Title:
ASSIGNEE
[NAME OF ASSIGNEE]
By:
	Name:
	Title:

2  Insert USD Revolving Commitments, Euro Revolving Commitments, Tranche A-5 Term Loan, Tranche A-6 Term Loan or Tranche A-7 Term Loan, as applicable.

3  Amounts in this column and in the column immediately to the right to be adjusted by the counterparties to take into account any payments or prepayments made between the Trade Date and the Effective Date.

4  Set forth, to at least 9 decimals, as a percentage of the Commitment/Loans of all Lenders thereunder.

5  To be completed if the Assignor and the Assignee intend that the minimum assignment amount is to be determined as of the Trade Date.

[Consented to and]6 Accepted:

BANK OF AMERICA, N.A., as

Administrative Agent

By:

Name:

Title:

[BANK OF AMERICA, N.A., as

USD L/C Issuer and USD Swingline Lender

By:

Name:

Title:]

[OTHER L/C ISSUERS], as

USD L/C Issuer

By:

Name:

Title:]

[FRESENIUS MEDICAL AG & Co. KGaA,

a German partnership limited by shares (Kommanditgesellschaft auf Aktien), represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner

By:

Name:

Title:

By:

Name:

Title:]

6  To be added only if the consent of the Administrative Agent is required by the terms of the Credit Agreement.

ANNEX 1 TO ASSIGNMENT AND ASSUMPTION

STANDARD TERMS AND CONDITIONS FOR

ASSIGNMENT AND ASSUMPTION

1.Representations and Warranties.

1.1Assignor.  [The][Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of [the][[the relevant] Assigned Interest, (ii) [the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Credit Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Credit Documents or any collateral thereunder, (iii) the financial condition of the Borrowers, any of their Subsidiaries or Affiliates or any other Person obligated in respect of any Credit Document or (iv) the performance or observance by the Borrowers, any of their Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Credit Document.

1.2.Assignee.  [The][Each] Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the requirements to be an assignee under Section 11.06(b)(iii), (v) and (vi) of the Credit Agreement (subject to such consents, if any, as may be required under Section 11.06(b)(iii) of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of [the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by [the][such] Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire [the][such] Assigned Interest, is experienced in acquiring assets of such type, (v) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to Section 7.01 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, (vi) it has, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, and (vii) if it is a Foreign Lender, attached hereto is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by [the][such] Assignee; and (b) agrees that (i) it will, independently and without reliance upon the Administrative Agent, [the][any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Credit Documents are required to be performed by it as a Lender.

2.Payments.  From and after the Effective Date, the Administrative Agent shall make all payments in respect of [the][each] Assigned Interest (including payments of principal, interest, fees and other amounts) to [the][the relevant] Assignor for amounts which have accrued to but excluding the Effective Date and to [the][the relevant] Assignee for amounts which have accrued from and after the

Effective Date.

3.General Provisions.  This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns.  This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument.  Delivery of an executed counterpart of a signature page of this Assignment and Assumption by telecopy shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption.  This Assignment and Assumption and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Assignment and Assumption and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.

Exhibit 2.13-10

FORM OF TRANCHE A-5 TERM LOAN NOTE

_______________ __, 20__

FOR VALUE RECEIVED, the undersigned (the “Tranche A-5 Term Loan Borrower”), hereby promises to pay to                      , or its successors or registered assigns (the “Tranche A-5 Term Loan Lender”), the aggregate unpaid principal amount of the portion of the Tranche A-5 Term Loan made by the Tranche A-5 Term Loan Lender under that certain Credit Agreement, dated as of October 30, 2012 (as amended, restated, increased, supplemented or otherwise modified from time to time, the “Credit Agreement”) among, inter alios, Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, Fresenius Medical Care Holdings, Inc., a New York corporation, the Guarantors identified therein, the Lenders party thereto and Bank of America, N.A., as administrative agent (in such capacity, the “Administrative Agent”).  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.

The Tranche A-5 Term Loan Borrower promises to pay interest on the unpaid principal amount of the portion of the Tranche A-5 Term Loan made by the Tranche A-5 Term Loan Lender from the date of such Tranche A-5 Term Loan until such principal amount is paid in full, at such interest rates and at such times as provided in the Credit Agreement.  All payments of principal and interest shall be made to the Administrative Agent for the account of the Tranche A-5 Term Loan Lender, at the Administrative Agent’s Office, in Dollars in Same Day Funds.  If any amount is not paid in full when due hereunder, such unpaid amount shall bear interest, to be paid upon demand, from the due date thereof until the date of actual payment (before as well as after judgment) computed at the applicable per annum rate set forth in the Credit Agreement.

This Tranche A-5 Term Loan Note is one of the Notes referred to in the Credit Agreement and is entitled to the benefits thereof and may be prepaid in whole or in part subject to the terms and conditions provided therein.  The portion of the Tranche A-5 Term Loan made by the Tranche A-5 Term Loan Lender may be evidenced by one or more loan accounts or records maintained by the Tranche A-5 Term Loan Lender in the ordinary course of business.  The Tranche A-5 Term Loan Lender may also attach schedules to this Tranche A-5 Term Loan Note and endorse thereon the date, amount and maturity of the portion of its Tranche A-5 Term Loan and payments with respect thereto.

Upon the occurrence and during the continuation of an Event of Default, all amounts then remaining unpaid on this Tranche A-5 Term Loan Note shall become, or may be declared to be, immediately due and payable, in each case as provided in the Credit Agreement, without diligence, presentment, protest and demand or notice of protest, demand, dishonor and non-payment of this Tranche A-5 Term Loan Note, all of which are hereby waived by the Tranche A-5 Term Loan Borrower, for itself and its successors and assigns.

THIS TRANCHE A-5 TERM LOAN NOTE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS TRANCHE A-5 TERM LOAN NOTE AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, this Note has been executed as of the day and year first above written.

BORROWER:	FRESENIUS MEDICAL CARE HOLDINGS, INC.,
	a New York corporation
	By:
	Name:
	Title:

Exhibit 2.13-11

FORM OF TRANCHE A-6 TERM LOAN NOTE

_______________ __, 20__

FOR VALUE RECEIVED, the undersigned (the “Tranche A-6 Term Loan Borrower”), hereby promises to pay to                      , or its successors or registered assigns (the “Tranche A-6 Term Loan Lender”) the aggregate unpaid principal amount of the portion of the Tranche A-6 Term Loan made by the Tranche A-6 Term Loan Lender under that certain Credit Agreement, dated as of October 30, 2012 (as amended, restated, increased, supplemented or otherwise modified from time to time, the “Credit Agreement”) among, inter alios, Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, Fresenius Medical Care Holdings, Inc., a New York corporation, the Guarantors identified therein, the Lenders party thereto and Bank of America, N.A., as administrative agent (in such capacity, the “Administrative Agent”).  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.

The Tranche A-6 Term Loan Borrower promises to pay interest on the unpaid principal amount of the portion of the Tranche A-6 Term Loan made by the Tranche A-6 Term Loan Lender from the date of such Tranche A-6 Term Loan until such principal amount is paid in full, at such interest rates and at such times as provided in the Credit Agreement.  All payments of principal and interest shall be made to the Administrative Agent for the account of the Tranche A-6 Term Loan Lender, at the Administrative Agent’s Office, in Euro in Same Day Funds.  If any amount is not paid in full when due hereunder, such unpaid amount shall bear interest, to be paid upon demand, from the due date thereof until the date of actual payment (before as well as after judgment) computed at the applicable per annum rate set forth in the Credit Agreement.

This Tranche A-6 Term Loan Note is one of the Notes referred to in the Credit Agreement and is entitled to the benefits thereof and may be prepaid in whole or in part subject to the terms and conditions provided therein.  The portion of the Tranche A-6 Term Loan made by the Tranche A-6 Term Loan Lender may be evidenced by one or more loan accounts or records maintained by the Tranche A-6 Term Loan Lender in the ordinary course of business.  The Tranche A-6 Term Loan Lender may also attach schedules to this Tranche A-6 Term Loan Note and endorse thereon the date, amount and maturity of the portion of its Tranche A-6 Term Loan and payments with respect thereto.

Upon the occurrence and during the continuation of an Event of Default, all amounts then remaining unpaid on this Tranche A-6 Term Loan Note shall become, or may be declared to be, immediately due and payable, in each case as provided in the Credit Agreement, without diligence, presentment, protest and demand or notice of protest, demand, dishonor and non-payment of this Tranche A-6 Term Loan Note, all of which are hereby waived by the Tranche A-6 Term Loan Borrower, for itself and its successors and assigns.

THIS TRANCHE A-6 TERM LOAN NOTE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS TRANCHE A-6 TERM LOAN NOTE AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, this Note has been executed as of the day and year first above written.

BORROWER:	FRESENIUS MEDICAL AG & Co. KGaA,
	a German partnership limited by shares (Kommanditgesellschaft auf Aktien), represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner
	By:
	Name:
	Title:
	By:
	Name:
	Title:

Exhibit 2.13-12

FORM OF TRANCHE A-7 TERM LOAN NOTE

_______________ __, 20__

FOR VALUE RECEIVED, the undersigned (the “Tranche A-7 Term Loan Borrower”), hereby promises to pay to                      , or its successors or registered assigns (the “Tranche A-7 Term Loan Lender”) the aggregate unpaid principal amount of the portion of the Tranche A-7 Term Loan made by the Tranche A-7 Term Loan Lender under that certain Credit Agreement, dated as of October 30, 2012 (as amended, restated, increased, supplemented or otherwise modified from time to time, the “Credit Agreement”) among, inter alios, Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, Fresenius Medical Care Holdings, Inc., a New York corporation, the Guarantors identified therein, the Lenders party thereto and Bank of America, N.A., as administrative agent (in such capacity, the “Administrative Agent”).  Capitalized terms used but not otherwise defined herein have the meanings provided in the Credit Agreement.

The Tranche A-7 Term Loan Borrower promises to pay interest on the unpaid principal amount of the portion of the Tranche A-7 Term Loan made by the Tranche A-7 Term Loan Lender from the date of such Tranche A-7 Term Loan until such principal amount is paid in full, at such interest rates and at such times as provided in the Credit Agreement.  All payments of principal and interest shall be made to the Administrative Agent for the account of the Tranche A-7 Term Loan Lender, at the Administrative Agent’s Office, in Euro in Same Day Funds.  If any amount is not paid in full when due hereunder, such unpaid amount shall bear interest, to be paid upon demand, from the due date thereof until the date of actual payment (before as well as after judgment) computed at the applicable per annum rate set forth in the Credit Agreement.

This Tranche A-7 Term Loan Note is one of the Notes referred to in the Credit Agreement and is entitled to the benefits thereof and may be prepaid in whole or in part subject to the terms and conditions provided therein.  The portion of the Tranche A-7 Term Loan made by the Tranche A-7 Term Loan Lender may be evidenced by one or more loan accounts or records maintained by the Tranche A-7 Term Loan Lender in the ordinary course of business.  The Tranche A-7 Term Loan Lender may also attach schedules to this Tranche A-7 Term Loan Note and endorse thereon the date, amount and maturity of the portion of its Tranche A-7 Term Loan and payments with respect thereto.

Upon the occurrence and during the continuation of an Event of Default, all amounts then remaining unpaid on this Tranche A-7 Term Loan Note shall become, or may be declared to be, immediately due and payable, in each case as provided in the Credit Agreement, without diligence, presentment, protest and demand or notice of protest, demand, dishonor and non-payment of this Tranche A-7 Term Loan Note, all of which are hereby waived by the Tranche A-7 Term Loan Borrower, for itself and its successors and assigns.

THIS TRANCHE A-7 TERM LOAN NOTE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS TRANCHE A-7 TERM LOAN NOTE AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, this Note has been executed as of the day and year first above written.

BORROWER:	FRESENIUS MEDICAL AG & Co. KGaA,
	a German partnership limited by shares (Kommanditgesellschaft auf Aktien), represented by FRESENIUS MEDICAL CARE MANAGEMENT AG, a German corporation, its general partner
	By:
	Name:
	Title:
	By:
	Name:
	Title:

EX-31.1

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Rice Powell, certify that:

1.

I have reviewed this report on Form 6-K of Fresenius Medical Care AG & Co. KGaA (the "Report").

2.

Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3.

Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

d)

disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2017 By:      /s/ RICE POWELL    
Rice Powell
Chief Executive Officer and
Chairman of the Management Board of the
General Partner

QuickLinks

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EX-31.2

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Brosnan, certify that:

1.

I have reviewed this report on Form 6-K of Fresenius Medical Care AG & Co. KGaA (the "Report");

2.

Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3.

Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

d)

disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2017 By:      /s/ MICHAEL BROSNAN    
Michael Brosnan
Chief Financial Officer and member of the
Management Board of the
General Partner

QuickLinks

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EX-32.1

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

       In connection with the report of Fresenius Medical Care AG & Co. KGaA (the "Company") on Form 6-K furnished for the month of November 2017 containing its unaudited financial statements as of September 30, 2017 and for the nine-months periods ending September 30, 2017 and 2016, as submitted to the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Rice Powell, Chief Executive Officer and Michael Brosnan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

By:      /s/ RICE POWELL                    
Rice Powell
Chief Executive Officer and
Chairman of the Management Board of the
General Partner

November 2, 2017

By:      /s/ MICHAEL BROSNAN        
Michael Brosnan
Chief Financial Officer and
member of the Management Board of the
General Partner

November 2, 2017

QuickLinks

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002